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Abstract 
Background and Aims 
The bacterium Pseudomonas aeruginosa is a versatile environmental organism which is 
capable of persisting within a diverse range of habitats. For people with cystic fibrosis (CF), P. 
aeruginosa is the most common bacterial species isolated from respiratory secretions and 
infection is associated with poor health outcomes and decreased life expectancy. 
 
Molecular-based epidemiological studies have shown that patients with CF can harbour 
indistinguishable genotypes (shared strains) of P. aeruginosa that have not been isolated from 
natural or commonly encountered environments sources. It is speculated that these shared 
strains are acquired by person-to-person transmission and have become highly niche-adapted 
to the CF airway. However, the specific mechanisms relating to the transmission, host 
adaptation and persistence of these strains remain uncertain. 
 
By thoroughly characterising P. aeruginosa isolates from a defined cohort of patients this thesis 
aims to determine the prevalence and diversity of strains among adults with CF, and using 
phenotypic and genomic methods, to explore the key differences pertaining to adaptation 
between shared and unique strains of P. aeruginosa strains sourced from a range of ecological 
settings.  
 
Methods 
Longitudinal analysis of respiratory pathogens from adults with CF was undertaken to 
determine the prevalence of P. aeruginosa and other major CF pathogens. Univariate analysis 
was conducted to determine change in prevalence over time. 
 
P. aeruginosa isolates at two time points from adults with CF underwent single nucleotide 
polymorphism (SNP) based genotyping to assess the incidence and prevalence of shared 
strains. Statistical analyses was undertaken to find associations between acquisition of shared 
strains and health outcomes. 
 
Bacterial motility and adhesion was determined for clinical (CF, non-CF and animal) and 
environmental P. aeruginosa isolates. Each assay was performed under varied atmospheric 
conditions. Regression analysis was performed to assess an association between genotype and 
phenotype. 
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CF and environmental P. aeruginosa isolates were grown a dynamic flow cell system to allow 
for the development and visualisation of biofilm structures. Following incubation and staining, 
three dimensional images were captured and resulting data analysed using Comstat software. 
Mixed effects models were used to compare relevant biofilm parameters. 
 
Bioinformatic analysis was performed on CF and environmental P. aeruginosa isolates. 
Genetic variants associated with phenotypic characteristics were identified. 
 
Results 
The prevalence of significant airway pathogens declined over the study period. For paediatric 
patients at the time of transition, this decline was correlated with an improvement in lung 
function. Interestingly, the prevalence of chronic P. aeruginosa infection remained stable. 
 
While the proportion of patients harbouring the shared strain AUST-02 declined over time, 
there was a marked increase in those infected with the AUST-06 strain. In contrast, the 
prevalence of AUST-01 and other non-shared strains remained stable. Patients who acquired 
AUST-06 reported the largest decline in lung function over time and patients harbouring 
AUST-02 showed an increased risk of death or lung transplantation.  
 
Environmental, animal and non-CF isolates displayed enhanced motility and adherence to a 
plastic surface in the microtitre assay; while those collected from CF patients, particularly 
shared strains displayed a reduction in these phenotypic characteristics. Incubation under 
anaerobic conditions further reduced phenotypes for all isolates. 
 
Unlike results from the microtitre assay, all isolates assessed using the flow cell system 
demonstrated adherence to the glass substrate and the ability to form biofilms. Morphologically 
all isolates were similar, although CF isolates produced significantly thicker biofilms with a 
greater biomass when compared to the environmental isolates. 
 
Bioinformatic analysis identified a range of genetic variants associated with the assessed 
phenotypic characteristics. Non-synonymous mutations in genes associated with recognised 
virulence genes, in particular those which regulate motility and biofilm formation, were 
identified in most strains. 
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Conclusions 
This thesis demonstrated that P. aeruginosa is still the most common pathogen isolated from 
adults with CF; although the prevalence of this organism has declined in recent years. 
Furthermore, despite few changes in patient management there has been an overall shift in the 
epidemiology of shared strain infections within this patient cohort.  
 
P. aeruginosa has developed a range of mechanisms in order to avoid attack by the host 
immune system and killing via antimicrobial substances. One of these mechanisms is growth 
within a protective biofilm structure. Although motility and adhesion, two traits required for 
biofilm development, were reduced amongst the CF isolates, they were still capable of forming 
a biofilm. Discordance of the bacterial adherence and flow cell assays provide evidence that 
the static microtitre assay may not be suitable for assessing biofilm forming capacity of P. 
aeruginosa isolates derived from the CF airway.  
 
Finally, a bacterial GWAS approach identified genetic variants suitable for use as targets in 
future studies aimed at determining the genetic mechanisms of these phenotypic characteristics. 
 
Overall, the results of this thesis demonstrate that adaptation and virulence of P. aeruginosa to 
the airways is multifactorial, complex and influences from the environment, host and the 
bacterium itself all affect its ability to infect and persist.  
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Chapter 1: Review of Literature 
 
1.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa can be found throughout natural and man-made environmental settings and 
is considered to be a medically important bacterium. Many of the traits which make  
P. aeruginosa so successful in adapting to new environmental challenges also make it capable of 
causing chronic infection in vulnerable people. 
 
The earliest report describing the genus Pseudomonas came in the late 19th century from the German 
botanist Walther Migula. He visualised motile cells with spores resembling the nanoflagellate Monas 
spp.. Hence the name, Pseudomonas, was generated from the identification of this false or ‘pseudo’ 
Monas spp. nanoflagellate (Palleroni 2010). 
 
The genus Pseudomonas belongs to the phylum Proteobacteria, and the family Pseudomonadaceae. 
The most clinically significant species of this genus is P. aeruginosa. This bacterium is a motile, non-
spore forming; gram-negative bacillus (GNB) ranging in size from 0.5 to 3.0 m. Colonial 
morphology can vary widely, from the more common non-mucoid, flat spreading colonies with rough 
edges, to small colony and mucoid forms. P. aeruginosa is capable of surviving in a range of 
environmental conditions including increased temperature and reduced oxygen (Gilligan et al. 2006; 
Kidd et al. 2011). The inability to ferment glucose places this bacterium into a broader group referred 
to as non-fermenting GNBs. Other bacteria in this group include Achromobacter species, 
Stenotrophomonas maltophilia and Burkholderia cepacia complex (Brenner et al. 2005). 
 
P. aeruginosa requires iron for growth and metabolic functions such as respiration and synthesis of 
deoxyribonucleic acid (DNA) (Saha et al. 2013). In a low iron environment, P. aeruginosa is able to 
sequester free iron using iron chelating compounds called siderophores. The water soluble 
siderophores produced by P. aeruginosa are pyoverdine and pyochelin (Saha et al. 2013). Under 
ultraviolet (UV) light, the expression of pyoverdine is indicated by a yellow-green fluorescence. 
Additional pigments produced by P. aeruginosa are pyocyanin, pyomelanin and pyorubin, which 
result in the blue, brown and red hues seen in bacterial colonies (Kodaka et al. 2003; Ogunnariwo 
and Hamilton-Miller 1975). 
 
1.1.1 Environmental influences effecting the acquisition of Pseudomonas aeruginosa 
Given the minimum nutritional requirements needed to support growth, and its capacity to survive 
under a range of environmental and physical conditions, P. aeruginosa is widely distributed 
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throughout the environment. Recent studies indicate that in household settings, P. aeruginosa is most 
commonly found in moist areas, particularly drains (Purdy-Gibson et al. 2015; Remold et al. 2011), 
but also other water-rich locations including swimming pools, as well as non-household environments 
such as river water, and it can also be isolated from vegetables and antiseptic solutions (Kidd et al. 
2012; Mena and Gerba 2009; Ogbulie et al. 2008; Pirnay et al. 2005; Remold et al. 2011; Zubko and 
Zubko 2013). P. aeruginosa has also been isolated from soil where it behaves as a saprophyte. 
Furthermore, many species of Pseudomonas, including P. aeruginosa play a role in bioremediation 
and pollution control (Silby et al. 2011). 
 
1.1.2 Clinical significance of Pseudomonas aeruginosa 
Owing to its large genome encompassing many regulatory genes, P. aeruginosa is able to readily 
adapt to new and changing environments (Silby et al. 2011). It also possesses a number of 
mechanisms which contribute to enhanced virulence and antimicrobial resistance. P. aeruginosa has 
high levels of intrinsic resistance and the capacity to acquire resistance to most antibiotic classes 
(Llanes et al. 2013). P. aeruginosa can also develop and grow within a sessile community structure 
which affords protection from antibiotics, host defence mechanisms, desiccation, UV light and 
disinfectants (Hogardt and Heesemann 2013). 
 
As a result of these enhanced tolerability and virulence traits P. aeruginosa is described as an 
opportunistic pathogen capable of causing acute and chronic infection in humans and animals (Kidd 
et al. 2012; Silby et al. 2011). Exogenous acquisition, primarily from exposure to environmental 
sources, is considered the most common route of infection. Community acquired infection include 
keratitis, skin infection, and otitis media and externa. Nosocomial sources are also important 
contributors to infection (Driscoll et al. 2007). 
 
1.1.2.1 Pseudomonas aeruginosa infection in animals 
In animals, P. aeruginosa has been reported as the most commonly isolated non-lactose fermenting 
GNB in samples cultured from a range of wild and domestic species (Kidd et al. 2012; Mathewson 
and Simpson 1982). It has been identified as the aetiological agent in a variety of infections (Allen et 
al. 2011; Diamond et al. 1979; Doerning et al. 1993; Freeman et al. 2009; Hariharan et al. 2006; Kidd 
et al. 2011; Lin and Petersen-Jones 2008; Lin and Petersen-Jones 2007; Momotani et al. 1995; 
Petersen et al. 2002; Salomonsen et al. 2013; Tiago et al. 2012; Wada et al. 2010; Westgate et al. 
2011). 
 
 
3 
 
1.1.2.2 Pseudomonas aeruginosa infection in humans 
P. aeruginosa is an opportunistic pathogen capable of causing acute or chronic infection and is rarely 
found colonising healthy persons. Indeed, large studies examining the microbiota of the skin, 
gastrointestinal and respiratory tracts of healthy individuals have shown that species from the phyla 
Firmicutes, Actinobacteria, non-Pseudomonas Proteobacteria and Bacteroidetes predominate, 
whereas Pseudomonas in particular is associated with relatively low bacterial biomass of potentially 
intermittent and environmental origin (Human Microbiome Project Consortium 2012; Koboziev et 
al. 2014; Sanford and Gallo 2013). This was highlighted in a recent study of healthy subjects by 
Charlson and colleagues suggesting that the presence of Pseudomonaceae in control samples was 
indicative of environmental contamination (Charlson et al. 2011). 
 
In humans, P. aeruginosa can cause nosocomial or community acquired infection similar to those 
observed in animals (Ott et al. 2013). It has been isolated from contact lens fluid causing keratitis and 
corneal ulcers, otitis media and externa, wound and skin infection, urinary tract infection, pneumonia 
and septicaemia (Bodey et al. 1983; Chalmers et al. 2014; Deb and Ray 2012; Hattemer et al. 2013; 
Hoddenbach et al. 2014; James et al. 2008; Kiem and Schentag 2013; Obritsch et al. 2004; Schaefer 
and Baugh 2012; Scheetz et al. 2009; Yildiz et al. 2012; Zilberberg and Shorr 2013). In the healthy 
host, respiratory infections are rapidly cleared by both the innate and acquired immune systems. 
Functioning mucociliary clearance and a range of immunological factors prevents the infection 
persisting. However, P. aeruginosa can cause chronic infections in people with diabetes, severe burns 
and the genetic disorder, cystic fibrosis (CF) (Buivydas et al. 2013; Fekih Hassen et al. 2014; Gibson 
et al. 2003; Shanmugam et al. 2013). 
 
1.1.2.2.1 Pseudomonas aeruginosa infection in people with cystic fibrosis  
In people with CF, P. aeruginosa is the most common bacterial species isolated from respiratory 
secretions. Acquisition of this bacterium is associated with accelerated pulmonary decline, reduced 
quality of life and decreased life expectancy (Emerson et al. 2002; Konstan et al. 2007; Sanders et al. 
2014). While the precise mechanisms of P. aeruginosa acquisition in people with CF are poorly 
understood, a growing body of evidence suggests that the local environment, geographic location and 
the climate in which people are residing may play a role. Seasonal effects, ambient temperature and 
the proximity to water, all impact on exposure to P. aeruginosa and subsequent infection in people 
with CF (Ramsay et al. 2016). Acquisition of P. aeruginosa occurs during childhood, although the 
highest prevalence is reported in adults where more than 60% of patients are infected (Cystic Fibrosis 
Australia 2016; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 2016). 
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As a result of the impaired function of the CF transmembrane conductance regulator (CFTR), the 
lungs of people with CF provide a heterogeneous environment. Within the airways there are varied 
oxygen gradients, a range of different microorganisms, thick sticky mucus and circulating and local 
antimicrobial substances. To survive and persist within this challenging environment, P. aeruginosa 
must adapt through a number of evolutionary processes (Winstanley et al. 2016). 
 
From initial infecting isolates which possesses a range of virulence factors, P. aeruginosa may 
undergo a number of genetic mutations and biological changes which result in the downregulation of 
many virulence mechanisms (Winstanley et al. 2016). Once P. aeruginosa infection is established in 
the CF airways, eradication is difficult to achieve and often leads to chronic infection. 
 
1.2 Cystic Fibrosis 
1.2.1 Disease mechanisms in cystic fibrosis 
CF is the most common life-threatening autosomal recessive genetic disease in Caucasians and is 
characterised by mutations in the CFTR gene. The first CFTR mutation was discovered in 1989, and 
since then more than 2000 mutations have been described (Cystic Fibrosis Mutation Database ; 
Kerem et al. 1989; Riordan et al. 1989). The CFTR gene encodes a chloride channel on the surface 
of epithelial cells where it is expressed. Based on the analysis of more than 160 disease-causing 
mutations, the genetic abnormalities can be divided into six classes (Boyle and De Boeck 2013). 
Severe sweat chloride and pancreatic phenotypes are seen in patients with two Class 1 to 3 mutations, 
and milder phenotypes are seen in patients with at least one Class 4 to 6 mutations (Bell et al. 2015). 
 
The most common CFTR mutation (referred to as p.F508del) is a deletion of the phenylalanine at 
position 508 of the CFTR protein. In Australia, 51.3% of patients with CF are homozygous for 
p.F508del, and a further 41.8% are heterozygous for this mutation (Cystic Fibrosis Australia 2016). 
In Australia, CF is observed in approximately 1 in ~3000 live births, with 1 in 25 of the population 
carriers of a CFTR mutation (Bell et al. 2011; Massie and Delatycki 2010; Massie et al. 2005). 
 
CF is a multi-system disease and the major organs which are affected include the lungs and upper 
respiratory tract, the gastrointestinal tract (including the hepatobiliary system) and the reproductive 
tract in males. The most severe and life limiting complication is chronic bronchial sepsis with 
associated inflammation, resulting in the structural airway changes of bronchiectasis (O'Sullivan and 
Freedman 2009; Ratjen et al. 2015). 
In healthy persons, the CFTR protein is responsible for maintaining the airway surface liquid (ASL) 
layer by controlling the movement of chloride, sodium and water within cells, thus ensuring the 
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functioning of cilia, which enables mucociliary clearance and protects the airways. When a mutation 
occurs to impair the functioning of the CFTR, the ASL is compromised, with altered composition and 
volume. Reduced mucociliary clearance, decreased ion and water transfer, and increased sodium 
absorption result in viscous mucus being trapped within the airways. This triggers a cycle of bacterial 
infection and inflammation, leading to cellular damage, bronchiectasis, respiratory failure and 
premature death (O'Sullivan and Freedman 2009; Ratjen et al. 2015). 
 
Changes in the dynamics of bacterial colonisation of the respiratory tract are seen during a patient’s 
lifetime. In childhood, the most commonly isolated bacteria are Staphylococcus aureus and 
Haemophilus influenzae, but by adolescence and early adulthood these bacteria have often been 
replaced by a dominant growth of P. aeruginosa (Chmiel et al. 2014; Cystic Fibrosis Australia 2015; 
Gibson et al. 2003; Lipuma 2010). Eradication regimes implemented by paediatric CF centres aim to 
eradicate initial P. aeruginosa infection, thereby limiting the early onset of chronic infection (Doring 
et al. 2012; Langton Hewer and Smyth 2014; Mayer-Hamblett et al. 2015; Ratjen et al. 2010; 
Treggiari et al. 2007; Wainwright et al. 2011). Through the reduction of chronic infection and 
successful infection control policies, the prevalence of P. aeruginosa has been decreasing over recent 
years. This is particularly evident in the adult population (Bell et al. 2011; Cystic Fibrosis Australia 
2015; Cystic Fibrosis Canada 2015; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 2016). 
Due to treatment developments and centre-based care from a multi-disciplinary medical team, the 
health and median survival for patients with CF has dramatically improved over the last two decades. 
As a result, there are now a greater proportion of older patients with CF who have better lung function 
and nutrition compared to patients from previous generations, although respiratory failure still 
remains the leading cause of morbidity and mortality (Buzzetti et al. 2009; Reid et al. 2011). 
 
1.2.2 Microbiology of the cystic fibrosis airways 
1.2.2.1 Microbial prevalence 
Infection of the CF airway is classically associated with an ensemble of microbial species including 
Staphylococcus aureus, P. aeruginosa, Haemophilus influenzae, Stenotrophomonas maltophilia, 
Achromobacter spp., Burkholderia cepacia complex, and Aspergillus spp. (Lipuma 2010). Lung 
microbiota composition evolves with age (Figure 1.1). Initial colonisers of the airways, often 
associated with early childhood, include methicillin sensitive S. aureus and H. influenzae. Intermittent 
infection caused by susceptible strains of P. aeruginosa can also be isolated during early life and 
these strains can be successfully eradicated via antibiotic therapy. Over time and often correlated with 
increasing age and prolonged antibiotic exposure, chronic infection with resistant  
P. aeruginosa strains becomes the classic scenario (Proesmans et al. 2006; Ratjen et al. 2007). 
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In Australian patients, the prevalence of other highly antibiotic resistant bacteria, such as methicillin 
resistant S. aureus increases with patients’ age, although rates are low when compared to international 
CF data registries. It is surmised that acquisition occurs due to frequent exposure to the general 
hospital population, explaining why rates of infection are greater in adult patients (Chmiel et al. 2014; 
Cystic Fibrosis Australia 2016; Cystic Fibrosis Foundation 2015; Gibson et al. 2003; Lipuma 2010; 
Surette 2014). Infection with other less common pathogens including a range of non-fermenting gram 
negative bacilli (e.g. S. maltophilia, Achromobacter spp., B. cepacia complex, Inquilinus limosus, 
Pandoraea spp. and Ralstonia spp.), fungal and non-tuberculous mycobacteria (NTM) species have 
also emerged in the CF population in recent years (Bar-On et al. 2015; Parkins and Floto 2015; Qvist 
et al. 2015; Ramsay et al. 2016; Surette 2014). 
 
 
Figure 1.1 The change in prevalence of the major airway pathogens isolated from people with cystic 
fibrosis over a lifetime.  
Permission obtained (Cystic Fibrosis Australia 2016) 
 
 
 
1.2.2.2 Microbiome of the cystic fibrosis airway 
The microbiome of the CF airways is complex and dynamic and can be influenced through numerous 
host, environmental and treatment factors. It has been succinctly described as “diverse, frequently 
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polymicrobial and constantly evolving” (Zemanick and Hoffman 2016). However, until recently the 
traditional view of respiratory infection focused on the dominant bacterial pathogens which could be 
readily identified using culture-dependent techniques (Burns and Rolain 2014). Rapid advances in 
the field of next-generation metagenomic sequencing has demonstrated that conventional culture-
dependent identification has vastly underestimated the diversity and abundance of the flora present 
in the airways of people with CF (Caverly et al. 2015). For example, anaerobic bacteria previously 
thought not to be present in the CF airways are now frequently encountered using culture-independent 
microbiome techniques (Sherrard et al. 2016). 
 
Increased life expectancy due to improvements in clinical interventions has been the success story of 
CF multi-disciplinary medical care in recent years, but this benefit has coupled with a number of 
detrimental health impacts. With increased patient longevity have come more intensive antibiotic 
treatments, increased exposure to bacteria and a longer life with very advanced lung disease. The 
cumulative effect of antibiotics, lung damage and bacterial exposure has seen the emergence of 
bacterial species not previously isolated, many of which are highly antibiotic resistant. In addition, 
numerous more genera have now been identified via the development of culture-independent 
techniques, but their relevance remains uncertain (Zemanick and Hoffman 2016). 
 
Microbiome studies conducted to date have shown four key findings in regards to the airway 
microbiota in people with CF. Firstly, higher degrees of bacterial community diversity and species 
richness have been observed in young patients, those with mild CF lung disease phenotypes and those 
who have received fewer antibiotic treatments (Coburn et al. 2015; Cox et al. 2010; Cystic Fibrosis 
Mutation Database ; Zhao et al. 2012). The most abundant species identified in these patients include 
those considered to be ‘normal oropharyngeal flora’, anaerobes and pathogens traditionally associated 
with early CF lung disease, such as Haemophilus and Staphylococcus (Cox et al. 2010; Rogers et al. 
2015; Surette 2014). Secondly, as patients age there appears to be an overall loss of bacterial diversity 
(fewer species) although the overall number of bacteria increases (abundance) (Coburn et al. 2015; 
Cox et al. 2010; Stokell et al. 2015; Zhao et al. 2012). Thirdly, decreased diversity is associated with 
the emergence of dominant genera that most frequently occur in patients with severe pulmonary 
disease (i.e. reduced lung function). Dominant genera frequently include Pseudomonas and 
Burkholderia (Coburn et al. 2015; Cox et al. 2010; Zemanick and Hoffman 2016; Zhao et al. 2012). 
Finally, despite clinical interventions and antibiotic treatment there is little overall variation in the 
microbiome of individual patients. Furthermore the clinical status, either stable or during pulmonary 
exacerbation, of the patients does not affect the stability of the dominant pathogens present (Carmody 
et al. 2013; Fodor et al. 2012; Stressmann et al. 2012). 
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Other investigations have demonstrated that changes in the microbiome distribution can occur during 
childhood, implying that disease progression may take place earlier than previously thought (Boutin 
et al. 2015). Furthermore, a correlation between CFTR severity, loss of airway diversity and 
increasing prevalence of the genus, Pseudomonadaceae has been also shown (Cox et al. 2010). 
 
1.2.2.3 Upper airway involvement in infection 
It has been postulated that the upper airways, particularly the paranasal sinus region, acts as a reservoir 
for P. aeruginosa. Similar to the changes which occur in the lower airways as a result of impairment 
to the CFTR functioning, the upper airways of people with CF are similarly affected. Symptoms noted 
in the sinuses include inflammation, thickening of the airway mucus and reduced mucociliary 
clearance (Chang 2014). 
 
As a result of these physiological changes, the sinus area is capable of harbouring bacteria that may 
migrate to the lungs, resulting in respiratory infections. The microbial diversity which is seen in the 
lungs also occurs in the upper airway of people with CF (Caverly et al. 2015; Digoy et al. 2012; 
Dosanjh et al. 2000; Mainz et al. 2009; Mak and Henig 2001; Muhlebach et al. 2006). Currently, the 
exact role and significance the upper airway plays in initial and recurrent infection of P. aeruginosa 
is unclear. It is also uncertain whether failure of eradication therapy is associated with ongoing 
colonisation of the sinuses. Interestingly, sinus surgery in conjunction with antibiotic therapy has 
been shown to reduce the prevalence of P. aeruginosa in the lower airway for some patients (Alanin 
et al. 2016). In a case study from Linnane and colleagues, in which they reviewed a single patient, it 
was demonstrated that sinus infection can persist over an extended period of time without resulting 
in lung function decline or evidence of lower respiratory tract infection (Linnane et al. 2015). Work 
from Denmark also shows that in both paediatric and adult cohorts, genotypically indistinguishable 
P. aeruginosa strains can be isolated simultaneously from the sinus and lungs of patients with 
intermittent and chronic infection (Hansen et al. 2011; Johansen et al. 2012). Similar findings were 
obtained from a large patient cohort assessing the prevalence and relatedness of P. aeruginosa (Mainz 
et al. 2009). Results from a paediatric cohort study using bronchoalveolar lavage (BAL) and 
oropharyngeal (OP) swab samples were less clear. While initial eradication therapy was successful 
in treating the lower respiratory tract infection, retention of the same strains within the oropharynx, 
following treatment, was frequently encountered. These results suggest that a reservoir, refractory to 
antibiotic treatment, exists within the upper airway, and that this has the potential to re-infect the 
lower airways (Kidd et al. 2015). These results demonstrate a new paradigm in the definition of 
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successfully treating P. aeruginosa infection and how eradication is defined clinically and 
microbiologically. 
 
1.2.3 Epidemiology of Pseudomonas aeruginosa in cystic fibrosis 
1.2.3.1 Infection status 
In general, the evolution of airway disease caused by P. aeruginosa colonisation and infection in 
individuals with CF follows a well recognised timeline. Initial colonisation often occurs during 
childhood and is commonly caused by the acquisition of environmental strains which are susceptible 
to antibiotics (Burns et al. 2001; Kidd et al. 2015; Ranganathan et al. 2013). Current standards of 
care recommend eradication therapy may be initiated at the time of first isolation to prevent an 
infection ensuing (Mogayzel et al. 2014). However, following a period of intermittently isolating P. 
aeruginosa from the airways, an intermittent infection, also caused by antibiotic susceptible strains, 
often develops (Mayer-Hamblett et al. 2015; Mogayzel et al. 2014; Ratjen et al. 2010; Wainwright 
et al. 2011). The goal of eradication therapy is to either prevent or delay the development of a 
persistent infection (Mogayzel et al. 2014). Despite the widespread use of antimicrobial therapy and 
successful initial eradication, ultimately many patients will go onto develop a chronic infection. 
Prolonged exposure to antibiotics and adaptation of the bacteria to the airways are two factors which 
influence the development of a chronic infection. 
 
Chronic infection is defined as a persistent growth which is not cleared despite antibiotic treatment. 
Currently there is limited consensus on how to define a chronic infection within a clinical setting 
(Pressler et al. 2011). For the purpose of this thesis, the following terms have been defined in 
accordance with the definitions proposed by Lee and colleagues (Lee JCF 2003). Based on quarterly 
sputum sample collection, chronic infection occurs when 50% or more of sputum samples are culture 
positive for P. aeruginosa within the previous 12 months and intermittent infection occurs when 50% 
or fewer sputum samples are culture positive for P. aeruginosa or when less than four samples are 
collected during the previous 12-month period. A range of clinical studies have demonstrated that 
following the development of a chronic infection, patients have poorer health outcomes. Compared 
to patients with no P. aeruginosa, initial colonisation or an intermittent infection, chronically infected 
patients are older, are more likely to have mucoid colony phenotypes, have higher specific P. 
aeruginosa serum antibody titres, have a greater requirement for antibiotics and lower lung function 
measurements and body mass index (BMI) (Ballmann et al. 1998; Lee et al. 2003; Pressler et al. 
2006; Pressler et al. 2009; Proesmans et al. 2006; Ratjen et al. 2007). Therefore, correctly 
categorising patients based on their infection status is clinically paramount for determining long-term 
health outcomes, treatment regimens and cohort segregation. The two measures routinely used to 
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determine chronicity are the isolation of the bacteria using traditional culture techniques and the 
identification of specific P. aeruginosa antibody levels within serum samples. 
 
Studies which define chronicity based on P. aeruginosa culture vary according to: i) the minimum 
number of positive sputum or upper airway samples required to be collected within a given timeframe, 
ii) whether consecutive positive culture results are required, and iii) the overall time in which the 
sampling is to occur (Ballmann et al. 1998; Demko et al. 1995; Hoiby 1974; Lee et al. 2003). For 
those studies which describe chronicity using serum antibodies alone or in conjunction with airway 
samples, a number of different P. aeruginosa specific antibodies have been suggested, but again the 
actual definition varies. Some studies have used a defined range to differentiate chronic from no 
Pseudomonas and intermediate infections, whereas other determine that a ‘rise’ in antibody 
precipitins from normal is indicative of a positive result (Hoiby et al. 1977; Pressler et al. 2006; 
Pressler et al. 2009; Proesmans et al. 2006; Ratjen et al. 2007). 
 
Both these existing methods used to describe a clinical infection of P. aeruginosa have limitations. 
Firstly, for patients who are non-productive, such as young children and those with mild lung disease, 
relying on culture results alone may underestimate the rates of infection and miss initial colonisation 
events. Furthermore, it is widely recognised that the airways and lungs of people with CF are 
regionally heterogeneous and samples such as sputum may underestimate infection status. While the 
use of serological testing may confirm the presence of P. aeruginosa prior to culture results, 
especially for those non-productive patients, it is difficult to confirm an active chronic infection from 
a colonisation event. The misdiagnosis of patients as either colonised or infected will impact on 
whether eradication or maintenance therapy is administered. Finally, these current studies categorise 
patients at a predetermined time point, with no assessment of previous infection status recorded. 
Again, due to sampling bias and the limitations with airway sample collection, this approach may 
also underestimate infection rates. Therefore, a comprehensive definition of chronic infection needs 
may need to include longitudinally collected historical culture results, current culture results, current 
P. aeruginosa specific antibody levels and antibiotic treatment regimens. However, due to the 
discordant definitions currently existing in the literature, this is difficult to achieve. 
 
While it is generally recognised that eradication of persistent infection through intensive antibiotic 
therapy is not possible, suppressive antibiotic treatment has proven very helpful in maintaining lung 
function and the health of patients over the long term. 
 
1.2.3.2 Acquisition and colonisation of Pseudomonas aeruginosa  
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As P. aeruginosa is widely distributed within the environment, it was initially believed that the 
primary source of acquisition for most patients with CF was the environment (Burns et al. 2001). 
Recent data generated using modern genotyping techniques provides additional support for this 
hypothesis with two independent infant cohort studies showing a predominance of commonly 
encountered environmental genotypes during early P. aeruginosa infection (Kidd et al. 2015; 
Ranganathan et al. 2013). Likewise, most of the earlier epidemiological studies demonstrate that 
person-to-person transmission rarely occurred, with most patients harbouring their own unique strains 
(Grothues et al. 1988; Romling et al. 1994). Nevertheless, sharing of indistinguishable strains was 
also described between siblings and in instances of intimate or close hospital contact, presumably 
through common source exposure or potentially through person-to-person spread (Govan 2000; 
Grothues et al. 1988; Schmid et al. 2008; Silbert et al. 2001; Spencker et al. 2000; Tümmler et al. 
1991). With advances in molecular genotyping techniques, it has now been shown that unrelated 
patients can often harbour genotypically indistinguishable (or shared) strains (Aaron et al. 2010; 
Armstrong et al. 2003; Cheng et al. 1996; Kidd et al. 2013; Scott and Pitt 2004). 
 
A variety of different shared strains have now been isolated from patients throughout Europe, North 
America and Australia, some of which are associated with increased hospitalisation and worse clinical 
outcomes (Fothergill et al. 2012; Kidd et al. 2013). Despite extensive sampling of home and natural 
environmental settings, no environmental reservoirs have been found for these shares strains of P. 
aeruginosa (Jones et al. 2003; Kidd et al. 2013). Alternative routes of transmission have been 
explored, with airborne transmission of cough aerosols recently suggested as playing a potential role 
in cross-infection (Knibbs et al. 2014; Wainwright et al. 2009). 
 
Infection control guidelines and segregation policies have now been implemented worldwide to limit 
the potential for cross infection (Conway et al. 2014; Saiman et al. 2014). Australian CF centres 
segregate patients on the basis of P. aeruginosa infection status during outpatient clinic visits and 
hospital admission (Cheng et al. 1996; Edenborough et al. 2004; Kidd et al. 2015; Pedersen et al. 
1986). In some centres patients are also placed into cohorts according to their  
P. aeruginosa genotype (Ashish et al. 2013; Griffiths et al. 2005; Kidd et al. 2015). Government 
Health Departments now recognise the importance in CF of single rooms and providing private 
facilities while patients are hospitalised. In addition, other initiatives have been implemented to 
reduce the spread of P. aeruginosa. For example, the North American CF Foundation (CFF) has 
changed their Infection Control Guidelines to prevent more than one patient with CF attending an 
organised CFF event (Jain and Kazmierczak 2014; Shepherd et al. 2014). 
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1.2.4 Identification and Genotyping of Pseudomonas aeruginosa 
1.2.4.1 Respiratory sampling 
OP swabs, sputum and BAL samples are the most commonly collected respiratory samples assessed 
for microbiological composition and antimicrobial susceptibility from individuals with CF. 
 
In young children incapable of expectorating sputum, OP swabs are collected as a surrogate for lower 
airway samples. A number of studies have demonstrated that, whilst not truly representation of the 
lower airway microbiology, this sample collection type is sufficient for routine surveillance 
(Armstrong et al. 1996; Kidd et al. 2015; Rosenfeld et al. 1999; Wainwright et al. 2011). Compared 
with BAL, OP swabs are non-invasive and simple to collect and culture. The CFF Pulmonary Clinical 
Practice Guidelines Committee has recommended that OP swabs be used to determine  
P. aeruginosa infection rather than BAL samples in non-productive patients (Mogayzel et al. 2014). 
 
Sputum samples are the most common samples collected to assess the composition of airway 
microorganisms from people with CF. The majority of adults with CF are productive and are able to 
easily produce sputum for testing. While the collection of sputum samples is non-invasive and well 
tolerated by most patients, there are limitations to this type of sampling. The lungs are a heterogeneous 
environment and sputum samples may not provide a representative sample of the whole airway. 
Furthermore, sputum samples are better suited to assess the presence or absence of microorganisms 
rather than the specific quantification of them. As such, there are inherent limitations in using sputum 
to determine colony forming units, specifically owing to the difficulties encountered when trying to 
prepare serial dilutions of purulent and mucoid samples. 
 
Samples obtained through BAL procedures are specific to the area of the lung from which they are 
collected. Additionally, as a result of the collection process, these samples are less viscous and have 
a lower mucus content, compared to sputum samples, therefore making them well suited to quantify 
the microorganisms present. However, BAL samples are costly to obtain and are invasive, requiring 
the patient to undergo general anaesthesia. Whilst BAL samples are not routinely collected, especially 
from adult patients, they are most commonly collected from children unable to provide a sputum 
sample (Burns and Rolain 2014). 
1.2.4.2 Laboratory identification of Pseudomonas aeruginosa 
Traditional culture and microscopy methods are most commonly used to isolate and identify  
P. aeruginosa from a range of sample types. P. aeruginosa grows readily on a range of non-selective 
agar including nutrient agar and broth, blood agar and MacConkey agar. Typically, the bacteria are 
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incubated in aerobic conditions at 37 °C, although P. aeruginosa is capable of growth at temperatures 
ranging from 4 °C to 45 °C (Burns and Rolain 2014; Gilligan et al. 2006). 
 
Routine identification of P. aeruginosa usually follows a simple algorithm, including identification 
of small, slightly curved gram negative rods, typical colonial morphology, oxidase positive, growth 
at 42 °C and susceptibility to colistin sulfate (Kidd et al. 2011). Furthermore various pigments 
produced by the bacterium can also assist in visual identification. 
 
Diagnostic laboratories utilise a range of commercial identification systems to confirm identification, 
these include API 20NE (bioMérieux) and VITEK®2 (bioMérieux). In recent years the addition of 
an automated microbiological identification system, using MALDI-TOF (Matrix Assisted Laser 
Desorption Ionization Time-of-Flight) technology into diagnostic laboratories has allowed for rapid, 
cheap and accurate identification of bacterial pathogens (Burns and Rolain 2014). Most studies agree 
that this identification platform produces reliable results for the majority of bacterial samples 
undergoing testing, although a few reports have demonstrated limitations in the database which can 
result in either misidentification or non-identification (AbdulWahab et al. 2015; Alby et al. 2013; 
Homem de Mello de Souza et al. 2014). 
 
Isolates from patients with CF may pose some difficulties in identification due to: i) the changes in 
metabolic and phenotypic characteristics during adaptation within the lung; ii) the polymicrobial 
nature of the clinical specimens; and iii) the isolation of non-fermenting GNBs (NF-GNB) with 
similar phenotypic profiles (e.g. Burkholderia sp, Achromobacter spp., S. maltophilia and Inquilinus 
limosus) that can be incorrectly identified as P. aeruginosa (Burns and Rolain 2014; Cystic Fibrosis 
Australia 2015; Kidd et al. 2009; Speert et al. 1990). 
 
With the development of respiratory microbiome analyses we now know that the diversity of 
microorganisms we have traditionally isolated using the aforementioned routine culture techniques 
describes only a small component of the bacterial and fungal population found in the CF airways 
(Caverly et al. 2015; Zemanick and Hoffman 2016). As microbiome analyses are costly, time 
consuming and require particular expertise to analyse they are currently not feasible for routine 
assessment on a regular basis. Therefore for the foreseeable future, traditional culture-based 
techniques will continue to provide physicians with diagnostic information on which to base their 
clinical decisions. 
 
1.2.4.3 Molecular identification of Pseudomonas aeruginosa 
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To overcome difficulties encountered when phenotypically and biochemically identifying  
P. aeruginosa, molecular-based identification methods have been developed, including a range of 
polymerase chain reaction (PCR) assays targeting P. aeruginosa-specific genes (Anuj et al. 2009; da 
Silva Filho et al. 1999; De Vos et al. 1997; Jaffe et al. 2001; Khan and Cerniglia 1994; Lavenir et al. 
2007; Qin et al. 2003). Increased sensitivity and specificity of P. aeruginosa PCR identification is 
also best achieved by using an assay with two different targets simultaneously (Anuj et al. 2009; Qin 
et al. 2003). 
 
1.2.4.4 Genotyping of Pseudomonas aeruginosa 
In light of the potential for cross-infection and poorer health outcomes associated with acquisition of 
shared P. aeruginosa, strains accurate diagnosis of these strains is vital. Techniques employed to 
determine strain relatedness must have high discriminatory power and typeability, be reproducible 
between laboratories, and be both time and cost effective. Various techniques have been developed 
focusing on different molecular methodologies. Two examples of fingerprint-based methods used to 
determine relatedness are pulsed-field gel electrophoresis (PFGE) which exploits low frequency 
restriction endonuclease recognition sites and the PCR-based method enterobacterial repetitive 
intergenic consensus (ERIC)-PCR which focuses on repetitive sequences throughout the genome 
(Renders et al. 1996; Syrmis et al. 2004; Tenover et al. 1995). 
 
To overcome limitations associated with the processing, analysis and interpretation of fingerprint 
based methods, categorical-based genotyping techniques have also been developed in recent years. 
The ArrayTube assay is a rapid and reproducible method used to type both the core and accessory 
genome of P. aeruginosa. DNA obtained from extension PCR using P. aeruginosa specific 
oligonucleotides is hybridised onto a commercially developed chip and, following conjugation, a 
binary code is obtained which is used to categorically genotype the bacteria (Wiehlmann et al. 2007). 
 
Multilocus sequence typing (MLST) characterises strains (or sequence types [STs]) on the basis of 
allelic changes among seven conserved housekeeping genes (Curran et al. 2004; Jolley and Maiden 
2010; Pseudomonas aeruginosa PubMLST Database 2012). Highly informative MLST-based single 
nucleotide polymorphisms (SNP) have also been utilised in real-time PCR and Sequenom iPLEX-
based strain typing assays, which allow for rapid, accurate and cheap testing to determine genetic 
relatedness (Anuj et al. 2011; Syrmis et al. 2013). A protocol based on twenty informative SNPs has 
been developed which will differentiate most clinically important STs individually or group them 
into closely related sub-groups (Syrmis et al. 2014). This methodology is specifically relevant for 
Australian patients with CF as it categorically differentiates the two major clonal strains, AUST-01, 
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AUST-02, from other strains. One limitation of MLST, and therefore SNP typing is that these 
methods only assess the diversity within the core genome. 
 
1.2.5 Shared strains of Pseudomonas aeruginosa  
Sharing of P. aeruginosa strains was first described when ceftazidime-resistant P. aeruginosa isolates 
from patients with CF attending a clinic in Liverpool, United Kingdom were observed. Molecular 
surveillance confirmed that the isolates were indistinguishable and this strain became known as the 
Liverpool Epidemic Strain (LES). Follow-up environmental studies failed to identify common 
sources for this genotype within the hospital setting (Al-Aloul et al. 2004; Cheng et al. 1996). The 
LES strain has subsequently been detected elsewhere in the United Kingdom (UK) and on other 
continents, including a substantial number of patients from Ontario, Canada (Aaron et al. 2010; Kidd 
et al. 2013; Scott and Pitt 2004). Since then, numerous studies have shown that patients can share the 
same strain of P. aeruginosa. 
 
Different shared strains have been isolated in Australia, Germany, England, Wales, Canada, The 
Netherlands and Belgium (Aaron et al. 2010; Armstrong et al. 2002; Ballmann et al. 1998; Cheng et 
al. 1996; de Vrankrijker et al. 2011; Dinesh et al. 2003; Jones et al. 2001; Kidd et al. 2013; O'Carroll 
et al. 2004; Romling et al. 1994; Scott and Pitt 2004; Speert et al. 2002; Van Daele et al. 2005; van 
Mansfeld et al. 2009). Some shared strains have been associated with poorer clinical outcomes, 
increased treatment requirements and premature death (Aaron et al. 2010; Al-Aloul et al. 2004; 
Armstrong et al. 2003; Armstrong et al. 2002; Bradbury et al. 2008; Cheng et al. 1996; Kidd et al. 
2013; O'Carroll et al. 2004). For many shared strains, an environmental reservoir has yet to be found, 
despite extensive sampling of communal areas within the CF clinics and hospitals, patients’ homes 
and the local environment (Armstrong et al. 2003; Bradbury et al. 2009; Cheng et al. 1996; Jones et 
al. 2001; Kidd et al. 2012; McCallum et al. 2001). The absence of many of these strains in the 
environment is indicative of host specificity and indirectly supports widespread cross-infection and/or 
niche specialisation. Indeed, the LES and Manchester epidemic strain (MAN) have been isolated from 
areas adjacent to infected patients, but no persistent environmental reservoir has been found (Panagea 
et al. 2005). 
 
One possible route of acquisition is airborne transmission, with studies showing that when patients 
cough, they expel viable P. aeruginosa in aerosol droplets within the respirable size range (Knibbs et 
al. 2014; Wainwright et al. 2009). P. aeruginosa can be readily isolated 4 meters from a patient during 
a coughing episode and up to 45 minutes after the cessation of coughing (Knibbs et al. 2014). 
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In contrast, several other P. aeruginosa strains shared by patients with CF do frequently occur in 
other ecological settings. For example, the shared CF strain from Germany, Clone C, has been isolated 
from a diverse range of environmental sources in Germany and many other settings around the world 
(Kidd et al. 2012; Scott and Pitt 2004; Wiehlmann et al. 2007). Likewise, several other shared strains 
(e.g. ST-155, ST-179) occurring in relatively small clusters of CF patients are frequently encountered 
in other clinical presentations and natural environmental settings (Kidd et al. 2012; Pseudomonas 
aeruginosa PubMLST Database 2012). 
 
1.2.5.1 Australian shared strains of Pseudomonas aeruginosa 
In the early 2000s, the first account of an Australian shared CF P. aeruginosa strain was reported in 
a paediatric clinic in Melbourne (Armstrong et al. 2003; Armstrong et al. 2002; Griffiths et al. 2005). 
This arose serendipitously when genotyping of P. aeruginosa isolates from children participating in 
a prospective infant cohort identified the same strain among five children who had died unexpectedly 
(Nixon et al. 2001). Subsequent screening of all patients with P. aeruginosa in the CF centre revealed 
that 55% of children shared the same strain (Armstrong et al. 2002). A few years later the same strain, 
designated “Pulsotype 1” (also known as the “Australian Epidemic Strain-I” or the “Melbourne 
strain”) was described in unrelated patients in Sydney and Brisbane (Anthony et al. 2002; Armstrong 
et al. 2003; O'Carroll et al. 2004). In a 2004 prevalence study, O’Carroll and colleagues described a 
new shared strain (Pulsotype 2) in patients from Brisbane, and reported a prevalence of 59% within 
their cohort. When compared to patients with unique strains, those with Pulsotype 2 were younger 
and had poorer lung function (O'Carroll et al. 2004). 
 
In a national cross-sectional study published in 2013, Kidd and colleagues, showed that 62% of 
Australian CF patients with P. aeruginosa harboured a shared strain, with unique strains isolated from 
only 38% of patients. Pulsotypes 1 and 2, (renamed AUST-01 and AUST-02) were isolated in 22% 
and 18% of patients, respectively. AUST-01 and AUST-02 infections were associated with increased 
treatment requirements and outpatient clinic visits (Kidd et al. 2013). Another important observation 
was that AUST-01 commonly appeared in patients residing in south eastern Australia, whereas 
AUST-02 was found mainly in patients residing in Brisbane and Perth (Kidd et al. 2013). Given the 
large geographical distances between CF clinics and the substantial number of participants, this study 
also provides evidence that exposure to common environmental sources was not responsible for the 
acquisition of AUST-01 and AUST-02. Despite conducting a large epidemiological study, Kidd and 
colleagues did not identify AUST-01 or AUST-02 strains from any P. aeruginosa isolates collected 
from the natural environment, non-CF patient infections or animal samples (Kidd et al. 2012). While 
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this was not an extensive national study testing a wide variety ecological settings, these data suggest 
that these strains have evolved fairly recently and are now adapted to the CF airways. 
 
1.2.5.2 Unique strains of Pseudomonas aeruginosa 
Unique strains are distinct strains found in individual patients. Acquisition of unique strains of  
P. aeruginosa, commonly thought to be sourced from the environment, still occurs. In a recent study 
by Kidd and colleagues, unique strains were more commonly identified among children when 
compared to adults (Kidd et al. 2013). Furthermore, the majority of P. aeruginosa strains associated 
with infections in very young children with CF are also commonly encountered in the environment 
(Kidd et al. 2012). Such strains show genetic variability when analysed by PCR strain typing methods 
(Kidd et al. 2011), but often belong to five distinct sequence types (ST-155, ST-179,  
ST-253, ST-266, and ST-381) which are common across various ecological niches in south east 
Queensland (animal and non-CF acute infections, environmental sampling and CF sputum 
collection), as well as in other  national and international settings (Garcia-Castillo et al. 2011; Johnson 
et al. 2007; Khan et al. 2008; Kidd et al. 2015; Kidd et al. 2012; Maatallah et al. 2011; Nemec et al. 
2010; Pseudomonas aeruginosa PubMLST Database 2012; Ranganathan et al. 2013; van Mansfeld 
et al. 2009; Waine et al. 2009). 
 
1.2.6 Genome of Pseudomonas aeruginosa 
In 2000 Stover and colleagues published the whole genome sequence of P. aeruginosa strain type 
PAO1, and since then numerous strains have had their whole genomes sequenced (Pseudomonas 
Genome DB ; Stover et al. 2000; Winsor et al. 2016; Winsor et al. 2011). PAO1 was originally 
isolated from a wound infection in 1955 (Holloway 1955), and since then has been widely 
characterised. In many studies, PAO1 is used as a baseline or comparator strain to which the wild-
type isolates are compared (Carter et al. 2010; Jeukens et al. 2014; Kukavica-Ibrulj et al. 2008; O'May 
et al. 2006; Yang et al. 2011). 
 
P. aeruginosa has a very large and complex genome (6.3 Mbp; G+C content 66.6%) consisting of 
two components, the core and accessory genomes. The highly regulated and conserved core genome 
makes up approximately 90% of the whole genome found in all strains. The functionality of many 
genes located within the core genome has been described, and they include genes responsible for 
respiration, antibiotic resistance, and biofilm formation (Dettman et al. 2013). The remainder of the 
genome is made up of the smaller accessory genome and comprises a range of genetic material which 
varies between strains. The accessory genome is the major driver behind the evolution of this 
organism, in particular the gain or loss of genetic material through horizontal gene transfer. In 
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addition, deletions, mutations and rearrangements also occur within the accessory genes. It has been 
noted that the accessory genome encodes various genes that enable increased survival and niche 
adaptation within specific strains (Dettman et al. 2013; Kung et al. 2010; Stewart et al. 2014). 
 
1.2.7 Population structure of Pseudomonas aeruginosa 
P. aeruginosa has been described as having a non-clonal epidemic population structure characterised 
by numerous singleton strains and a small number of abundant genotypes, and large BURST groups 
(BGs) consisting of three or more STs (i.e. clonal complexes) (Kidd et al. 2012; Maatallah et al. 2011; 
Pirnay et al. 2009). The largest BG (termed BG01) comprises numerous strains collected from a range 
of ecological settings, including the shared CF strains AUST-02 and the LES. It is also widely 
recognised that the majority of P. aeruginosa strains are globally distributed and there appears to be 
little correlation between ecological setting and genotype. This implies that most strains, irrespective 
of geographical or ecological origin, are capable of establishing infection in the susceptible host. 
Indeed, commonly encountered strains (e.g. ST-155, ST-179, ST-253, ST-266 and ST-381) have been 
isolated from patients with CF and numerous other non-CF infections (Kidd et al. 2015; Kidd et al. 
2012; Ranganathan et al. 2013; Scott and Pitt 2004; van Mansfeld et al. 2009; Wiehlmann et al. 
2007). In contrast, some of the most frequently encountered shared CF strains (AUST-01, AUST-02, 
AUST-06 from Australia, LES from the UK and the Dutch strains ST-406 and 497) have rarely been 
isolated outside of the CF lung. These data provide evidence of host specificity and indirectly support 
the potential for widespread cross-infection and niche specialisation of these strains. 
 
1.3 Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway 
A range of mechanisms now referred to as pathoadaptive traits, have been identified to characterise 
the change which occurs when a bacterium causing an acute, virulent, early infection develops into 
one causing a persistent, chronic infection. This transformation is the result of a number of 
evolutionary changes which occur as P. aeruginosa adapts to the CF airway. These changes include 
a range of phenotypic adaptions, genomic mutations and metabolic variations. Loss of motility and 
type III secretion, enhancement of mucoidy, increased antibiotic resistance, development of small 
colony variants, changes to the lipopolysaccharide, O-antigen and pyocyanin expression, auxotropy, 
defects to bacterial communication and hypermutability are all traits which comprise the 
pathoadaptive process (Cullen and McClean 2015; Hauser et al. 2011; Hogardt and Heesemann 2010; 
Sousa and Pereira 2014). Many of these changes are interlinked, thus enhancing the bacterium’s 
capacity to withstand eradication by the host immune system and by antibiotic therapy within this 
unique environmental condition (Folkesson et al. 2012). 
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Early infecting strains of P. aeruginosa are frequently described as motile, non-mucoid, primarily 
acquired from environmental sources, having increased susceptibility to antibiotics and existing in a 
free-living or planktonic state (Luzar et al. 1985; Smith et al. 2006), whereas isolates obtained from 
chronic infection demonstrate reduced virulence and increased antimicrobial resistance. Chronic 
infection isolates are also often mucoid in appearance, have lower expression of pyocyanin, are non-
motile and frequently possess mutations in associated virulence genes. Furthermore, bacteria isolated 
from chronic infections can be found living in community formations and cellular aggregates (Harmer 
et al. 2013; Hogardt and Heesemann 2010; Manos et al. 2013). 
 
While many studies demonstrate this cascade of adaptive mechanisms during transition from initial 
to chronic infection, not all work is confirmatory. In a study conducted by Mayer-Hamblett and 
colleagues, they demonstrated that a proportion of phenotypic changes typically recognised in chronic 
infection were identified in initial infecting isolates from paediatric patients prior to the onset of 
conventionally diagnosed chronic infection (Mayer-Hamblett et al. 2014). Explanations for these 
results include i) these changes are intrinsic to the bacteria rather than a product of the environmental 
conditions in which they exist (Hauser et al. 2011), ii) adaption within the sinuses, prior to migration 
to the lower airway, has already taken place (Hansen et al. 2011; Johansen et al. 2012; Manos et al. 
2013; Markussen et al. 2014) and iii) adaptation has already occurred in one CF patient prior to 
acquisition by another as a result of patient-to-patient transmission. 
 
Additionally, large variations of these phenotypic characteristics have been noted within and between 
patients, in isolates from a range of ecological and clinical niches, and, interestingly, also from 
genetically identical strains (Clark et al. 2015; Cullen et al. 2015; Darch et al. 2015; Harmer et al. 
2013; Mayer-Hamblett et al. 2014). These studies clearly show that P. aeruginosa has a high degree 
of phenotypic heterogeneity (Cullen et al. 2015). 
 
Recently, whole genome sequencing, expression studies and transcriptome analyses have enhanced 
our existing knowledge of adaptive mechanisms. Overall, these studies demonstrate that, although 
the genome of P. aeruginosa is well conserved showing modest levels of genetic variability, both 
non-synonymous mutations and recombination events do play an important role in phenotypic 
diversification (Darch et al. 2015; Grosso-Becerra et al. 2014; Harmer et al. 2013; Markussen et al. 
2014; Marvig et al. 2015). Such studies have identified a range of virulence genes associated with the 
phenotypic characteristics displayed by P. aeruginosa during infection (Marvig et al. 2015; Marvig 
et al. 2015). 
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Currently the exact mechanisms which drive adaptation and diversification are not fully understood, 
although antibiotic pressure, the heterogeneity of the airways, and the natural versatility of  
P. aeruginosa all play a significant role in this process (Dettman et al. 2013; Markussen et al. 2014; 
Sousa and Pereira 2014). 
 
1.3.1 Respiration 
To aid survival P. aeruginosa has adapted to a variety of fluctuating environmental conditions, 
including the ability to grow under diverse atmospheric conditions (Alvarez-Ortega and Harwood 
2007; Comolli and Donohue 2002; O'May et al. 2006; Yoon et al. 2002). Although traditionally 
referred to as an aerobic bacterium, due to the ability survival and grow under reduced oxygen 
concentrations, it is now often described as a facultative anaerobe. P. aeruginosa can be exposed to 
a large fluctuation of oxygen levels depending on setting and surround environmental conditions. 
Many of the specific physiological conditions of the CF airways, such as increased mucus production, 
increased absorption of salts and hypoxic areas, as well as specific traits such as the capacity to grown 
in reduced oxygen environments, all contribute to the varied respiration pathways which P. 
aeruginosa can utilise (Hogardt and Heesemann 2013; Hoiby et al. 2010; Worlitzsch et al. 2002). 
 
The preferred mechanism of P. aeruginosa for respiration is via the aerobic pathway using oxygen 
as the final electron receptor as this form of respiration is the most efficient in terms of replication, 
producing the highest energy yield and enhanced rates of growth (Alvarez-Ortega and Harwood 2007; 
Hogardt and Heesemann 2013; Schobert and Jahn 2010). However, a number of studies have 
described the growth characterisitics of P. aeruginosa under different oxygen concentrations. This 
work has shown that as oxygen concentrations decrease there is a corresponding increase in the 
doubling time of growth. Furthermore, data confirms that while aerobic growth is the most efficient, 
growth under microaerophilic conditions is preferable to growth anaerobically. In addition, under 
anaerobic conditions, it has been demonstrated that the expression of many genes and virulence 
factors are impaired. Motility is reduced, quorum sensing (QS) is down regulated and biofilm 
formation and maturation occurs more slowly (Alvarez-Ortega and Harwood 2007; Hogardt and 
Heesemann 2013; Lee et al. 2011; O'May et al. 2006; Schobert and Jahn 2010; Waite and Curtis 
2009; Wu et al. 2005; Yoon et al. 2002). 
 
Many enzymes, compounds, pathways and genes have been shown to play an important role in 
respiration, biofilm formation, dispersal and motility. These include, the oxidases enzymes, in which 
mutations have been shown to impede microaerophilic respiration and biofilm production, ii) nitrate 
or nitrite, compounds used as an alternative final electron receptor, to facilitate growth under 
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anaerobic conditions, known as denitrification, and iii) regulators such as Anr, Pseudomonas 
quinolone signal (PQS) and RhlR, which are integral for anaerobic growth, denitrification and 
quorum sensing, biofilm maturation and motility. Mutations in these genes have been shown to impair 
many of these functions (Alvarez-Ortega and Harwood 2007; Barraud et al. 2009; Hassett et al. 2002; 
Hogardt and Heesemann 2013; Kolpen et al. 2014; Schobert and Jahn 2010; Yoon et al. 2002). 
 
Methods assessing motility and surface adhesion lend themselves to testing under various 
atmospheric conditions. As P. aeruginosa requires the presence of an alternative electron acceptor 
for growth in anaerobic conditions, the addition of potassium nitrate to the medium helps support 
growth under reduced oxygenation (O'May et al. 2006; Yoon et al. 2011; Yoon et al. 2002). However, 
despite the fact that these studies are not technically difficult, little is actually known about the impact 
of microaerophilic conditions on P. aeruginosa motility and biofilm development, and currently there 
are limited data pertaining to the phenotypic behaviours of clinically important strains grown in 
anaerobic conditions. 
 
1.3.2 Quorum Sensing 
Bacterial communication or QS is the term given to the regulation of bacterial behaviour in response 
to fluctuations in cell population density. This form of cell-to-cell communication is based on the 
generation and release of signalling molecules called autoinducers. QS is often referred to as being 
‘density-dependent’ as a critical density of bacterial cells is required for autoinducer levels reach a 
threshold stimulatory concentration, bind to a transcriptional activator protein, resulting in the 
expression of the target gene (De Kievit and Iglewski 1999; De Kievit and Iglewski 2000; Eberl and 
Tummler 2004; Hoiby et al. 2011; Miller and Bassler 2001). This coordinated communication is 
associated with a range of important physiological activities. Studies have demonstrated that 
mutations in genes involved in QS pathways affect biofilm formation, adhesion, motility and 
virulence (Bjarnsholt et al. 2010; Davies et al. 1998; Heydorn et al. 2002; Pearson et al. 2000). 
 
Within P. aeruginosa two quorum sensing systems have been described, the las and rhl systems. 
These systems do not act independently of each other and there is a hierarchy in the signalling 
cascade. In both of these systems a synthase and activator protein are present. LasI, the synthase 
protein of the las system, produces the autoinducer 3-oxo-C12-homoserine lactone (3-oxo-C12-HSL) 
that binds to the transcriptional activator protein (LasR) at a threshold concentration. The resulting 
LasR-3-oxo-C12-HSL complex is then able to bind to promotor regions upstream of genes encoding 
for a range of virulence factors (such as elastase, exotoxin A and alkaline protease) and also regulates 
the rhl system. Through the induction of the rhl transcriptional activator protein, RhlR, binding with 
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C4-homoserine lactone (C4-HSL) occurs, leading to the synthesis of the autoinducer synthase protein 
(RhlI). This complex, Rh1R-C4-HSL, can also activate the transcription of additional virulence 
factors (such as rhamnolipid, alkaline protease, elastase, pyocyanin and cyanide) and can activate 
genes under the control of LasR. These systems do not act independently of each other and there is a 
hierarchy in the signaling cascade with the las system regulating the AHL proteins of the rhl system 
(Eberl and Tummler 2004). In addition to the aforementioned AHL autoinducer signaling molecules, 
a third autoinducer, 2-heptyl-3-hydroxy-4-quinolone, is produced by P. aeruginosa. This 
autoinducer, referred to as PQS, facilitates interaction between the las & rhl systems and has a role in 
the expression of their proteins (Bjarnsholt et al. 2010; De Kievit and Iglewski 2000; Eberl and 
Tummler 2004; Miller and Bassler 2001). 
 
Specific environmental conditions and host immune factors have been associated altering  
P. aeruginosa QS response. Both phosphate and iron are essential requirements for survival and 
energy production. In times of limitation, P. aeruginosa has been shown to increase QS and in-turn 
virulence factor expression. Under anaerobic conditions, transcriptional regulators in conjunction 
with the QS systems allow for continued bacterial growth and virulence expression. Finally, examples 
of the interaction between P. aeruginosa and host immune factors have demonstrated an increase in 
the QS activity in the presence of immune cells (Lee and Zhang 2015). By understanding the 
mechanisms and conditions which promote bacterial QS, this may provide the basis for future 
therapeutic targets aimed at limiting cellular communication and bacterial infection.  
 
Loss of QS functionality has been described as being greater in isolates from chronically infected 
patients with CF compared to those from patients with intermittent infections (Bjarnsholt et al. 2010). 
Furthermore, it has been shown that the level of signalling molecules reduces as infection duration 
increases (Jiricny et al. 2014). Studies exploring QS gene expression demonstrated decreased 
expression from shared strains compared to non-shared strains from CF patients. This phenotype was 
more evident within the biofilm producing cells when compared to planktonic cells, suggesting QS 
is no longer necessary in established biofilm infection (Manos et al. 2009; Manos et al. 2008). 
Additionally, strain type and host environment may also be influencing expression and phenotype 
(Salunkhe et al. 2005). Finally, it has also been shown that the expression of these molecules is 
suppressed under anaerobic conditions, further impacting the cells’ ability to communicate when 
growing in oxygen-limited environments, such as the CF airway and within biofilms (Lee et al. 2011; 
Yoon et al. 2002) (Figure 1.2). 
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LOW CELL DENSITY HIGH CELL DENSITY 
  
Planktonic cells Bacterial community 
Low levels of autoinducers High levels of autoinducers 
Individual behaviour Collective behaviour 
No quorum sensing Quorum sensing 
No phenotypic changes Gene expression causing phenotypic changes 
      Autoinducer                    Receptor               DNA              Genes regulated by autoinducers 
Figure 1.2 The effect of cell density and autoinducer concentration on gene expression. 
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1.3.3 Motility 
P. aeruginosa has the ability to utilise a range of motility mechanisms to colonise abiotic and biotic 
surfaces, and to form biofilms (Davey and O'Toole G 2000; Harshey 2003). P. aeruginosa utilises 
the cell surface organelles, flagella and pili, for motility. The three predominant forms of motility are 
termed ‘swimming’, ‘swarming’ and ‘twitching’ (Harshey 2003; Mattick 2002; Partridge and 
Harshey 2013). 
 
Swimming through liquid medium and swarming across a solid surface requires propulsion and 
torque provided by terminal polar flagella (Harshey 2003; Murray and Kazmierczak 2006; Partridge 
and Harshey 2013). The flagellum is comprised of a basal body and a motor situated within the cell 
membrane, a rod which extends through the peptidoglycan and outer layers of the cell, to which the 
hook and filament are attached. The tail like filament of the flagellum structure consists of the protein 
flagellin (Guttenplan and Kearns 2013; Harshey 2003). 
 
Regulation of flagellum development, rotation and cellular movement requires a complex series of 
interactions involving flagellum gene expression, chemotaxis and flagellum movement (Guttenplan 
and Kearns 2013; Murray and Kazmierczak 2006). Swimming and swarming actions are driven by a 
rotating flagellum which provides P. aeruginosa with forward propulsion, though there are 
fundamental differences distinguishing the two motility functions. Swimming motility is unicellular 
movement within liquid propelled by single polar flagellum on the bacterium. Anticlockwise 
flagellum rotation results in forward propulsion, whereas clockwise revolutions move the bacteria in 
a tumbling motion (Harshey 2003; Partridge and Harshey 2013). Swimmer cells use chemical signals 
to alter the direction of movement in response to chemotaxis (Figure 1.3A) (Harshey 2003). 
 
Swarmer cells must overcome three main challenges to allow movement across a surface, including 
dehydration, friction and water tension. Consequently, the bacterium synthesises and secretes 
osmoprotectant molecules to draw water to the surface and increase hydration. The production of 
biosurfactants (e.g. rhamnolipids) assists with reducing friction and overcoming the surface tension 
between water molecules. Several other mechanisms include the formation of swarmer cell raft 
aggregations that facilitate movement in a coordinated fashion, and increasing the number of flagella 
from one to two, which in turn increases the force used to provide movement (Figure 1.3B) (Partridge 
and Harshey 2013). 
 
Twitching motility involves the movement of cell surface appendages called pili. For colonisation 
and infection of host cells to occur, pathogenic bacteria must recognise receptors on host cells in order 
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to attach to them. In addition to motility, pili are involved in other cellular functions including DNA 
transfer, bacteriophage infection, conjugation, cell aggregation, biofilm formation and host cell 
invasion (Harshey 2003; Mattick 2002; Proft and Baker 2009). Pili protrude through the cell 
membrane at both poles and are the major cell surface organelles involved in surface adhesion. In  
P. aeruginosa, specific pili, Type IV pili (T4P), are synthesised within the cell and this process 
involves a range of proteins (PilA, PilC, PilB, PilQ) for both assembly and rapid disassembly, leading 
to twitching movement (Mattick 2002; Proft and Baker 2009). Bacteria engaged in twitching motility 
move in an ever expanding motion outwards (Figure 1.3C). This action results in small clusters of 
cells which join together to form a lattice-like framework of cells, with the leading edge actively 
involved in migration, attachment and biofilm formation. It is widely recognised that a transition 
occurs when bacteria switch from a motile free living organism to a non-motile organism growing 
within a biofilm community. One important signalling molecule which is involved in the transition 
from motile to sessile forms is Cyclic-di-GMP (c-di-GMP). High levels of this signalling molecule 
are known to impact upon motility and increase the formation of biofilms, whereas the degradation 
of this molecule favours biofilm dispersal and a return to a planktonic and motile lifestyle (Hogardt 
and Heesemann 2013). 
 
Several studies have shown that motility and adhesion play important roles in triggering host immune 
responses, biofilm formation and the development of chronic infection (Alm and Mattick 1995; Amiel 
et al. 2010; Klausen et al. 2003; Yang et al. 2011). Furthermore, these studies demonstrate that the 
specific genetic mutations and the environmental conditions that the strains are exposed to can affect 
an organism’s capacity to establish infection. 
 
The most commonly used method of visualising the motility of P. aeruginosa is the inoculation of 
bacterial suspensions into media of differing viscosities. To demonstrate swimming motility, the 
bacterial suspension is inoculated into a semi-viscous medium. For swarming activity, the bacterial 
suspension is inoculated onto the surface of a semisolid medium with the organisms using flagella to 
propel themselves in an outward motion. Motility driven by the action of pili can be demonstrated 
using a semisolid agar and inoculating the isolate onto the plastic/agar interface at the base of a petri 
dish. The pili will attach to the plastic surface and the growth from twitching motility can then be 
visualised (Alm and Mattick 1995; Darzins 1993; Murray et al. 2010; O'May et al. 2006; Rashid and 
Kornberg 2000; Yoon et al. 2002). 
 
Although the current literature discussing the motility of P. aeruginosa isolated from patients with 
CF reports varied findings depending on the particular strains studied, the strong consensus is that 
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motility is important during the initial infective process. As P. aeruginosa undergoes the transition 
from an acute to chronic infection, the level of motility reduces. However due to isolate selection, 
patient cohort and specific mechanisms inherent to the bacteria, studies have demonstrated discordant 
findings when demonstrating an association between motility and eradication success. An Australian 
based study showed that isolates which are susceptible to eradication are more motile than those 
strains that are able to persist (chronic infection) within the lungs (Harmer et al. 2013; Manos et al. 
2013), whereas a European study showed there was a tread to greater motility in persistent isolates 
compared to those which were successfully eradicated (Tramper-Stranders et al. 2012). These results 
highlight the complexity of determining and reporting phenotypic characteristics.  
 
Several studies have examined the motility characteristics of shared strains isolated from patients 
with CF. However, owing to the relatively small numbers of isolates analysed, comparisons across 
the existing literature are difficult, and inconsistencies between studies are apparent. Hare and 
colleagues have described similar motility results between AUST-01 and other laboratory strains, 
whereas Harmer and colleagues reported that AUST-01 had reduced motility during both early and 
late infections, when compared to unique strains. Finally, Manos and colleagues reported that 
planktonic AUST-01 displayed greater motility compared with unique strains. Additionally, it has 
been demonstrated that AUST-01 isolates in the biofilm stage can upregulate the flagellin-encoding 
gene flaA, consistent with the retention of motility throughout its entire life cycle (Hare et al. 2012; 
Harmer et al. 2013; Manos et al. 2008). These discordant results may be secondary to i) selective 
pressures that the specific bacterial strains studied were under at the time of collection from the lungs, 
ii) the large diversity seen within P. aeruginosa genome or iii) methodological variations within the 
testing protocols. Expression of pilA and retention of twitching motility has also been confirmed 
amongst a small number of AUST-02 strains (Manos et al. 2009). Studies focusing on the LES 
describe various motility patterns depending on the particular isolate studied (Carter et al. 2010; 
Fothergill et al. 2012; Jeukens et al. 2014; Kukavica-Ibrulj et al. 2008; Salunkhe et al. 2005). Finally, 
motility studies utilising a broad isolate selection, including shared strains, demonstrate that isolates 
obtained from patients with CF have decreased motility compared to other clinical and environmental 
isolates (Head and Yu 2004; O'May et al. 2006). Environmental conditions such as oxygen tension 
may also impact on motility, given the fact that it is an energy dependent process, but limited work 
has been undertaken in the field although reduced motility capabilities of  
P. aeruginosa under anaerobic conditions have been described in a small number of strains isolated 
from patients with CF (O'May et al. 2006). Further phenotypic analysis in parallel with genomic 
studies on a large well characterised collection of bacterial strains will help elucidate the mechanisms 
which control motility. 
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Figure 1.3 Depiction of the three types of bacterial motility which Pseudomonas aeruginosa can 
utilise during adaptation. 
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Pilus Retraction 
C. Twitching Motility 
Flagellum 
B. Swarming Motility 
Flagellum 
A. Swimming Motility 
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1.3.4 Biofilm Formation 
Bacterial biofilms are complex communities consisting of microorganisms encased in a protective 
extracellular matrix (Costerton et al. 1995; Costerton et al. 1999; Hall-Stoodley et al. 2004). Biofilms 
can be either attached to biotic or abiotic surfaces (termed “Growth Mode 1”) (Harshey 2003), or 
form free-floating unattached cellular aggregates (termed “Growth Mode 2”) (Hassett et al. 2010; Su 
and Hassett 2012). The complex process of P. aeruginosa biofilm formation comprises five 
developmental stages, which typically occur under favourable environmental conditions involving 
numerous genes and regulatory pathways (Figure 1.4) (Harshey 2003). 
Stage 1: Planktonic cells possessing cell surface appendages necessary for motility (T4P and flagella) 
attach to a surface and form a monolayer of cells. At this stage, surface attachment/aggregation is still 
very loose and the developing biofilm can be easily disrupted. 
Stage 2: There is a continuous influx of motile cells to the site of biofilm initiation, which then adhere 
and begin to express extra-polymeric substances (EPS) resulting in irreversible surface attachment 
and microcolony formation. 
Stage 3: Cellular proliferation and the loss of motility organelles mark the beginning of the 
maturation process. 
Stage 4: Biofilm maturation and thickening is now complete. The initial flat mass of cells transforms 
into a three dimensional structure which can often resemble the stem and cap of a mushroom. An 
oxygen gradient forms throughout the structure, resulting in limited oxygenation at the base. 
Stage 5: This final stage results in the dispersal of planktonic cells back into the environment. These 
“dispersal” cells are often motile, possess increased virulence and have the ability to seed onto 
surfaces and form new biofilms. Structurally, the cap of the biofilm collapses, allowing the planktonic 
cells to swim out and resulting in a hollow core consisting of persister cells. The process of dispersal 
can be triggered by environmental stimuli or a physiological event (Costerton et al. 1999; Hall-
Stoodley et al. 2004; Hassett et al. 2002). 
 
Another key development during biofilm maturation is the formation of water channels which 
facilitate the transfer and/or removal of nutrients, water and waste by-products throughout the 
structure. However, due to the heterogeneous nature of these channels, an uneven distribution of water 
and nutrients occurs resulting in differentiation of cellular function (Hall-Stoodley et al. 2004; 
Hogardt and Heesemann 2013). The cellular composition of a biofilm is divided into three broad 
groups: i) those bacterial cells which make up the basic structure of the biofilm; ii) cells which are 
expelled from the biofilm (dispersers); and iii) cells that remain (persisters) (Costerton et al. 1999; 
Hall-Stoodley et al. 2004). One of the defining features of the biofilm is the secretion of an 
extracellular matrix by the bacteria, thereby forming a protective coating or physical barrier, 
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comprising polysaccharides, extracellular DNA and proteins. EPS also provide structural support and 
aid in irreversible surface attachment. Importantly, this matrix plays an essential role in QS by 
facilitating the interactions of signalling molecules. 
 
Unlike planktonic cells in the metabolically active exponential growth phase, cells within a biofilm 
maintain a relatively low level of metabolic activity. Coupled with the physical protection afforded 
by the biofilm matrix, subdued metabolic activity provides a degree of protection from bactericidal 
and bacteriostatic antibiotic activity. 
 
Similar to results generated from motility assays, biofilm formation also appears to be strain specific. 
Studies focusing on the LES have demonstrated a range of biofilm characteristics amongst the isolates 
studied (Fothergill et al. 2012; Jeukens et al. 2014; Salunkhe et al. 2005; Winstanley et al. 2009). In 
addition, a range of results have been generated from unique strains possessing the same genetic 
background (Head and Yu 2004). Shared strains produce thicker and larger biofilms compared to 
unique strains, while isolates from chronically infected patients demonstrate enhanced biofilm 
forming capabilities compared to those cultured from initial infection (Harmer et al. 2013; Manos et 
al. 2008). However, when CF isolates have been compared to isolates cultured from other human 
clinical presentations, they display thinner and smaller biofilms which take longer to develop (O'May 
et al. 2006). A small number of environmental isolates have been tested under the same experimental 
biofilm-forming conditions as CF and non-CF clinical isolates. Although there is considerable 
variation amongst all the isolates, there is no distinguishing biofilm phenotypic feature that 
differentiates isolates according to origin. It has also been demonstrated that biofilm production does 
not change when tested at either 30 C or 37 C (Head and Yu 2004). Studies correlating motility 
capabilities with biofilm formation have provided discordant findings. Head and colleagues and 
Kukavica-Ibrulj and colleagues found no correlation between motility and biofilm formation, while 
O’May and colleagues and Jeukens and colleagues observed that non-motile isolates were also poor 
biofilm producers (Head and Yu 2004; Jeukens et al. 2014; Kukavica-Ibrulj et al. 2008; O'May et al. 
2006). Although all of the aforementioned studies used the microtitre plate based assay (or a similar 
variation), inconsistencies within reported results may be due to variations in the specific 
methodology used. Results may therefore vary according to incubation protocols and the exact abiotic 
surface used. 
 
Early work on seeding dispersal comparing isogenic mutants, a mucoid CF strain and PAO1, 
concluded that although all strains developed biofilms at very similar rates, biofilm thickness, 
hollowing and the ability to undergo seeding dispersal differed between strains. A QS mutant was 
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unable to disperse cells, leading to the conclusion that the ability to sense cell density and nutrients 
is required to initiate the release of cells (Purevdorj-Gage et al. 2005). Additionally, it has been shown 
that a mucoid isolate from a patient with CF could not initiate hollowing or seeding dispersal. Taken 
together, Purevdorj-Gage and colleagues speculated that seeding dispersal may be specific to 
environmental strains, while the transmission of clinical strains may occur independently of this 
mechanism (Purevdorj-Gage et al. 2005). More recently, analysis of a larger number of clinical CF 
strains has shown that biofilms produced by these isolates do undergo cellular dispersal. Kirov and 
colleagues found that, although isolates from chronically infected patients developed less adherent 
microcolonies than PAO1, and developed them at a slower rate, they still displayed similar seeding 
dispersal events. This active dispersal of motile cells back into the environment is thought to enhance 
genetic diversity and survival of P. aeruginosa. Effluent collected from flow cell experiments 
demonstrates that a range of phenotypically distinct isolates originating from a single colony 
morphotype as the original inoculum are released following seeding dispersal (Kirov et al. 2007).
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Figure 1.4 The five developmental stages involved in biofilm formation. 
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1.3.4.1 Biofilm Models 
Depending on the model being utilised, bacterial adhesion, biofilm structure, or both factors can be 
determined in vitro. Nevertheless, it should be noted that the term ‘biofilm’ is often used to describe 
both modes of growth within a community formation. The two most commonly used methods for the 
investigation of bacterial ‘biofilm’ growth, are the microtiter plate based assay and the flow cell 
model (Azeredo et al. 2017). 
 
The static microtitre plate based assays is a highly reproducible and repeatable model which allows 
for rapid, high throughput screening of bacterial adhesion capacity under different atmospheric 
conditions using standardised experimental parameters (O'Toole 2011). Adhesion of the bacterial 
cells to the walls of the wells in a 96 well microtitre plate can be quantified using a plate reader to 
determine optical density following a simple stain and decolourisation technique. (O'Toole 2011; 
Stepanovic et al. 2007). This methodology does not allow the assessment of bacterial community and 
structural formation. 
 
Alternatively, the flow cell model is considered a “gold standard” assay which facilitates the 
visualisation of substratum bacterial adhesion, biofilm formation and maturation under hydrodynamic 
conditions. This model requires specialised equipment and expertise, and owing to several technical 
aspects, this methodology faces some issues with variability and reproducibility. Nevertheless, 
standardisation of various technical aspects can reduce this variability (Heydorn et al. 2002; Heydorn 
et al. 2000). This method allows for factors such as nutrient availability, the introduction of 
supplements and antimicrobials, medium flow rate, time and temperature to be altered and assessed. 
Depending on the organism being tested and the operational parameters applied, the flow cell model 
can run over many days. In contrast to the microtitre plate based assay, this model allows the 
examination of complex biofilm structures in the absence of planktonic cells which are removed by 
the media flow. Collection of effluent for assessment of dispersed cell morphology including the 
development of small colony variants is also easily achieved with this model. Visualisation of the 
three dimensional (3D) biofilm structure is undertaken using confocal laser scanning microscopy 
(CLSM), thus allowing non-invasive analysis in real time. Introduction of fluorescent stains prior to 
microscopy, or the use of fluorescently tagged bacteria, can reveal the composition of the biofilm, the 
ratio of live to dead cells, and allow the determination of seeding dispersal (Crusz et al. 2012; Kirov 
et al. 2007). Results from the CLSM can be analysed using specialised Comstat software which 
allows assessment of various parameters including biomass, thickness and surface area (Comstat2 
2015; Heydorn et al. 2000; Voorregaard 2008). While much of the literate surrounding bacterial 
biofilm formation utilises high throughput screening assays, there is a lack of evidence-based science 
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that confirms the correlation of these methodologies to those which assess biofilm structural 
development. Inherent design differences make these comparisons difficult. Commonly utilised 
biofilm devices such as the microtitre plate assay and the Calgary device have been designed to assess 
the biofilm forming capacity of cells. Both techniques are screening methods which allow for high 
throughput analysis and incubation under varied growth conditions. Results generated are easily 
interpreted; however, they may be limited due to loosely adhered cells being removed during washing 
and cellular death following exhaustion of nutrients. In contrast, the flow cell apparatus allows for 
the visualisation of biofilm development and structure. Experimental conditions can be altered to 
assess growth under antibiotic pressure. While this device can be optimised more accurately mimic 
in vivo conditions, it requires specialised equipment and technical expertise to undertake and interpret 
(Azeredo et al. 2017). Each of the different biofilm devices have been designed to assess different 
aspects of development and as a result there is little consensus between these techniques and their 
interpretation. Furthermore, there is limited data presented which associate in vitro biofilm 
capabilities with clinical outcomes for people with CF. Previously, much work has been undertaken 
that describes the phenotypic and biofilm characteristics of isolates obtained from patients with CF. 
Furthermore, genetic analysis has demonstrated a number of mutations which directly impact the cells 
ability to be motile, adhere and disperse. However, due to limitations in experimental design the 
translation of in vitro results to in vivo impact remains incomplete.  
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1.4 Research Aims and Objectives 
1.4.1 Background and Scope 
P. aeruginosa is the most commonly isolated bacterial pathogen from respiratory secretions obtained 
from patients with CF. Intermittent infection with P. aeruginosa is often seen in childhood, while by 
adulthood many patients have developed chronic infection (Bell et al. 2011; Cystic Fibrosis Australia 
2015). Early infecting strains, thought to be primarily acquired from environmental sources, are 
usually motile, susceptible to antipseudomonal antibiotics and exist in a free-living state (Luzar et al. 
1985; Smith et al. 2006). These early infecting strains, which typically cause intermittent infection, 
can be cleared by activation of host immune pathways or by antibiotic treatment (Gibson et al. 2003). 
Once a strain becomes established within the lower airway, it begins to adapt to the CF lung and 
eradication is no longer possible. 
 
Adaptation of P. aeruginosa involves a cascade of physiological, metabolic and morphological 
changes which affect their mode of growth, expression of virulence factors and interactions with host 
immune cells, resulting in chronic infection (Smith et al. 2006). Genomic studies have described the 
presence of a number of genes and regulatory pathways which are thought to play a significant role 
in loss of virulence factors and adaptation of P. aeruginosa to the environment (Marvig et al. 2015; 
Winstanley et al. 2016). Important adaptive changes include loss of motility, tolerance to decreased 
oxygen levels, and the establishment of complex biofilm communities (Hogardt and Heesemann 
2013; Hoiby et al. 2011). 
 
The scientific literature details many studies describing the motility and biofilm forming 
characteristics of P. aeruginosa isolated from patients with CF (Carter et al. 2010; Clark et al. 2015; 
Cullen et al. 2015; Fothergill et al. 2012; Grosso-Becerra et al. 2014; Head and Yu 2004; Jiricny et 
al. 2014; Kukavica-Ibrulj et al. 2008; Manos et al. 2013; O'May et al. 2006). Overall, these studies 
demonstrate that during chronic infection, P. aeruginosa adopts a biofilm mode of growth, but there 
appears to be some variability in each strain’s biofilm forming capacity. Likewise, there seems to be 
some inter-strain variation with respect to motility (Jeukens et al. 2014; Winstanley et al. 2009). 
However, it must be noted that in most of these studies the overall number of isolates (in particular, 
those of environmental origin) tested and the diversity of the strains used was limited. Typically, most 
studies have relied on using the PAO1 strain or knockout mutants as comparators (Carter et al. 2010; 
Jeukens et al. 2014; Jiricny et al. 2014; Kukavica-Ibrulj et al. 2008; Manos et al. 2008; Manos et al. 
2013; O'May et al. 2006; Yang et al. 2011). While a standard needs to be included to account for 
inter-run variation and to set a baseline for isolate comparison, the expression and capabilities of this 
strain needs to be known in the context of the broader population so that degrees of change from this 
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baseline can be interpreted correctly. When a comparison to a known negative (such as a mutant) is 
made, care also needs to be taken when determining the level of positivity assigned to a strain, as next 
to a true negative, most isolates will appear positive. 
 
In some instances the fundamental principles underpinning bacterial adhesion and initial microcolony 
development (i.e. functioning cell surface organelles, flagella and pili) also remain uncertain (Proft 
and Baker 2009; Stoodley et al. 2002). Again, these differences may simply reflect inter-strain 
variability; however, most studies have utilised poorly characterised strains of an unknown genetic 
background. Other sources of variability could be associated with methodological inconsistencies, 
including the use of experimental conditions (e.g. reduced temperature and oxygen availability), 
which do not reflect those encountered in the CF airway. 
 
Epidemiological investigations have demonstrated that patients with CF can share indistinguishable 
strains of P. aeruginosa, and it is speculated that acquisition occurs by patient-to-patient transmission 
(Knibbs et al. 2014; Wainwright et al. 2009). In Queensland, the predominant shared strain is AUST-
02 (Kidd et al. 2013). Ecological studies to date have failed to find this strain in any environmental 
setting apart from respiratory secretions collected from patients with CF (Kidd et al. 2012). In 
2007/2008, AUST-02 was the predominant strain isolated from 40% of patients with a confirmed P. 
aeruginosa infection living in Queensland, Australia. This strain is of particular importance given its 
potential for patient-to-patient spread, lack of environmental reservoir and association with increased 
hospitalisation and treatment requirements (Kidd et al. 2013; Knibbs et al. 2014). Currently little is 
known about the phenotypic and genotypic characteristics of the AUST-02 strain as many of the 
previous studies have focused on the shared CF strains, LES and AUST-01, prevalent in Europe and 
Australia, respectively. This work has described these strains as strong biofilm producers when 
compared to PAO1 (Carter et al. 2010; Fothergill et al. 2012; Manos et al. 2008). 
 
Therefore, to improve understanding of the adaptive biology of P. aeruginosa and, more specifically, 
the AUST-02 strain, a large component of this PhD thesis is devoted to defining the motility and 
biofilm-forming capacity of numerous isolates selected from a well characterised biobank (Kidd et 
al. 2012). The isolates in the biobank have been genotyped using MLST, providing the opportunity 
to study the phenotypic and genomic differences between isolates from similar and distant genetic 
backgrounds. In addition, access to multiple isolates of the same ST that have been cultured from 
different ecological settings (e.g. ST-155, ST-179, ST-242, ST-266, ST-381), may help to explain 
why some P. aeruginosa strains are more common and appear to have an enhanced capacity to adapt 
and survive in new environments. 
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While the majority of P. aeruginosa strains are capable of surviving in various ecological niches, 
properties such as patient-to-patient transmissibility and adaptation to specific hosts (i.e. patients with 
CF), are features of the AUST-02 strain. Therefore, comparing AUST-02 with other closely related 
CF (non-shared), non-CF, animal and environmental strains may provide the key to identifying 
specific adaptations that allow transmission and persistence to occur. 
 
To better understand these processes and to add to the existing knowledge of bacteria adaptation, 
during this PhD project I will focus on adhesion, motility and biofilm formation of P. aeruginosa 
isolates obtained from a range of clinical and environmental settings, under varied atmospheric 
conditions. Furthermore, I will be ascertaining if AUST-02 possesses any of the aforementioned 
adaptive mechanisms and determining how they may be relevant in the establishment and persistence 
of airway infection in people with CF. Finally, through the use of whole genome sequencing and 
bacterial genome-wide association study I will aim to further comment on the diversity of the strains 
studied and determine if any mutations identified can explain the phenotypic characteristics 
described. 
 
National CF data registries collate and present clinical, microbiological and demographic data on 
patients (Cystic Fibrosis Australia 2016; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 
2016). While the broad overview provided by the registries captures changing trends over time, due 
to their large scale, the fine nuances of the impact of antibiotic exposure, acquisition of new bacteria 
or changing bacterial genotypes within patient cohorts are not able to be presented. Studies which 
focus on the specific epidemiological trends of a single centre, or defined groups of patients, are better 
able to comment on emerging pathogens, diversity within individual species, changing acquisition 
rates and the health outcomes associated with these events (Kidd et al. 2015; Millar et al. 2009; 
O'Carroll et al. 2004; Spicuzza et al. 2009; Valenza et al. 2008). By doing so, surveillance studies 
using defined patient cohorts, conducted within clinics following recognised standards of care, may 
generate results which can be extrapolated into the wider CF community. In this PhD project I will i) 
describe the changing prevalence of relevant bacterial and fungal pathogens identified from sputum 
samples collected from a local adult CF centre, ii) genotype P. aeruginosa isolates collected during 
two cross-sectional studies iii) identify new acquisitions of shared strains within this cohort, and iv) 
determine if clinical decline is associated with acquisition. 
 
This thesis aims to provide a detailed microbiological epidemiological surveillance of both the 
bacterial species and strain diversity of patients attending a single CF specialist centre. In addition, 
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health outcomes, effectiveness of antibiotic treatment and the robustness of a research-based 
definition used to categorise chronic infections will be assessed and validated within a dynamic 
clinical setting. Furthermore, by determining the fundamental biological differences which may exist 
between shared strains and those readily isolated from numerous settings, improvements in 
preventing acquisition, eradicating infections and ongoing treatments may be developed. 
 
1.4.2 Broad Research Aims 
This thesis aims to determine the longitudinal prevalence and diversity of P. aeruginosa within an 
adult CF clinic and through comparison with non-CF and environmental isolates, identify important 
biological characteristics in the context of CF airway infection and cross-infection. 
  
1.4.3 Specific Research Aims 
The specific aims of the research describe in this thesis were to: 
1. To determine the change in prevalence over time for P. aeruginosa and a range of other significant 
CF pathogens in a local CF population. 
2. To determine the impact of Pseudomonas eradication therapy on patients at time of transition into 
the adult CF centre. 
3. Validate the robustness of the ‘Leed’s Criteria’ for defining chronic P. aeruginosa in a dynamic 
adult CF centre. 
4. To determine the incidence and prevalence of shared strains in a local CF population using isolates 
collected at two defined time points. 
5. To assess the clinical impact following acquisition of a shared P. aeruginosa strain. 
6. Through the use of phenotypic assays, identify the adaptation mechanisms of a large number of 
well characterised P. aeruginosa isolates with particular focus on the comparison of: 
a. Isolates from patients with CF and the environment,  
b. Isolates that share close evolutionary relationships and, 
c. Genetically indistinguishable isolates. 
7. Determine if the high throughput rapid plate-based adhesion assay can be used interchangeably 
with (or even replace) the flow cell as an indicator of biofilm forming capacity. 
8. Undertake bioinformatic analysis on a subset of isolates to identify genetic variants responsible 
for phenotypic characteristics. 
 
 
Chapter 2: Prevalence of Pseudomonas aeruginosa in an adult CF centre  
2.1 Abstract 
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Background: Increased patient longevity and aggressive antibiotic treatment are thought to impact on 
the microbial composition of the airways of adults with cystic fibrosis (CF). In this study we sought 
to determine if a temporal change in the airway microbiology of adults with CF has occurred over 
time. 
 
Methods: Longitudinal analysis of sputum microbiology results was undertaken on patients attending 
a large adult CF centre. Clinical status and health outcomes of transitioning patients were also 
assessed.  
 
Results: A decrease in the prevalence of Pseudomonas aeruginosa, Staphylococcus aureus, 
Burkholderia cepacia complex and Aspergillus spp. (P = 0.001, P < 0.001, P = 0.002 and P < 0.001, 
respectively) occurred. Improvements in lung function among transitioning patients infected with P. 
aeruginosa were observed.  
 
Conclusion: Overtime a decline in the prevalence of many CF airway pathogens has occurred. 
Significantly an incremental improvement in lung function was reported for transitioning patients 
with current P. aeruginosa infections.  
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2.2 Introduction 
Cystic fibrosis (CF) is a multisystem disease, in which a great burden of the morbidity and mortality 
results from chronic suppurative lung disease. Pathophysiologically the disease is characterised by 
dehydration of the airway surface liquid, elevated mucus production and increased susceptibility to 
infections (O'Sullivan and Freedman 2009; Ratjen et al. 2010). A number of microorganisms are 
associated with CF airway infections, the prevalence of which varies according to patient age (Chmiel et 
al. 2014; Lipuma 2010; O'Sullivan and Freedman 2009). Haemophilus influenzae and methicillin-
sensitive Staphylococcus aureus (MSSA) are frequently the earliest pathogens isolated in children and 
this is often (Salsgiver et al. 2015; Spicuzza et al. 2009; Valenza et al. 2008) followed by Pseudomonas 
aeruginosa (Chmiel et al. 2014; Lipuma 2010; O'Sullivan and Freedman 2009). Early infection in 
children can progress to a chronic infection where eradication cannot be achieved. So, early treatment 
aims to prevent or delay the time to chronic infection. Aggressive antibiotic therapy is recommended at 
the time of P. aeruginosa acquisition and is usually successful in achieving initial eradication (Doring et 
al. 2012; Langton Hewer and Smyth 2014; Mayer-Hamblett et al. 2015). Programs aimed at eradicating 
early P. aeruginosa infection have been widely adopted over the past two decades with rates of P. 
aeruginosa infection progressively declining in young people especially in children and adolescents with 
CF (Cystic Fibrosis Trust 2015; Cystic Fibrosis Trust 2006; Razvi et al. 2009; Salsgiver et al. 2015). It 
is less clear what impact these early changes are having on adult populations on rates of P. aeruginosa 
and other pathogens such as nontuberculous mycobacteria (NTM) infection, methicillin-resistant S. 
aureus (MRSA) and emergent bacteria (Stenotrophomonas maltophilia and Achromobacter spp.) (Cystic 
Fibrosis Australia 2015; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 2015; Millar et al. 2009; 
Salsgiver et al. 2015; Valenza et al. 2008). 
 
P. aeruginosa remains the most prevalent microorganism isolated from adults with CF (Cystic Fibrosis 
Australia 2015; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 2015; Lipuma 2010; Millar et al. 
2009; Salsgiver et al. 2015; Valenza et al. 2008). Once established P. aeruginosa infections are difficult 
to eradicate and classically have been associated with accelerated lung function decline and poorer 
survival (Emerson et al. 2002). Several studies have defined the term, chronic infection, to provide a 
basis for diagnosing persistent infection (Lee et al. 2003; Pressler et al. 2011). Despite the ongoing debate 
about a strict definition to describe chronic P. aeruginosa infection, this term is now widely used 
including in some CF Data Registries to stratify infection status. Clinically this definition may guide the 
physician in determining a therapeutic approach for the patient. However, the utility of these definitions 
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in clinical practice is limited by the inability of some patients to provide sufficient sputum samples within 
a given time period, inadequate sample quality and limited follow-up review. Furthermore, such criteria 
are yet to be validated in adults with CF. 
 
The aims of this study were to determine the prevalence of infection in an adult population of patients 
with CF and to assess the utility of the Leed’s criteria in adults within a clinical setting to define 
chronicity of P. aeruginosa (Lee et al. 2003). Furthermore, we were particularly interested in the clinical 
and microbiological characteristics of patients, but due difficulties associated with patient movement into 
and from this clinic (death, transplant and transfer to another care centre), the clinical impact of changing 
pathogen prevalence was reported only for those patients transitioning to adult care to determine changes 
occurring during the modern era of eradication therapy.  
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2.3 Methods 
2.3.1 Study population 
All patients with CF attending The Prince Charles Hospital (TPCH) Adult CF Centre located in 
Queensland, Australia, between 1st January 2001 and 31st December 2014 were included in the study. 
Clinical measurements were excluded following transplantation. The centre provides care for 
Queensland, the Northern Territory and northern New South Wales adults with CF, with national 
standards of care recommending a minimum of four multi-disciplinary outpatient reviews per year (Bell 
and Robinson 2008).  
 
In 2013, there was a median of six (interquartile range [IQR]: 2 - 11) outpatient attendances at TPCH 
Adult CF Centre. Sputum samples were collected at each review and at the beginning and completion of 
all intravenous antibiotic treatment courses (inpatient and or hospital-in-the-home). Expectorated sputum 
was primarily collected with induced sputum sampled in selected non-productive patients with 
unexplained clinical decline (total 3260 samples from 469 patients). Induced sputum samples were 
unable to be differentiated from expectorated sputum as both were coded in the same way. Bronchoscopy 
samples were rarely collected and usually when unexplained clinical decline had occurred. During the 
study period, 51 bronchoscopic samples (bronchoalveolar lavage and bronchial washings) from 34 
patients were collected representing 1.5% of the total samples submitted for culture. The sampling 
frequency from bronchoscopy samples did not change over time. Upper airway samples for 
bacteriological analysis were not routinely performed. This study was approved by TPCH, Human 
Research Ethics Committee (HREC/13/QPCH/51). 
 
2.3.2 Sample collection and microbiological analysis 
Only results from sputum sample processing were included in this study. Sputum culture and 
microbiological identification was undertaken by a routine diagnostic laboratory using a combination of 
best practice standard phenotypic and molecular techniques (Gilligan et al. 2006). Apart from the 
introduction of bacterial identification using the bioMerieux VITEK® MS (Mass spectrometry microbial 
identification system) in 2011, all other isolation and identification techniques remained consistent. 
 
All fungal species reported were grown on routine bacterial culture media and specific NTM testing 
using standard solid and liquid culture media for mycobacteria were undertaken in the Mycobacterial 
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Reference Laboratory when requested by the treating physician (i.e. annually, when clinically suspected 
or when NTM had previously been cultured). 
 
2.3.3 Microbiological and clinical data collection 
Sputum microbiology results were obtained electronically from the Pathology Queensland Clinical and 
Scientific Information System (AUSLAB). In the first instance clinical data were obtained from the 
TPCH CF patient database and hospital medical records, and if unavailable, information from either the 
Australian CF Data Registry or the referring CF centre at the time of transition were used. Notably, 
centres enter clinical and microbiological data into the Australian CF Data Registry on an encounter-
basis allowing the capture of all sputum samples collected in each year. Of the 217 transitioning patients, 
sputum microbiological results were obtained from letters provided at the time of health-care facility 
transition (n = 6), the Australian CF Data Registry (n = 13) and the TPCH CF patient database (n = 198). 
 
Due to yearly fluctuations in patient numbers, assessing the clinical characteristics of all patients at one 
given time was not possible with this data; therefore, the clinical characteristics were presented for 
transitioning patients at time of entry to TPCH. Furthermore, the impact of reduced pathogen rates in 
younger, transitioning patients on prevalence rates of specific pathogens in the whole clinic will be 
‘diluted’ by the proportion of existing patients with chronic infection with common CF pathogens (e.g. 
P. aeruginosa) only. 
 
Age-adjusted pulmonary function using recognised prediction equations (Hankinson et al. 1999; Wang 
et al. 1993), and standard deviation z-scores for body mass index (BMI) (calculated using United States 
National Centre for Health Statistics and Centres for Disease Control and Prevention normalised growth 
reference values) were determined for all patients aged two to 20 years. Patients older than 20 years at 
the time of transition were removed from analysis (n = 14). Cystic fibrosis transmembrane conductance 
regulator (CFTR) function was defined as minimal function (Class I, II or III mutations), residual 
function (≥ 1 allele with a Class IV or V mutation) and unknown function (Clinical and Functional 
Translation of CFTR (CFTR2) ; Cystic Fibrosis Foundation 2014; Green et al. 2010). 
 
Patients attending TPCH on the first occasion were defined as new patients and were stratified into one 
of three groups: i) transitioning patients that had their care transferred from a paediatric CF Centre (n = 
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217), ii) transferring patients from another adult CF Centre (n = 107), and iii) adults diagnosed with CF 
for the first time (n = 12). 
 
Patient infection status was also stratified according to those: i) with chronic P. aeruginosa infection, ii) 
in whom P. aeruginosa infection status was intermittent, iii) with no P. aeruginosa infection, and iv) 
where no sputum sample was collected. The Leed’s criteria (Lee et al. 2003) were used for the initial 
assessment of chronic P. aeruginosa infection. If a patient could not meet the definition due to an 
insufficient number of cultures, then a modified definition was used.  
 
Chronic P. aeruginosa infection in patients providing four or more sputum samples in a calendar year 
was determined when > 50% of sputum samples were culture positive exactly as for the Leed’s criteria. 
The key modification was in instances where fewer than four samples were collected or less than 50% 
of samples were culture positive; data from the previous year was reviewed and if the patients also 
fulfilled the above criteria they were also classified as having chronic infection.  
 
In cases where insufficient information allowed a patient to be defined as chronic, the patient was 
classified as having an intermittent P. aeruginosa infection. If a patient was not seen at the CF centre in 
a specific calendar year their data was not included for that year. 
 
To account for a relatively small number of transitioning patients per annum, the study period was 
divided into tertiles (i.e. 2001 - 2004, 2005 - 2009, 2010 - 2014). Prevalence of each microorganism was 
defined for each patient where at least one positive culture result was available within a calendar year.  
 
2.3.4 Statistical analyses 
SPSS version 22 was used for statistical analysis. Associations for categorical variables were examined 
using the Pearson Chi-squared test and Fisher’s Exact test when more than 20% of the expected values 
were less than five. If the P value was significant (P≤ 0.05) pairwise comparisons between each of the 
tertile periods were further examined. Continuous variables were examined using the Mann-Whitney U 
test. To assess if lung function was dependent on P. aeruginosa status and year of entry into the adult CF 
centre (n = 469), linear regression models for forced expiratory volume in one second (FEV1) and forced 
vital capacity (FVC) percent predicted (%pred) containing terms P. aeruginosa status, year of entry and 
their interaction were examined. As the interaction term was significant a one-way analysis of variance 
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(ANOVA) of FEV1 and FVC by year of entry, stratified by P. aeruginosa status was used to further 
explore the interaction. Where the global ANOVA P-value was significant (P ≤ 0.05) a least significant 
difference post hoc test was completed to detect which cohort years were different for  
P. aeruginosa status.  
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2.4 Results 
2.4.1 Study Population 
Over the 14-years a total of 469 individuals (n = 3260 patient years) attended TPCH Adult CF Centre 
including 336 new patients, which consisted of 217 transitioning patients, 107 transferring patients and 
12 patients who were diagnosed in adulthood (Figure 2.1). Seventy-eight patients underwent lung 
transplantation (male = 34) and 49 died (male = 22) during the study period, with a median of four years 
attendance for clinical review at TPCH prior to transplant or death. Patients were typically young adults 
and they remained at the centre for median six years and provided a median of three sputum samples 
annually (Table 2.1). 
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Figure 2.1 Patient movement occurring at The Prince Charles Hospital Adult Cystic Fibrosis Centre 
between 2001 and 2014.  
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a Patients exiting TPCH; Includes all patients leaving The Prince Charles Hospital Adult Cystic Fibrosis 
Centre during the calendar year 
b Transplant; Patients who have undergone lung transplantation during the calendar year 
c Deceased; Patients who have died during the calendar year 
d Relocated; Patients who have transferred to another CF centre during the calendar year 
e Temporary; Patients who have temporary left The Prince Charles Hospital Adult Cystic Fibrosis Centre 
during the calendar year 
f Patients entering TPCH; Includes all new patients arriving to The Prince Charles Hospital Adult Cystic 
Fibrosis Centre during the calendar year 
g Adult; Adult transfer patients entering The Prince Charles Hospital Adult Cystic Fibrosis Centre and 
patients newly diagnosed as adults during the calendar year 
h Paediatric; Transitioning patients entering The Prince Charles Hospital Adult Cystic Fibrosis Centre 
during the calendar year 
i Temporary; Patients who have temporary returned to The Prince Charles Hospital Adult Cystic Fibrosis 
Centre during the calendar year 
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Table 2.1 Characteristics of the 469 patients attending The Prince Charles Hospital Adult Cystic Fibrosis 
Centre between 2001 and 2014. 
 
Patient Characteristics  
Age at initial review; median years (IQR) a 20.0 (18.0-27.0) 
Gender; no. of males (%) 242 (51.6) 
Deaths; no. (%) 49 (10.4) 
Age at death; median years (IQR) 28.3 (20.8-37.2) 
Lung transplantation; no. (%) 78 (16.6) 
Age at transplantation; median years (IQR) 29.8 (25.0-37.5) 
Years attending TPCH; median (IQR) 6.0 (2.5-11.0) 
Annual sputum collection; median (IQR) 3.0 (1.0-6.0) 
a The Prince Charles Hospital Adult Cystic Fibrosis Centre (transitioning from paediatric care or 
transferring from another adult care centre) 
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2.4.2 Infection Prevalence 
One or more CF pathogens were isolated in 98% (2678/2735 patient years) of all patients able to produce 
sputum samples. There was a significant decrease in prevalence over time for total  
P. aeruginosa infection (P = 0.001), MSSA (P < 0.001), MRSA (P < 0.001), B. cepacia complex  
(P = 0.002) and Aspergillus spp. (P < 0.001) isolation (Table 2.2). Thirty-four patients underwent 51 
bronchoscopy procedures with the annual number similar over the study period, rates of P. aeruginosa 
infection were lower in this cohort (56.9% of samples, compared with 74.7% of all sputum samples,  
P = 0.006) and rates of NTM infection were not significantly different (7.8% of samples, compared with 
4.0% of all sputum samples, P = 0.150). 
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Table 2.2 Tertile groupings by years of infection prevalence for the 469 patients attending The Prince Charles Hospital Adult Cystic Fibrosis 
Centre between 2001 and 2014, n (%). 
 
Year 
Number 
of 
patient 
years 
Pseudomonas aeruginosa Staphylococcus aureus 
Achromobacter 
spp. 
S. 
maltophilia 
B. cepacia 
complex 
Aspergillus 
spp. 
Scedosporium 
spp. 
NTM % 
No 
pathogen 
detected 
No sample 
collected 
Positive Chronic$ MSSA MRSA 
2001-2004 751 574 (76.4)a 488 (65.0) 302 (40.2)a 62 (8.3) 53 (7.1) 53 (7.1)b 63 (8.4) 227 (30.2)a 13 (1.7) 22 (2.9) 131 (17.4)ab 113 (15.0)a 
2005-2009 1160 900 (77.6)a 796 (68.6) 457 (39.4)a 53 (4.6) 67 (5.8) 112 (9.7) 67 (5.8)c 313 (27.0)a 29 (2.5) 48 (4.1) 171 (14.7)a 157 (13.5)a 
2010-2014 1349 962 (71.3) 907 (67.2) 394 (29.2) 38 (2.8) 68 (5.0) 88 (6.5)b 63 (4.7)c 254 (18.8) 32 (2.4) 64 (4.7) 280 (20.8)b 255 (18.9) 
Total 3260 2436 (74.7) 2191 (67.2) 1153 (35.4) 153 (4.7) 188 (5.8) 253 (7.8) 193 (5.9) 794 (24.4) 74 (2.3) 134 (4.1) 582 (17.9) 525 (16.1) 
P value*  0.001 0.250 < 0.001 < 0.001 0.160 0.010 0.002 < 0.001 0.520 0.130 < 0.001 0.001 
a, b, c numbers within columns with a letter in common are not significantly different. 
* Significant decrease in P. aeruginosa, MSSA, MRSA, B. cepacia complex and Aspergillus infections and a significant increase in 
Stenotrophomonas maltophilia infection. 
MSSA: methicillin sensitive Staphylococcus aureus; MRSA: methicillin resistant Staphylococcus aureus; S. maltophilia: Stenotrophomonas 
maltophilia; NTM: nontuberculous mycobacteria. 
% Nontuberculous mycobacteria species: M. abscessus (n = 66), M. avium (n = 8), M. bolletii (n = 1), M. chelonae (n = 2), M. fortuitum (n = 
3), M. intracellulare (n = 55), M. lentiflavium (n = 1), M. massilense (n = 1), M. scrofulaceum (n = 2), M. shimoide (n = 1), M. simiae (n = 1), 
M. species (n = 1); seven patients had more than one NTM infection. 
$ A modification of the Leed’s criteria was used to define chronic P. aeruginosa infection: i) in patients providing four or more sputum samples 
in a calendar year was determined when > 50% of sputum samples were culture positive and ii) in instances where fewer than four samples 
were collected or less than 50% of samples were culture positive; data from the previous year was reviewed and if the patients also fulfilled 
the above criteria they were also classified as having chronic infection. 
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2.4.3 Leed’s Criteria in an Adult CF Centre 
Over the period 2001 to 2014, a total of 3262 patient-years were studied and a median of three  
(IQR: 1 - 6) sputum samples per patient per year were collected. When patients who did not provide any 
samples in a year were excluded, a median of four (IQR: 2 - 7) samples were collected. Of these patients, 
those who provided > 4 samples represented 1441 of 2735 patients-years (53%).  
 
To illustrate the impact of applying the Leed’s versus the Modified Leed’s criteria for defining chronic 
P. aeruginosa infection, data from 2013 and 2014 were compared using both definitions. Using the 
Leed’s criteria to define patients with chronic P. aeruginosa infection (> 50% of > 4 samples analysed) 
in 2013, 190 patients were identified, yet if we then examined the same cohort using the prior year (2012), 
an additional 25 patients were identified (Table 2.3A). Similarly, in examining the 2014 data and 
applying the Leed’s criteria, we identified 193 patients and then when we applied the extended year 
criteria, 28 additional patients were identified (Table 2.3B). Using the modified Leed’s criteria, 67% of 
CF adults had chronic P. aeruginosa infection and this prevalence remained stable over time  
(P = 0.250). 
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Table 2.3 Comparisons of Leeds Criteria with the Modified Criteria to define Pseudomonas aeruginosa 
infection status a.  
 
Panel A 
YEAR 2013 - TOTAL PATIENTS = 267 
 
Chronic  
P. aeruginosa 
infection 
Indeterminant  
P. aeruginosa 
infection 
No P. aeruginosa 
isolated 
No sample collected 
Leed’s 
Criteria 
190 6 28 43 
Modified 
Criteria 
215 6 
No Pa 
isolated b 
Chronic 
infection 
No 
sample c 
Chronic 
Infection 
19 9 27 16 
 
Panel B 
YEAR 2014 - TOTAL PATIENTS = 282 
 
 
Chronic  
P. aeruginosa 
infection 
Indeterminant  
P. aeruginosa 
infection 
No P. aeruginosa 
isolated 
No sample collected 
Leed’s 
Criteria 
193 6 36 47 
Modified 
Criteria 
221 6 
No Pa 
isolated b 
Chronic 
infection 
No 
sample c 
Chronic 
Infection 
25 11 30 17 
a A modification of the Leed’s criteria was used to define chronic P. aeruginosa infection: i) in patients 
providing four or more sputum samples in a calendar year was determined when > 50% of sputum 
samples were culture positive and ii) in instances where fewer than four samples were collected or less 
than 50% of samples were culture positive; data from the previous year was reviewed and if the patients 
also fulfilled the above criteria they were also classified as having chronic infection. 
b No Pa isolated:  No P. aeruginosa isolated 
c No Sample:   No sample collected 
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2.4.4 Transitioning Patients 
A total of 217 transitioning patients were identified moving into adult care over the 14 years, with 
between seven and 25 new patients (median: 14) annually. There were no differences in the mean patient 
age at entry (P = 0.350), distribution of CFTR genotypes (P = 0.740) or proportion of patients with 
pancreatic insufficiency (P = 0.270). We observed significant improvements in lung function (FEV1 
%pred P = 0.008; FVC %pred; P < 0.001) and nutritional status (P = 0.048) and an increase in patients 
diagnosed with CF-related diabetes (P = 0.031) over time (Table 2.4). Improvements in lung function 
appeared to be dependent upon P. aeruginosa infection status (Table 2.5). There was a significant and 
incremental improvement in lung function across cohorts for patients with  
P. aeruginosa infection. 
 
Overall, we observed that there was a 13% increase in the number of patients unable to provide a sputum 
sample, and an 8% reduction in organisms isolated when comparing the 2010 - 2014 cohort with the 
2001 - 2004 cohort (Table 2.6). P. aeruginosa, MSSA and Aspergillus spp. represented the most common 
pathogens detected in transitioning patients. At the time of transition, P. aeruginosa was cultured from 
138/217 (64%) patients, with 80% of these patients suffering chronic infection (110/138). Over the 14 
years, there was a significant decrease in the prevalence of total P. aeruginosa (P = 0.010). The frequency 
of chronic P. aeruginosa infection also decreased, with patients transitioning between 2010 - 2014 17% 
less likely to have chronic P. aeruginosa (43%) than those who transitioned in the 2001 - 2004 cohort 
(61%), though this was not statistically significant (P = 0.087). We also observed an increase in the 
prevalence of S. maltophilia (P = 0.019), while the prevalence of other CF pathogens did not change 
significantly over cohorts.  
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Table 2.4 Clinical characteristics of the 217 transitioning patients at the time of first review at The Prince 
Charles Hospital Adult Cystic Fibrosis Centre. 
 
 
2001 to 2004 
n = 76 
2005 to 2009 
n = 60 
2010 to 2014 
n = 81 
P value 
Sex, males, n (%) 46 (60.5) 29 (48.3) 36 (44.4) 0.120 
Age at transition, years, mean (SD) 17.6 (1.7) 17.7 (1.4) 17.9 (0.9) 0.350 
CFTR genotypes; n (%) a    0.740 
Two Class I-III mutations 57 (78.1) 42 (71.2) 59 (73.8) 
 One or two Class IV or V mutations 3 (4.1) 6 (10.2) 6 (7.5) 
Non classified 13 (17.8) 11 (18.6) 15 (18.8) 
CF related diabetes; n (%) 4 (5.3) 6 (10.0) 15 (18.5) 0.031 
Pancreatic insufficiency; n (%) 72 (94.7) 53 (88.3) 71 (87.7) 0.270 
BMI z-score; median (IQR) b,c 19.4 (17.8-21.4) 20.1 (18.6-22.2) 20.2 (19.0-22.9) 0.048 
FEV1 % predicted; mean (SD) d,e 64.5 (24.6) 66.9 (20.7) 75.1 (20.5) 0.008 
FVC % predicted; mean(SD) d,e 74.7 (22.4) 77.2 (18.6) 87.0 (16.3) < 0.001 
a CFTR genotypes defined Green et al. No CFTR genotype available on 5 patients, therefore not included 
(n = 212) 
b BMI percentiles for boys and girls (2 - 20 years) 
c Missing data on one patient; 14 patients > 20 years, therefore z-score not calculated (n = 202) 
d Calculated using Hankinson et al 1999 and Wang et al 1993. 
e Missing data on one patient (n = 216) 
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Table 2.5 Change in lung function parameters over time when compared to year of entry and 
Pseudomonas aeruginosa status for 217 transitioning patients at time of first review at The Prince Charles 
Hospital Adult Cystic Fibrosis Centre. 
 
  Year of Entry * 
P. aeruginosa 
status 
Outcome 2001 to 2004 # 2005 to 2009 ^ 2010 to 2014 $ 
P value  
(all years) 
Positive 
FEV1 % Predicted, 
mean (95% CI) 
59.1 (53.6 - 64.7) a 66.0 (59.1 - 72.9) ab 73.6 (67.2 - 80.0) b 0.006 
Chronic  55.6 (49.5 - 61.8) a 64.0 (56.3 - 71.7) ab 71.6 (64.6 - 78.6) b 0.008 
Positive 
FVC % Predicted, 
mean(95% CI) 
70.1 (65.3 - 74.9) a 75.7 (69.7 - 81.8) a 86.3 (80.7 - 91.9 ) < 0.001 
Chronic 66.9 (61.6 - 72.3) a 74.5 (67.8 - 81.2) a 85.0 (78.9 - 91.1)  0.001 
* Means within rows with a superscript letter in common did not differ significantly (P ≥ 0.05) 
# 2001 - 2004: Positive P. aeruginosa n = 58, Chronic P. aeruginosa infection n = 46 
^ 2005 - 2009: Positive P. aeruginosa n = 37, Chronic P. aeruginosa infection n = 29 
$ 2010 - 2014: Positive P. aeruginosa n = 43, Chronic P. aeruginosa infection n = 35 
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Table 2.6 Prevalence of infection among the 217 transitioning patients at the time of first review at The Prince Charles Hospital Adult Cystic 
Fibrosis Centre, n (%). 
 
Years 
Number 
of 
patients 
Pseudomonas aeruginosa Staphylococcus aureus 
Achromobacter 
spp. 
S. 
maltophilia 
B. cepacia 
complex^ 
Aspergillus 
spp. 
Scedosporium 
spp. 
NTM% 
No 
pathogen 
detected 
No sample 
collected 
Positive Chronic$ MSSA MRSA 
2001-2004 76 58 (76.3)a 46 (60.5) 27 (35.5) 5 (6.6) 2 (2.6) 0 (0.0) 3 (3.9) 16 (21.1) 1 (1.3) 1 (1.3) 14 (18.4) 8 (10.5) 
2005-2009 60 37 (61.7)ac 29 (48.3) 22 (36.7) 3 (5.0) 1 (1.7) 5 (8.3)c 0 (0.0) 16 (26.7) 5 (8.3) 2 (3.3) 16 (26.7) 16 (26.7)c 
2010-2014 81 43 (53.1)a 35 (43.2) 21 (25.9) 2 (2.5) 5 (6.2) 6 (7.4)c 2 (2.5) 21 (25.9) 3 (3.7) 6 (7.4) 21 (25.9) 19 (23.5)c 
Total 217 138 (63.6) 110 (50.7) 70 (32.3) 10 (4.6) 8 (3.7) 11 (5.1) 5 (2.3) 53 (24.4) 9 (4.1) 9 (4.1) 51 (23.5) 43 (19.8) 
P value*  0.010 0.087 0.30 0.51 0.43 0.019 0.38 0.69 0.14 0.18 0.43 0.037 
a, b, c numbers within columns with a letter in common are not significantly different 
* Significant decrease in P. aeruginosa infection and a significant increase in Stenotrophomonas maltophilia infection. Rates of ‘no sample 
collected’ increased from the first study period 2001 - 2004. 
MSSA: methicillin sensitive Staphylococcus aureus; MRSA: methicillin resistant Staphylococcus aureus; S. maltophilia: Stenotrophomonas 
maltophilia; NTM: nontuberculous mycobacteria. 
^ Burkholderia cepacia complex species: B. cepacia (n = 1), B. cenocepacia (n = 2), B. multivorans (n = 2), Indeterminant B. cepacia complex 
species (n = 1); one patient had more than one B. cepacia complex infection. 
% Nontuberculous mycobacteria species: M. abscessus (n = 6), M. avium (n = 1), M. chelonae (n = 1), M. intracellulare (n = 2); two patients 
had more than one NTM infection. 
$A modification of the Leed's criteria was used to define chronic P. aeruginosa infection: (i) in patients providing four or more sputum samples 
in a calendar year was determined when >50% of sputum samples were culture positive and (ii) in instances where fewer than four samples 
were collected or less than 50% of samples were culture positive; data from the previous year were reviewed and if the patients also fulfilled 
the above criteria they were also classified as having chronic infection. 
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2.4.5 Changing approach to therapy  
Infants and young children in the study were given eradication therapy from 1999 and protocols aimed 
to eradicate the first and subsequent P. aeruginosa isolation of older children commenced at the Royal 
Children’s Hospital (RCH) (Queensland) in 2004. For patients who were cared for at the RCH prior 
to transition to TPCH, microbiology results for this time were accessed (n = 189). Rates of P. 
aeruginosa infection in this subset were consistently high over all 3-yearly tertiles, however a 24% 
decrease in chronic infections was reported for the same time (Table 2.7). This change in practice 
was accompanied by a more intensive approach to regular sputum or upper airways sampling for 
microbiological culture.  
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Table 2.7 Changing rates of never, ever and chronic Pseudomonas aeruginosa infection in children 
transitioning from paediatric care a.  
 
Yearly Tertile Total 
Never Isolated  
P. aeruginosa 
Ever Isolated  
P. aeruginosa 
Chronic P. aeruginosa 
infection 
2001 - 2004 63 1 (1.6) 62 (98.4) 46 (73.0) 
2005 - 2009 54 8 (14.8) 46 (85.2) 29 (53.7) 
2010 - 2014 72 5 (6.9) 67 (93.1) 35 (48.6) 
a Children transitioning to TPCH from the RCH and excludes children transitioning from other 
Queensland and interstate hospitals (n = 28) as comprehensive (all of life) review of all microbiology 
culture results was not possible. 
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2.5 Discussion 
Eradication therapy following P. aeruginosa acquisition is aimed at preventing the establishment of 
chronic infection in people with CF. This treatment is a widely recognised standard of paediatric CF 
care, is effective (i.e. culture negative) in up to 90% of patients and has been shown to extend the 
time to re-infection (i.e. next positive culture) (Doring et al. 2012; Langton Hewer and Smyth 2014; 
Mayer-Hamblett et al. 2015). In association with aggressive P. aeruginosa eradication protocols, and 
with a decreasing prevalence of P. aeruginosa infection, particularly in younger patients (Cystic 
Fibrosis Trust 2015; Cystic Fibrosis Trust 2006; Razvi et al. 2009; Salsgiver et al. 2015; Spicuzza et 
al. 2009), CF Patient Registries have demonstrated improving lung function and nutritional status, 
particularly over the past two decades (Cystic Fibrosis Foundation 2015). Such trends are less clear 
in adults (Lipuma 2010; Millar et al. 2009) and in particular rates of chronic infection remain 
uncertain due to the differences in definitions applied across studies (Pressler et al. 2011). In this 
study we sought to determine whether there has been a temporal change in the airway microbiology 
of adults with CF, with a specific focus on those transitioning from paediatric to adult CF care. 
 
Our analysis demonstrates an overall decrease in the prevalence of total P. aeruginosa infection over 
14 years in both the entire adult and transitioning patient cohorts. Additionally, these data 
demonstrated an overall decrease in prevalence of several other CF pathogens within the adult cohort. 
The decline in rates of P. aeruginosa infection is most likely attributable to an increase in the number 
of transitioning patients free of P. aeruginosa infection. Indeed, between 2001 and 2014, the 
frequency of P. aeruginosa (total and chronic) infection reduced by > 10%. The proportion of patients 
who could not provide a sputum sample also increased. Taken together, these data reflect the findings 
of other recent studies, indicating a healthier CF population at the time of transition from paediatric 
to adult care, in whom lower rates of P. aeruginosa infection are linked with improved clinical 
outcomes such as lung function and lung transplantation (Burgel et al. 2015; VanDevanter et al. 
2008). Given the association of P. aeruginosa infection with accelerated lung function decline, 
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pulmonary exacerbations and increased mortality, successful eradication will remain an important 
component of CF care, however it may not be without risk. Increased exposure to antibiotics 
throughout life may lead to antibiotic allergy and toxicity, and the emergence of antibiotic-resistant 
airway pathogens (Bell and Reid 2014; Chmiel et al. 2014; Smith et al. 2016). Changing airway 
microbiology is presenting novel challenges for adult CF care, including how to best manage 
increasing centre size with cohorts of patients requiring different and increasingly complex 
approaches to infection control (Bell and Reid 2014). Furthermore, considering alternative 
approaches to microbiology surveillance in older patients including performing sputum induction 
may need to increasingly be adapted.  
 
Here we observed an increase in the prevalence of S. maltophilia infection in younger patients at the 
time of transition to adult care that is consistent with other studies, although due to the small number 
of isolations reported this result needs to be interpreted with caution (Parkins and Floto 2015).  
 
We have also shown a decreased prevalence of MSSA in the entire cohort over time that may reflect 
an ageing population. Although we demonstrated a decrease in the prevalence of Aspergillus spp. 
over time there were no major changes to laboratory practice or reporting that might obviously 
account for this, although again focus on intensive antibacterial treatments may contribute. The 
overall prevalence of MRSA also decreased throughout the study and the decrease in MRSA may 
also in part be related to the use of eradication protocols (Garske et al. 2004). Patients diagnosed with 
MRSA infection were managed according to strict infection control practices with eradication therapy 
established in 2001. The declining prevalence of MRSA in this patient population is exceptional 
particularly when compared to CF Centres in the USA where there has been a progressive increase 
in its prevalence over the past 15 years (Cystic Fibrosis Foundation 2015). Consistent with our earlier 
work, we demonstrated that fewer patients acquired B. cepacia complex infection in the latter part of 
the study (Ramsay et al. 2013; Zlosnik et al. 2015), which may reflect stringent infection control 
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practices and the use of antibiotic therapy to attempt to eradicate Burkholderia (Chmiel et al. 2014). 
Nevertheless, new cases of sporadic B. cepacia complex infection continue, emphasising the need for 
vigilant microbiological surveillance (Ramsay et al. 2013; Zlosnik et al. 2015).  
 
A key finding of our study is the observation of declining prevalence of P. aeruginosa and improving 
pulmonary function of the transitioning patients. It is likely that aggressive strategies aimed at early 
identification by increased culture sampling and eradication of P. aeruginosa infection are important 
components of the improvements in lung function observed here. This study was not able to determine 
individual details of prior eradication therapy courses for all patients in the cohort. Rates of ‘never’ 
isolating P. aeruginosa infection have varied but were higher in the second and third periods of the 
study compared with the 2001 - 2004 period. ‘Ever’ P. aeruginosa isolation has been stable over 
time, yet rates with chronic P. aeruginosa infection have trended lower over time. The timing of such 
changes parallels with the changes in practice at the paediatric hospital, specifically the introduction 
of improved microbiological surveillance and antibiotic eradication therapy. Interestingly, 
transitioning patients with P. aeruginosa infection (total and chronic) demonstrated improved lung 
function which was not observed for those patients who did not have P. aeruginosa infection, which 
most likely reflects the relative preservation of lung function that we observed in patients without P. 
aeruginosa infection. 
 
The definition of chronic P. aeruginosa infection had received considerable attention over the past 
20 years and has been particularly important in the era of studies evaluating the effectiveness of  
P. aeruginosa eradication, yet the definition of chronic infection by the Leed’s criteria has not been 
validated in the clinical care of adults with CF (Lee et al. 2003). Whilst, a relatively easy definition 
to apply, in routine clinical practice the provision of four or more samples in a year was only seen in 
~50% of patients, even when those unable to provide any samples were excluded (median samples 
analysed over the 14-year study was 4). We modified the criteria and determined that > 50% of 
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samples collected had P. aeruginosa cultured in a given year and if insufficient results were available, 
results from the prior year informed infection status and this identified many patients who fulfilled 
the criteria in the prior year but not in the subsequent year. Further studies are required to determine 
the value of this modification.  
 
There are several limitations to this study. First, this cohort was a single adult centre study with most 
transitioning patients coming from local paediatric CF Centres. Importantly, whilst Registry data can 
provide information about the changing microbiological epidemiology over time, the depth of the 
information and its completeness may vary within Registries. Data presented in this study were 
obtained from a microbiology-specific database; as such we cannot comment on the relationship 
between P. aeruginosa prevalence and lung function or how treatments may be affecting the 
microbial diversity of the airways. Further, linkages with changing management approach (e.g. 
eradication therapy) are limited at this time point. Our study allows analysis of why such changing 
microbiology profiles may be occurring. Second, these analyses only included routine microbiology 
data generated by clinical laboratories and with the introduction of culture independent methods 
understanding the diversity of microorganisms in the CF airway has occurred, yet these advances had 
not at this point been incorporated into routine clinical practice. One significant change to 
microbiological identification which occurred during the study was the introduction of bioMerieux 
VITEK® MS. This methodology has been shown to accurately and rapidly identify a range of 
significant microbiological pathogens (Desai et al. 2012). Finally, unlike other studies which 
demonstrated a reduction respiratory pathogens, in particular P. aeruginosa infections, following the 
prescription of CFTR modulators (Heltshe et al. 2015; Hisert et al. 2017), due to the small number 
of patients within this cohort receiving ivacaftor treatment, this study was unable to determine if 
colonisation was affected. 
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In conclusion, we demonstrate the prevalence of P. aeruginosa, and several other common respiratory 
pathogens has decreased over the past 14 years in this adult CF cohort, despite no change to 
eradication techniques or hospital management protocols during that time. Of particular note we 
observed that lung function has improved in transitioning patients with P. aeruginosa infection. 
Furthermore, we have adapted the definition of chronic infection to better suit a clinical setting, and 
by doing so demonstrate that prevalence of chronic P. aeruginosa remains unchanged in this adult 
centre, despite a decline in total P. aeruginosa infection prevalence. Amongst many challenges, how 
best to manage the growing number of healthier patients who have fewer respiratory infections will 
continue in adult CF centres. 
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Chapter 3: Longitudinal analysis of Pseudomonas aeruginosa genotypes 
 
3.1 Abstract 
Background: Shared strains of Pseudomonas aeruginosa have been isolated from patients with cystic 
fibrosis (CF) in many countries worldwide. Respiratory infection caused by these strains has been 
associated with poor health outcomes for patients. Due to the lack of an environmental reservoir, 
patient to patient transmission is the most likely source of acquisition. Consequently, cohort 
segregation has been vital in reducing and preventing acquisition of these shared strains. Currently 
limited work has been conducted to assess strain diversity without the implementation of such an 
intervention. Therefore, through the use of longitudinally collected P. aeruginosa isolates, this study 
will assess the change in strain diversity, incidence and clinical impact of shared strains prior to the 
implementation of patient segregation. 
 
Methods: Sputum samples from patients with CF attending The Prince Charles Hospital, Australia 
were collected at two cross sectional time points (Baseline and Final) and screened for  
P. aeruginosa. Isolates were genotyped (SNP-based assay) and strain diversity at both time points 
determined. In addition, clinical measures, including age, sex, CFTR genotype, co-morbidities, 
hospitalisation, lung function and nutritional status were collected. 
 
Results: The prevalence of the AUST-02 strain decreased (P = 0.020) the prevalence of the  
AUST-06 strain increased (P = 0.001) during this study. Following adjustment for clinical 
characteristics patients with the AUST-02 strain were > 3 times more likely to die or require lung 
transplantation. This result was reflected in the high number of patients harbouring this strain that did 
die or required lung transplantation during this study (20%). Despite no change to clinical 
characteristics over time for the entire cohort, patients who acquired a shared strain, in particular 
AUST-06, reported the largest decline to health over the study period.  
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Conclusion: This study confirms that high rates of strain diversity is present within this cohort and 
despite the change in the prevalence of specific shared strains, overall no change in the rates of shared 
strains were noted. Similar to previous reports, patients harbouring a shared strain infection have a 
greater requirement for hospital-based care and a greater decline in lung function compared to patients 
with no shared strain infection’. However, further characterisation, yet to be undertaken, of AUST-
02 virulence using animal and other experimental models is needed to better understand the impact 
this infection has on the health of patients.  
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3.2 Introduction 
Cystic fibrosis (CF) is the most common autosomal recessive disorder affecting Caucasians. The 
leading cause of mortality and morbidity among people with CF is chronic suppurative lung disease, 
often a result of respiratory infection caused by the bacterium Pseudomonas aeruginosa (Ratjen et 
al. 2015). Acquisition of P. aeruginosa from environmental sources has historically been considered 
the primary route of acquisition; however, person-to-person transmission and nosocomial acquisition 
have also been identified as potential infection sources (Jones et al. 2003; Kidd et al. 2013; Kidd et 
al. 2015; Knibbs et al. 2014; Ranganathan et al. 2013; Saiman et al. 2014; Wiehlmann et al. 2012). 
To reduce the risk of cross-infection infection control guidelines recommend the implementation of 
numerous practices including hand hygiene, rigorous cleaning of equipment and facilities designated 
areas for airway clearance and nebuliser use and single rooms for hospital admissions (Saiman et al. 
2014). Improved infection control has been shown to reduce the incidence and prevalence of P. 
aeruginosa infection, as well as, the onset of chronic infection in several settings (Frederiksen et al. 
1999; Wiehlmann et al. 2012). 
 
Genotyping of P. aeruginosa isolates has shown that unrelated patients can harbour genetically 
indistinguishable (shared) strains which have been associated with increased treatment burden and 
poorer health outcomes compared to patients infected with unrelated (non-shared) strains (Aaron et 
al. 2010; Armstrong et al. 2002; Cheng et al. 1996; Kidd et al. 2013; O'Carroll et al. 2004; Scott and 
Pitt 2004; van Mansfeld et al. 2009). Cohort segregation based on shared strain infection status has 
demonstrated that separation of patients, limiting interactions during all hospital attendances and also 
preventing social contact, can have a substantial impact on the incidence and prevalence of shared 
strain infections (Ashish et al. 2013; Griffiths et al. 2005). However, not all studies have reported a 
significant change to rates of P. aeruginosa acquisition based on these interventions. van Mansfeld 
and colleagues reported that although no new acquisitions of a predominant Dutch shared strain were 
identified following the introduction of strict segregation, overall there was no change in the incidence 
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of chronic infection (van Mansfeld et al. 2016). Conversely, the implementation of patient 
segregation has not been shown to significantly affect the rates of non-shared strain infections (Ashish 
et al. 2013; Griffiths et al. 2005; Jones et al. 2005), and furthermore, the strict adherence to infection 
control and hygiene practices has increased the heterogeneity of strains, suggesting environmental 
acquisition is still occurring (Griffiths et al. 2005; Kidd et al. 2013; Matt et al. 2014).  
 
Despite evidence of reduced shared strain infection supporting cohort segregation not all CF centres 
have the facilities, resources and infrastructure to genotype isolates on a regular basis and provide 
single room inpatient accommodation for all patients. Over the past ten to fifteen years, there has 
been a gradual update to more stringent cohort segregation as hospitals and CF centres have adapted 
resources and facilities to ensure that such care to be implemented. In a prospective observational 
study conducted by Aaron and colleagues, although they reported a high prevalence of shared strains, 
there were relatively few new acquisitions observed during the study. It is also unclear if the 
prevalence rates of shared strain infections within this cohort changed over time (Aaron et al. 2010). 
Within Australia, cross-sectional analyses have identified a number of prevalent shared strains and 
demonstrated a decline in these strains following implementation of cohort segregation(Bradbury et 
al. 2008; Griffiths et al. 2005; Kidd et al. 2013; O'Carroll et al. 2004; Tingpej et al. 2010). To date 
longitudinal analyses of changing prevalence of shared strains have been limited. 
 
Therefore, the aim of this prospective longitudinal study was to undertake a seven year study in which 
the prevalence and incidence of predominant shared stains was evaluated within the adult CF 
population at The Prince Charles Hospital (TPCH), Brisbane, Australia. A secondary aim of this work 
was to determine if acquisition of a shared strain was associated with worse clinical outcomes. 
 
3.3 Materials and Methods 
3.3.1 Study Population 
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This study comprised of patients recruited into a national cross-sectional study (i.e. the Australian 
Clonal Pseudomonas in CF [ACPinCF] Study) aimed at assessing the prevalence and clinical impact 
of shared P. aeruginosa strain infections within the Australian CF population (Kidd et al. 2013). 
During the ACPinCF Study patients provided expectorated sputum samples at recruitment and 
annually thereafter for up to five years. Briefly, P. aeruginosa (three colonies per sample) isolated 
from culture positive samples were transferred to a research lab for confirmatory molecular 
identification and genotyping. 
 
The current investigation was focused on one of the largest adult ACPinCF Study centres (TPCH, 
Brisbane, Queensland; ACPinCF study identifier QLD02 (Kidd et al. 2013) and assessed the cross-
sectional prevalence of the three predominant shared strains, AUST-01, AUST-02 and AUST-06 
(point prevalence ≥ 10%) at recruitment (Baseline; 2007 – 2009) and then after approximately five 
years (Final; 2012 – 2014) or study censor point (i.e. death, lung transplantation, patient relocation or 
no further P. aeruginosa isolated). For inclusion into this study, P. aeruginosa positive sputum 
samples had to be collected from patients at least one sampling time points. Comparison of each 
patient’s P. aeruginosa genotyping results at the two time points was undertaken to identify potential 
incidence cases of shared strain infection. For patients identified as an incidence case, genotyping of 
annually collected isolates was performed. Clinical characteristics, including age, sex, CFTR 
genotype, co-morbidities, number of days in hospital and number of hospital admissions were 
collected at Baseline and Final sample collection. Lung function (i.e. forced expiratory volume in 1 
second [FEV1]) and nutrition (body mass index [BMI]; kg/m
2) data recorded at each hospital visit 
across the study period was collected for all participants (Hankinson et al. 1999; Wang et al. 1993). 
Baseline clinical data and bacterial isolates collected from ACPinCF Study participants that were 
recruited to other study centres and transferred to TPCH during the study period were also included 
in the analysis.  
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3.3.2 Sample collection and isolate identification 
Sputum P. aeruginosa isolates were cultured and identified by diagnostic microbiology laboratories 
using standard techniques (Kidd et al. 2009). When P. aeruginosa was identified, three 
morphologically distinct colonies (where possible) were selected for inclusion in this study and 
forwarded onto the research laboratory for storage at -80 °C until required for further testing (Kidd 
et al. 2013). 
 
3.3.3 Isolate storage and retrieval 
On arrival in the research laboratory each isolate was sub-cultured onto nutrient agar to assess purity 
and then stored at -80 °C in 15% glycerol (Kidd et al. 2009). When required for testing, each stored 
isolate was cultured overnight on LB agar at 37 °C and then sub-cultured using the same conditions 
prior to analysis (Syrmis et al. 2013).  
 
3.3.4 DNA Extraction 
Heat denatured bacterial DNA was prepared as follows. A 1.0 McFarland suspension was prepared 
from a 24-hour single-colony subculture in 2.0 mL of water and heated for 20 minutes at 95 °C. Each 
suspension was then centrifuged at 14,000 rpm for 4 minutes, with the supernatant stored at  
-80 °C prior to genotyping (Anuj et al. 2009; Syrmis et al. 2013).  
 
3.3.5 Confirmatory Identification 
All isolates underwent P. aeruginosa-specific real time duplex PCR assay targeting the ecfX and gyrB 
genes to confirm their identity (Anuj et al. 2009). Each PCR reaction mix consisted of 12.5 µL of 
Qiagen Quantitect Probe Master Mix, 10 pmol/µL each forward and reverse primer (Table 3.1),  
20 pmol/µL of each TaqMan probe (Table 3.2) and 2 µL of DNA template, made up to a final reaction 
volume of 25 µL with DNA-free water. Thermal cycling conditions comprised a single initial cycle 
at 95 °C for 15 minutes, followed by 50 cycles of 95 °C for 15 seconds and 60 °C for 60 seconds and 
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one final cooling cycle of 40 °C for 30 seconds. Cycling and amplicon detection was performed on a 
LightCycler®480 instrument. The fluorescent probes for ecfX and gyrB were labelled with Yakima 
Yellow (YAK) and a fluorescein, FAM, so they could be detected in the JOE (523 - 568 nm) and 
FAM (483 - 533 nm) channels, respectively (Anuj et al. 2009; Kidd et al. 2009). Control strain 
isolates including Achromobacter xylosoxidans LMG 1863 and representative AUST-01 and AUST-
02 P. aeruginosa isolates were included in each assay.  
 
Table 3.1 Primers used in P. aeruginosa specific real time duplex PCR assay. 
 
Name Primer Sequence 5'-3' 
ecfX-fwd CGCATGCCTATCAGGCGTT 
ecfX-rvs GAACTGCCCAGGTGCTTGC 
gyrB-fwd CCTGACCATCCGTCGCCACAAC 
gyrB-rvs CGCAGCAGGATGCCGACGCC 
 
Table 3.2 Probes used in P. aeruginosa specific real time duplex PCR assay. 
 
Name Probe Sequence 5'-3' 
ecfX-probe JOE-ATGGCGATTTGCTGCGCTTCCT-BHQ1 
gyrB-probe FAM-CCGTGGTGGTAGACCTGTTCCCAGACC-BHQ1 
 
3.3.6 20-SNP iPLEXMassARRAY  
A combination of 20 informative single nucleotide polymorphisms (SNPs) capable of differentiating 
the dominant shared strains were identified from sequence data found on the  
P. aeruginosa PubMLST website (Jolley and Maiden 2010; Pseudomonas aeruginosa PubMLST 
Database 2012). As described by Syrmis and colleagues, 24 amplification and 21 extension primers, 
have been designed to identify the 20 most informative SNPs (Syrmis et al. 2014; Syrmis et al. 2013). 
All PCRs described below were prepared and performed by AGRF using the Agena Bioscience, Inc. 
iPLEX® assay protocols and analysed on the MassARRAY® System and using TyperAnalyzer 
software. 
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3.3.7 DNA Amplification 
Each reaction contained 1 x PCR buffer (supplemented with 2 mM MgCl2), 2 mM MgCl2, 500 µM 
dNTP mix, 100 nM of each amplification primer, (Syrmis et al. 2014; Syrmis et al. 2013) 1 U/rxn 
PCR enzyme and 2 µL of DNA template, adjusted with water to a final volume of 5 µL. Thermal 
cycling run conditions for the amplification PCR were, an initial cycle of 95 °C for 2 minutes, 
followed by 45 cycles of 95 °C for 30 seconds, 56 °C for 30 seconds and 72 °C for 60 seconds with 
a final extension cycle at 72 °C for 5 minutes. SAP treatment, to dephosphorylate unincorporated 
dNTP’s, was then performed to prepare the template for SNP analysis. The SAP reaction mixed 
consisted of 1X SAP buffer and 0.5 U/µL SAP enzyme, adjusted with water to a final volume of 7 
µL. An initial incubation of 37 °C for 40 minutes and enzyme deactivation of 85 °C for 5 minutes 
constituted the thermal cycling conditions (Syrmis et al. 2013).  
 
3.3.8 Extension PCR 
A prepared amplification PCR template iPLEX (Sequenom) reaction mix was added to each well. 
This extension mix contained 0.2 µL iPLEX Buffer Plus, 0.2 µL iPLEX Termination Mix, 0.94 µL 
extension primers and 0.04 µL iPLEX enzyme adjusted with water to a final volume of 2µL. Thermal 
cycling conditions consisted of an initial cycle of 95 °C for 30 seconds, followed by 40 cycles of 95 
°C for 5 seconds, with five subcycles of 52 °C for 5 seconds and 80 °C for 5 seconds, completed with 
one cycle of 72 °C for 3 minutes (Syrmis et al. 2013).  
 
 
 
3.3.9 Definitions 
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Shared Strains: Comprise AUST-01, AUST-02 and AUST-06 which represented the most prevalent 
(point prevalence of ≥ 10%) P. aeruginosa strains isolated within TPCH Adult CF centre between 
2007 and 2009 (Kidd et al. 2013). 
 
Minor Shared Strains: Refer to strains which have been identified in two or more of the participants 
of this current study with a point prevalence of < 10%. In some analyses (unique and minor shared 
strain) are referred to as ‘non-shared strains’.  
 
Unique Strains: Refer to singleton strains which have only been isolated in one patient throughout 
the duration of the study (Kidd et al. 2013).  
 
Hospital Admissions: The number of hospital admissions resulting from respiratory symptoms 
occurring during the calendar year in which Baseline and Final sample collections were obtained. 
Hospital Days: The number of inpatients days, resulting from respiratory symptoms which occurred 
during the calendar year in which Baseline and Final sample collections were obtained. 
 
3.3.10 Statistical Analysis 
For continuous variables summary statistics are presented as either mean (standard deviation, SD) or 
median (interquartile range, IQR) depending on the distribution. For categorical variables summary 
statistics are presented as frequency (percentage). Differences between groups at baseline were 
investigated using linear regression with 'group' included as the main effect. Differences across time 
were investigated using linear regression with time included as the main effect.  
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3.4 Results 
3.4.1 Study Population 
Figure 3.1 shows a total of 266 patients provided one or more P. aeruginosa-positive sample during 
the study period. One hundred and seventy-one patients were recruited and managed within TPCH 
Adult CF Centre (ACFC), TPCH at Baseline (2007 – 2009), and 222 patients provided a Final  
P. aeruginosa-positive sample between 2012 and 2014. After Baseline recruitment, 67 patients 
transferred into TPCH from other CF centres, 28 existing patients produced P. aeruginosa-positive 
sputum cultures and 44 patients were censored prior to study completion (death n = 8, lung 
transplantation n = 21, relocation n = 14, and no P. aeruginosa isolated n = 1). Of the 171 patients 
recruited to TPCH at Baseline, 127 (74.3%) also provided a P. aeruginosa-positive sputum at the 
Final sample collection time point.  
 
The overall mean duration between Baseline and Final sample collection for the entire patient cohort 
was 4.3 years (SD ± 1.6 years) and the mean annualised rate of lung function decline for all patients 
was -1.3 FEV1 % predicted. With the exception of age, there were no differences in the clinical 
characteristics of the patients that provided samples at the Baseline (n = 171) and Final  
(n = 222) sample collection time points (Table 3.3A). In contrast, the 127 patients who attended the 
TPCH throughout the study experienced an increased number of hospital admissions (P = 0.034) and 
in- patient days (P = 0.009) and a reduction in lung function (P = 0.002) at the latter sample collection 
time point (Table 3.3B). 
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Figure 3.1 Flowchart of patient recruitment and censoring from Baseline (2007-2009) and Final (2012-2014) sample collection at The Prince Charles 
Hospital Adult CF Centre, (n = 266). 
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Table 3.3A Clinical characteristics of study participants attending The Prince Charles Hospital Adult 
CF Centre across the Baseline (n = 171) and Final (n = 222) sample collection time points. 
 
 Baseline Final P-value 
Subjects, n 171 222  
Age at collection, years, mean (95% CI) 28.4 (27.1 - 29.7) 30.2 (29.0 - 31.5)  
Sex, males, n (%) 102 (59.6) 124 (55.9) 0.451 
CFTR, n (%)    
Minimal function 135 (78.9) 176 (79.3) 
0.920 
Residual function 12 (7.0) 13 (5.9) 
Not classified 16 (9.4) 24 (10.8) 
Not available 8 (4.7) 9 (4.1) 
Pancreatic Insufficient, n (%) 159 (93.0) 206 (92.9) 0.942 
Insulin Dependent Diabetes, n (%) 30 (17.5) 38 (17.1) 0.934 
FEV1 % predicted, mean (95% CI) 59.8 (56.4 - 63.1) 60.8 (57.7 - 63.9)a 0.655 
Mean (95% CI) Annual FEV1 % predicted decline -1.3 (-1.4 to -1.2)  
BMI, mean (95% CI) 22.0 (21.5 - 22.6) 22.5 (22.0 - 23.0)a 0.246 
Hospital Admissions - Respiratory, median (IQR) 1.0 (0.0 - 2.0) 1.0 (0.0 - 3.0) 0.319 
Hospital Days - Respiratory, median (IQR) 11.0 (0.0 - 23.0) 13.0 (0.0 - 33.0) 0.088 
a FEV1 % predicted and BMI data were not available for five and two patients, respectively. 
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Table 3.3B Clinical characteristics of study participants attending The Prince Charles Hospital Adult 
CF Centre throughout the study (n = 127). 
 
 Baseline Final P-value 
Age at collection, years, mean (95% CI) 27.9 (26.5 - 29.2) 33.0 (31.6 - 34.3) - 
Sex, male n (%) 83 (65.4) - 
CFTR, n (%)    
Minimal function 108 (85.0) 
- 
Residual function 10 (7.9) 
Not classified 8 (6.3) 
Not available 1 (0.8) 
Pancreatic Insufficient, n (%) 119 (93.7) 119 (93.7) 1.000 
Insulin Dependent Diabetes, n (%) 16 (12.6) 22 (17.3) 0.572 
FEV1 % predicted, mean (95% CI) 64.7 (61.2 - 68.1) 56.8 (53.1 - 60.5)a 0.002 
Mean (95% CI) Annual FEV1 % predicted decline -1.3 (-1.4 to -1.2)  
BMI, mean (95% CI) 22.4 (21.8 - 23.1) 23.2 (22.5 - 23.8)a 0.127 
Hospital Admissions - Respiratory, median (IQR) 1.0 (0.0 - 2.0) 1.0 (0.0 - 3.0) 0.034 
Hospital Days - Respiratory, median (IQR) 10.0 (0.0 - 22.0) 14.0 (0.0 - 34.0) 0.009 
a FEV1 % predicted and BMI data were not available for two and one patients, respectively.  
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3.4.2 Strain diversity  
A total of 509 and 658 isolates were available for genotyping at the Baseline and Final collection time 
points, respectively. Of the 246 patients for which isolates were available for genotyping at both time 
points, 159 (65%) showed the same P. aeruginosa strain(s) at Baseline and Final sample collection. 
Of these patients, shared strain retention was noted for 81 patients (51%).  
 
Over the study period a significant decrease in the prevalence of the AUST-02 shared strain, 
(Baseline: 37.4%, Final: 26.6%; P = 0.020) and an increase in the prevalence of the AUST-06 shared 
strain (Baseline: 11.1%, Final: 24.8%; P = 0.001) was observed. In contrast, the prevalence of AUST-
01 (Baseline: 12.3%, Final: 11.3%; P = 0.760), minor shared (Baseline: 33.9%,  
Final: 32.9%; P = 0.830) and unique strain (Baseline: 20.5%, Final: 22.5%; P = 0.620) infections 
remained similar (Table 3.4). 
 
Table 3.4 Strain diversity of Pseudomonas aeruginosa isolates cultured from study participants 
attending The Prince Charles Hospital Adult CF Centre across the Baseline (n = 171) and Final  
(n = 222) sample collection time points.  
 
P. aeruginosa strain 
Baseline Final 
Percentage Mean Difference  
(95% CI) 
P-value n = 171 n = 222 
n (%) n (%) 
AUST-01 21 (12.3) 25 (11.3) -1.0 (-7.5 - 5.4) 0.760 
AUST-02 64 (37.4) 59 (26.6) -10.9 (-20.1 - 1.6) 0.020 
AUST-06 19 (11.1) 55 (24.8) 13.7 (6.2 - 21.0) 0.001 
Minor Shared strains 58 (33.9) 73 (32.9) -1.0 (-10.4 - 8.4) 0.830 
Unique strains 35 (20.5) 50 (22.5) 2.1 (-6.1 - 10.2) 0.620 
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3.4.3 Clinical characteristics of patients stratified according to strain type infection 
The clinical characteristics of patients attending TPCH for the complete duration of the study  
(n = 127) stratified according to strain type infection at Baseline and Final sample collection time 
points are presented in Table 3.5. Despite the decline in prevalence over time, patients harbouring the 
AUST-02 strain remained the largest proportion of this cohort. Patients with AUST-01, AUST-02 
and AUST-06 were younger at Baseline sample collection compared with those harbouring minor 
shared and unique strains. Males comprised almost all the patients in the AUST-01 strain group; 
whereas the gender distribution for all other strain groups was more reflective of the entire cohort. 
Rates of co-morbidities were similar across each of the strain groups.  
 
The association between strain and clinically relevant parameters was explored. This analysis 
revealed that compared to the AUST-02 strain group, patients with AUST-06 infection showed 
significantly poorer lung function (FEV1% predicted: 46.4% versus 59.8% [P = 0.011]) at Baseline 
sample collection. Mean FEV1% predicted of AUST-06 infected patients at Baseline was also 
substantially lower than those showing AUST-01 (55.6%), minor shared (59.6%) and unique strain 
(54.8%) infection; though, these differences were not statistically significant. At Baseline, patients 
with AUST-02 and minor strain infections also experienced less hospital admissions (Minor,  
P = 0.007) and fewer inpatient days (AUST-02, P = 0.036, Minor, P = 0.012) compared to patients 
in the AUST-06 strain group. When assessing the deterioration in clinical markers across the study 
period no differences in the annual decline of lung function or rates of hospitalisation at the Final 
sample collection time point across the different strain groupings was observed. However, this 
analysis did indicate a trend towards greater FEV1 % predicted decline for patients with AUST-06 
infection. In addition, all patient groups, particularly those with AUST-06, showed a significantly 
increased annual decline in nutritional status compared to patients with AUST-01 infection.  
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Table 3.5 Clinical characteristics of subjects treated within at TPCH ACFC throughout the study, stratified according to P. aeruginosa genotype at the baseline and final collection time points. 
 
 AUST-01 AUST-02 AUST-06 Minor Unique 
 Baseline Final Baseline Final Baseline Final Baseline Final Baseline Final 
Subjects, n (%) 15 (11.8) 14 (11.0) 46 (36.2) 42 (33.1) 15 (11.8) 31 (24.4) 44 (34.7) 42 (33.1) 24 (18.9) 24 (18.9) 
Age at collection, years, mean (95% CI) 26.4 (22.7 - 30.1) 31.2 (27.3 - 35.0) 25.7 (23.8 - 27.5) 30.7 (28.8 - 32.6) 26.2 (22.9 - 29.6) 33.5(30.8 - 36.3) 29.3 (26.9 - 31.6) 35.0 (32.5 - 37.5) 31.7 (27.5 - 35.9) 35.3 (31.1 - 39.4) 
Sex, males, n (%) 14 (93.3) 14 (100.0) 31 (67.4) 29 (69.1) 8 (53.3) 19 (61.3) 27 (61.4) 25 (59.5) 14 (58.3) 14 (58.3) 
CFTR, n (%)            
Minimal function 13 (86.7) 12 (85.7) 41 (89.1) 38 (90.5) 11 (73.3) 27 (87.1) 38 (86.4) 34 (81.0) 20 (83.3) 21 (87.5) 
Residual function 2 (13.3) 2 (14.3) 3 (6.5) 2 (4.8) 3 (20.0) 3 (9.7) 1 (2.3) 2 (4.8) 3 (12.5) 2 (8.3) 
Not classified 0 (0.0) 0 (0.0) 2 (4.4) 2 (4.8) 0 (0.0) 0 (0.0) 5 (11.4) 6 (14.3) 1 (4.2) 1 (4.2) 
Not available 0 (0.0) 0 (0.0)  0 (0.0) 1 (6.7) 1 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Pancreatic Insufficient, n (%) 15 (100.0) 14 (100.0) 45 (97.8) 42 (100.0) 14 (93.3) 29 (93.6) 40 (90.9) 38 (90.5) 21 (87.5) 22 (91.7) 
Insulin Dependent Diabetes, n (%) 0 (0.0) 0 (0.0) 6 (13.0) 7 (16.7) 3 (20.0) 9 (29.0) 8 (18.2) 8 (19.1) 3 (12.5) 5 (20.8) 
FEV1 % predicted, mean (95% CI) a 55.6 (45.4 - 65.8) 52.4 (39.8 - 64.9) 59.8 (54.3 - 65.3) * 54.2 (47.7 - 60.7) 46.4 (38.4 - 54.4) 44.1 (37.4 - 50.9) 59.6 (53.3 - 65.9) 54.5 (47.8 - 61.3) 54.8 (48.3 - 61.3) 46.8 (37.5 - 56.1) 
Mean (95% CI) Annual FEV1% predicted decline -1.3 (-2.4 to -0.2) -1.6 (-2.3 to -0.9) -2.3 (-3.8 to -0.9) -1.3 (-2.0 to -0.7) -1.1 (-2.0 to -0.2) 
BMI, mean (95% CI) b 22.4 (20.3 - 24.4) 25.0 (23.0 - 27.0) 22.3 (21.3 - 23.3) 22.3 (21.1 - 23.4) 21.8 (20.3 - 23.3) 21.9 (20.6 - 23.3) 22.7 (21.6 - 23.8) 23.8 (22.3 - 25.4) 22.3 (20.4 - 24.1) 21.9 (20.3 - 23.5) 
Mean (95% CI) Annual BMI decline 0.47 (0.29 to 0.66) 0.13 (0.01 to 0.24) ^ -0.02 (-0.28 to 0.23) ^ 0.08 (-0.03 to 0.20) ^ -0.01 (-0.17 to 0.14) ^ 
Hospital Admissions - Respiratory, median (IQR) 1 (1 - 2) 1 (0 - 2) 1 (0 - 2) * 1 (1 - 3) 2 (0 - 4) 3 (2 - 4) 1 (0 - 1) * 1 (0 - 2) 1 (0 - 2) 2 (0.5 - 3) 
Hospital Days - Respiratory, median (IQR) 11 (7 - 14) 14 (0 - 20) 10.5 (0 - 24) 13 (8 - 36) 12 (0 - 51) 42 (17 - 63) 8 (0 - 13) * 11.5 (0 - 20) 7 (0 - 22.5) 14 (4.5 - 32.5) 
a FEV1 % predicted results unavailable from between 1 and 8 patients 
b BMI results unavailable for between 1 and 9 patients 
* Compared to AUST-06 Baseline results these results were statistically different (P ≤ 0.05) 
^ Compared to the mean annual decline of AUST-01 these results were statistically different (P ≤ 0.05) 
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3.4.4 Clinical characteristics of patients with a stable P. aeruginosa genotype infection 
Of the 159 patients who retained the same P. aeruginosa genotype(s) throughout the study period, 
non-shared and shared strains were reported in 73 and 86 of subjects, respectively. Fifty-one (32%) 
of these patients attended a centre other than TPCH at Baseline, while 78 (49%) attended TPCH 
throughout the entire study period. The remaining 30 patients provided P. aeruginosa sample for 
genotyping up until the point of censoring and did not contribute Final samples due to lung 
transplantation (n = 11), death (n = 5), relocation to another CF centre (n =11), lack of sputum 
productivity (n = 1).  
 
Table 3.6 shows that compared to patients with stable shared infection, those with stable non-shared 
strain infections were older and more likely to be female, but showed similar lung function and 
nutritional parameters. Furthermore, decline in lung function over time did not differ between the two 
groups (P = 0.133). Importantly, there was a significant difference in hospitalisation rates between 
the two groups at Baseline. Patients with a non-shared strain infection had on average one admission 
fewer than those with a shared strain (P = 0.010) and 14 fewer days in hospital  
(P = 0.001) per year; however, when this was compared at study completion there was no difference 
(Admissions P = 0.354, Days P = 0.096) (Table 6).  
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Table 3.6 Comparison of clinical characteristics of the study participants with a stable infection at Baseline and Final sample collection time points. 
 
 Same Non-Shared Strain at both collection time points Same Shared Strain at both collection time points 
 Baseline Final Baseline Final 
 n = 73 n = 86 
Age at collection, years, mean (95% CI) 28.4 (25.8 - 31.0) 32.4 (30.0 - 35.0) 24.1 (22.6 - 25.6) 28.6 (27.1 - 30.1) 
Sex, males, n (%) 28 (38.4) 56 (65.1) 
Lung Transplantation, n (%) 4 (5.5) 9 (10.5) 
Deceased, n (%) 3 (4.1) 2 (2.3) 
Pancreatic Insufficient, n (%) 63 (86.3) 65 (89.0) 84 (97.7) 84 (97.7) 
Insulin Dependent Diabetes, n (%) 9 (12.3) 13 (17.8) 12 (14.0) 15 (17.4) 
FEV1 % predicted, mean (95% CI) 61.1 (58.0 - 66.3) a 58.6 (53.1 - 63.9)  66.1 (61.1 - 71.2) 59.4 (53.8 - 65.0) c 
BMI, mean (95% CI) 21.6 (20.7 - 22.4) a 22.0 (21.2 - 22.9) b 21.6 (20.8 - 22.3) 22.4 (21.6 - 23.3) c 
Hospital Admissions - Respiratory, median (IQR) 1.0 (0.0 - 1.0) * 1.0 (0.0 - 2.0) 1.0 (1.0 - 3.0) * 1.0 (0.0 - 3.0) 
Hospital Days - Respiratory, median (IQR) 3.0 (0.0 - 14.0) * 12.0 (0.0 - 26.0) 13.0 (3.0 - 28.0) * 15.0 (0.0 - 36.0) 
Clinical parameters were unavailable for a number of patients at both time points; therefore total numbers tested a n = 71, b n = 69, c n = 80. 
* Denotes a statistical difference between Baseline results (P = ≤ 0.05) 
FEV1 % predicted decline was not calculated as 51 patients had care at another CF for the Baseline sample collection. 
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3.4.5 Clinical characteristics of patients who acquired a new shared strain infection 
Thirty-four patients acquired a new shared strain of P. aeruginosa during the study. As there was 
only one patient who acquired AUST-01 and one patient that acquired AUST-02 and AUST-06 
combined, they were excluded from further analysis. Of the 32 incident cases analysed, eight (25%) 
patients acquired AUST-02, while 24 (75%) acquired AUST-06. Of the 24 patients that acquired 
AUST-06, 16 (67%) were managed at TPCH ACFC throughout the entire study period. Therefore, 
the increased prevalence of the AUST-06 strain could not be explained by new cases coming into 
TPCH ACFC from other healthcare settings.  
 
The clinical characteristics of patients with an existing AUST-02 infection and those who acquired 
this strain during the study are presented in Table 3.7. This analyses shows that these patient groups 
were similar for age, gender distribution, CFTR genotype and co-morbidities. Patients who acquired 
AUST-02 appeared to have greater lung function decline (Retention: -1.8 FEV1 % predicted, 
Acquisition: -4.0 FEV1 % predicted; P = 0.894), though this was not significant. Nutritional status  
(P = 0.629) and hospitalisation requirements (Admissions, P = 0.671; Days, P = 0.878) were similar 
between the groups. Interestingly, a significant increase in the number of hospital days at Baseline 
compared to Final sample collection was observed for the patients who acquired an AUST-02 
infection (Baseline n = 4, Final n = 11.5; P = 0.04), whereas there was no change to hospital days 
reported for the patients who retained an AUST-02 infection (Baseline n = 12, Final n = 13.5;  
P = 0.51). 
 
The clinical characteristics of patients with an existing AUST-06 infection are compared with those 
who acquired this strain during the study in Table 3.8. This analyses shows patients who acquired the 
AUST-06 strain were older and that the proportion of patients with minimal CFTR function and  
co-morbidities were similar between the two patient groups. The lung function values reported at 
Baseline were considerably different between the groups, this however did not achieve significance 
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(P = 0.115). Comparison of Baseline and Final clinical data showed that patients who acquired 
AUST-06 had similar lung function decline (Retention: -2.6 FEV1 % predicted, Acquisition:  
-2.8 FEV1 % predicted; P = 0.121), hospitalisation rates (Admissions, P = 0.676; Days, P = 0.907) 
and better nutrition that those who retained this strain over time (P = 0.015).   
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Table 3.7 Clinical characteristics of patients with a recent AUST-02 acquisition compared to those who retained an AUST-02 infection for the duration 
of the study. 
 
  Retention of AUST-02 strain   Acquisition of AUST-02 strain 
 n = 36   n = 6 
  Baseline Final   Baseline  Final 
Average age at collection, years, mean (95% CI) 25.4 (23.3 - 27.4) 30.6 (28.5 - 32.6)   26.6 (17.9 - 35.2) 31.4 (23.1 - 39.7) 
Sex, males, n (%) 25 (69.4)   4 (66.7) 
CFTR, n (%)       
Minimal function 33 (91.7)   5 (83.3) 
Residual function 2 (5.6)   0 (0.0) 
Not classified 1 (2.8)   1 (16.7) 
Not available 0 (0.0)   0 (0.0) 
Lung Transplantation, n (%) 1 (2.8)   1 (16.7) 
Deceased, n (%) 2 (5.6)   2 (33.3) 
Pancreatic Insufficient, n (%) 36 (100.0) 36 (100.0)   6 (100.0) 6 (100.0) 
Insulin Dependent Diabetes, n (%) 4 (11.1) 6 (16.7)   1 (16.7) 1 (16.7) 
FEV1 % predicted, mean (95% CI) 70.6 (64.8 - 76.4) 61.3 (54.0 - 68.6) 
a   66.5 (43.4 - 89.6) 48.8 (31.2 - 66.4) 
Mean (95% CI) Annual FEV1% predicted decline -1.8 (-2.5 to -1.1) 
b   -4.0 (-9.8 to 1.8) 
BMI, mean (95% CI) 22.1 (21.0 - 23.2) 22.6 (21.5 - 23.8)   20.2 (16.6 - 23.7) 19.6 (16.3 - 22.9) 
Mean (95% CI) Annual BMI decline 0.1 (-0.3 to 0.2)   -0.1 (-0.6 to 0.3) 
Hospital Admissions - Respiratory, median (IQR) 1.5 (1.0 - 2.0) 1 (1.0- 3.0)   1.0 (0.0 - 4.0) 1.0 (0.0 - 2.0) 
Hospital Days - Respiratory, median (IQR) 12.0 (3.0 - 23.0) 13.5 (9.0 - 36.0)   4.0 (0.0 - 21.0) * 11.5 (0.0 - 22.0) * 
a n = 36, b n = 35 
* Denotes a statistical difference in change over time for those patients who acquired AUST-02 (P = ≤ 0.05) 
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Table 3.8 Clinical characteristics of patients with a recent AUST-06 acquisition compared to those who retained an AUST-06 infection for the duration 
of the study.  
 
  Retention of AUST-06 strain   Acquisition of AUST-06 strain 
 n = 14   n = 17 
  Baseline Final   Baseline  Final 
Average age at collection, years, mean (95% CI) 26.1 (22.5 - 29.7) 31.2 (27.6 - 34.9)   30.3 (26.2 - 34.4) 35.4 (31.3 - 39.5) 
Sex, males, n (%) 7 (50.0)   12 (70.6) 
CFTR, n (%)       
Minimal function 10 (71.4)   17 (100.0) 
Residual function 3 (21.4)   0 (0.0) 
Not classified 0 (0.0)   0 (0.0) 
Not available 1 (7.1)   0 (0.0) 
Lung Transplantation, n (%) 0 (0.0)   0 (0.0) 
Deceased, n (%) 0 (0.0)   0 (0.0) 
Pancreatic Insufficient, n (%) 13 (92.9) 13 (92.9)   16 (94.1) 16 (94.1) 
Insulin Dependent Diabetes, n (%) 3 (21.4) 4 (28.6)   3 (17.7) 5 (29.4) 
FEV1 % predicted, mean (95% CI) 56.7 (46.7 - 66.7) 43.2 (32.7 - 53.7)   65.5 (53.7 - 77.3) 49.9 (41.8 - 57.9) 
a 
Mean (95% CI) Annual FEV1% predicted decline -2.6 (-3.8 to -1.4)   -2.8 (-4.8 to -0.8) 
a 
BMI, mean (95% CI) 20.9 (19.2 - 22.6) 21.0 (19.0 - 22.9) *   22.3 (20.5 - 24.2) 22.7 (20.4 - 25.0) * 
Mean (95% CI) Annual BMI decline 0.01 (-0.2 to 0.2)   0.07 (-0.2 to 0.3) 
Hospital Admissions - Respiratory, median (IQR) 2.0 (0.0 - 4.0) 3.0 (2.0 - 3.0)   1.0 (0.0 - 2.0) 3.0 (2.0 - 4.0) 
Hospital Days - Respiratory, median (IQR) 20.0 (0.0 - 51.0) 39.0 (17.0 - 53.0)   10.0 (0.0 - 30.0) 42.0 (20.0 - 65.0) 
a Results unavailable for one patient 
* Denotes a statistical difference in change over time between patients who retained and acquired AUST-06 (P = ≤ 0.05) 
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3.4.6 Patient outcomes 
Eleven percent of the study population either died (n = 8) or required lung transplantation (n = 21) by 
the Final sample collection time point. Patients with an AUST-02 infection comprised the largest 
proportion of these patients (20%), while only one patient with an AUST-06 infection underwent lung 
transplantation. The rates of transplantation and death in the remainder of the population (AUST-01 
[8.7%], minor shared [9.1%], unique [11.1%]) were very similar (Table 3.9).  
 
Table 3.9 Rates of death and/or lung transplantation of patients at Final sample collection time point, 
stratified according to Pseudomonas aeruginosa genotype.  
 
Strain 
Survival Death and/or lung transplantation 
n (%) n (%) 
AUST-01 (n = 23) 21 (91.3) 2 (8.7) 
AUST-02 (n = 50) 40 (80.0) 10 (20.0) 
AUST-06 (n = 30) 29 (96.7) 1 (3.3) 
Minor (n = 66) 60 (90.9) 6 (9.1) 
Unique (n = 45) 40 (88.9) 5 (11.1) 
The minor strain cohort, as presented in this table, is used as the reference group for the univariable 
analysis in Table 3.10. 
 
The association between the composite endpoint (death or transplantation) and the presence of 
specific shared strain infection were assessed. This analysis showed that AUST-02 infection was 
associated with a higher risk of death and transplantation when compared to patients with minor 
shared strain infection. Following adjustment for the variables age (Odds Ratio (OR): 3.45,  
P = 0.05), FEV1 % predicted (OR: 4.68, P = 0.04) and CFTR class (OR: 3.93, P = 0.04), AUST-02 
remained significantly associated with risk of death and transplantation (Table 3.10A). Furthermore, 
this association held, even after adjusting for age and CFTR class (OR: 4.89, P = 0.04) and CFTR 
class and FEV1% predicted (OR: 7.50, P = 0.02) (Table 3.10B). This association was not observed 
among patients infected with AUST-01 or unique strains. 
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Table 3.10 Univariate (A) and multivariate analysis (B) of Baseline patient data (n = 171) assessing the risks of dying or requiring lung transplantation, 
using Pseudomonas aeruginosa genotype and clinical variables. 
 
A. Univariate Analysis 
Strain type N n (%) 
Strain Age FEV1%pred BMI CFTR Class 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Minor Only 46 5 (10.9) Reference strain Reference strain Reference strain Reference strain Reference strain 
Unique Only 28 5 (17.9) 1.78 (0.47 - 6.81) 0.40 1.48 (0.37 - 6.00) 0.58 1.57 (0.32 - 7.67) 0.58 1.76 (0.44 - 7.01) 0.42 2.28 (0.53 - 9.85) 0.27 
AUST-01 Only 17 2 (11.8) 1.09 (0.19 - 6.25) 0.92 1.27 (0.21 - 7.53) 0.79 1.21 (0.17 - 8.66) 0.85 1.19 (0.20 - 7.12) 0.85 1.53 (0.24 - 9.57) 0.65 
AUST-02 Only 44 10 (22.7) 2.41 (0.75 - 7.74) 0.14 3.45 (1.00 - 11.90) 0.05 4.68 (1.04 - 20.90) 0.04 2.10 (0.63 - 6.94) 0.23 3.93 (1.08 - 14.24) 0.04 
 
B. Multivariate Analysis 
Strain type N n (%) 
Age & CFTR Class FEV1%pred & CFTR Class 
OR (95% CI) P-value OR (95% CI) P-value 
Minor Only 46 5 (10.9) Reference strain Reference strain 
Unique Only 28 5 (17.9) 1.48 (0.29 - 7.57) 0.64 1.88 (0.33 - 10.78) 0.48 
AUST-01 Only 17 2 (11.8) 1.27 (0.18 - 9.17) 0.81 1.44 (0.18 - 11.74) 0.73 
AUST-02 Only 44 10 (22.7) 4.89 (1.06 - 22.56) 0.04 7.50 (1.44 - 39.03) 0.02 
n = The number of patients to die or undergo lung transplantation 
N = The total number of patients with a particular P. aeruginosa genotype at Baseline sample collection time point 
At Baseline there were no patients harbouring only the AUST-06 strain to die or required lung transplantation during the study period. 
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3.5 Discussion 
This longitudinal study confirms that shared P. aeruginosa strains remain prevalent within TPCH 
ACFC patient population. Key findings of this investigation included that the frequency of  
AUST-02 infection declined, while in parallel, there was a significant and unexpected increase in the 
prevalence of AUST-06 infections. At Baseline sample collection the prevalence of AUST-01 and 
AUST-06 infections within this patient population were similar; however unlike AUST-06,  
AUST-01 infection rates remained stable for the study duration. Likewise, the prevalence of unique 
and minor shared strain infection remained unchanged during this period. Notably, the vast majority 
of patients that acquired AUST-06 were treated at TPCH ACFC throughout the study period. Taken 
together, these data suggest that there has been a surge in the transmission of the AUST-06 shared 
strain, but this appears to have occurred independently of other breakdowns in infection control within 
this CF centre. 
 
Several studies examining the clinical impact of shared strain infection in CF have shown adverse 
outcomes, including increased lung function decline and nutritional status , increased risk of death or 
transplantation and increased hospitalisation and treatment requirements (Aaron et al. 2010; Al-Aloul 
et al. 2004; Jones et al. 2010; O'Carroll et al. 2004; van Mansfeld et al. 2016). Within the Australian 
CF population, two predominant shared strains, AUST-01 and AUST-02, have been identified and 
associated with an increased rate of death in young children (AUST-01) and increased treatment 
requirements in children and adults with CF (AUST-01 and AUST-02) (Armstrong et al. 2002; 
Griffiths et al. 2005; Kidd et al. 2013; O'Carroll et al. 2004). A national study of patients attending 
18 Australian CF centres, demonstrated a prevalence of 22% and 18% for AUST-01 and AUST-02 
strains, respectively. AUST-01 was isolated from patient’s at all 18 centres and AUST-02 isolated 
from patients attending16 of the 18 centres. A third and less common shared strain, AUST-06, was 
initially identified in 2001 in patients from North Queensland and subsequent studies have confirmed 
that this strain is largely restricted to patients receiving care (current or previously) in Queensland 
(Kidd et al. 2013; O'Carroll et al. 2004). 
 
As shown in other studies, these results also indicate that the clinical impact of shared strain  
P. aeruginosa infection is may be strain specific. The results presented here confirm that at time of 
clinical data collection, patients with shared stain infection were younger than those with a non-shared 
strain infection (Aaron et al. 2010; van Mansfeld et al. 2009). A Canadian study, examining the 
impact of a highly prevalent shared strain, Liverpool epidemic strain (LES), compared the clinical 
outcomes of patients harbouring LES to those harbouring a unique strain over a three year period. 
This study observed no difference in lung function at baseline, the rate of lung function decline, 
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antibiotic requirements or nutritional status. However, patients with LES were at greater risk of death 
or transplantation (Aaron et al. 2010). Another study undertaken in The Netherlands, reported that 
the prevalent shared strain within this CF population was associated with a greater usage of inhaled 
antibiotics yet, there was no difference when lung function decline or risk of death or transplantation 
were compared to patients free from shared strain infections (van Mansfeld et al. 2016). Here we 
confirm that one shared strain, AUST-02 is associated with increased death and transplantation, while 
a second shared strain, AUST-06 is associated with reduced lung function and increased 
hospitalisation. 
 
This study also compared the clinical characteristics of patients who retained and acquired either 
AUST-02 or AUST-06 strains over time. Although under-powered, these data show that patients who 
retained a shared strain over time had a higher lung function at Baseline (AUST-02 only) and reduced 
decline in FEV1 over time (AUST-02 and AUST-06). Furthermore, these patients had fewer hospital 
episodes over time, when compare to the new incidence cases. Similarly, these data suggest a trend 
to young patients with better lung function being more likely to acquire these shared strains, and 
following acquisition have greater clinical decline. Interestingly, data presented here suggested that 
the clinical outcomes of patients who retain a shared strain infection for an extended duration, appears 
to stabilise.  
 
A number of clinically relevant observations were made when assessing this entire cohort. The annual 
lung function decline of all patients over the study duration was less than previously reported for 
similarly aged patients with P. aeruginosa infections (Konstan et al. 2012; Ren et al. 2012). 
Interestingly, clinical characteristics assessed at Baseline and Final sample collection time points 
remained stable over time. Additionally, patients from the TPCH with a stable shared strain infection 
were more likely to be younger, male, require lung transplantation, have a greater requirement for 
hospitalisation and have slightly greater lung function decline compared to those with a stable non-
shared strain infection.  
 
Focusing of on strain-specific outcomes, these analyses demonstrate that patients with shared strain 
infection were younger than those with a non-shared strain infection, which may account for the 
observation of a milder clinical phenotype and fewer hospitalisation episodes. Together these factors 
may limit exposure to source of infection due to lower requirements for hospital based care. The rates 
of co-morbidities were similar across the study for each of strain groups, however patients with 
AUST-06 has the highest rates of insulin-requiring CF related diabetes. The lung function of patients 
with AUST-01, AUST-02 and non-shared strains were not different at Baseline and study completion 
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with a similar decline in FEV1 % predicted. In parallel, the rates hospitalisation was similar for 
patients within these strain groups.  
 
During the national study, AUST-02 was the dominant shared strain at TPCH and this study confirms 
the previous results, despite the recent decline in AUST-02 prevalence (Kidd et al. 2013). Three 
factors may be responsible; firstly, the low rates of incidence cases since 2007, secondly, high rates 
of death or transplantation observed; and thirdly, an increase in the clinic population over this time, 
including patients without Pseudomonas infection (Ramsay et al. 2017). The prevalence of AUST-
06 increased significantly during this study, largely due to new acquisitions occurring within TPCH 
ACFC. As strict cohort segregation was not logistically feasible during the observation period, 
patient-to-patient transmission of this strain is most likely route of acquisition. Supporting this 
hypothesis, AUST-06 patients appeared to be the most unwell patients (trend towards the poorest 
FEV1 % predicted) with the highest hospitalisation rates of all the strain groups. The resulting high 
rates of patient attendance to clinic will have most likely increased exposure and acquisition of 
AUST-06 strains (Kidd et al. 2015; Knibbs et al. 2014; Wainwright et al. 2009). Additionally, 
environmental studies in Queensland have not isolated AUST-06 in other clinical or natural settings 
beyond patients with CF (Kidd et al. 2012). Despite these findings, the rates of death and 
transplantation for patients with AUST-06 were low (at least at this point in time). By way of contrast, 
patients with AUST-02 infection had the highest rates of death or transplantation during the study. 
Further work examining virulence determinants of AUST-06 strains should be undertaken to 
determine if there are intrinsic mechanisms which enhance acquisition and transmission. Subsequent 
strain-specific factors may be important to explain why AUST-06 increased in prevalence, whereas 
despite similar baseline prevalence AUST-01 remained stable throughout the study. 
 
This study has a number of limitations and include; firstly, three P. aeruginosa isolates per sputum 
sample were collected annually for each patient which may have underestimated the diversity of 
strains within the airway of the participants. Previous work conducted by Kidd and colleagues 
demonstrated high level of genotype concordance when multiple isolates from a single patient 
undergo typing, suggesting that isolate selection is unlikely to impact the rates of strain diversity in 
this population (Kidd et al. 2013). Secondly, Pseudomonas genotyping was based on a 20-SNP assay 
which is able to accurately confirm the known shared strains infections within this patient population; 
however, the assay has lower discrimination than a MLST-based approach. Therefore, this technique 
may restrict the detection of recently emergent strains. Thirdly, the focus of this study was on the 
collection of clinical parameters, and was not designed to review patient-to-patient interactions which 
may have occurred during outpatient visits, inpatient hospitalisations or outside of the hospital 
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environment. This limits our ability to provide evidence regarding potential modes of acquisition such 
as person-to-person transmission. Fourthly, results analysed from this were generated from sputum 
samples collected annually and thus, the exact time of acquisition can only be estimated. As such, 
increased sample frequency and invasive sampling approaches may have provided a more accurate 
means of determining the point at which each shared strain was acquired. Finally, as only the 34 
patients who acquired a shared strain infection had comprehensive analyses of P. aeruginosa isolates 
collected annually between Baseline and Final collection time points to confirm date of acquisition, 
some incidence cases may be underestimated as specific infections could be intermittent.  
 
This current study reports an increase in the prevalence of the AUST-06 strain and a decline in AUST-
02 strain. Within this patient cohort AUST-02 strain infection was associated with an increased risk 
of death or transplantation, whereas, only one patient co-infected with the AUST-06 strain (and 
AUST-02) required lung transplantation. However, a trend towards lower lung function and increased 
hospital requirements was noted in patients with an AUST-06 infection. These results demonstrate 
the complexity of infection and how dynamics such as patient population and clinical outcomes can 
influence prevalence. Nevertheless, the lack of an environmental reservoir and the increase of shared 
strains implicate patient to patient transmission as the driving force behind these infections. Evidence 
of strain diversity demonstrated by the high rates of non-shared strains confirms that environmental 
acquisition is also occurring within a portion of patients. Since the completion of this study a purpose-
built CF inpatient facility has been commissioned allowing enhanced patient segregation with single 
room accommodation for all patients. Surveillance of the impact of the new facility and enhanced 
infection control procedures is underway.  
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Chapter 4: Phenotypic characteristics of Pseudomonas aeruginosa 
 
4.1 Abstract 
Background: The environmental bacterium P. aeruginosa is the most prevalent pathogen isolated 
from respiratory secretions in people with cystic fibrosis (CF) and infection is associated with adverse 
clinical outcomes. Studies have demonstrated that during establishment of chronic airway infection 
in people with CF, P. aeruginosa undergoes a number of phenotypic changes including biofilm 
development, loss of motility and the expression of mucoidy colonial phenotype. However, few 
studies have phenotypically characterised isolates obtained from a range of environmental niches and 
clinical conditions under varied atmospheric conditions with the aim of determining pathoadaptive 
traits unique to isolates derived from the CF airways. 
 
Methods: A total of 167 P. aeruginosa isolates collected from the environment, animal, non-CF 
human infections and people with CF underwent a number of phenotypic tests to determine colonial 
morphology, motility and initial biofilm adhesion under different atmospheric conditions (aerobic, 
microaerophilic and anaerobic conditions). 
 
Results: Overall, most isolates displayed pigmented, non-mucoid morphotypes. Phenotypically, 
isolates obtained from the environment, animals and non-CF patients were similar, all displaying high 
levels of motility and adhesion capabilities. In contrast, CF isolates were predominantly non-motile 
and non-adherent under each different atmospheric condition. The greatest difference in phenotypes 
was noted when comparing CF and environmental isolates. Overall, motility and adhesion was 
negative associated with growth under anaerobic conditions compared with aerobic conditions. 
 
Conclusions: This work suggests the CF isolates are intrinsically different from isolates collected 
from all other niches. Despite an overall reduction in the phenotypic characteristics displayed by the 
CF isolates, non-shared strains displayed greater phenotypic diversity compared to shared strains. 
This study demonstrates that a phenotypic gradient from poorly niche adapted (environmental 
isolates) to highly niche adapted (shared CF strains) can be demonstrated when assessing isolates 
from varied settings. 
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4.2 Introduction 
Pseudomonas aeruginosa is an environmental bacterium possessing a range of pathoadaptive traits 
and virulence mechanisms which promote colonisation, survival, and proliferation (Cullen and 
McClean 2015; Hauser et al. 2011; Hogardt and Heesemann 2010; Sousa and Pereira 2014; 
Winstanley et al. 2016). For people with cystic fibrosis (CF), P. aeruginosa is a highly prevalent 
pathogen isolated from respiratory secretions and is associated with increased mortality and 
exacerbations, accelerated rate of lung function decline and decreased quality of life (Elborn 2016; 
Ratjen et al. 2015). Within the lungs, P. aeruginosa utilises these adaptive traits to evade the host 
immune system in order to establish a chronic infection. These mechanisms include, but are not 
limited to, loss of motility and type III secretion, enhancement of a mucoid phenotype, increased 
antibiotic resistance, development of small colony variants, changes to lipopolysaccharide, O-antigen 
and pyocyanin expression, growth within sessile community formations and defects to bacterial 
communication and hypermutability (Cullen and McClean 2015; Folkesson et al. 2012; Winstanley 
et al. 2016). Many of these pathoadaptive traits are essential to support the formation of bacterial 
communities, known as biofilms. Growth within biofilms is preferential as structural and metabolic 
features provide protection from the host immune system and antimicrobial agents and peptides 
(Alhede et al. 2014). 
 
Typically, colonisation of the CF airways occurs in childhood and is characterised by intermittent 
infection which can be initially eradicated by the use of anti-pseudomonal antibiotics (Folkesson et 
al. 2012). Genotypically, isolates from early infections are heterogeneous and patients will usually 
harbour individual strains (Kidd et al. 2015; Ranganathan et al. 2013). Over time P. aeruginosa will 
often re-infect and ultimately establish chronic infection within the airway (Folkesson et al. 2012). 
Over the past 20 years, strain typing of isolates has shown that genotypically indistinguishable 
(shared) strains can be isolated from unrelated patients and in some instances are associated with 
adverse health outcomes (Aaron et al. 2010; Armstrong et al. 2002; Cheng et al. 1996; Kidd et al. 
2013; O'Carroll et al. 2004; Scott and Pitt 2004; van Mansfeld et al. 2009). Environmental reservoirs 
for shared P. aeruginosa strains have not been identified, suggesting niche adaptation within the CF 
airway and the potential for acquisition by cross-infection with highly adapted bacteria (Jones et al. 
2003; Kidd et al. 2012). 
 
Phenotypic analysis of P. aeruginosa has primarily focused on describing characteristics of isolates 
obtained from people with CF. Overall, these analyses indicate that isolates obtained from early and 
intermittent infections possess a range of virulence factors, show a non-mucoid and pigmented 
appearance, and have propensity for aerobic and free-living (or planktonic) growth. Whereas, isolates 
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obtained from chronically infected patients, including those with a shared strain will often be 
phenotypically distinct from non-shared strains or those obtained during intermittent infection. 
(Costerton et al. 1999; Head and Yu 2004; Hogardt and Heesemann 2010; Hunter et al. 2012; Li et 
al. 2005; Mahenthiralingam et al. 1994; Manos et al. 2013; Mayer-Hamblett et al. 2014; Mayer-
Hamblett et al. 2014; Murray et al. 2010). Typically, these isolates will be non-motile, display a 
mucoid appearance, grow within biofilm formations, and exhibit increase resistance to many anti-
pseudomonal antibiotics (Lee et al. 2005; Mahenthiralingam et al. 1994; Manos et al. 2013; Mayer-
Hamblett et al. 2014; Tingpej et al. 2007). However, not all isolates from people with CF will conform 
to these phenotypic generalisations. Isolates from initial and early infection have been shown to 
display mucoid, and motile phenotypes (Burns et al. 2001; Mayer-Hamblett et al. 2014), and 
conversely shared strains and P. aeruginosa isolated from chronically infected patients can display 
non-mucoid phenotypes (Jeukens et al. 2014; Manos et al. 2013).  
 
Compared to isolates from people with CF, those obtained from non-CF human infections and the 
natural environment often demonstrate enhance phenotypic characteristic, although an extensive 
study of these isolates has not been conducted (Head and Yu 2004; Mahenthiralingam et al. 1994; 
Murray et al. 2010). In contrast to non-CF isolates, P. aeruginosa isolated from people with CF have 
been frequently exposed to antibiotics and host immune factors resulting in highly niche adapted 
strains in chronic lung infection. Therefore, recent studies sought to characterise the evolution 
strategy of P. aeruginosa including pathways, which enable survival and persistence within the CF 
airways (Jeukens et al. 2014; Manos et al. 2009; Manos et al. 2008; Silby et al. 2011; Stover et al. 
2000). Whether similar mechanisms are exhibited by Australian P. aeruginosa CF strains is currently 
unknown.  
 
Therefore, to address this knowledge gap, through the use of phenotypic assays, this study aimed to 
characterise and compare adaptive traits of a large number of isolates collected from in different 
clinical and environmental niches with the aim of identifying particular mechanisms which may be 
advantageous during niche adaptation. Interestingly, from these investigations I observed that isolates 
from people with CF possessed a very distinct phenotype to those of isolates from varied clinical and 
environmental settings. This work highlights that despite lacking mechanisms previously associated 
with the establishment of infection, the shared CF strain, AUST-02, is still commonly isolated from 
chronically infected patients.  
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4.3 Materials and Methods 
4.3.1 Isolate Selection 
One hundred and sixty-seven P. aeruginosa isolates obtained from environmental settings and clinical 
sources found in South East Queensland, Australia, as previously described by Kidd and colleagues, 
were selected for testing (Kidd et al. 2013; Kidd et al. 2012). They included isolates sampled from 
the environment (n = 34), animals (n = 14), non-CF human infections (n = 20), and sputum samples 
from people with CF (n = 99). P. aeruginosa strain PAO1 (ATCC 15692), originally isolated from 
cutaneous infection in a patient who had suffered burns and supplied by Professor John Mattick from 
the University of Queensland (UQ) was used as a reference strain (Holloway 1955). 
 
Thirty-three environmental isolates were collected in 2009 from urban, rural and industrial regions 
of three local riverine systems and one additional isolate was obtained from a household sink drain 
(Kidd et al. 2012). Animal isolates included five isolates which were obtained from UQ Veterinary 
School and nine isolates from a private animal pathology service. All isolates were collected during 
2007 and 2008 and included samples collected from ears (n = 8), respiratory secretions (n = 2), urine 
(n = 1), milk (n = 1) and the reproductive tract (n = 2). Animal species included: canine  
(n = 9), equine (n = 2), feline (n = 2), and caprine (n = 1). The non-CF clinical specimens included 
isolates collected from respiratory secretions (n = 7), including three from patients with non-CF 
bronchiectasis), blood (n = 5), wound (n = 2), urine (n = 4) and ear (n = 2) infection samples. The 
three non-CF bronchiectasis respiratory samples were collected from patients who were cared for at 
The Prince Charles Hospital (TPCH) and the remaining 17 samples were collected from patients who 
attended the Royal Brisbane and Women’s Hospital (RBWH) (2002 - 2008). 
 
Ninety-six of the 99 isolates obtained from people with CF were collected between 2002 and 2014 
from adults (75%) and children (25%) whilst participating in a national multi-centre cross sectional 
prevalence study (Kidd et al. 2013). All patients resided in South Eastern Queensland and attended 
CF clinics based at one of four CF centres. Three isolates; Canadian P. aeruginosa strain  
A 01-127-A (ST-146) isolated from a person with CF and supplied by Dr Shawn Aaron from 
University of Ottawa, Ontario; and P. aeruginosa strains CF1 (ST-146) and CF7 (ST-146) both 
clinical isolates obtained from people with CF and supplied by Ms Deirdre Gilpin and Professor Stuart 
Elborn from Queen’s University, Belfast were included in the analysis. 
 
Collectively, 57 individual STs were represented within this isolate collection. This included 20 
isolates from five STs found across all four different ecological niches (i.e. ST-155, ST-179,  
ST-253, ST-266, ST-381) and 56 isolates representing the two major CF shared strains found in 
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people with CF residing in Queensland, Australia. (ST-775 [AUST-02, n = 50]; ST-801 [AUST-06, 
n = 6]) (Kidd et al. 2012) (Figure 4.1).The remaining 91 isolates was comprised of singletons, with 
unique ST, and pairs and triplicates sharing individual STs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Distribution of individual sequence types (ST) selected for analysis in the motility and 
adhesion assays. 
 
4.3.2 Sample collection 
Clinical samples were cultured by Queensland Pathology diagnostic microbiology laboratories 
(human non-CF and CF specimens) and UQ Veterinary School (animal specimens). Standardised 
phenotypic and biochemical techniques, as described previously, were used for the identification of 
P. aeruginosa (Kidd et al. 2009). When P. aeruginosa was identified, isolates selected for inclusion 
in this study and forwarded onto the research laboratory for storage at -80 °C until required for further 
testing (Kidd et al. 2013). As described by Kidd and colleagues, environmental samples of surface 
water and air-water interface swabs were collected from local riverine systems and identified. Each 
water sample was filtered (47 mm, 0.45 µm cellulose filter) prior to microbiological analysis. All 
samples were cultured onto M-PA-C agar (BD BBL™, North Ryde, Australia) and incubated 
aerobically at 42 °C for up to 48-hours (Kidd et al. 2012). 
4.3.3 Isolate storage and retrieval 
Environment CF 
Non-CF Animal 
1 1 
1 
0 0 
0 
0 
20 
4 
3 
5 
5 
3 
7 
7 
99 
 
Each isolate was sub-cultured onto nutrient agar (Oxoid Australia Pty. Ltd., Adelaide, Australia) to 
assess purity. Isolates were then prepared for storage as follows. Each bacterium was subcultured into 
Luria-Bertani, Miller broth (Oxoid Australia Pty. Ltd., Adelaide, Australia) (LB broth) and incubated 
overnight at 37 °C. From this inoculum a 15% glycerol (Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia) stock was prepared and stored at -80 °C until required (Kidd et al. 2009). When isolates 
were required for further testing, they were retrieved from storage and cultured onto Luria-Bertani, 
Miller agar (BD Difco™, North Ryde, Australia) (LB agar) and incubated at 37 °C for  
24-hours. A subsequent sub-culture, using the same conditions, was performed prior to analysis 
(Syrmis et al. 2013). 
 
4.3.4 DNA Extraction 
Heat denatured bacterial DNA was prepared as follows. A 1.0 McFarland suspension was prepared 
from a 24 hour single-colony subculture in 2.0 mL of water (Baxter Healthcare Pty. Ltd., Coorparoo, 
Australia) and heated for 20 minutes at 95 °C. Following a short period of cooling, the suspensions 
were centrifuged at 14,000 rpm for 4 minutes. The supernatant was then stored at  
-80 °C prior to genotyping (Anuj et al. 2009; Syrmis et al. 2013). 
 
4.3.5 Confirmatory Identification 
All isolates underwent the P. aeruginosa specific real time duplex PCR assay, targeting the ecfX and 
gyrB genes, to confirm identification (Anuj et al. 2009). Each PCR reaction mix was comprised of, 
12.5 µL of Qiagen Quantitect probe master mix, 10 pmol/µL each forward and reverse primer (Table 
4.1), 20 pmol/µL of each TaqMan probe (Table 4.2) and 2 µL of DNA template, made up to a final 
reaction volume of 25 µL using water. 
 
The thermal cycling conditions were as follows. An initial hold of one cycle at 95 °C for  
15 minutes, followed by 50 cycles of 95 °C for 15 seconds and 60 °C for 60 seconds and one final 
cooling cycle of 40 °C for 30 seconds. Cycling and amplicon detection was performed on a 
LightCycler®480 instrument. The fluorescent probes for ecfX and gyrB were labelled with Yakima 
Yellow (YAK) and a fluorescein, FAM, so they could be detected in the JOE (523 - 568 nm) and 
FAM (483 - 533 nm) channels, respectively (Anuj et al. 2009; Kidd et al. 2009). Control isolates, 
including Achromobacter xylosoxidans LMG 1863 and a representative of control strains, AUST-01 
and AUST-02, were included in each assay. 
 
 
Table 4.1 Primers used in P. aeruginosa specific real time duplex PCR assay. 
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Name Primer Sequence 5'-3' 
ecfX-fwd CGCATGCCTATCAGGCGTT 
ecfX-rvs GAACTGCCCAGGTGCTTGC 
gyrB-fwd CCTGACCATCCGTCGCCACAAC 
gyrB-rvs CGCAGCAGGATGCCGACGCC 
 
Table 4.2 Probes used in P. aeruginosa specific real time duplex PCR assay. 
 
Name Probe Sequence 5'-3' 
ecfX-probe JOE-ATGGCGATTTGCTGCGCTTCCT-BHQ1 
gyrB-probe FAM-CCGTGGTGGTAGACCTGTTCCCAGACC-BHQ1 
 
4.3.6 Multilocus sequence analysis 
All reagents, primers and thermal cycling conditions used were identical to those found on the 
Pseudomonas aeruginosa MLST website (Jolley and Maiden 2010; Pseudomonas aeruginosa 
PubMLST Database 2012). MLST sequencing was performed by the Australian Genome Research 
Facility (AGRF). DNA sequences were analysed using Sequence Scanner v1.0 and Vector NTI 
Advance 11.0 software as described previously by Kidd and colleagues (Kidd et al. 2011). 
 
4.3.7 Morphology 
Visual inspection of the bacterial colonies following overnight growth on LB agar was performed to 
determine mucoid and pigment production (Mayer-Hamblett et al. 2014; Tingpej et al. 2007). 
Pigment production included the presence of pyocyanin (blue-green) and pyomelanin (brown) 
(Appendix 3.2). 
 
4.3.7.1 Motility Assays 
Motility assays were performed on all isolates listed in Appendix 3.1. Three technical replicates 
(repeated measures of the same bacterial suspension) were tested to determine swimming, swarming 
and twitching capabilities. All motility assays were performed under aerobic (21% O2, 0.04% CO2), 
anaerobic (0% O2, 20% CO2) and microaerophilic (5% O2, 15% CO2) atmospheric conditions and 
incubated for 24-hours at 30 °C. 
 
 
4.3.7.2 Swimming Motility 
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Isolates were grown on LB agar at 37 °C for 24-hours prior to preparation of a single colony 
subculture into LB broth. Swim media was prepared and inoculated as follows, LB broth 
supplemented with 0.3% Bacto agar (w/v) (BD Bacto™, North Ryde, Australia) was inoculated using 
a 5 µL volume of the overnight LB culture into the centre of the agar to demonstrate swimming 
motility (O'May and Tufenkji 2011; O'May et al. 2006; Rashid and Kornberg 2000) (Appendix 3.3A). 
 
4.3.7.3 Swarming Motility 
Isolates were grown on LB agar at 37 °C for 24-hours prior to preparation of a single colony 
subculture into LB broth. Swarm media was prepared and inoculated as follows, nutrient broth (Oxoid 
Australia Pty. Ltd., Adelaide, Australia) supplemented with 0.5% Bacto agar (w/v) and 0.5% Glucose 
(w/v) (Sigma-Aldrich Pty. Ltd., Castle Hill, Australia) was surface inoculated with a 5 µL volume of 
the overnight LB culture to demonstrate swarming motility (O'May and Tufenkji 2011; O'May et al. 
2006; Rashid and Kornberg 2000) (Appendix 3.3B). 
 
4.3.7.4 Twitching Motility 
All isolates were initially grown on LB agar at 37 °C for 24-hours. LB broth supplemented with  
1% Bacto agar (w/v) was prepared to a depth of 3 mm to assess twitching motility (O'May et al. 2006; 
Rashid and Kornberg 2000). A single colony isolated from the aforementioned LB agar subculture 
was stab inoculated to the plastic/agar interface at the base of the petri dish containing the twitch agar 
using a sterile toothpick. Following 24-hours incubation, the zone of growth was measured (standard 
methodology). After additional 24-hours incubation the media was dehydrated and removed. The 
zone of growth, adhered to the petri dish, was then stained with 0.25% Coomassie® Brilliant Blue 
(w/v) (Bio-Rad Laboratories Pty. Ltd., Gladesville, Australia) for 15 minutes at room temperature to 
enable measuring (extended methodology) (Alm and Mattick 1995; O'May and Tufenkji 2011). 
Comparisons of the zone sizes collected from the standard and extended methodologies were 
conducted to determine if measurement through the agar alone was sufficient to accurately determine 
a positive result (Appendix 3.3C). 
 
4.3.7.4.1 Interpretation of motility assays 
The zone of growth (diameter mm) was measured for all isolates after 24-hours incubation. From 
these individual measurements (in triplicate for each bacteria tested), the mean area (A = πr2) to 
represent each isolate, was calculated to determine the motility characteristics. The following criteria 
were used to determine motility. Firstly, the area of growth had to be ≥ 10% of the control PAO1 
isolate (Murray et al. 2010), and/or the total area of growth must be ≥ 20 mm2 to be considered motile. 
Isolate growth determined to be ≤ 20 mm2 is equal to the size of the initial inoculum, therefore it was 
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concluded that whilst the bacteria was able to grow they were non-motile (Lee et al. 2005; 
Mahenthiralingam et al. 1994). 
 
4.3.7.5 Microtitre plate-based assay 
Bacterial adhesion of all isolates (Appendix 3.1) was assessed using a microtitre plate-based assay 
(O'Toole 2011). Overnight bacterial cultures in LB broth were adjusted to 0.5 McFarland (1.5 x 108 
colony forming units (CFU)/ml) and further diluted to a 1 in 100 suspension using LB broth. Three 
wells (technical replicates) of a round bottom polystyrene microtitre plate (Greuber Bio-One 
International GmbH, Kremsmünster, Austria) were inoculated with 200 µL of each bacterial 
suspension and incubated for 24-hours under aerobic, anaerobic and microaerophilic atmospheric 
conditions at 30 °C. Following incubation the microtitre plate was inverted and the bacterial 
suspension was shaken out. The plate was then submerged in water and washed three times, with the 
water being smacked out of the plates in between each wash. To stain the adhered growth,  
200 µL of 0.1% crystal violet (Merck Millipore, Merck and Co., Bayswater, Australia) was dispensed 
into each well and incubated at room temperature for 30 minutes. Following incubation the stain was 
smacked out of the plate and washed three times in water. To quantify the amount of adhered bacterial 
growth 200 µL of 95% ethanol was dispensed into each well and incubated for 30 minutes at room 
temperature. A plate reader was used to quantify absorbance using optical density read at optical 
density 595 nm (OD595nm), using a blank of uninoculated LB broth (O'Toole 2011) (Appendix 3.4). 
 
4.3.7.5.1 Interpretation of microtitre plate assay 
All isolates were cultured in triplicate (technical replicates) and a duplicate of each assay was then 
performed on a second 96-well plate to account for inter-run variability. Quantification of the 
bacterial adhesion was determined using the equations proposed by Stepanovic and colleagues (Table 
4.3) where the OD595nm of the test and the blanks are compared (Stepanovic et al. 2000; Stepanovic 
et al. 2007). For this analysis those that returned a weak, moderate or strong result were determined 
to be positive for adhesion. 
 
 
 
 
 
Table 4.3 Equation for the quantification of bacterial adherence as determined by the microtitre assay. 
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Calculation  Result 
OD ≤ Odc  Absent 
Odc < OD ≤ 2 x Odc Weak adhesion to the microtitre plate 
2 x ODC < OD ≤ 4 x ODC Moderate adhesion to the microtitre plate 
4 x Odc < OD  Strong adhesion to the microtitre plate 
 
Abbreviations: OD, Optical density read at OD595nm; Odc, average OD of 95% ethanol blanks +  
(3 x SD); SD, standard deviation of the 95% ethanol blanks. 
 
4.3.7.6 Anaerobic and microaerophilic atmospheric conditions 
Media prepared for these assays were supplemented with 10% Potassium Nitrate (Sigma-Aldrich Pty. 
Ltd., Castle Hill, Australia) to support growth under anaerobic and microaerophilic conditions 
(O'May et al. 2006; Yoon et al. 2002). Reduced atmospheric conditions (anaerobic and 
microaerophilic) were obtained using the GENbox commercial system as developed by bioMérieux 
(BioMerieux Australia Pty. Ltd, Murarrie, Australia). Either GENbox Anaer or GENbox Microaer 
generator sachets were included when plates were incubated in the airtight box. According to 
manufacturer’s guidelines these sachets will produce the desired atmospheric condition within one 
hour of activation. Included in each batch was a colour indicator strip, as supplied by bioMérieux and 
P. aeruginosa inoculated onto a blood agar plate, without supplementation. The desired atmospheric 
conditions were confirmed by the colour change of the indicator strip and subdued P. aeruginosa 
growth.  
 
4.3.8 Statistical Analyses 
Categorical data (i.e. niche versus phenotype in different atmospheric conditions) were examined 
using a Chi-square with Yates continuity correction. Bonferroni corrections were performed to adjust 
for multiple comparisons. Simple regression and correlation was used to examine the association 
between motility (Pearson correlation coefficient) and adhesion assays (Spearman's rank correlation 
coefficient). Intraclass correlation coefficients (ICC) were calculated using two-way random effects 
with a consistency metric. For variables that showed considerable skewness, data were transformed 
the (log (1+x) and performed the linear modelling on the log scale). Comparisons were not adjusted 
for multiple testing. Generalised Bland-Altman plots followed the extension suggested by Jones and 
colleagues (Jones et al. 2011). These plots represent a graphical method for assessing agreement with 
the mean between multiple observers using continuous measures. Each dot in these plots represents 
a single isolate with up to three replicates accounted for. Statistical analyses were performed using 
the commercially available statistical packages; R and SPSS version 22 (IBM Corp. Released 2013. 
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IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp, http://www.R-
project.org). A P value ≤ 0.05 indicated statistical significance. 
 
4.4 Results 
4.4.1 Morphotype 
The CF isolates were less often pigmented compared with environmental isolates and were less often 
mucoid than the non-CF human isolates. The non-shared CF strains tended to be more pigmented and 
more often mucoid compared to AUST-02 and AUST-06 strains (Table 4.4).  
 
Table 4.4 Colonial morphotypes of Pseudomonas aeruginosa isolates collected from human, animal 
and environmental sources, n (%).  
 
Ecological niche or strain 
Colonial morphotype 
Mucoid Pigmented 
Panel A. All isolates§   
Environmental (n = 34) 8 (23.5) 27 (79.4) a 
Animal (n = 14) 4 (28.6) 8 (57.1) 
Non-CF (n = 20) 8 (40.0) a 10 (50.0) 
Cystic fibrosis (n = 99) 13 (13.1) a 42 (42.4) a 
   
Panel B. Cystic fibrosis isolates#   
Non-Shared Strains (n = 33)* 6 (18.2) 18 (54.5) 
AUST-02 (n = 50) 3 (6.0) 21 (42.0) 
AUST-06 (n = 6) 0 (0.0) 0 (0.0) 
AUST-01 (n = 6)† 4 (66.7) 3 (50.0) 
LES (n = 4)† 0 (0.0) 0 (0.0) 
§ Bonferroni correction adjusted for 6-way comparison. 
# Bonferroni correction adjusted for 3-way comparison (Non-Shared, AUST-02 and AUST-06). 
* Strains found only in individual patients or < 10 of patients in attendance at TPCH. 
† Due to small numbers and as the focus of this study was on the prevalent shared strains identified 
within the local TPCH CF population, these strains were not included in analysis. 
a Values within columns showing a letter in common were significantly different (P ≤ 0.05) following 
Bonferroni correction. 
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4.4.2 Motility Assays 
4.4.2.1 Reproducibility of the motility assays 
Limits of agreement measures for each motility assessed in aerobic conditions demonstrated excellent 
reproducibility (swim motility, ICC: 0.937 [95% CI: 0.915 to 0.954], P < 0.001; swarm motility, ICC: 
0.943 [95% CI: 0.926 to 0.957], P < 0.001; twitch motility, ICC: 0.973 [95% CI: 0.965 to 0.980], P 
< 0.001). Similar results were also obtained when assessed using microaerophilic and anaerobic 
conditions (Figure 4.2). In the majority of cases less than 10% of strain comparisons fell outside of 
±1.96SD of the mean. High levels of agreement were also observed within groups when niche, 
atmospheric conditions and motility was more closely analysed (Appendix 3.5). 
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Figure 4.2 Reproducibility assessment of 1) swim, 2) swarm and 3) twitch motility under a) aerobic, b) microaerophilic and c) anaerobic conditions 
using a generalised Bland-Altman Plot.  
Bounds for this plot are ISO-defined reproducibility limits, defined as ±1.96 SD. Each isolate, tested in triplicate, is represented by three dots of an 
individual colour.  
Note: Different values for both the x and y axis as determined by the specific motility and atmospheric conditions being analysed.  
1B. 1C. 1A. 
2A. 2B. 2C. 
3A. 3B. 3C. 
1A. ICC: 0.973 (95% CI: 0.915 to 0.954), P < 0.001 
1B. ICC: 0.696 (95% CI: 0.598 to 0.773), P < 0.001 
1C. ICC: 0.857 (95% CI: 0.813 to 0.891), P < 0.001 
2A. ICC: 0.943 (95% CI: 0.926 to 0.957), P < 0.001 
2B. ICC: 0.966 (95% CI: 0.956 to 0.974), P < 0.001 
2C. ICC: 0.972 (95% CI: 0.963 to 0.978), P < 0.001 
3A. ICC: 0.973 (95% CI: 0.965 to 0.980), P < 0.001 
3B. ICC: 0.964 (95% CI: 0.953 to 0.972), P < 0.001 
3C. ICC: 0.702 (95% CI: 0.615 to 0.773), P < 0.001 
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4.4.2.2 CF isolates had reduced motility compared to isolates from other clinical and 
environmental sources 
Overall, isolates cultured from the patients with CF demonstrated reduced swimming, swarming and 
twitching motilities under each atmospheric condition when compared with all other isolates tested. 
More specifically, the CF isolates displayed significantly reduced swimming, swarming and 
twitching capabilities across all atmospheric conditions compared with environmental isolates. Apart 
from anaerobic twitching motility (P = 0.090), all of the non-CF isolates produced significantly larger 
zones of motility when compared to those generated by CF isolates. Overall, animal and CF isolates 
were the most similar (to each other), with only swarm (aerobic and microaerophilic) and twitch 
(aerobic, microaerophilic, anaerobic) motilities achieving a statistical difference (Table 4.5, Panel A). 
Overall, these analyses demonstrate that niche adapted CF strains possess similar motility traits. 
These data are reflective of previous reported results which demonstrate that isolates obtained from 
chronic infections display reduced motility compared to those from intermittent infections. 
 
4.4.2.3 Variable motility results of shared and non-shared strains obtained from people 
with CF 
When compared to the non-shared CF strains, AUST-02 displayed a significant reduction in all 
motilities. In contrast, the non-shared CF and AUST-06 strains shared similar motility characteristics 
across all atmospheric conditions. AUST-06 displayed reduced motility characteristics compared to 
isolates obtained from the environment, animal and non-CF settings, however these results did not 
always reach a significant difference. Whereas, AUST-02 displayed significantly reduced motility 
when compared to isolates collected from these niches. Despite the phenotypic heterogeneity noted 
when comparing the shared strains with isolates from all other niches, the AUST-02 and AUST-06 
strains displayed very similar motility characteristics to each other. (Table 4.5, Panel B).  
 
4.4.2.4 Environmental, animal and non-CF isolates display similar motility capabilities 
Environmental, animal and non-CF human isolates displayed enhanced motility characteristics, with 
the majority positive in all assays (Table 4.5, Panel A).  
 
4.4.2.5 Isolates had impaired motility under anaerobic conditions 
The majority of isolates demonstrated a reduction in swim, swarm and twitch motilities when tested 
under anaerobic conditions, compared to characteristics observed in aerobic conditions (Table 4.5). 
Twitch motility demonstrated the greatest reductions when grown in anaerobic conditions. 
Environmental (P < 0.001), non-CF (P = 0.024), all CF (P = 0.001) and non-shared CF (P < 0.001) 
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isolates all reported significant reductions. Furthermore, swimming motility of the AUST-02 strain 
also displayed a significant reduction when tested anaerobically (P = 0.010). 
 
Interestingly, rather than being negatively correlated with motility, an increase in swarming was noted 
when the environmental isolates were tested in anaerobic conditions (P = 0.036). When tested in 
aerobic conditions 68% of the isolates displayed a positive swarming motility, whereas, this increased 
to 91% of isolates that swarmed under anaerobic conditions. (Appendix 3.6). 
 
4.4.2.6 Twitch results 
In line with the swim and swarm motility assays, the twitch motility assays were initially assessed 
after a 24-hour incubation period. Due to difficulties measuring the area which the bacteria travelled 
away from the inoculation site through the agar, the medium was dehydrated, removed and the zone 
of motility stained to more accurately assess twitch capabilities. The additions to the methodology 
resulted in larger zones for all isolates apart from AUST-06. This is most likely due to the small 
numbers of isolates tested. Despite this a significant change in the result was only reported for nine 
comparisons (16.7%) (Appendix 3.7).  
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Table 4.5 Motility assays tested on Pseudomonas aeruginosa isolates collected from human, animal and environmental sources, conducted under various 
atmospheric conditions, n (%). 
 
Ecological niche or strain 
Swim-Positive Swarm-Positive Twitch-Positive 
O2 MA AnO2 O2 MA AnO2 O2 MA AnO2 
Panel A. All isolates§          
Environmental (n = 34) 34 (100.0) a 33 (97.1) a 32 (94.1) a 23 (67.6) a 19 (55.9) a 31 (91.2) acd 28 (82.4) a 33 (97.1) ade 10 (29.4) a 
Animal (n = 14) 12 (85.7) 12 (85.7) 9 (64.3) 9 (64.3) b 9 (64.3) b 5 (35.7) c 10 (71.4) b 9 (64.3) bd 4 (28.6) b 
Non-CF (n = 20) 19 (95.0) b 18 (90.0) b 18 (90.0) b 13 (65.0) c 13 (65.0) c 10 (50.0) bd 12 (60.0) c 12 (60.0) ce 4 (20.0) 
Cystic fibrosis (n = 99) 49 (50.0) ^ab 49 (50.0) ^ab 37 (37.4) ab 22 (22.2) abc 9 (9.1) abc 16 (16.1) ab 18 (18.2) abc 20 (20.2) abc 3 (3.0) ab 
          
Panel B. Cystic fibrosis isolates#          
Non-Shared Strains (n = 33)* 23 (69.7) y 22 (66.7)y 20 (60.6) y 15 (45.5) y 9 (27.3) y 13 (39.4) y 16 (48.5) y 18 (54.5) y 1 (3.0) 
AUST-02 (n = 50) 18 (36.0) y 16 (32.0)y 6 (12.0) yz 5 (10.0) y 0 (0.0) y 2 (4.0) y 2 (4.0) y 1 (2.0) y 1 (2.0) 
AUST-06 (n = 6) 4 (66.7) 5 (83.3) 6 (100.0) z 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 1 (16.7) 
AUST-01 (n = 6)† 2 (33.3) 3 (50.0) 4 (66.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 
LES (n = 4)† 2 (50.0) 3 (75.0) 1 (25.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
§ Bonferroni correction adjusted for 6-way comparison. 
# Bonferroni correction adjusted for 3-way comparison (Non-Shared, AUST-02 and AUST-06). 
^ n = 98 
* Strains found only in individual patients or < 10 of patients in attendance at TPCH. 
† Due to small numbers and as the focus of this study was on the prevalent shared strains identified within the local TPCH CF population, these strains 
were not included in analysis. 
a,b,c,d,e Values within columns showing a letter in common were significantly different (P ≤ 0.05) following Bonferroni correction. 
y,z Values within columns showing a letter in common were significantly different (P ≤ 0.05) following Bonferroni correction. 
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4.4.2.7 Correlation between motilities 
The analysis showed that there was a positive correlation when comparing results generated from all 
isolates for each motility tested under all atmospheric conditions. As an example, there was a positive 
correlation between swim with swarm motilities under aerobic conditions (R = 0.463;  
P < 0.001), yet only 22% of the variation in swim results was explained by the swarm motility. Similar 
correlations were seen when comparing swim with twitch and swarm with twitch under aerobic, 
microaerophilic and anaerobic conditions (Figure 4.3, Appendix 3.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Pearson Correlation coefficient results of log transformed data comparing swim, swarm 
and twitch results following 24-hours incubation in aerobic conditions.  
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4.4.3 Microtitre plate based assay 
4.4.3.1 Reproducibility of microtitre plate based assay 
The adhesion assay demonstrated highly reproducible results when both within and between run 
variability were analysed. Overall, results obtained from tests performed under aerobic (ICC: 0.972 
[95% CI: 0.966 to 0.977], P < 0.001), microaerophilic (ICC: 0.986 [95% CI: 0.984 to 0.989],  
P < 0.001) and anaerobic (ICC: 0.986 [95% CI: 0.983 to 0.989], P < 0.001) conditions determined 
that agreement measures for this assay were excellent (Figure 4.4, Appendix 3.9). Furthermore, high 
levels of agreement were also observed within groups when niche and atmospheric conditions were 
analysed.  
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Figure 4.4 Reproducibility assessment of the microtitre plate based assay under a) aerobic, b) 
microaerophilic and c) anaerobic conditions using a generalised Bland-Altman Plot.  
Bounds for this plot are ISO-defined reproducibility limits, defined as ±1.96 SD. Each isolate, tested 
in triplicate, at two different time points (Run 1 and Run 2) is represented by three dots of an 
individual colour.  
 
 
 
 
 
Run 1 
Run 1 
A. Aerobic atmosphere 
Run 2 
B. Microaerophilic atmosphere 
C. Anaerobic atmosphere 
Run 2 
Run 1 Run 2 
A.   
Run 1     ICC: 0.970 (95% CI: 0.961 to 0.977), P < 0.001 
Run 2     ICC: 0.974 (95% CI: 0.966 to 0.980), P < 0.001 
B.   
Run 1     ICC: 0.982 (95% CI: 0.977 to 0.986), P < 0.001 
Run 2     ICC: 0.991 (95% CI: 0.988 to 0.993), P < 0.001 
C.  
Run 1     ICC: 0.987 (95% CI: 0.983 to 0.990), P < 0.001 
Run 2     ICC: 0.985 (95% CI: 0.981 to 0.989), P < 0.001 
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4.4.3.2 Enhanced adhesion of non-CF clinical and environmental isolates 
Isolates from people with CF demonstrated reduced adhesion under each atmospheric condition when 
compared with isolates collected from the environment, animal and non-CF human sources. Apart 
from the comparison between CF and animal isolates under aerobic conditions (P = 0.068) the CF 
isolates displayed significantly less adhesion for all other assays. When environmental isolates where 
compared to those collected from animal and non-CF infections, only adhesion tested in aerobic 
conditions resulted in a significant difference (P = 0.030) (Table 4.6, Panel A).  
 
4.4.3.3 Adhesion characteristics of isolates obtained from people with CF 
When the non-shared CF strains were compared to the AUST-02 and AUST-06 strains these isolates 
displayed enhanced adhesion capabilities. Both shared strains (AUST-02 and AUST-06) 
demonstrated significantly reduced adhesion capabilities compared to environmental, animal and 
non-CF isolates, under each atmospheric condition. Finally, no difference was noted when  
AUST-02 and AUST-06 were compared with both displaying poor adhesion characteristics (Table 
4.6, Panel B).  
 
4.4.3.4 Reduced adhesion when tested anaerobically 
Apart from animal isolates and the AUST-06 strains, for which there was no change, all other isolate 
groups demonstrated poorer adhesion capabilities when tested anaerobically, compared to aerobic 
conditions. However, these results only reached significance for isolates collected from people with 
CF (P = 0.001), including both the non-shared strains (P = 0.045) and AUST-02  
(P = 0.004) (Table 4.6, Appendix 3.6). 
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Table 4.6 Microtitre plate-based assays tested on Pseudomonas aeruginosa isolates collected from 
human, animal and environmental sources, conducted under different atmospheric conditions, n (%). 
 
Ecological niche or strain 
Adhesion-Positive 
Aerobic Microaerophilic Anaerobic 
All isolates §    
Environmental (n = 34) 34 (100.0) ac 28 (82.4) a 30 (88.2) a 
Animal (n = 14) 10 (71.4) c 11 (78.6) b 10 (71.4) b 
Non-CF (n = 20) 17 (85.0) b 14 (70.0) c 15 (75.0) c 
Cystic Fibrosis (n = 99) 41 (41.1) ab 25 (25.3) abc 18 (18.2) abc 
    
Cystic fibrosis isolates #    
Non-Shared Strains (n = 33) * 24 (72.7) yz 19 (57.6) y 15 (45.5) y 
AUST-02 (n = 50) 15 (30.0) y 5 (10.0) y 3 (6.0) y 
AUST-06 (n = 6) 0 (0.0) z 0 (0.0) 0 (0.0) 
AUST-01 (n = 6) † 1 (16.7) 0 (0.0) 0 (0.0) 
LES (n = 4) † 1 (25.0) 1 (25.0) 0 (0.0) 
§ Bonferroni correction adjusted for 6-way comparison. 
# Bonferroni correction adjusted for 3-way comparison (Non-Shared, AUST-02 and AUST-06). 
* Strains found only in individual patients or < 10 of patients in attendance at TPCH. 
† Due to small numbers and as the focus of this study was on the prevalent shared strains identified 
within the local TPCH CF population, these strains were not included in analysis. 
a,b,c Values within columns showing a letter in common were significantly different (P ≤ 0.05) 
following Bonferroni correction. 
y,z Values within columns showing a letter in common were significantly different (P ≤ 0.05) 
following Bonferroni correction. 
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4.4.3.5 Correlation between adhesion and motility assays results across all atmospheric 
conditions 
Positive correlations between the three motilities and adhesion under all atmospheric conditions 
demonstrated that there was a direct relationship for swimming (R = 0.390; P < 0.001), swarming  
(R = 0.464; P < 0.001) and twitching (R = 0.447; P < 0.001) when compared to adhesion (Appendix 
3.10). 
 
4.4.4 Genotypically indistinguishable strains found across all niches 
Five distinct MLST sequence types (ST-155, -179, -253, -266, -381) were each isolated from 
specimens collected from the natural environment, animal, non-CF human infections and people with 
CF (Isolates n = 20). Overall, regardless of origin, these isolates behaved more similarly to those 
isolated from non-CF settings (environment, animal and non-CF), than those isolated from people 
with CF. Collectively these isolates displayed high rates of motility and adhesion. As described in 
Table 4.11, 50% of these isolates were non-pigmented, only one isolate displayed a mucoid 
phenotype, and under aerobic conditions 95%, 75% and 65% of all isolates could swim, swarm and 
twitch, respectively. Overall, 85% of isolates showed positive adhesion in the microtitre plate based 
assay (Table 4.7).  
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Table 4.7 Phenotypic characteristics of the 20 isolates possessing 5 common MLST types isolated from each of the niches, n (%). 
 
Ecological 
niche 
  Swim-Positive Swarm-Positive Twitch-Positive Adhesion-Positive 
Mucoid Pigment O2 MA AnO2 O2 MA AnO2 O2 MA AnO2 O2 MA AnO2 
Environment 3 (60) 0 (0) 5 (100) 5 (100) 4 (80) 4 (80) 2 (40) 4 (80) 4 (80) 5 (100) 1 (20) 5 (100) 5 (100) 5 (100) 
Animal 2 (40) 1 (20) 5 (100) 5 (100) 3 (60) 3 (60) 3 (60) 2 (40) 3 (60) 3 (60) 1 (20) 3 (60) 4 (80) 4 (80) 
Non-CF 1 (20) 0 (0) 5 (100) 5 (100) 4 (80) 4 (80) 1 (20) 2 (40) 2 (40) 2 (40) 1 (20) 5 (100) 4 (80) 5 (100) 
CF 4 (80) 0 (0) 3 * (60) 4 * (80) 4 (80) 4 (80) 2 (40) 1 (20) 4 (80) 5 (100) 0 (0) 4 (80) 4 (80) 3 (60) 
Total 10 (50) 1 (5) 18 † (95) 19 †  (100) 15 (75) 15 (75) 8 (40) 9 (45) 13 (65) 15 (75) 3 (15) 17 (85) 17 (85) 17 (85) 
* Total n = 4, one isolate showed an uninterpretable result 
† Total n = 19 
 
117 
 
4.5 Discussion  
Isolates obtained from a range of clinical settings, including CF, non-CF infections, animal sources 
and the environment all underwent testing using a range of agar and microtitre based assays in various 
atmospheric gradients to assess motility and adhesion capabilities. Compared to isolates obtained 
from the natural environment, isolates cultured from people with CF showed substantially reduced 
motility and adherence. These phenotypic traits were most pronounced in isolates belonging to shared 
CF strains and provide further evidence of the highly adapted nature of these genotypes in the CF 
airway. 
 
An Australian study which reported the high prevalence of numerous genetically indistinguishable 
strains of P. aeruginosa within the national CF population, demonstrated that the presence of these 
strains was detrimental to the long-term health of patients (Kidd et al. 2013). Furthermore, a 
systematic survey of the local environment and non-CF clinical infections failed to isolate any of the 
predominant shared Australian CF strains (Kidd et al. 2012), suggesting niche adaptation of these 
strains to the CF airways. Therefore, it has been hypothesised that traits associated with persistence 
and establishment of infection, such as the production of alginate, the development of a mucoid 
morphology, the production of siderophores and motility mediated by cell surface organelles, may be 
a contributing factor to the niche adaptation seen amongst these strains (Folkesson et al. 2012; Sousa 
and Pereira 2014; Winstanley et al. 2016). In addition, it is surmised that strains isolated from other 
sources, with varied genotypes, would not possess mechanisms essential for supporting long term 
colonisation.  
 
Interestingly, observations from these assays demonstrated both concordant and discordant findings 
when compared to existing reports in the scientific literature. However, care needs to be taken when 
interpreting and comparing results across studies, due to differences in experimental design and 
isolate selection. The key findings from this study are: i) the significant reduction, compared to the 
reference strain PAO1, of all phenotypic characteristics seen in isolates from people with CF, 
especially the shared strain AUST-02, ii) enhanced motility and adherence capabilities displayed by 
isolates collected from the environment, iii) greater similarities between the non-CF isolates, 
collected from human and animal infections, with the environmental isolates rather than the CF 
clinical isolates, iv) the reduction in motility and adherence for the majority of isolates, regardless of 
acquisition source, when tested in anaerobic conditions, and v) the influence of genotype rather than 
infection status (chronic or intermittent) or origin on phenotypes studied here. Overall, compared to 
existing data these results demonstrate how different conditions, protocol design and isolate selection 
influence results. 
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The CF isolates tested in this study were predominantly isolated from adults with a longstanding 
chronic P. aeruginosa infection (Kidd et al. 2013); however, despite this, a clear distinction between 
the ability to be motile was evident between the non-shared CF strains and the shared strain AUST-
02. More specifically, it was observed that the genotypically heterogeneous CF strains displayed a 
range of different motility traits, demonstrating greater similarities with the isolates from different 
clinical and environmental niches compared to the AUST-02 strains. Interestingly, there were no 
differences noted when these non-shared strains were compared to the other highly prevalent shared 
strain, AUST-06; although these data are difficult to interpret due to a relatively small sample size. 
These data suggest that rather than being solely associated with chronicity, the genes which regulate 
motility may be absent or non-functional in the AUST-02 strain. Furthermore, AUST-02 has only 
been isolated from the CF airway and to date; there has been no evidence of colonisation in any other 
clinical or environmental setting. Together these results, absent motility and the lack of an 
environmental reservoir, suggest a very high level of niche adaptation by AUST-02 to the CF airway. 
 
In contrast to this study, genotyping results on the isolates undergoing testing have not been reported 
for much of the published data. One study which did base isolate selection on genotyping results was 
the study conducted by Jeukens and colleagues. This study focused on the Liverpool epidemic strain 
(LES), a highly prevalent strain most commonly isolated from patients residing in the United 
Kingdom and Canada (Aaron et al. 2010; Scott and Pitt 2004). Results from this study demonstrated 
that compared to a reference strain and isogenically similar strains, each of LES isolates displayed 
either a reduced or absent phenotype (Jeukens et al. 2014). However, rather than selecting isolates 
based on strain type a large proportion of existing work undertaken in this area has been conducted 
on isolates stratified according to disease severity. These studies agree that isolates obtained from 
chronic infection sources have reduced motility phenotypes compared to isolates from early infection 
(Burke et al. 1991; Cullen et al. 2015; Jeukens et al. 2014; Lee et al. 2005; Mahenthiralingam et al. 
1994; Manos et al. 2013; Mayer-Hamblett et al. 2014). It is difficult to determine if results from these 
studies are biased based on genotypes as only a few include these data. However, for those studies 
which do comment, isolates with unique sequence types comprise the majority of strains (Head and 
Yu 2004; Manos et al. 2013). Rather than demonstrating a loss of motility based on infection status, 
I have shown that isolates from chronically infected patients, with a unique sequence type more 
closely resembled isolates from other clinical settings with moderate to high levels of positive motility 
reported.  
 
Similar to this study, a number of published studies have included non-CF and/or environmental 
isolates for comparison (Cullen et al. 2015; Head and Yu 2004; Jeukens et al. 2014; 
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Mahenthiralingam et al. 1994; O'May et al. 2006). Results from the current work are concordant with 
these earlier studies; both demonstrating enhanced motility among isolates arising from ecological 
niches outside of CF.  
 
To date the majority of studies previously reported have been conducted under aerobic atmospheric 
conditions with very few reporting motility characteristics under a reduced oxygen environment. Due 
to CF-specific increases in epithelial oxygen consumption, linked to increased airway surface liquid 
volume absorption and mucus stasis, varied oxygen gradients are present within mucus residing on 
epithelial surfaces (Worlitzsch et al. 2002). To reflect these conditions, all aspects of this study were 
performed in aerobic, microaerophilic and anaerobic conditions. Overall, this study demonstrated that 
swim and twitch motility for the majority of isolates was reduced when assessed in microaerophilic 
and anaerobic conditions alike; although these results rarely achieved statistical significance. 
Interestingly, swarming was not negatively correlated with anaerobic conditions to the same degree 
as swim and twitch were. When assessing the impact of anaerobic conditions on all isolates, there 
was only a 3% decline observed for swarming motility compared to a 23% and 28% reduction in 
swimming and twitching, respectively. As this result may be biased due to the large number of swarm 
negative AUST-02 strains, adjustment for all CF isolates resulted in an increase from 37% to 68% 
for swarming in anaerobic conditions. Isolates from the environmental demonstrated an enhanced 
capability to swarm under anaerobic conditions and this may reflect the diverse settings these 
organisms are collected from. O’May and colleagues, performed similar analyses, comparing the 
motility of CF and non-CF isolates in aerobic and anaerobic conditions. This study reported a marked 
decrease in each motility when tested anaerobically, regardless of clinical source. More specifically, 
100% of CF isolates displayed smaller motility zones when swarm was tested anaerobically compared 
to aerobically, whereas, only 50% of the non-CF isolates demonstrated a reduced swarm zone (O'May 
et al. 2006). Results from both studies demonstrate that atmospheric conditions do impact motility 
and this effect is more pronounced for the clinical isolates obtained from people with CF. Therefore, 
data reporting motility tested only in aerobic conditions should be interpreted with care as outcomes 
may vary when assessed under different experimental conditions. 
 
Similar to the motility results, a significant reduction in the adhesion capabilities was noted for the 
CF isolates, in particular the shared CF strains. These studies were conducted using a polystyrene 
microtitre plate in aerobic, microaerophilic and anaerobic conditions. Strong adhesion to the plastic 
surface was observed for the environmental, animal and non-CF isolates. As mentioned previously 
the isolates obtained from people with CF were predominantly associated with chronic infections. 
Unrelated to infection status, the non-shared CF strains displayed greater similarities regarding 
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adhesion with the isolates collected from the environment, animal and human clinical infections than 
with the shared CF strains. Overall, the shared strains displayed virtually no adherence to the plastic 
substrate. These results are of interest, as both shared and non-shared CF strains, causing chronic 
infections displayed very different abilities to adhere in this assay. Assessing these results, in 
isolation, suggests that this specific trait may not be currently required to facilitate the establishment 
and persistence of an infection and following adaptation to the CF airway adherence is selected 
against. 
 
Due to large variations between methodologies and experimental conditions which exist within the 
published literature, it is difficult to compare and contrast the adhesion capabilities of P. aeruginosa 
isolates (Azeredo et al. 2017). Regardless of these differences, the consensus among the literature, 
demonstrates that the CF strains display poorer adhesion compared to non-CF strains (Cullen et al. 
2015; Head and Yu 2004; Jeukens et al. 2014; O'May et al. 2006). However, there does appear to be 
greater heterogeneity seen in the published literature when comparing shared and non-shared CF 
strains to each other and to non-CF isolates. There are reports of both enhanced and subdued 
adherence among these comparisons (Cullen et al. 2015; Head and Yu 2004; Jeukens et al. 2014; 
O'May et al. 2006). Again, similar to the published data on motility, these results are also highly 
influenced by isolates obtained from sources where P. aeruginosa has been associated with a chronic 
infection. 
 
As observed for motility when tested anaerobically, bacterial adhesion was also reduced when tested 
in oxygen limiting conditions. Only a slight reduction in adhesion was observed for environmental 
and non-CF isolates and no change in adherence capabilities were reported for animal isolates. 
However, there was a statistical significance reported when the CF isolates were tested anaerobically, 
including both the non-shared and AUST-02 strains alike. These data contrast earlier studies which 
demonstrated that rather than having a negative impact on adherence, the lack of oxygen can actually 
enhance this phenotype (O'May et al. 2006; Yoon et al. 2002). Again, the degree to which this result 
is observed appears to be dependent upon methodology and strain. While, consistently poorer biofilm 
producers than PAO1, CF and non-CF strains have all demonstrated improved adherence under 
anaerobic conditions, although this increase is often modest (O'May et al. 2006). By utilising a 
number of static adhesion assays designed to better replicate the growth mode of P. aeruginosa in 
mucus plugs, Yoon and colleagues, were able to clearly demonstrated that not only could P. 
aeruginosa form biofilms and adhere to surfaces under anaerobic conditions, this phenotype was 
enhanced when compared to growth in aerobic conditions. Nevertheless, these results must be 
interpreted with caution as only the PAO1 strain underwent testing (Yoon et al. 2002). Regardless, 
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these studies, together with the current work demonstrate that while atmospheric conditions can 
influence the degree of adhesion, it does not prevent it from occurring.  
 
Analysis in this chapter also revealed a strong correlation between motility and adhesion capabilities. 
Specifically, these data showed that those isolates which were able to swim were also able to swarm 
and twitch. Furthermore, isolates which displayed enhance motility also demonstrated an enhanced 
capacity for adherence in the microtitre plate. Similar to other phenotypic traits, contrasting evidence 
determining an association between motility and the ability to form biofilms has also been reported. 
Jeukens and colleagues showed that isolates lacking motility were unable to adhere to the surface of 
the microtitre plate, whereas motile isolates produced thicker biofilms. This observation was 
independent of twitching motility (Jeukens et al. 2014). Results from studies assessing the motility 
and adhesion capabilities of a number of non-CF clinically significant isolates demonstrated enhanced 
motility and biofilm formation for all isolates (Murray et al. 2010; O'May et al. 2006). In addition, 
Murray and colleagues reported an inverse relationship between the ability to swim and twitch 
compared to the development of biofilm under static conditions (Murray et al. 2010).  
 
Several studies have observed that as the infection duration increases, CF isolates have a tendency to 
become non-motile. However a similar reduction in adherence has not been reported for all studies 
(Cullen et al. 2015; Head and Yu 2004; Lee et al. 2005). Lee and colleagues demonstrated a 
corresponding reduction in both motility and adhesion using the microtitre plate-based assay (Lee et 
al. 2005). These results were replicated using the flow chamber, demonstrating that as a chronic 
infection developed the corresponding reduction in motility lead to decreased attachment of cells to 
the coverslip and a reduction in microcolony development. As this assessment was qualitative, the 
degree of reduction could not be determined. Furthermore, this study reported that twitching motility, 
mediated by functional type IV pili, resulted in uniform biofilms with an even homogeneous layer of 
cells at the coverslip; whereas isolates that were unable to twitch produced thin biofilms with an 
uneven, heterogeneous appearance (Lee et al. 2005). However, Head and Yu concluded that there 
was no association between motility and biofilm formation using a plate-based assay. They 
demonstrated that a number of isolates with increased motility had reduced biofilm formation and 
conversely a number produced thick biofilms. This study determined that although all isolates 
possessed flagella, is not a fundamental mechanism required for biofilm formation. Furthermore, they 
determined that isolates lacking the ability to twitch produced high levels of biofilm (Head and Yu 
2004).  
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To my knowledge, the current study is the first to assess bacterial motility and adherence among 
genotypically indistinguishable strains isolated from different ecological niches. Twenty isolates 
comprising five distinct MLST sequence types (ST-155, -179, -253, -266, -381) cultured from four 
different ecological niches were included for testing. These particular strains have previously been 
isolated during environmental surveillance, clinical diagnosis and epidemiological surveys (Kidd et 
al. 2015; Kidd et al. 2012; Ranganathan et al. 2013). Irrespective of acquisition source, these strains 
displayed phenotypic characteristics similar to other isolates obtained from non-CF settings (i.e. the 
environment, animals or non-CF patient sources). Retention of motility and adhesion capabilities 
reflect the diversity and highly adaptable nature of these strains. Longitudinal analysis of phenotypic 
characteristics during the establishment of a chronic infection in a person with CF would be needed 
to determine, if over time and due to ongoing exposure to host factors and antimicrobial substances, 
whether these strains adapt to the CF airways in a manner similar to that seen with the AUST-02 
strain. 
 
During the establishment of an infection, P. aeruginosa uses motility and adhesion to colonise and 
develop bacterial community structures known as biofilms. P. aeruginosa possess cell surface 
organelles, pili and flagella which are responsible for cellular movement (swim, swarm and twitch) 
and the adhesion of the bacterial cells to each other, biotic or abiotic surfaces. These cellular 
mechanisms are complex and are regulated by a number of interconnecting pathways, genetic 
mutations and cell-density-dependent communication (Alhede et al. 2014; Alhede et al. 2011; 
Bjarnsholt 2013; Costerton et al. 1995; Davey and O'Toole G 2000; Winstanley et al. 2016). The 
development of biofilms within the lungs and a corresponding decline in cellular motility are often 
cited as indication that a chronic infection has ensued. Over recent years a number of methodologies 
have been developed which use surface adhesion to infer biofilm development (Azeredo et al. 2017; 
McBain 2009; Roberts et al. 2015). Static growth in the microtitre plate based assay is the mostly 
commonly used experimental design and allows for the quantification of cells displaying adhesion to 
be easily measured. This method is high throughput and easy to use and interpret (Azeredo et al. 
2017; Roberts et al. 2015). From this study, results would suggest that the CF isolates, in particular 
the AUST-02 strain, which are non-motile and almost universally non-adherent would not be able to 
adhere to surfaces within the airways and therefore may be unable to establish robust biofilms. As 
this strain is most often isolated from people with CF and chronic infection these data appear to be at 
odds with earlier work which suggest that as organisms adapt to the CF airway there is a progression 
from planktonic to biofilm-associated growth. 
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A big challenge facing this study was the isolate selection. While a wide variety of unique and shared 
genotypes, isolated from a vast range of clinical and environmental settings were chosen, a large 
proportion of the isolates tested belonged to the AUST-02 genotype. The AUST-02 strain was a 
particular focus of this study due to: i) its high prevalence within the Queensland CF population, ii) 
the absence of an environment reservoir, iii) its association with patient to patient transmission, and 
iv) the likelihood that it is highly adapted to the CF airway. By including so many of these strains for 
analysis it could be argued that this is repetition of a single strain and therefore multiple testing is 
potentially superfluous and creates bias in the interpretation of the results. From the stark results 
obtained, distinctively different phenotype is still evident for all of the CF isolates, regardless of the 
inclusion of the AUST-02 strains or not. Furthermore, works undertaken by colleagues assessing 
diversity within the AUST-02 strain have identified sub-types, each with different prevalence, 
phenotypic traits and antimicrobial profiles (Sherrard et al. 2017; Tai et al. 2015). Although sub-type 
analysis was not undertaken on these isolates, phenotypic results from these tests have identified a 
small number of strains with different characteristics, however overall the AUST-02 demonstrated an 
absence of motility and adhesion traits. Therefore, testing a large number of the AUST-02 strains was 
warranted.  
 
Despite high levels of reproducibility reported among the various methodologies employed 
throughout these analyses, this study had a number of limitations specific to assay design. Firstly, the 
approach of qualitatively reporting the colonial morphology, rather than assessing these traits through 
quantitative assessment may have underestimated the prevalence of certain phenotypes within the 
isolates tested. Secondly, rather than using established knockout mutants, known to display or 
suppress the desired phenotypic characteristic, as reference strains, all test isolates were compared to 
the P. aeruginosa strain, PAO1. Although PAO1 is often cited as a reference strain throughout the 
published literature, this strain may not be the most appropriate choice for the comparison of test 
isolates. PAO1 has been utilised as a reference strain for more than 60 years, and is now considered 
a laboratory strain, displaying distinct characteristics from clinical strains. Therefore, using this strain 
as the reference to which all other isolates are categorised may result in the misinterpretation of 
phenotypic characteristics as displayed by the test isolates. Thirdly, results generated using the static 
biofilm methodology was not confirmed using a dynamic system, such as the flow chamber, for a 
more thorough comparison. Although this additional testing would have been time consuming and 
expensive there is little published data to suggest correlation between the two assays. Fourthly, due 
to the small number of AUST-06 strains included for testing, these results must be interpreted with 
care. At the time of commencing this study the AUST-02 was the predominant shared strain identified 
at the TPCH Adult CF Clinic and therefore was the focus of the study. Finally, no genetic analysis 
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was undertaken on these isolates. By omitting analysis such as whole genome sequencing to identify 
mutations associated with the presence or absence of phenotypic characteristics, and by not 
confirming the effect of these mutations on protein functionality through expression assays, it is 
difficult to determine if the in vitro phenotypes reported in these studies will be an accurate 
representation of characteristics which may be displayed in vivo. Furthermore, the effect of selective 
pressures such as host immune factors and antibiotic exposure may also contribute to discrepancies 
between the in vitro and in vivo results. Therefore, these factors need to be considered when 
interpreting results generated from these analyses. 
 
Overall, these data also provide compelling evidence that exposure to different atmospheric 
conditions plays an important role in bacterial motility and adherence, and have important 
implications for our understanding biofilm biology in CF airways and highlight the need for cautious 
interpretation of earlier work in this field that primarily focused on aerobic experimental conditions. 
Furthermore, I demonstrate that P. aeruginosa isolated from the airways of chronically infected 
people with CF show reduced motility and adhesion as compared to isolates arising from other 
ecological settings. These phenotypic characteristics were most evident among shared CF strains, in 
particular the AUST-02 strain, and thus provide further evidence that these genotypes are highly 
adapted to the CF airway. Due to the complexity of airway infection process in CF, including the role 
of host factors and bacterial virulence, it is difficult to directly relate results from phenotypic analyses 
to broader health outcomes, in particular how reduced motility and altered adhesion capabilities 
impact on lung function. Future studies on a sub-set of these isolates, displaying distinct phenotypic 
characteristics, will be undertaken to elucidate additional adaptive mechanisms. A dynamic flow cell 
apparatus will be utilised to determine the influence these traits have on the development of sessile 
community formations known as biofilms. Furthermore, whole genome sequencing will be performed 
to provide further mechanistic insights to the biofilm, motility and adhesion characteristics of both 
environmental and significant clinical strains of P. aeruginosa.  
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Chapter 5: Biofilm development of Pseudomonas aeruginosa 
 
5.1 Abstract 
Background: The bacterium P. aeruginosa undergoes a number of phenotypic changes during the 
establishment of chronic infection in people with cystic fibrosis (CF). Previous phenotypic analysis 
of a large isolate cohort demonstrated that isolates from acute non-CF infections and the environment 
were highly motile and displayed enhanced adhesion in a microtitre plate-based assay. In contrast, 
isolates from CF patients, including the prevalent Australian shared strain, AUST-02, were non-
motile and almost universally non-adherent. By studying a subset of isolates displaying either 
enhanced or absent phenotypic characteristics, this study aimed to determine if motility and adhesion 
are required for the development of micro-colonies in mature biofilms. 
 
Methods: Eighteen isolates (AUST-02 n = 12, environment n = 6) were grown within a flow cell 
system used to visualise the maturation dynamics of in vitro biofilm structures. Following incubation 
at 30°C for 72-hours a live/dead stain was injected into the flow-cell chamber. Three dimensional 
images were captured with confocal microscopy and analysed by Comstat software. Effluent was 
serially diluted and quantified to determine bacterial dispersal levels. Comparative analysis of six 
environmental and 8 individual patient AUST-02 isolates was undertaken. In addition, six 
longitudinally collected AUST-02 isolates (including two isolates included in the comparative 
analysis) arising from two patients was assessed for changes in biofilm parameters over time. Mixed 
effects models were used to compare relevant biofilm parameters, with a P value of <0.05 considered 
significant. 
 
Results: Analysis comparing biofilm development of eight AUST-02 isolates and six environmental 
isolates demonstrated that the AUST-02 strains formed thicker biofilms (P < 0.001) with increased 
biomass (P = 0.012) and greater surface area coverage (P = 0.002) compared to the environmental 
isolates. Furthermore, significantly more organisms were cultured from the effluent of the AUST-02 
strain flow cells (3.0 x 108 versus 6.2 x 107; P = 0.008), suggesting enhanced dispersal. Six 
longitudinally collected isolates (including two isolates included in the comparative analysis) from 
two patients demonstrated that there was no change to any of the biofilm parameters overtime 
(biomass P = 0.089, maximum thickness P = 0.461, surface area P = 0.164).  
 
Conclusions: AUST-02 form robust mature biofilm structures despite apparent poor motility and 
surface adhesion. These results vary from published work, highlighting the variability and diversity 
of P. aeruginosa.  
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5.2 Introduction 
Bacterial biofilms represent an adaptive growth mode which allows for the colonisation and survival 
of microorganisms under extreme environmental conditions (Hall-Stoodley et al. 2004; Hall-
Stoodley and Stoodley 2009; Hall-Stoodley and Stoodley 2005). Biofilms develop when there is an 
influx of motile planktonic cells adhering to either a surface and or to each other, followed by the 
production of extracellular polymeric substances (EPS) and the formation of three dimensional (3D) 
cellular structures (Hall-Stoodley et al. 2004; Wilkins et al. 2014). EPS, comprising of extracellular 
DNA, proteins and polysaccharides is integral to the structural formation of biofilms.  
 
In contrast to bacterial cells living within the protection of a biofilm structure, planktonic cells are 
exposed to varied environmental conditions, host immune factors and antimicrobial substances. 
These cells are distinct from their biofilm counterparts and have been shown to possess a range of 
characteristics, not displayed by isolates within biofilms. During the transition from a planktonic 
mode of growth, bacterial cells undergo a range of adaptations promoting biofilm formation, which 
increases the bacterium’s ability to withstand eradication via the host immune system and 
antimicrobial resistance (Alhede et al. 2009; Chua et al. 2015; Colvin et al. 2011; Leid et al. 2005; 
Roberts et al. 2015; Stoodley et al. 2002; Winstanley et al. 2016). From a clinical perspective, the 
formation of biofilms is particularly relevant as they have been associated with a number of infective 
processes including catheter colonisation, implanted device, cutaneous and chronic respiratory 
infection (Bjarnsholt 2013).  
 
Pseudomonas aeruginosa is an environmental bacterium which is capable of existing in both 
planktonic and biofilm growth states. This opportunistic pathogen most commonly causes infections 
in immunocompromised hosts and is frequently associated with multidrug resistance (Llanes et al. 
2013; Silby et al. 2011). P. aeruginosa is the most prevalent pathogen isolated from the respiratory 
tract of people with cystic fibrosis (CF) and is the leading cause of morbidity and mortality among 
this patient group (Emerson et al. 2002; Sanders et al. 2014). As a result of increased resistance to 
anti-pseudomonal antibiotics, the establishment of chronic infection and biofilm growth, eradication 
of P. aeruginosa from the airways is extremely difficult (Vidya et al. 2016). Because of these unique 
properties and owing to its significant clinical relevance,  
P. aeruginosa is an excellent model to assess biofilm growth. 
 
Phenotypic characterisation of P. aeruginosa isolated from people with CF has demonstrated the 
importance of functional pili and flagella during the attachment process and subsequent formation of 
biofilm structures. Non-motile isolates display poor adhesion and reduced structural formation of the 
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biofilms compared to isolates demonstrating enhanced motility (Chiang and Burrows 2003; Jeukens 
et al. 2014; Lee et al. 2005; O'Toole and Kolter 1998). However, not all studies demonstrate a strong 
correlation between motility, adhesion and biofilm formation. When assessing non-CF clinical 
isolates, Murray and colleagues demonstrated that while swim and twitch motility mediated by 
flagella and pili were required for biofilm development, the lack of a swarming motility phenotype 
did not impede biofilm development (Murray et al. 2010). Likewise, Head and Yu describing the 
characteristics of CF, non-CF and environmental isolates reported that there was no correlation 
between biofilm formation and motility (Head and Yu 2004). In addition, duration of infection and 
strain type appear to influence the phenotypic characteristics, with a reduction in motility and biofilm 
formation noted for persistent and chronic isolates, as well as, isolates belonging to some prevalent 
shared CF strains (Duong et al. 2015; Jeukens et al. 2014; Lee et al. 2005; Manos et al. 2013; Mayer-
Hamblett et al. 2014).  
 
There are several different in vitro models that can be used to assess bacterial cellular adherence and 
biofilm formation (Azeredo et al. 2017; Crusz et al. 2012; McBain 2009; Roberts et al. 2015); 
therefore, it is feasible that variations in the methods used may also play an important role in the lack 
of concordance between studies. Owing to their high throughput nature, microtitre plate-based models 
offer a rapid means of screening large numbers of isolates to determine cellular adhesion and short-
term biofilm forming capacity using a range of different experimental conditions. However, due to 
nutrient depletion these assays cannot be performed over extended time periods. Furthermore, they 
provide no information on the structure of the biofilms generated. In contrast, the flow cell method 
allows for the maturation of biofilms within a dynamic system. This apparatus utilises an intricate 
system of tubing and a pump to allow for the continual supply of nutrients and the removal of 
planktonic cells and effluent over the duration of the experiment. While this methodology allows for 
the microscopic visualisation of architectural biofilm features and assessment of bacterial biofilm 
dispersal, it too has several limitations. Temperature and pressure changes within the system can 
promote the formation of air bubbles which can impact on the growth, and even destroy the biofilm. 
Bacterial overgrowth of isolates can impede biofilm maturation. System assembly is also technically 
challenging, and time consuming, thus relatively low throughput and individual modifications in 
addition to the published methodology are required to optimise specific experimental conditions 
(Azeredo et al. 2017; Crusz et al. 2012; Heydorn et al. 2000).  
 
It is hypothesised that those isolates which demonstrate strong adhesion capabilities in the microtitre 
assay will also develop biofilm structures within the flow cell model. Furthermore, for the persistent 
clinical isolates, length of infection will impact biofilm development. Unfortunately, due to a lack of 
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consensus in the scientific literature regarding methodology, experimental conditions, analysis 
techniques and bacterial strains, it is difficult to determine the most appropriate protocol to use when 
determining an isolate’s capability to establish a biofilm. Furthermore, there has not been a 
comparison of non-motile, poorly adherent shared CF strains versus highly motile and adherent 
isolates obtained from natural environment sources to assess specific bacterial growth characteristics. 
To address these knowledge gaps, this study aimed to: i) assess the concordance and reproducibility 
of the static microtitre plate-based biofilm model and the dynamic flow cell assay, ii) assess the in 
vitro biofilm forming capacity and extent of bacterial dispersal among isolates derived from different 
ecological backgrounds and possessing distinct motility and adherence phenotypes, and iii) determine 
whether duration of infection impacts biofilm development.  
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5.3 Methods 
5.3.1 Isolate Selection 
In Chapter 4 it was demonstrated that across a range of atmospheric conditions, isolates from 
environmental settings showed a highly motile (i.e. swim, swarm and twitch) and adherent phenotype 
utilising a microtitre plate-based assay. In contrast, isolates belonging to the AUST-02 shared strain 
were most frequently non-motile and non-adherent. Based on these data it was hypothesised that the 
AUST-02 strain would show a reduced capacity to adhere to substratum and form mature biofilm 
structures in the flow cell assay, whereas environmental organisms would produce long-term biofilms 
of increased biomass. To this end, six environmental and 12 AUST-02 isolates were selected for 
analysis in the flow cell system (Table 5.1). 
 
The environmental P. aeruginosa isolates were collected in 2009 during a survey of three riverine 
systems situated in South East Queensland, Australia (Kidd et al. 2012). Multilocus sequence typing 
(MLST) confirmed that all isolates possessed individual sequence types (ST-155, -179, -253 [aka 
PA14], -266, -381 and -471) which have also been isolated from persons with CF residing in South 
East Queensland (Kidd et al. 2012). The 12 AUST-02 isolates were collected between 2002 and 2013 
from sputum samples provided by CF patients participating in one of two cross sectional prevalence 
studies (Kidd et al. 2013; O'Carroll et al. 2004). All patients resided in South East Queensland at the 
time of collection and attended CF clinics at The Prince Charles Hospital (TPCH) or Royal Children’s 
Hospital (RCH), Brisbane. All 12 AUST-02 isolates were confirmed by MLST as ST-775 which is 
exclusively linked to this prevalent Queensland shared strain (Kidd et al. 2011; Kidd et al. 2012; 
Pseudomonas aeruginosa PubMLST Database 2012). The AUST-02 isolate collection comprised six 
isolates each cultured from individual patients, as well as, six longitudinally collected isolates 
obtained from two chronically infected patients during the years 2002, 2007 and 2013 (Kidd et al. 
2013) (Table 5.1). Patient 1, a 16-year-old male (at 2002), and Patient 2, a 14-year-old female (at 
2002), first acquired P. aeruginosa at the ages of 10 and 8 years, respectively. Patient 1 was 
heterozygous the p.F508del mutation (p.F508del/N130K), whereas Patient 2 was homozygous for 
p.F508del mutation. Two of the longitudinally collected isolates were used alongside the other six 
AUST-02 isolates for the broader comparisons with the environmental isolates, and all six were used 
to assess the association between phenotype and biofilm formation over time. In addition, P. 
aeruginosa strain PAO1 was used as a control isolate for all assays (Holloway 1955). 
 
 
 
5.3.2 Sample Collection, Isolate Processing and Phenotypic Analysis 
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Sample collection and culture, bacterial identification, MLST and phenotyping (i.e. colonial 
morphology; swim, swarm and twitch motility; microtitre plate-based assay using LB broth) of the 
18 test isolates was performed as detailed in Chapter 4 (Sections 4.3.1 – 4.3.7). For the purposes of 
this study a subset analyses of the phenotypic characteristics was undertaken for all 18 isolates. 
 
5.3.3 Growth curve analysis 
Bacterial fitness and generation time was determined for the all isolates, including PAO1 (n = 4, 
biological replicates). A 50 µL aliquot of an overnight bacterial culture prepared in LB media was 
diluted into 20 mL of M63 media and aerobically incubated with shaking (37 °C/200 rpm). Density 
readings and total viable counts enumerated on Mueller-Hinton agar were determined after 0, 4, 8, 
12, 16, 24 and 36 hours (McCaughey et al. 2013; Sherrard et al. 2017). 
 
5.3.4 Extended Microtitre Plate-based Assay Analysis 
In order to more closely represent and replicate the conditions within the flow cell, the microtitre 
plate-based assay was repeated using M63 media (as described in Section 4.3.7.5). Bacterial adhesion 
was tested in this model on all 18 isolates after 24hours incubation in microaerophilic conditions.  
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Table 5.1 Isolate selection for in vitro flow chamber experiments, (n = 18). 
 
Number Source Sample Type 
Year of 
Collection 
Additional sample & 
genotype information 
MLST Mucoid Pigment 
1 Environment Water 2009 Brisbane River; Urban 155 - + 
2 Environment Swab; Air/Water Interface 2009 Logan River; Rural 179 - - 
3 Environment Swab; Air/Water Interface 2009 Brisbane River; PA14; Urban 253 - - 
4 Environment Water 2009 Brisbane River; Rural 266 - + 
5 Environment Water 2009 Brisbane River; Urban 381 - + 
6 Environment Water 2009 Brisbane River; Urban 471 - + 
7 CF (Adult) Sputum 2007 Shared CF strain; AUST-02 775 - - 
8 CF (Adult) Sputum 2005 Shared CF strain; AUST-02 775 - - 
9 CF (Adult) Sputum 2007 Shared CF strain; AUST-02 775 - - 
10 CF (Adult) Sputum 2008 Shared CF strain; AUST-02 775 - + 
11 CF (Paediatric) Sputum 2007 Shared CF strain; AUST-02 775 - + 
12 CF (Paediatric) Sputum 2007 Shared CF strain; AUST-02 775 + + 
13 a CF (Paediatric) Sputum 2002 Shared CF strain; AUST-02 775 - - 
14 a,c CF (Adult) Sputum 2007 Shared CF strain; AUST-02 775 - + 
15 a CF (Adult) Sputum 2013 Shared CF strain; AUST-02 775 - - 
16 b CF (Paediatric) Sputum 2002 Shared CF strain; AUST-02 775 - + 
17 b CF (Adult) Sputum 2007 Shared CF strain; AUST-02 775 - + 
18 b,c CF (Adult) Sputum 2013 Shared CF strain; AUST-02 775 - + 
a Longitudinally collected isolates from Patient 1; CF chronically infected with AUST-02. 
b Longitudinally collected isolates from Patient 2; CF chronically infected with AUST-02. 
c Included in both environmental and AUST-02 comparison and longitudinal analysis. 
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5.3.5 Flow Cell Assay 
The flow cell system was set up in accordance with the model described by Crusz and colleagues 
with minor modifications (Crusz et al. 2012). Figure 5.1 shows the main components of the system 
which comprised: i) one litre glass bottles (Schott AG, Mainz, Germany) for housing sterile media to 
support the growth of the target microorganisms and to act as a waste receptacle; ii) bubble traps 
(Technical University of Denmark) in which the media flows through prior to reaching the flow cell 
to facilitate the removal of any bubbles; iii) a constructed flow cell in which the bacteria grow and 
adhere to the glass substratum allowing for visualisation using a confocal microscope; iv) and a 
peristaltic pump (Ismatec®, Process Pumps, Boronia, Australia) which drives the media through the 
system. All components were joined by silicon tubing of various internal diameters (ID) (Dow 
Corning Australia Pty Ltd, North Ryde, Australia; Saint-Gobain, Pinkenba, Australia) and plastic 
connectors (Cole-Parmer Instrument Company, Illinois, USA). Owing to the increased forces exerted 
on the pump tubing, stronger Ismaprene tubing (internal diameter 1.02 mm, Idex Health & Science 
GmbH, Wertheim, Germany) was used. Excluding the waste bottles, all components of the flow cell 
system were placed at the same level. Waste bottles were positioned below the apparatus to facilitate 
media flow and prevent bubble formation.  
 
5.3.5.1 Flow Cell Construction 
Flow cells used in this study were manufactured by the Department of Systems Biology, Technical 
University of Denmark. Each flow cell was machine manufactured from Perspex and consisted of 
three parallel chambers each of a 40 x 4 x 0.3 mm internal diameter. Glass coverslips (24 x 50 mm; 
Menzel-Gläser®, Branschweig, Germany), which act as the substratum for bacterial growth, were 
adhered to the flow cell using silicon glue. Prior to bonding, and to enhance bacterial adhesion, each 
coverslip was washed for two hours in a solution of two parts 15.7 M HNO3 (nitric acid) and one part 
2 M HCl (hydrochloric acid) (Aqua Regia), rinsed in running water and then stored in 80% (v/v) 
ethanol (Fischer et al. 2008). Upon use each coverslip was briefly flamed and then gently adhered to 
a thin layer of silicone glue applied along the length of the Perspex ridge running between the flow 
cell channels. Constructed flow cells were left overnight to allow the silicon glue to set, and then 
visually inspected to ensure nil leakage, even coverslip adherence and optimal fluid movement. 
 
5.3.5.2 Sterilisation and Washing of the Flow Cell System 
Sterilisation of the flow cell system was achieved by pumping one litre of 0.5% (v/v) NaClO (sodium 
hypochlorite; Labtek Pty. Ltd., Brendale, Australia) through the system for three hours at a speed of 
80 mL per hour per channel. The system was then emptied and one litre of sterilised  
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Milli-Q water was run through it for three hours to remove any traces of residual bleach. Flow cell 
sterilisation was performed both prior to and following each experiment. 
 
5.3.5.3 Media Preparation 
Minimal media, M63, was used for all flow cell experiments and initial bacterial suspension 
preparation. M63 contained 15 mM (NH4)2SO4 (ammonium sulfate), 22 mM KH2PO4 (potassium 
dihydrogen phosphate), 40 mM K2HPO4 (potassium phosphate dibasic) supplemented with filter 
sterilised 1 mM MgSO4 (magnesium sulfate), 10 µM FeCl3 (iron III chloride) and 5 mM glucose 
following autoclave sterilisation.  
 
5.3.5.4 Filling of the Flow Cell System 
Following assembly and cleaning of the flow cell system, the M63 media was passed through the 
system prior to inoculation. Media was introduced into the system at 3.0 mL h-1 channel-1 and let run 
through until all tubes were comprehensively filled with media running into the effluent bottle. The 
pump was then stopped and the caps on the bubble traps removed. Under the influence of gravity the 
bubble traps filled with media. Once full, the bubble trap caps were replaced and the media flow was 
resumed at 3.0 mL per hour per channel (50 µL/minute) overnight prior to inoculation.  
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Figure 5.1 Schematic of flow chamber apparatus and experimental design. 
Medium Bottle (1L) Bubble Trap Flow Cell Peristaltic Pump 
Effluent Bottle (1L) 
a 
a 
b 
b c 
Direction of flow 
Tubing set up: 
a Approximately 50 cm of Silastic Laboratory Tubing (ID 2.64 mm, Dow Corning Corp.) 
b Approximately 20 cm of Versilic tubing (ID 1.00 mm, Saint-Gobain Grp.) 
c Approximately 40 cm of 2-Stop Pharmed® Ismaprene tubing (ID 1.02 mm, Idex Health & Science LLC.) 
# Tubing connected with Y 1/8” connector (Cole-Parmer Instrument Co.) 
• Tubing connected with 1/8” ID X 1/16” ID reducer connector (Cole-Parmer Instrument Co.) 
^ Tubing connected with 1/16” straight connector (Cole-Parmer Instrument Co.) 
† VUCUSIP™ Green Lid GL45 with tube fittings (Integra Biosciences AG) 
‡ 0.20 µm filter (Sartorius Stedim Ministart®)  
% Denotes the position of Ratchet Clamps (Cole-Parmer Instrument Co.) 
*Inoculation site 
b b 
* 
# 
# 
# 
# 
• 
• 
• 
• 
• 
• 
^ % % 
† 
† 
‡ 
‡ 
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5.3.5.5 Preparation of Bacterial Inoculum 
All isolates were tested in triplicate (biological replicates) with 10 mL of M63 broth inoculated with 
1 µL of bacteria. Following overnight incubation at 37 °C/200 rpm, the bacterial suspension was 
adjusted to an optical density of 0.1 nm (OD600nm = 0.1), using sterile M63 media. The control PAO1 
strain and was tested on two separate occasions (technical replicates) with a total of four biological 
replicates. 
 
5.3.5.6 Flow Cell Inoculation 
Prior to flow cell inoculation the flow of media was paused, the tubing between the bubble traps and 
the flow cells was clamped and the waste bottles placed higher than the flow cell to prevent air being 
drawn into the system and media washing back through the tubing. To allow for a downstream flow 
as the flow cells were inoculated, the pump tubing was also released from the pump cassettes. In 
addition, tubing at the site of inoculation was sterilised using 80% (v/v) ethanol. Using a 1 mL 27-
gauge syringe, 800 µL of bacterial suspension was drawn up and 400 µL expelled from the syringe 
to remove any bubbles. The syringe was then inserted into the tubing and manipulated into the inlet 
port of the flow cell where 300 µL of the bacterial suspension was slowly injected into the chamber. 
The needle puncture site was then sealed using silicon glue. For each flow cell, individual chambers 
were inoculated with one of the three biological replicates for every isolate selected for testing. After 
all three chambers were inoculated the flow cell was inverted and incubated for two hours. After 
incubation, the pump tubing was reattached, the metal clamps released and the flow cell returned to 
an upright position. The waste bottles were lowered to below the height of the system and the pump 
was then resumed at 3.0 mL per hour per channel  
(50 µL/minute) .The flow cell system was incubated at 30 °C for 72-hours. Each day the tubing 
upstream of the flow cell was thoroughly checked for bacterial overgrowth and bubble formation in 
the chambers. 
 
5.3.5.7 Flow Cell Effluent Collection and Analysis 
After the 72-hour incubation period, an aliquot of the media was collected from downstream of the 
peristaltic pump to assess colonial morphology and total colony forming unit (CFU) counts of 
dispersed cells arising from each flow cell. Approximately 1 mL of waste media was aseptically 
collected and serially diluted (Neat, 10-2 to 10-8) in 0.9% NaCl (Sodium Chloride, normal saline). Ten 
microlitres of each diluted sample was then spread onto LB agar, incubated aerobically at  
37 °C for 72-hours with the mean CFUs/mL for each organism determined from across the CFU 
counts of respective biological replicates (Kirov et al. 2007). The combined total number of different 
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colonial morphotypes arising from the effluent of each isolate was also recorded, with a representative 
of each stored in 15% glycerol at -80 °C for future analysis. 
 
5.3.5.8 Flow Cell Staining 
Following effluent collection the pumps were stopped, the media flow halted and tubes clamped as 
per the methodology described in the inoculation of flow cells (Section 5.3.5.6). A final volume of  
300 µL of 10020 nM FilmTracer™ LIVE/DEAD® Biofilm Viability Kit stain (Invitrogen™, Thermo 
Fisher Scientific Inc, Newstead, Australia), was the injected into each chamber as per injection 
method described previously. This stain composed of the nucleic acid stains SYTO®9 and propidium 
iodine, to facilitate the visualisation of live intact cells and dead cell, respectively. Each flow cell was 
protected from light and incubated for 20 minutes followed by a 10-minute media wash at 3.0 mL per 
hour per channel (50 µL/minute). 
 
5.3.5.9 Microscopy 
Following staining the bacterial structure was imaged using a Zeiss 780 NLO confocal laser scanning 
microscope (CLSM; Carl Zeiss Microscopy, Oberkochen, Germany). For each flow cell four Z-stacks 
(0.71 µm intervals) were imaged at a distance of 1 cm from the inlet valve using a Plan-Apochromat 
63x/1.4 oil DIC M27 objective lens. The SYTO9 stain was used to visualise the live cells via the 
excitation and emission wavelengths of 488 nm and 523 nm, respectively. Propidium iodine using 
excitation and emission wavelengths of 561 nm and 620 nm, respectively, was used to visualise the 
dead cells. 
 
5.3.5.10 Flow Cell Data Analysis 
Analysis of the flow cell CLSM results was undertaken by both qualitative and quantitative methods. 
Qualitative assessments were undertaken by categorically defining the biofilm characteristics and 
structures of each isolate tested (Figure 5.2). Cellular adhesion to the substratum (glass coverslip) 
was described as either a patchy uneven distribution of cells forming an irregular monolayer 
(Heterogeneous; Figure 5.2A), or a uniform growth of cells, forming an even monolayer 
(Homogeneous; Figure 5.2B). Two previously defined quantitative descriptions were used to 
categorise the three dimensional cellular structures identified within the flow cell chambers (Petrova 
et al. 2012). Microcolonies (Figure 5.2C, D, G and H) were defined as larger cellular formations 
measuring greater than 50 µm in diameter and or greater than 30 µm in height, whereas small cellular 
formations measuring less than 50 µm in diameter and less than 30 µm in height were categorised as 
cell clusters (Figure 5.22E and F). 
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Quantification of the CLSM z-stack results was achieved using Comstat version 2.1 software 
(Heydorn Micro 2000, Vorregaard tech Uni of Denmark 2008, www.comstat.dk). The following 
parameters were calculated: biomass (µm3/µm2), maximum thickness (µm) and surface area (µm2).  
 
 
 
Figure 5.2 Examples of various flow cell biofilm architectural features.  
A) A heterogeneous monolayer demonstrating poor attachment to the substratum; B) A 
homogeneous monolayer demonstrating uniform cellular attachment to the substratum; C & D) 
Microcolonies (≥ 50 µm diameter ± ≥ 30 µm height); E & F) Cell clusters (< 50 µm diameter and 
< 30 µm height); G) A microcolony with dead cells (red) at the centre; H) Microcolonies joined 
by a ‘bacterial bridge’ (Scale 20 µm). 
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5.3.6 Statistical Analysis 
Categorical data, niche (environmental or CF shared strain, AUST-02) versus phenotype (motility 
and adherence) in different atmospheric conditions (aerobic, microaerophilic, anaerobic) were 
examined using Chi-square with Yates continuity correction to confirm the same association as 
previous reported in Chapter 4. Statistical analysis was performed using SPSS version 22, with a  
P value ≤ 0.05 indicating statistical significance.  
 
To account for replicates in both flow cell and adhesion assays, individual results were combined and 
compared as follows.  
 
Flow Cell Assay Analysis: For each experiment, one flow cell, consisting of three chambers 
(Chamber 1[C-1], Chamber 2[C-2] and Chamber 3[C-3]) were each inoculated with biological 
replicates of an individual isolate, therefore triplicates of each isolates were prepared for biofilm 
analysis. Four z-stacks were captured from each chamber; therefore a total of 12 z-stacks were 
recorded. Quantification of z-stacks was undertaken using the computer program Comstat. All  
z-stack results generated from Comstat for the environmental isolates in C-1 were combined, as too 
were the results from isolates tested in C-2 and again for the isolates tested in C-3. Z-stack results 
from the AUST-02 strains were also combined according to chambers. Results from the  
i) environmental isolates grown in C-1 were compared to the AUST-02 strains grown in C-1,  
ii) environmental isolates grown in C-2 were compared to the AUST-02 strains grown in C-2, and iii) 
environmental isolates grown in C-3 were compared to the AUST-02 strains grown in C-3. Mixed 
effects model, Pearson correlation coefficient and density estimate curves all used these data 
comparisons to be calculated. 
 
Microtitre Plate-Based Assay Analysis: Three technical replicates (Well 1[W-1], Well 2 [W-2] and 
Well 3[W-3]) of each isolate were assessed at two different time points (biological replicates, 
Replicate 1[R-1] and Replicate 2[R-2]). To assess results across replicates (W-1, W-2 and W-3) and 
time points (R-1 and R-2), all results obtained in W-1 at both time points (R-1 and R-2) were 
combined. This was repeated for results obtained from W-2 and W-3 at time points, R-1 and R-2. 
Therefore, the results from the: i) environmental isolates grown in W-1 (R-1 and R-2 combined) were 
compared to the AUST-02 strain grown in W-1 (R-1 and R-2 combined), ii) environmental isolates 
grown in W-2 (R-1 and R-2 combined) were compared to the AUST-02 strain grown in  
W-2 (R-1 and R-2 combined), and iii) environmental isolates grown in W-3 (R-1 and R-2 combined) 
were compared to the AUST-02 strain grown in W-3 (R-1 and R-2 combined). Mixed effects model 
used these data comparisons to be calculated. 
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Mixed effects models with replicate nested within specimen identification including fixed effects, 
were performed to compare niche effect with interaction with time. Density estimate curves, using 
Gaussian kernel, were generated to compare strains.  
 
Least squared estimates and 95% confidence intervals included fixed effects with their interactions. 
For variables that showed considerable skewness, the data was transformed with log (1+x) and the 
linear modelling was performed on the log scale. Comparisons were not adjusted for multiple testing. 
Statistical analyses were performed in R (R Core Team, 2017) with the lsmeans, lme4 and the MAd 
packages. 
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5.4 Results 
5.4.1 Colonial morphology and motility 
Subset analyses of colonial pigmentation, mucoidy and swim, swarm and twitching motilities for the 
14 (environmental [n = 6] and AUST-02 [n = 8]) isolates revealed similar results to those obtained in 
Chapter 4. All six of the environmental isolates displayed a non-mucoid colonial morphotype, with 
four also showing pyocyanin-related blue-green pigmentation when grown on LB agar. Only one 
AUST-02 isolate displayed a mucoid colonial morphotype and five produced pigmentation (one 
showed pyocyanin-related blue-green pigmentation and four showed pyomelanin-related brown 
pigmentation) on LB agar (Table 5.1). When swimming, swarming and twitching motility was 
assessed, the environmental isolates displayed substantial phenotypic heterogeneity, whereas the 
motility attributes of the AUST-02 strain isolates were much more tightly clustered (Figure 5.3A-I). 
Nevertheless, with the exception of anaerobic twitching motility, isolates collected from the 
environment showed significantly enhanced motility across the range of atmospheric conditions as 
compared to AUST-02 (Figure 5.3A-I). 
 
5.4.2 Microtitre Plate-based Assay Analysis 
Figure 5.3J-L shows that compared to the AUST-02 strain isolates, the six environmentally-derived 
isolates displayed an enhanced capacity to adhere to a polystyrene surface as demonstrated by the 
static microtitre plate-based assay. Consistent with the findings of Chapter 4, significant differences 
in bacterial adherence between the two groups were noted in all aerobic (P = 0.005), microaerophilic 
(P = 0.005) and anaerobic (P = 0.005) conditions. Likewise, when analysed in the mixed effects 
model comparing ecological niche by replicate analysis, the environmental isolates also showed an 
increased propensity for cellular adhesion across all atmospheric conditions (Table 5.2; P ≤ 0.005). 
 
Repeat of the microaerophilic microtitre plate-based assay using minimal M63 media demonstrated 
similar results to that of LB broth with the environmental isolates showing increased adherence in the 
model (Figure 5.3M; P = 0.031). However, although all the environmental isolates retained the ability 
to adhere to the polystyrene surface, there was an overall reduction in the degree of binding noted. In 
contrast, adherence of the AUST-02 strains was not reduced in minimal media, with two of the 
isolates demonstrating improved adherence to the microtitre plate as compared to microaerophilic 
growth in LB. Altogether, these data suggest that nutrient restriction not only decreases bacterial 
generation, but may also impact on cellular adherence to abiotic surfaces. 
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Figure 5.3 Phenotypic testing of multiple P. aeruginosa 
isolates from environmental sources (n = 6) and people 
with CF (AUST-02 strain, n = 8).  
Tested phenotypes include (a) swim, (b) swarm and (c) 
twitch motilities in aerobic conditions; (d) swim, (e) swarm 
and (f) twitch motilities in microaerophilic conditions; (g) 
swim, (h) swarm and (i) twitch motilities in anaerobic conditions; adhesion results from the microtitre 
plate-based assay using LB media in (j) aerobic, (k) microaerophilic and (l) anaerobic conditions and 
(m) adhesion results from the microtitre plate-based assay using M63 media in microaerophilic 
conditions. The average motility result tested in triplicate and six replicates from the microtitre assay 
are presented, with error bars representing the mean and standard deviation.  
(d) 
(a) (c) (b) 
(i) (h) (g) 
(f) (e) 
(j) (k) (l) 
(m) 
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Table 5.2 Mixed effects model comparing optical density measurements from the plate-based 
adhesion assays for niche by replicate analysis of environmental isolates (n = 6) and AUST-02 strains 
(n = 8) following 24-hours incubation.  
 
Atmospheric 
condition 
AUST-02 Strains (n = 8) Environmental Isolates (n = 6) 
P-value Replicate 1 Replicate 2 Replicate 1 Replicate 2 
lsmeans (95% CI) lsmeans (95% CI) lsmeans (95% CI) lsmeans (95% CI) 
Aerobic 0.33 (-0.22 - 0.88) 0.20 (-0.35 - 0.75) 1.33 (0.70 - 1.97) 1.37 (0.74 - 2.01) 0.005 
Microaerophilic 0.17 (-0.44 - 0.78) 0.28 (-0.33 - 0.89) 1.98 (1.27 - 2.68) 1.62 (0.92 - 2.33) < 0.001 
Anaerobic 0.33 (-0.45 - 1.11) 0.29 (-0.49 - 1.07) 1.95 (1.05 - 2.85) 1.66 (0.76 - 2.56) 0.006 
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5.4.3 Bacterial growth curve analysis 
From the growth curve analysis and calculation of the generation time, there appeared to be a fitness 
cost associated with the AUST-02 strains. Compared to the control strain, PAO1 (mean doubling 
time, 29 minutes) and the environmental isolates (mean doubling time, 43 minutes), the AUST-02 
strains (mean doubling time, 92 minutes) was slower to grow (Figure 5.4).  
 
 
 
Figure 5.4 Growth curve results displaying the A) bacterial density (OD600nm) and B) CFUs/mL of 
the 18 isolates to undergo analysis in the flow cell apparatus (environmental n = 6, AUST-02, n = 12) 
and control strain PAO1 (biological replicates, n = 4). 
 
A. 
B. 
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5.4.4 Qualitative Flow Cell Analysis 
Results of the qualitative flow cell analyses are presented in Table 5.3. A total of 76 CLSM z-stacks 
from the six environmental isolates were reviewed with cellular structures identified in 57% of 
images, with the majority of containing only one cellular structure (70%) per image. Collectively, a 
total of 63 environmental isolate biofilm structures were reported, 26 (41%) of which were defined 
as microcolonies. There was no difference in the number of environmental isolates which 
demonstrated either homogeneous adherence to the coverslip or poor adhesion and a heterogeneous 
monolayer. The proportion of microcolonies and cell clusters formed by the environmental isolates 
was similar to the reference strain, PAO1. 
 
In contrast to microtitre plate-based model, all eight of the AUST-02 isolates were capable of 
adhering to the glass substratum used the flow cell apparatus. Similar to the environmental isolates, 
47 (49%) of the 97 AUST-02 CLSM z-stacks reviewed showed a homogeneous biofilm monolayer. 
Cellular structures (n = 129), including both cell clusters and microcolonies were identified in 62% 
of all the AUST-02 images captured. Thirty-five (27%) and 94 (73%) were categorised as cell clusters 
and microcolonies, respectively. 
 
When comparing the environmental and AUST-02 strains it was revealed that both groups shared 
many similar structural characteristics when grown in the flow cell chambers. There was no difference 
in the proportion of images containing cellular structures (P = 0.585), nor was there any disparity in 
homogenous monolayer development at the substratum (P = 0.364). However, when all the cellular 
structures, in each z-stack were categorised into either small cell clusters or the larger microcolony 
structures, the AUST-02 strains produced significantly more microcolonies than the environmental 
isolates (P < 0.001). Furthermore, the AUST-02 isolates produced substantially more cellular 
structures per z-stack compared to the environmental isolates. On average there were 2.2 cellular 
structures identified per z-stack from the AUST-02 strain compared to 1.5 reported from the 
environmental isolates. While the height of the cellular structures was greater for the AUST-02 strains 
(P = 0.010), the environmental isolates produced microcolonies with larger diameters  
(P = 0.021). Representative images of the AUST-02 and environmental isolates can be found in 
Appendix 5.1. 
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Table 5.3 Descriptive features of biofilm characteristics. 
 
Parameter PAO1 Environmental isolates AUST-02 strains P-value a 
Number of isolates analysed 1 6 8  
Total number of z-stacks reviewed 13 76 97  
     
Individual z-stack features     
Homogeneous monolayer; z-stacks, n (%) 6 (46.2) 43 (56.6) 47 (48.5) 0.364 
Cellular structures *; z-stacks, n (%) 13 (100.0) 43 (56.6) 60 (61.9) 0.585 
Number of all cellular structures per z-stack:     
1 3 (23.1) 30 (69.8) 34 (56.7)  
2 4 (30.8) 7 (16.3) 9 (15.0)  
3 3 (23.1) 5 (11.6) 6 (10.0)  
4 2 (15.4) 1 (2.3) 5 (8.3)  
5 1 (7.7) 0 (0.0) 2 (3.3)  
6 0 (0.0) 0 (0.0) 1 (1.7)  
7 0 (0.0) 0 (0.0) 2 (3.3)  
8 0 (0.0) 0 (0.0) 0 (0.0)  
9 0 (0.0) 0 (0.0) 1 (1.7)  
     
Total number of microcolonies detected, n (%) 18 (54.5) 26 (41.3) 94 (72.9) < 0.001 
Total number of cell clusters detected, n (%) 15 (45.5) 37 (58.7) 35 (27.9) < 0.001 
     
Size of all cellular structures     
Diameter µm, mean ± SD (range) 38.2 ± 16.0 (11.6 - 64.8) 38.6 ± 17.8 (13.7 - 89.6 ) 39.0 ± 16.1 (11.9 - 84.6) 0.880 
Height µm, mean ± SD (range) 34.7 ± 22.2 (8.6 - 84.3) 33.3 ± 26.9 (7.9 - 162.1) 41.9 ± 18.3 (6.4 - 92.2) 0.010 
     
Size of microcolonies     
Diameter µm, mean ± SD (range) 47.2 ± 11.6 (28.9 - 64.8) 52.2 ± 18.9 (21.1 - 89.6) 44.3 ± 15.1 (18.9 - 84.6 ) 0.021 
Height µm, mean ± SD (range) 49.7 ± 19.6 (11.4 - 84.3) 54.5 ± 30.9 (21.4 - 162.1) 50.1 ± 14.0 (30.7 - 92.2) 0.294 
a A two-way unpaired t-test was performed between environmental and AUST-02 isolates only. 
* Cell clusters and microcolonies combined. 
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5.4.5 Quantitative Flow Cell Analysis 
Quantitative assessment of the CLSM images using Comstat analysis software demonstrated that 
compared to the environmental isolates, the AUST-02 isolates displayed enhanced biofilm formation. 
Mixed effects models, presenting least square means determined that the AUST-02 strains formed 
thicker biofilms (P < 0.001), with increased biomass (P = 0.012) and greater surface area coverage 
(P = 0.002) than the environmental isolates, when assessing the live cells comprising the biofilm only 
(Table 5.4). These data were further supported by the results from the Pearson Correlation Co-
efficient analyses which demonstrated that the Comstat live cell parameters displayed a strong 
correlation with each of the other parameters (Table 5.5). Therefore, this data demonstrates that 
biofilms comprising of greater biomass will also be thicker and cover more surface area.  
 
To complement the Comstat-based analyses we also used density curves estimates to visualise and 
compare the log biomass, maximum thickness and surface area of the environmental and AUST-02 
isolate groups across the three flow cell chambers (Figure 5.5). It was observed that the three curves 
produced by the environmental isolates, representing combined results generated from chambers 1, 2 
and 3, clustered tightly together for biomass, maximum thickness and surface area coverage. 
Likewise, the AUST-02 isolate curves showed similar clustering, but these were distinct from the 
environmental isolate curve clusters. The AUST-02 curves also showed increased percent density as 
compared to the environmental isolate curves. 
 
Altogether, the quantitative analyses of biofilm growth and architecture within the flow cell apparatus 
indicated that the AUST-02 isolates produced larger biofilms structures as compared to the 
environmental isolates (Table 5.3). Coupled with the qualitative assessments these data confirm that 
the AUST-02 strain is capable of forming robust biofilm structures and can adhere to a glass 
substratum. 
 
5.4.6 Reproducibility of in vitro biofilm methodologies 
As previously described in Chapter 4, when using Luria Broth as the growth medium, a high degree 
of reproducibility was determined for the microtitre plate based assay. Briefly, intra class correlations 
(ICC) determined that agreement measures for this assay were excellent (ICC: aerobic 0.972 [95% 
CI: 0.966 – 0.977] P < 0.001, microaerophilic 0.986 [95% CI: 0.984 – 0.989] P < 0.001, anaerobic 
0.986 [95% CI: 0.983 – 0.989] P < 0.001). As this methodology was determined to be highly 
reproducible, this analysis was not repeated when testing was conducted under microaerophilic 
conditions using minimal growth medium. 
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Density estimate curves were used to assess the reproducibility of the flow cell results. As 
demonstrated in Figure 5.5, the three curves produced by the environmental isolates, representing 
combined results generated from chambers 1, 2 and 3, clustered tightly together for biomass, 
maximum thickness and surface area coverage. Therefore, there was a high degree of reproducibility 
across chambers and between experiments. Results from the AUST-02 strains also demonstrated high 
levels of reproducibility. 
 
Table 5.4 Mixed effects model comparing quantitative live cell parameters generated from 
environmental (n = 6) and AUST-02 strains (n = 8) following 72-hours of growth within the flow cell 
model.  
 
 Live Cells stained with SYTO9  
Biofilm Parameter 
AUST-02 Isolates 
(n = 8) 
Environmental Isolates 
(n = 6) 
P-value 
lsmeans (95% CI) lsmeans (95% CI) 
Biomass (µm3/µm2) 1.66 (1.15 – 2.17) 1.21 (0.64 – 1.78) 0.012 
Maximum Thickness (µm) 3.91 (3.66 – 4.16) 3.48 (3.21 – 3.76) < 0.001 
Surface Area (µm2) 12.55 (12.13 – 12.98) 12.08 (11.61 – 12.55) 0.002 
 
Table 5.5 Results of Pearson Correlation Coefficient comparing environmental and AUST-02 isolate 
(n = 14) biofilm measurements as determined by Comstat for the live cells in combined z-stacks from 
CLSM analysis.  
 
Biofilm Measurements 
Live cells - SYTO9 
r P-value 
Biomass vs. Maximum Thickness 0.65 < 0.001 
Biomass vs. Surface Area 0.70 < 0.001 
Maximum Thickness vs. Surface Area 0.44 < 0.001 
 
  
148 
 
 
 
 
Figure 5.5 Density estimate curves (i.e. biomass, maximum thickness and surface area of the live 
biofilm cells) showing clustering of the two isolate groups and the reproducibility of the flow cell 
methodology.  
All results obtained from chamber 1 (C-1) across each independent experiment were combined and 
compared with all results obtained from chamber 2 (C-2) and chamber 3 (C-3) for environmental 
isolates and AUST-02 strains. 
 
5.4.7 Effluent Isolate Analysis 
Each individual flow cell experiment generated between one and four morphologically distinct 
presumptive P. aeruginosa isolates from the effluent collected at the conclusion of each experiment. 
All isolates retrieved from the effluent were non-mucoid. Pigmentation was produced by 64% of 
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isolates grown in the effluent of the environmental isolates, which reflected the morphotypes of the 
‘parent’ isolates. Whereas, there was a significant increase in the number of dispersed cells from the 
AUST-02 strains displaying pigmentation (92%) compared to original ‘parent’ strain (50%) on which 
the experiment was conducted (Fisher’s Exact Test P = 0.009).  
 
The overall number of CFUs/ml enumerated from the effluent samples was significantly greater for 
the AUST-02 isolate group (Students T-test P = 0.008) (Table 5.6). As previously shown the AUST-
02 strains developed more robust flow cell biofilms compared to the environmental strains. Therefore 
the analysis was repeated to account for any influence which biofilm biomass or surface area may 
have on bacterial shearing and/or cell dispersal. Following adjustment, the difference in CFUs/ml 
obtained from the bacterial effluent was no longer significant between the two isolate groups (biomass 
adjusted P = 0.092; surface area coverage adjusted P = 0.121), indicating the size of the biofilm is a 
contributing factor to bacterial dispersal. 
 
Table 5.6 Number of morphologically distinct isolates and average CFU/ml collected from the long-
term flow cell following 72-hours incubation at 37 °C for the isolates included in the environmental 
and AUST-02 comparison analysis (n = 14). 
 
Isolate 
Number 
Source 
Sequence 
Type 
Average CFUs/ml per 
isolate 
Maximum number of 
morphotypes detected 
across 3 chambers 
1 Environment 155 8.9 x 107 3 
2 Environment 179 1.1 x 107 2 
3 Environment 253 9.9 x 107 4 
4 Environment 266 1.2 x 107 2 
5 Environment 381 1.3 x 108 1 
6 Environment 471 3.1 x 107 4 
 Mean ± SD  6.2 x 107 ± 5.1 x 107 6.5 ± 2.9 
7 CF (Adult) 775 7.2 x 107 3 
8 CF (Adult) 775 7.3 x 108 3 
9 CF (Adult) 775 1.2 x 108 4 
10 CF (Adult) 775 1.0 x 108 4 
11 CF (Paediatric) 775 5.5 x 108 1 
12 CF (Paediatric) 775 2.9 x 108 2 
14 CF (Adult) 775 1.3 x 108 2 
18 CF (Adult) 775 3.9 x 108 2 
 Mean ± SD  3.0 x 108 ± 2.4 x 108 6.3 ± 2.3 
 PAO1  3.3 x 108 3 
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5.4.8 Longitudinally collected AUST-02 strains 
Patient 1, a young child time at time of P. aeruginosa acquisition, was infected for 6 years prior to 
participation in this study. All isolates collected over the eleven year period retained a non-mucoid 
morphotype, however overtime these isolates became non-pigmented. Other than limited variations 
in swimming motility reported, these isolates were non-motile and non-adherent. Patient 2 was 
infected with P. aeruginosa for six years prior to sample collection during 2002. There was no change 
noted over time regarding morphology and similar to other AUST-02 strains, these isolates were 
predominantly non-motile and non-adherent (Table 5.7). 
 
As demonstrated in Figure 5.6, despite the appearance of a downward trend, no change was noted for 
any biofilm parameter as assessed using Comstat software in either patient overtime (Biomass P = 
0.089, maximum thickness P = 0.461, surface area P = 0.164). Furthermore, similar longitudinal 
trajectories were reported when comparing biofilm formation from Patient 1 with Patient 2 (Biomass 
P = 0.834, maximum thickness P = 0.508, surface area P = 0.869) (Table 5.8). 
 
 
Figure 5.6 The change over time and comparison of longitudinal trajectories of biofilm forming 
characteristics obtained from Patient 1 (Pt ID 1) and Patient 2 (Pt ID 2), chronically infected with 
AUST-02, collected in the years 2002, 2007 and 2013. 
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Table 5.7 Results from the phenotypic and microtitre plate-based assays for the longitudinally collected isolated isolates from two patients chronically 
infected with AUST-02 (n = 6).  
 
Isolate 
Number 
 
CFTR 
Year of 
collection 
Age at 
collection 
Swim Swarm Twitch LB Media @ 24-hours M63 under MA 
conditions at 24-
hours 
 
O2 MA AnO2 O2 MA AnO2 O2 MA AnO2 O2 MA AnO2 
13 
Patient 1 p.F508del/N130K 
2002 16 - + - - - - - - - - - - - 
14 2007 21 - - - - - - - - - - - - - 
15 2013 27 - - + - - - - - - - - - - 
16 
Patient 2 p.F508del/p.F508del 
2002 14 - - - - - - - - - - - - + 
17 2007 19 - - - + - - - - - - - - - 
18 2013 25 - - - - - - - - - - - - - 
 
Table 5.8 Comparison of biofilm production between two patients chronically infected with the AUST-02 strain during the years 2002, 2007 and 2013.  
 
 Live Cells stained with SYTO9  
Biofilm Parameters 
Change over time 
Longitudinal Trajectory               
(Patient 1 vs Patient 2 over time) 
P-value P-value 
Biomass (µm3/µm2) 0.089 0.834 
Maximum Thickness (µm) 0.461 0.508 
Surface Area (µm2) 0.164 0.869 
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5.5 Discussion 
Using isolates obtained from the environment and the airways of people with CF this study 
determined that not only do these isolates differ phenotypically, but assays designed to infer similar 
mechanistic traits can report discordant results. More specifically, this study demonstrated that 
bacterial motility and adhesion are not unequivocally linked with an organism’s ability to form robust 
long term biofilms. These results show for the first time that although the CF shared strain, AUST-
02, showed subdued motility and poor adherence to an abiotic surface, compared to environmental 
isolates, it exhibited an enhanced capacity to form biofilms within a flow cell model. Furthermore, 
under these experimental conditions there did not appear to be any differences noted in the biofilm 
forming capacity of isolates collected longitudinally from patients with chronic AUST-02 infection. 
Overall, these data not only reveal novel insights into the infection biology of the prevalent Australian 
shared strain, AUST-02, but it also draws attention to the fact that some in vitro biofilm models may 
not be suitable for assessing the ‘global’ biofilm forming capacity of clinical isolates.  
 
Bacteria have two predominant modes of growth – as a free-living (or planktonic) single cells, or 
within sessile structured communities referred to as biofilms (Costerton et al. 1995). Biofilms adhere 
to biotic or abiotic surfaces, and more recently cellular aggregates consisting of bacteria adhering to 
each other have been described (Alhede et al. 2014; Alhede et al. 2011; Bjarnsholt 2013; Costerton 
et al. 1995; Rybtke et al. 2015). Biofilm growth provides protection to the bacterial cells from 
exposure to antimicrobial substances and fluctuations in environmental conditions. During the 
transition from a planktonic to a biofilm lifestyle the bacteria undergo many mechanistic changes 
(Costerton et al. 1995; Hogardt and Heesemann 2010; Stoodley et al. 2002; Winstanley et al. 2016). 
Two well described phenotypic characteristics associated with biofilm development are bacterial 
motility and adhesion capability. Overwhelmingly, the data currently presented in the scientific 
literature describes the ability to adhere and the loss of motility to be correlated with biofilm 
formation. However, not all studies demonstrate such a clear link between these phenotypic 
characteristics and the enhanced ability to develop biofilms. 
 
To more accurately assess biofilm development of the selected bacterial strains, all isolates were 
grown within a continuous flow cell apparatus. Eight AUST-02 strains possessing the same MLST 
profile were compared with six environmental isolates belonging to different genetic backgrounds. 
Despite differences in origin and genetic composition of these strains, all isolates shared a similar 
capacity for adherence and the generation of a homogeneous cellular monolayer within this flow cell 
model. However, during closer assessment of the bacterial structures comprising the biofilm, it was 
revealed that AUST-02 strains produced biofilm structures that were thicker, covered more surface 
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area and contained more biomass than those from environmental sources. Finally, the AUST-02 
strains produced significantly greater numbers of microcolonies than the environmental isolates, 
though it should be noted that the size of these structures across the two groups were not dissimilar.  
 
These data highlight the adaptability of P. aeruginosa and demonstrate that irrespective of the genetic 
background or origin of individual strains, all isolates possess the traits and mechanisms which enable 
them to form biofilms. It is difficult to compare or contrast these results with published data as this 
was the first study to assess biofilm formation of the AUST-02 strain in a continuous flow cell model. 
Furthermore, of the data currently available in the published scientific literature there is little 
concordance regarding methodologies and experimental conditions, rendering direct comparisons 
difficult. Nevertheless, several studies have assessed biofilm formation and motility among non-
clinical and clinical strains, including those belonging to prevalent shared CF strains.  
 
Due to the ease of use, high throughput and cost effectiveness the static biofilm model, in various 
forms, is most often used to infer adhesion and biofilm formation capabilities. To date, much of the 
current work available on this topic has focused on shared CF strains with high prevalence and 
associated with poorer clinical outcomes. These strains include isolates belonging to the Liverpool 
epidemic strain, prevalent throughout the UK and Canada, and the AUST-01 strain found within the 
Australian CF population. Despite the use of 96-well plates and similar experimental conditions, 
discordant results have been obtained for isolates belong to the LES. When compared to PAO1, two 
independent reports demonstrate reduced adherence (Cullen et al. 2015; Jeukens et al. 2014), whereas 
a further two studies observed enhanced adherence for the same strains (Carter et al. 2010; Kukavica-
Ibrulj et al. 2008). Interestingly, while the study conducted by Kukavica-Ibrulj and colleagues 
reported no correlation with motility characteristics, similar to adhesion, the studies conducted by 
Cullen and colleagues and Jeukens and colleagues reported a reduction in motility compared to PAO1 
(Cullen et al. 2015; Kukavica-Ibrulj et al. 2008).  
 
Bacterial adhesion of the AUST-01 strain has also been assessed in various static biofilm models. 
Compared to PAO1, reduced adherence was observed when assessed in the microtitre plate, glass 
coverslip and borosilicate glass tube models (Cullen et al. 2015; O'May et al. 2006). In addition, these 
studies reported impaired motility compared to PAO1 which is similar to other work comparing other 
shared CF strains with those isolated from other clinical presentations (Cullen et al. 2015; Head and 
Yu 2004; Jeukens et al. 2014; O'May et al. 2006). In this study, the shared strain, AUST-02 displayed 
impaired motility and reduced adhesion under static conditions, when compared to both the PAO1 
reference strain and a number of environmental isolates.  
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Given the complexity of assessing biofilm formation using the continuous flow cell model, fewer 
studies have been conducted. However, one study has demonstrated that LES can produce biofilms 
containing greater biomass when compared with PAO1 (Rojo-Molinero et al. 2016). Likewise, 
AUST-01 has been shown to produce thicker biofilms, covering a larger surface area as compared to 
both PAO1 and non-shared CF strains (Manos et al. 2008). Although CF strains, including AUST-01 
were slower to attach and form a monolayer compared to PAO1 in a continuous flow model, Kirov 
and colleagues reported that by 24-hours microcolony development had occurred and at the cessation 
of the experiment, these strains had produced biofilms with comparable thickness to PAO1 consisting 
of well-defined structures (Kirov et al. 2007). Whilst similar levels of adhesion and monolayer 
attachment in the flow cell model were seen when AUST-02 was compared with both PAO1 and 
environmental isolates, this current study reported that biofilms produced by AUST-02 were of a 
greater biomass and consisted of more cellular structures. Collectively, both the current and earlier 
data do indicate that highly prevalent shared CF strains show an enhanced capacity for forming 
biofilms in continuous flow cell models.  
 
A major finding of this study was the discordant results observed when assessing bacterial adhesion 
between the static microtitre plate-based assay and the continuous flow cell model. Despite using the 
same isolates and maintaining consistent experimental conditions throughout, the environmental 
isolates arising from various genetic backgrounds and sample sites demonstrated enhanced adhesion 
in both methods, whereas the AUST-02 strains only achieved a high level of adherence in the flow 
cell model. A number of earlier studies have also compared the adherence of both clinical and 
environmental isolates on different abiotic surfaces including glass and plastic. Overall, these data 
indicate that adhesion capabilities show uniformity across different substrates (Deligianni et al. 2010; 
Head and Yu 2004; Lee et al. 2005; O'May et al. 2006). Therefore, the between group differences in 
adhesion we observed here may indicate that the AUST-02 strain has a strain specific impairment in 
its capacity to adhere to polystyrene; however, several aspects of the experimental design also require 
careful consideration. Compared to the flow cell model which was conducted over an extended period 
with a continual supply of fresh media, the static microtitre plate-based model was performed over a 
shorter duration with a fixed supply of media and nutrients. As shown in the fitness experiments, 
under aerobic conditions, the AUST-02 generation time was substantially longer than that of the 
environmental isolates. Therefore, it is feasible that the length of the microtitre plated-based 
experiments may have been insufficient to enable adherence of the AUST-02 strains. Depletion of 
nutrients within the media may have also occurred which resulted in bacterial senescence or death 
prior to attachment. However, it was important note that when using the nutrient rich media, LB, the 
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same lack of adhesion was noted. As results from this experiment were only obtained following 24-
hours of incubation, the precise impact of the growth rates and respiration under reduced oxygenation 
of the individual bacterial strains could not be concluded.  
 
Few studies comment on the final growth stage of a biofilms life, the dispersal event, in which motile 
cells are actively expelled from the biofilm structure. In this model the newly released planktonic 
cells are washed downstream by the continual flow of media were they can be collected and studied. 
Studies assessing the characteristics of cells collected following a dispersal event report different 
phenotypic and morphological characteristic to those of the parental strain (Kirov et al. 2007; Woo 
et al. 2012; Workentine et al. 2010). Dispersed cells collected from the current study also possessed 
different colonial morphologies compared to those initially inoculated into the flow cell chambers. 
When compared to the environmental isolates, the AUST-02 strains also generated significantly 
greater numbers of dispersed cells. To determine whether the increased number of dispersed cells 
was influenced by the mass or surface area of the biofilm, repeat analysis, adjusting for these 
parameters was performed. This analysis demonstrated that biomass of the biofilm was indeed a major 
contributing factor of cellular dispersal. These data are supported by earlier work from Purevdorj-
Gage and colleagues who also showed that microcolony size and mass correlates with hollowing and 
dispersal events (Purevdorj-Gage et al. 2005). It is therefore tempting to speculate that a combination 
of increased biofilm biomass and cellular dispersal could be important for person-to-person 
transmission and niche adaptation of the AUST-02 strain within the CF airway microenvironment.  
 
To comment on the impact of infection duration and how chronicity influences biofilm formation and 
maturation, P. aeruginosa collected from two patients were analysed over a 12-year period. 
Unfortunately, neither patient had isolates retained from the time of initial infection, therefore a 
representative of an early infecting strain could not be included in this analysis. Regardless, this 
current study revealed no marked difference in either mass or structure of the biofilm over the 
observational period. Furthermore, the phenotypic characteristics of these isolates did not alter over 
time, remaining non-motile and non-adherent under static conditions. These results contrast those of 
Lee and colleagues, who demonstrated that as infection duration progresses there is a corresponding 
reduction in the organism’s ability to adhere to the glass coverslip and form a biofilm within a 
continuous flow cell model (Lee et al. 2005). Interestingly, this decline in biofilm development 
corresponded to the loss of motility for these strains.  
 
Although this study was thorough in the investigation of adhered biofilm development, it did not 
assess the presence of bacterial cluster formation. Studies have identified bacterial clusters within 
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sputum samples from patients with CF (DePas et al. 2016). The presence of varied phenotypes within 
the airways may contribute to the enhanced persistence and poor efficiency of eradication therapies, 
but due to experimental design this feature could not be identified or studied.  
 
There are a number of limitations to the current study, both regarding the isolate selection and the 
protocol design. Firstly, due to the time taken to run each experiment and the complexity of this study 
design it was only feasible to assess biofilm development on a modest number of isolates. In addition, 
whilst the clinical isolates all belonged to the same genotype and were obtained from the airways of 
people with CF, the environmental isolates represented six unique sequence types. Consequently, it 
is possible that the variance in genotype and collection site may have played a role in these findings. 
Secondly, as previously stated, the initial or early infecting isolates were unavailable for testing, so 
longitudinal isolates collected many years after the onset of the chronic infection were analysed. 
Therefore, specific mechanistic changes which may occur during the period between initial 
acquisition and the onset of chronic infection could not be determined and any inference of 
phenotypic characteristics from this work must be interpreted with caution. Thirdly, due to limitations 
regarding protocol design the daily monitoring of the developing biofilms using the CLSM could not 
be undertaken. Hence, specific details regarding developmental stages and dispersal events were not 
included in analysis. To address this, further work is planned to more accurately monitor dispersal 
events of both environmental and clinical isolates. Fourthly, this study did not perform any i) 
microscopy to determine the presence or absence of cell surface structures such as pili or flagella, ii) 
genetic analysis to identify mutations recognised to control motility, adherence or biofilm 
development and iii) expression studies to confirm the effects of the mutations. However, whole 
genome-based studies are now planned with the aim of providing additional mechanistic insights. 
Finally, results generated from in vitro testing may not accurately represent in vivo conditions. Under 
these experimental conditions there were no fluctuations in nutrient content, oxygenation, 
temperature or exposure to a range of antimicrobial substances, whereas in the human host or within 
some natural environmental settings the bacteria would be exposed to a range of fluctuating 
conditions, numerous other organisms and many antimicrobial substances. So, while these results 
reflect the conditions under which they are tested, caution must be applied when extrapolating into 
clinical situations. Due to experimental design, it was not feasible to demonstrate an association 
between the capacity to form biofilms and the clinical impact caused by infections with these strains. 
However, these results suggest that despite the downregulation of many traits required to form 
biofilms, the AUST-02 strains retain this capability. Therefore, it is hypothesised that other 
mechanisms which regulate biofilm formation are present in these bacteria. Clinically, these strains 
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would demonstrate a greater resistance to anti-pseudomonal antibiotics and enhance persistence, 
leading to poor prognosis for patients with an infection. 
 
Overall, the results from study show that despite similar levels of adherence, as demonstrated by 
homogeneous monolayer development on the glass coverslip within the continuous flow cell model, 
the AUST-02 strain, formed thicker biofilms consisting of well-developed cellular structures, 
compared to environmental isolates. Furthermore, results obtained from high throughput 
methodologies, such as a static microtitre plate-based model cannot be used to infer behaviour within 
a continuous flow cell model. Therefore, caution must be shown when i) choosing a method to assess 
in vitro biofilm formation ii) interpreting results and iii) inferring in vivo capabilities of a P. 
aeruginosa strain. Together with existing work, this study highlights the adaptive nature of  
P. aeruginosa and lends further weight to the importance of understanding the mechanistic 
differences which underpin persistence and infection. 
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Chapter 6: Genomic analysis of Pseudomonas aeruginosa 
6.1 Abstract 
Background: Due to the high prevalence and association with adverse clinical outcomes, the presence 
of the bacterium Pseudomonas aeruginosa in the airways of people with cystic fibrosis (CF) is highly 
clinically relevant. During the establishment of chronic respiratory infections in people with CF, P. 
aeruginosa evolves specific characteristics that make this pathogen better adapted to the lung 
environment. Many previous studies have highlighted the complexity of this process and currently 
the molecular basis underpinning many of these phenotypic adaptations remain poorly understood. 
Therefore, using a comparative genomic approach this study aims to identify the genetic basis of 
mechanisms key to airway adaptation.  
 
Methods: Thirty P. aeruginosa isolates obtained from either patients with CF or the local environment 
underwent phenotypic testing to determine motility and adhesion capabilities. Following this, whole 
genome sequencing and bioinformatic analysis was performed on all isolates. To assess correlation 
between phenotypic characteristics and genome, two analyses were performed; genome wide 
association studies (GWAS) and genome mapping and assembly to allow for the visualisation of 
specific variants within each isolate.  
 
Results: GWAS identified a number of genetic variants which may affect the phenotypic capabilities 
of these isolates. Closer examination of these variants within each of the isolates showed that while 
a number of these mutations were highly correlated with the loss of function, no single variant could 
fully account for the phenotype expressed.  
 
Conclusion: Rather than identifying a genetic variant responsible for these phenotypic characteristics 
this study has confirmed that the mechanisms responsible for specific bacterial traits (including 
motility and adhesion) are complex and multifactorial. This combined approach has highlighted a 
number of genes, which would be good targets for future analysis using a functional approach to 
assess the genetic variant’s contribution to phenotype.  
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6.2 Introduction 
Pseudomonas aeruginosa is the leading cause of respiratory infections in people with cystic fibrosis 
(CF) (Cystic Fibrosis Australia 2016; Cystic Fibrosis Foundation 2015; Cystic Fibrosis Trust 2016). 
Importantly and of clinical relevance, individuals with CF that become chronically infected with P. 
aeruginosa have significantly poorer health outcomes than non-infected individuals (Lee et al. 2003; 
Vidya et al. 2016). When a patient first becomes infected with wild-type P. aeruginosa the bacterium 
is not necessarily well adapted to life in the CF lung. Over time, the pathogen evolves and adapts to 
the lung environment generally transitioning from a motile free-floating planktonic cell into a non-
motile cell living within a complex bacterial community, known as a biofilm (Cullen and McClean 
2015; Sousa and Pereira 2014; Winstanley et al. 2016). Growth within a biofilm community offers 
several advantages, including increased tolerance to antibiotic treatment and physical protection from 
external environmental factors (Costerton et al. 1995). Multiple studies have attempted to identify 
candidate genes that exhibit altered expression profiles or mutational adaptation as the bacterium 
becomes better suited to the lung environment. Many such screening studies have identified genes 
essential for motility or biofilm formation, an observation which have been confirmed by the 
construction of knockout strains (Dasgupta et al. 2003; Hammond et al. 2015; Marvig et al. 2013; 
Marvig et al. 2015; Mattick et al. 1996; Mena and Gerba 2009; Oliver and Mena 2010; Semmler et 
al. 2000). However, rather than the identification of single genes or gene variants responsible for 
specific phenotypic changes, these studies have suggested that these mechanisms are complex and 
multifactorial. 
 
Following whole genome sequencing (WGS) and bioinformatic analysis; two differing approaches 
can be used to identify candidate genes associated with phenotypic characteristics. Firstly, a targeted 
approach, based on a literature search to identify genes known to effect protein function resulting in 
altered phenotype can be performed, followed by read mapping and sequence alignment identifying 
nucleotide substitutions within these candidate genes. The predicted effect of the amino acid sequence 
variation can be determined and results visualised. This methodology is limited as only genes 
currently known to be associated with phenotype may be analysed (Sherrard et al. 2017).  
 
Alternatively, genome-wide association studies (GWAS) to identify genetic variants correlated with 
disease. A GWAS is an unbiased, statistically based screening method that can determine if genetic 
variants, such as single nucleotide polymorphisms (SNPs), insertions and deletions (indels) or entire 
genes are over-represented within a specific population possessing a phenotypic trait compared with 
matched controls (Bush and Moore 2012; Corvin et al. 2010; Read and Massey 2014). While this 
approach has been readily used to identify genetic polymorphisms associated with specific inherited 
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genetic disease in humans (Hardy and Singleton 2009; Manolio 2010), only recently has this 
technique been applied to bacterial genomics to assist in further determining the mechanisms 
associated with resistance, transmission and adaptation (Chen and Shapiro 2015; Power et al. 2017; 
Read and Massey 2014).  
 
Results from Chapter 4 demonstrated that P. aeruginosa obtained from the environment are 
phenotypically distinct from clinical strains obtained from patients with CF. As isolates from these 
studies fall within two defined groups (e.g. motile versus non-motile), this collection is suitable for 
GWAS style approach to identify genetic variants, which may be responsible for these phenotypes. 
Furthermore, existing studies have highlighted many target genes which may affect protein function, 
which can be rapidly screened for genetic variants.  
 
Although P. aeruginosa has been extensively studied the molecular basis of many phenotypes 
remains poorly characterised and based on previous results, it is difficult to associate a given mutation 
with a specific phenotypic characteristic; however, using a well characterised selection of isolates 
and by performing thorough genomic analyses, it is hypothesised that mutations known to effect 
protein function will be identified. Therefore, this chapter comprehensively characterises three 
motility phenotypes (swarming, swimming and twitching) and bacterial adhesion, under three 
atmospheric conditions (aerobic, microaerophilic and anaerobic) in 30 P. aeruginosa strains. These 
isolates were then subjected to WGS and large-scale comparative genomics analysis to identify the 
genetic basis of motility and adhesion in this collection.  
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6.3 Materials and Methods 
6.3.1 Isolate Selection 
Based on phenotypic characteristics determined in Chapter 4, isolate selection included 
environmental isolates which displayed enhanced motility and adhesion, as well as CF clinical strains 
which showed impairment of these phenotype characteristics. Overall, 30 P. aeruginosa strains were 
selected for whole genome sequencing and analysis comprising13 AUST-02, five AUST-06 and one 
unique strain isolated from respiratory samples of people with CF with a chronic infection and 11 
isolates obtained from the natural environment (Kidd et al. 2013; Kidd et al. 2012) (Table 6.1).  
 
6.3.2 Isolate storage, retrieval, identification and genotyping 
Refer to sections 3.3.2 to 3.3.6 from Chapter 3 and sections 4.3.1 to 4.3.6 from Chapter 4 for isolate 
handling, preparation and identification techniques used in this Chapter. Twenty-two isolates 
underwent multilocus sequence typing (MLST) to confirm their genotype, while SNP typing was 
performed on the remaining eight isolates. In silico MLST analysis of the eight isolates that 
underwent SNP typing confirmed that four isolates belonged to ST-775 (AUST-02), three were 
confirmed as ST-801 (AUST-06), and one isolate (AUS883) comprised a novel double-locus variant 
(DLV) of ST-801 (Table 6.1).  
 
6.3.3 Phenotypic Assays 
All methodologies and interpretation are described in section 4.3.7 from Chapter 4. Results from 
media based motility assays and microtiter plate-based model obtained from Chapter 4 (Table 4.5) 
are presented for all isolates listed in in Table 6.1. 
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Table 6.1 Complete list of isolates used for phenotypic testing and genomic analysis. 
 
WGS Number Source Isolate source 
Sequence 
Type 
AUS276 Environmental Water 9 
AUS465 Environmental Water 147 
AUS438 Environmental Water 155 
AUS502 Environmental Swab: Air/Water Interface 179 
AUS222 Environmental Swab: Air/Water Interface 209 
AUS227 Environmental Water 216 
AUS343 Environmental Water 266 
AUS306 Environmental Water 381 
AUS504 Environmental Swab: Air/Water Interface 389 
AUS503 Environmental Swab: Air/Water Interface 810 
AUS449 Environmental Water 930 
A2_08 CF Patient (Adult) Sputum 775 
A2_07 CF Patient (Adult) Sputum 775 
A2_04 CF Patient (Adult) Sputum 775 
A2_29 CF Patient (Adult) Sputum 775 
AUS727 CF Patient (Adult) Sputum 775 
A2_06 CF Patient (Adult) Sputum 775 
A2_11 CF Patient (Adult) Sputum 775 
A2_13 CF Patient (Paediatric) Sputum 775 
A2_18 CF Patient (Paediatric) Sputum 775 
A2_19 CF Patient (Paediatric) Sputum 775 
A2_41 CF Patient (Adult) Sputum 775 
AUS717 CF Patient (Adult) Sputum 775 
A2_43 CF Patient (Paediatric) Sputum 775 
AUS883 CF Patient (Adult) Sputum Novel ST* 
AUS77 CF Patient (Paediatric) Sputum 801 
AUS884 CF Patient (Adult) Sputum 801 
AUS885 CF Patient (Adult) Sputum 801 
AUS396 CF Patient (Adult) Sputum 801 
AUS886 CF Patient (Adult) Sputum 801 
* Double-locus variant to ST-801. 
 
6.3.4 DNA extraction 
Genomic DNA was prepared using the UltraClean® Microbial DNA Isolation Kit (Mo Bio) with the 
following modifications to the protocol. Prior to extraction, samples were cooled on ice for  
1 hour, pelleted at 14,000 x g for 1 minute and washed twice using 0.9% Sodium chloride at  
14,000 x g for 1 minute. To increase DNA yield each sample was heated at 70°C for 10 minutes and 
bump vortexed for 15 seconds at 2 minute intervals. During precipitation of the non-DNA material 
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the samples were cooled on ice for 10 minutes and mixed gently. Centrifugation speed and time was 
increased to 12, 000 x g and 1 minute during the DNA binding steps and the final elution volume was 
increased to 100 µL.  
 
Genomic DNA quantity and concentration was determined using NanoDrop Spectrophotometry 
(Thermo Scientific Inc.). Library preparation and WGS were carried out at either the Australian 
Genomic Research Facility (AGRF), Melbourne, Australia or at the University of Laval, Québec, 
Canada using the Illumina HiSeq 2500 platform and Illumina MiSeq instrument, respectively 
(Sherrard et al. 2017). 
 
6.3.5 Variant identification and genome wide association analysis 
Genome wide association studies were performed using the SPANDx pipeline (Sarovich and Price 
2014) and PLINK (Purcell et al. 2007). P. aeruginosa strain PAO1 was used as the reference genome 
(Accession number: NC_002516) (Stover et al. 2000). Variants including both SNPs and indels were 
identified and annotated using BWA for read alignment (Li and Durbin 2009), SAMtools for read 
filtering and parsing, Picard (GitHub Inc Picard) for data filtering, the Genome Analysis Tool Kit 
(GATK) for base quality score recalibration, variant determination, data filtering and improved 
insertion-deletion calling, VCFtools for SNP and indel matrix construction, and SnpEff for variant 
annotation. Variants were then tested for association with phenotypes using PLINK (Figure 6.1). 
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                    Figure 6.1 Genome wide association workflow. 
 
6.3.6 Genome mapping and assembly 
In parallel with the GWAS analyses each assembled and annotated genome was compared with the 
PAO1 reference genome to identify genetic differences and functionally important mutations. To this 
end, Kraken (v0.10.4; (Wood and Salzberg 2014)) was used to compare the whole genome 
sequencing reads to known P. aeruginosa sequences to confirm genus and species and identify any 
DNA considered to be contamination. Nesoni (v0.128; (GitHub Inc Nesoni) was then used to filter 
out adapter sequences and low quality regions within the whole genome sequencing reads. SHRiMP2 
(David et al. 2011), as implemented within the Nesoni toolset, was thereafter used to map the reads 
to the PAO1 genome (Stover et al. 2000). SNPs (leading to synonymous (SMs) or non-synonymous 
mutations (NSMs) or premature stop codons) and indels were called using Nesoni. Ambiguous calls 
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were also clearly highlighted and were not included in the final analysis. In parallel to mapping, de 
novo assembly was also performed using Velvetoptimiser (v2.2.5; (GitHub Inc VelvetOptimiser)) 
and Velvet (Zerbino and Birney 2008) to assemble the whole genome sequencing reads. Assembled 
contigs were reordered against PAO1 using Mauve (v.2.4.0; (Darling et al. 2010)) and annotated 
using Prokka (v1.10; (Seemann 2014)). Gene annotations from PAO1 were used as the primary 
reference (Sherrard et al. 2017). Finally, a BLAST (Basic Local Alignment Search Tool) alignment 
of all predicted coding regions (using the genome assemblies generated) against the panel of genes 
of interest was performed to identify large genetic differences between the AUST-02, AUST-06 and 
environmental isolates and PAO1. When the nucleotide identity of a target gene was ≥97% (compared 
to PAO1), then any variants called by Nesoni were manually inspected. Functionally important 
mutations were defined as premature stop codons or frame-shift mutations. The effect of amino acid 
changes on protein function (effect or no effect) can be predicted using computational algorithms 
(Prickett et al. 2017). PROVEAN (Protein Variation Effect Analyzer) was used to filter the remaining 
missense and in-frame mutations into those that were predicted to be functionally important or neutral 
using the default score thresholds (Choi and Chan 2015; J Craig Venter Institute).  
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6.4 Results 
6.4.1 Motility in P. aeruginosa varies considerably across a diverse strain collection 
Thirty strains were tested for their ability to swim, swarm and twitch in different atmospheric 
conditions. Regardless of the atmospheric conditions, the clinical strains displayed reduced motility 
compared to isolates from the environment. Only 6% and 31% of all the motility tests performed 
returned a positive result for the AUST-02 and AUST-06 strains, respectively. Despite displaying 
substantial phenotypic heterogeneity, 81% of all motility assays performed on isolates obtained from 
an environmental origin showed evidence of motility (Figure 6.2a – i).  
 
6.4.2 Environmental isolates display enhanced adhesion capabilities 
All of the environmentally-derived isolates displayed adhesion capabilities in the static microtitre 
plate-based assay under each atmospheric condition. In contrast, only three AUST-02 isolates and 
none of the AUST-06 strains showed adhesion in this model (Figure 6.2j – l).  
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(c) (a) (b) 
(d) (e) (f) 
(g) (h) (i) 
(j) (k) (l) 
         
 
         
 
         
 
         
Figure 6.2 Phenotypic testing of multiple P. aeruginosa isolates from environmental (n = 11) or 
clinical sources (AUST-02 strain, n = 13; AUST-06 strain, n = 6).  
Tested phenotypes include (a) swim, (b) swarm and (c) twitch motilities in aerobic conditions; (d) 
swim, (e) swarm and (f) twitch motilities in microaerophilic conditions; (g) swim, (h) swarm and (i) 
twitch motilities in anaerobic conditions; adhesion results from the microtitre plate-based assay using 
LB media in (j) aerobic, (k) microaerophilic and (l) anaerobic conditions. The average motility result 
was tested in triplicate and six replicates from the microtitre assay are presented, with error bars 
representing the mean and standard deviation. 
Note: Adapted from data presented in Chapter 4. Subset analysis of isolates undergoing WGS. 
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6.4.3 Phylogenetic reconstruction shows that there is little within ST variation 
Phylogenetic reconstruction using 115,494 genome-wide orthologous SNPs showed that all the 
AUST-02 isolates were very closely related showing negligible within sequence type (ST) variation. 
Likewise, the AUST-06 and AUS883 DLV isolates formed a tightly clustered phylogenetic clade 
(Figure 3). In comparison, the environmental isolates showed greater diversity and were separated by 
considerable genetic distance from the AUST-02 and AUST-06 clades. Mapping of the phenotypic 
data against the phylogenetic tree showed that there was considerable population bias for some 
phenotypes. The most extreme example was observed with the anaerobic swimming phenotype being 
completely absent in the AUST-02 clade and present in all other isolates.  
 
 
Figure 6.3 Phenotypic trait data correlated with maximum-parsimony phylogenetic reconstruction 
using 115494 genome-wide SNPs.  
Solid shapes represent a functional phenotype.  
Abbreviations: BF, biofilm formation (adhesion); O2, aerobic; MA, microaerophilic; An, anaerobic. 
 
6.4.4 GWAS 
AUST-02 Clade 
AUST-06 Clade 
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All SNPs and indels were identified, annotated and tested for correlation with specific phenotypes. 
The most significant associations (up to five) between genotype and phenotype are presented in 
Appendix 5.1. Several candidate mutations were identified that were significantly associated with the 
majority of phenotypes (Table 6.2). Results for specific phenotypes are presented below.  
 
6.4.5 Genome mapping and assembly 
Using the results generated from the GWAS analysis, genome mapping and assembly was performed 
to identify nucleotide substitutions from the candidate genes displaying strong correlation with the 
phenotypes described (Table 6.3).  
 
6.4.6 Swim Motility 
6.4.6.1 GWAS 
No single genetic variant explained a negative swim motility phenotype within this sample set; 
however, several strongly associated variants were identified through GWAS analysis and included 
putative enzymes, hypothetical proteins, outer membrane proteins associated with alginate 
production, efflux pumps and iron sequestration determinants. Interestingly, the ten most significant 
genetic variants were very similar for aerobic and microaerophilic swimming motilities (Appendix 
5.1). Two of these indel variants, aprE and pscK, have been previously been associated with bacterial 
motility (Table 6.2). Unfortunately, under anaerobic conditions, genetic variants underpinning 
swimming motility were not able to be identified due to severe population stratification that 
phenotypically and genetically separated the AUST-02 group from all other strains (Figure 6.3). 
Visualisation of this population bias is presented in the GWAS Manhattan Plot below (Figure 6.4). 
 
6.4.6.2 Genome mapping and assembly 
Analysis of this sample set showed that the AUST-02 aprE gene possessed an indel at -78 base-pairs 
(bp) upstream of the start site, which may affect expression of this gene leading to reduced motility. 
Likewise, the AUST-02 pscK gene contained an in-frame deletion (Cys152del) which was predicted 
to alter its function. Comparisons to phenotypic results confirmed that both of these indels appeared 
to be very strongly correlated with swimming motility under each atmospheric condition. Excluding 
two phenotypic outliers (A2_04 and A2_43), the presence of these indels appears to impair swimming 
motility, whereas, 15/17 of the AUST-06 clade and environmental strains in which these mutations 
not identified were capable of swimming motility across the various atmospheric conditions. 
Interestingly, complete correlation was noted for anaerobic swimming; however, this could not be 
corroborated by GWAS analysis. In addition, all of the AUST-02 and AUST-06 clade strains 
contained other deleterious mutations within the aprE (E75V) and pscK (RRL161_163R) genes. 
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However, each of these variants did not appear to impede swimming motility as all but one of the ST-
801 strains carried this mutation and retained positive aerobic, microaerophilic and anaerobic 
swimming phenotypes. Notably, the environmental isolates showed high level homology with the 
PAO1 aprE and pscK sequences which corresponded with a positive swimming motility phenotype 
in all instances (Table 6.3). Finally, GWAS analysis of aerobic and microaerophilic swimming 
identified a duplication within the PA1874 gene (Ser150_Gly151dup). This gene has previously 
associated with resistance mechanisms of bacteria comprising biofilm structures, but given that 100% 
of the isolates showed low nucleotide identity to PA01 we were unable to determine if duplication of 
this loci may also impact on swimming motility.  
 
Figure 6.4 Manhattan plot showing population stratification impeding the identification of genetic 
variants correlating with the anaerobic swimming motility.  
Red and blue lines represent significance cutoffs 1 x 10-5 and 1 x 10-7 respectively. 
 
 
6.4.7 Swarm Motility 
6.4.7.1 GWAS  
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Presented in Appendix 5.1 are the top four genetic variants identified by GWAS analysis for 
swarming motility under aerobic conditions. This analysis did not identify any indels associated with 
aerobic swarming. No correlation was observed when these four variants and the phenotypic 
characteristics displayed by all isolates were compared. When this analysis was performed on the 
isolates under reduced oxygen environments, a number of different variants demonstrating high levels 
of correlation were identified. Indeed, the presence of these variants was able to differentiate the 
swarm negative AUST-02 and AUST-06 isolates from the swarm positive environmental isolates. 
These variants include a number of hypothetical proteins, enzymes and an outer membrane efflux 
system protein (Appendix 5.1). Two SNP variants within PA1908 and PA4881, were shown to 
correlate completely with swarm motility under microaerophilic conditions and three SNP variants, 
within PA0209, PA1997 and hpaA, were highly correlated with swarm motility under anaerobic 
conditions (Table 6.2). Furthermore, GWAS analysis did show that the genes flgK, fimV, xcpQ and 
clpB to be associated with swarming in reduced oxygen environments (Table 6.2). 
 
6.4.7.2 Genome mapping and assembly 
The genes which were highly correlated with phenotype and those previous associated with motility 
and adhesion identified during GWAS analysis were more closely examined using mapping and 
assembly techniques. These analyses showed that compared to the reference PAO1 strain, a number 
of isolates displayed low nucleotide identity to the highlighted genes. For example, 11 of the AUST-
02 isolates displayed less than 50% nucleotide identity with the PAO1 PA1908 gene sequence. 
Likewise, 100% of the clinical strains and four environmental isolates (AUS222, AUS438, AUS502, 
AUS504) demonstrated low sequence homology with the PAO1 PA4881 gene. In each of these 
instances this sequence variation was predicted to have functional consequences on protein synthesis 
and/or function. 
 
This analysis also revealed that the majority of variants identified by the GWAS analyses comprised 
synonymous mutations (SMs), which in some cases correlated strongly with a lack of swarming 
motility (Table 6.3). Indeed, the G91A PA1908 gene SM was detected in 11 isolates (including 
AUST-02, AUST-06 and environmental), nine of which were negative for microaerophilic swarming 
motility. Similarly, the SM clpB V846L variant was also highly correlated with negative swarming 
under microaerophilic conditions. Other examples included PA1997 G215D and hpaA gene I477V 
variants which both often correlated with a non-swarming phenotype in anaerobic conditions. 
Overall, we identified only one gene showing a loss-of-function mutation (i.e. fimV 
Gly682_Asp683insGlyAspLeuGlySer) among variants detected by GWAS analyses of the swarming 
motility phenotype. This indel was present in all but one (A2_19) of the clinical isolates, and two 
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environmental isolates (AUS227, AUS449). Phenotypic comparison confirmed a very strong 
correlation in microaerophilic or anaerobic conditions.  
 
6.4.8 Twitch Motility 
6.4.8.1 GWAS 
GWAS did not identify any variants to be significantly correlated with twitching under anaerobic 
conditions and due to population bias no SNPs were identified when twitching was assessed 
microaerophilically. Nevertheless, GWAS identified SNP variants within PA4781, PA4782, PA5484, 
PA5492 and PA0683 that were significantly correlated with loss of twitch motility in aerobic 
conditions. While this analysis identified a number of indels, none displayed a high correlation with 
phenotypic traits, however indels within xcpQ, fimV and pilQ genes, previously associated with 
motility and adhesion were identified following GWAS (Table 6.2, Appendix 5.1). As demonstrated 
in Figure 6.5, the indel in xcpQ was highly correlated with twitching under microaerophilic conditions 
for this data set. Other variants were identified through GWAS analysis, but are not currently known 
to influence aerobic twitching motility, included frameshift mutations associated with antibiotic 
tolerance, iron sequestration and cell wall biosynthesis, as well as hypothetical protein and an enzyme 
associated with carbon utilisation (Appendix 5.1). 
 
6.4.8.2 Genome mapping and assembly 
Assessment of genetic composition determined that with the exception of the A2_18 strain, mutations 
within PA4781 (L158F), PA4782 (A6V), PA5484 (E54K), PA5492 (V191I) and PA0683 (E240G) 
genes correlated strongly with the loss of a twitching phenotype. However, each of these SNPs were 
not predicted to result in deleterious mutations. Interestingly, while both AUST-02 and environmental 
strains share less than 90% nucleotide identity with the pilQ gene from PAO1, the clinical strains 
were almost entirely twitch negative while the converse was true for the environmental strains. The 
fimV gene was also highly heterogeneous with numerous indels noted mainly across the clinical 
isolates. Consequently, it is difficult to correlate any one variant with a particular phenotype and given 
the population stratification of the dataset parallel evolution is highly likely to have occurred as these 
respective populations have adapted to their host. Nevertheless, it is interesting to note that the fimV 
Gly682_Asp683insGlyAspLeuGlySer indel which was associated with loss of swarming motility, 
strongly correlated with a lack of twitching motility, particularly under microaerophilic conditions 
(Table 6.3).  
All the clinical strains and two environmental strains (AUS227, AUS449) demonstrated low 
nucleotide identity with the xcpQ sequence of the PAO1 strain, which was not seen within the 
environmental cohort Targeted analysis of the remaining environmental strains to determine the 
173 
 
presence of the xcpQ indel as identified by GWAS (Glu417_Ser418delinsAla) did not identify this 
variant in any strains. Therefore this variant is not fully associated with loss of motility (Table 6.3).  
 
Figure 6.5 Manhattan plot for microaerophilic twitching motility.  
Red and blue lines represent significance cutoffs 1 x 10-5 and 1 x 10-7 respectively. The one variant 
above the red line is an indel within xcpQ (Glu417_Ser418delinsAla). 
 
6.4.9 Adhesion and initial biofilm formation 
6.4.9.1 GWAS 
GWAS analysis was successful when identifying both SNPs and indels for adhesion under each of 
the atmospheric conditions (Appendix 5.1). Many different variants associated with bacterial 
adhesion were identified, including those involved with antibiotic tolerance, secretion systems, iron 
sequestration, bacterial communication and genetic recombination. Included were a number of 
variants previously associated with motility and adhesion phenotypes. GWAS identified three SNPs 
in PA2069, PA3292 and gcvP1, to be functionally important during aerobic bacterial adhesion (Table 
6.2, Appendix 5.1), and a further two SNP variants within PA0144 and PA2125, which may play a 
role during bacterial adhesion under reduced oxygen environments. Informative indels in four genes 
(opr86, pilQ, xcpQ, and PA4156) were also identified (Table 6.2). 
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6.4.9.2 Genome mapping and assembly 
Each of the genes identified by GWAS demonstrated a high degree of sequence heterogeneity, with 
none correlating completely with the displayed phenotypes. Poor nucleotide identity with the PA0144 
was noted for all the clinical strains and five of the environmental isolates. Of those isolates with a 
low nucleotide identity to PAO1, this correlated with non-adherence for all of the AUST-06 isolates, 
77% of the AUST-02 isolates and did not infer non-adherence in the environmental isolates. The 
PA2125 gene had a number of different SNPs though none were associated with a loss of function 
(Table 6.3). However, the SM identified by GWAS (K67T) was found in a half of the adhesion-
positive environmental isolates and absent from all other isolates. Similar results were found when 
the SMs from PA2069 (A480E), PA3292 (S202P) and gcvP1 (S98P) genes, none could be used to 
determine phenotypic traits. A six bp deletion (PMK674_676Q) in the opr86 gene was identified in 
all the AUST-02 strains, 77% of which were non-adherent in both aerobic and microaerophilic 
conditions. This deleterious mutation was not noted in any other isolate. The two opr86 indels 
(Arg668FS, Thr673_Met675del) identified by GWAS, were not shown to demonstrate a high level 
of correlation with loss of adhesion; however, this analysis was hampered by poor sequence quality 
in many of the strains. Interestingly, the environmental isolates comprised the majority of isolates in 
which these variants were identified. As each of these strains displayed strong adhesion capabilities, 
it is apparent that these variants do not have a substantial impact on cellular adhesion. Both the AUST-
02 and environmental strains had very large genetic variations within pilQ compared to PAO1; 
however, phenotypically these strains displayed contrasting morphologies. Furthermore, all AUST-
06 strains were non-adherent but possessed a pilQ SM (A106T) that was not predicted to effect protein 
function. All the clinical isolates displayed low nucleotide identity with PAO1 for the xcpQ gene. 
Although the majority of the clinical strains were non-adherent, the two environmental isolates with 
this genetic variation still displayed bacterial adherence when using a static biofilm model (Table 
6.2). Finally, the presence of a number of deleterious mutations and a frameshift mutation (Gly471FS) 
was identified in PA4156, although none correlated completely with a loss of adhesion capability 
within this isolate collection (Table 6.3).  
 
 
 
6.4.10 Other mutations associated with phenotypic traits 
Using mapping and assembly tools to more closely assess the genomes of the isolates tested has 
demonstrated that a number of variants can be associated with phenotypes, different to those 
identified in the GWAS analysis (Table 6.3).  
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The single bp deletion (C152del) identified in the pscK gene appeared to be more strongly correlated 
with anaerobic swimming than swimming under aerobic or microaerophilic conditions. The 
mutations, E75V and A168S (aprE gene) and the 6 bp deletion in pscK displayed greater synergy 
with a loss of adhesion and twitch motility, respectively than swim motility. Further work is needed 
but from this analysis, it appears that a number of NSMs and SMs within the opr86 gene may 
functionally impact anaerobic swimming, whereas, two SMs (K8T and N272S) in the PA4156 gene 
may affect anaerobic twitching capabilities. The SMs in PA2125 (E395D and H396D) and PA1997 
(E11K) identified in AUST-02 strain only appear to be associated with anaerobic swimming. Finally, 
the indel within the fimV gene, demonstrated correlation with loss of motility and adhesion under 
each different atmospheric condition. This correlation was strongest for swarm and twitching under 
microaerophilic conditions, as predicted by GWAS, and anaerobic adhesion. Interestingly, this 
mutation did not appear to functionally affect swimming motility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2 Informative variants and recognised genes which have demonstrated an association with 
defined phenotypic characteristics following GWAS analysis. 
 
Phenotype 
Identified 
Gene 
Variant 
Effect of mutation 
* 
Statistical 
Significanc
e (P-value) 
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Swim 
O2 & 
MA 
aprE upstream modifier NSM 4.4 x 10-7 
pscK Cys152del NSM 4.4 x 10-7 
PA1874 Ser150_Gly151dup NSM 4.4 x 10-7 
Swarm 
O2 flgK Asn372Ser Unknown   2.2 x 10-2 
MA 
PA1908 Gly91Ala SM 2.5 x 10-10 
PA4881 Ile52Val SM 1.5 x 10-8 
clpB Val846Leu SM 2.6 x 10-8 
fimV Gly682_Asp683insGlyAspLeuGlySer NSM 7.3 x 10-6 
AnO2 
PA1997 Gly215Asp SM 2.0 x 10-8 
hpaA Ile477Val SM 2.0 x 10-8 
PA0209 Ala229Val SM 5.0 x 10-8 
xcpQ Glu417_Ser418delinsAla Unknown 5.0 x 10-6 
fimV Gly682_Asp683insGlyAspLeuGlySer NSM 2.0 x 10-4 
Twitch 
O2 
PA4781 Leu158Phe SM 1.6 x 10-8 
PA4782 Ala6Val SM 1.6 x 10-8 
PA5484 Glu54Lys SM 1.6 x 10-8 
PA5492 Val191Ile SM 1.6 x 10-8 
PA0683 E240G SM 1.6 x 10-8 
xcpQ Glu417_Ser418delinsAla Unknown 7.1 x 10-6 
pilQ Gln628FS Unknown 8.0 x 10-6 
MA fimV Gly682_Asp683insGlyAspLeuGlySer NSM 9.0 x 10-7 
Adhesio
n 
O2 
PA2069 Ala480Glu SM 7.0 x 10-7 
PA3292 Ser202Pro SM 7.0 x 10-7 
gcvP1 Ser98Pro SM 7.0 x 10-7 
opr86 Arg668FS Unknown 2.6 x 10-5 
opr86 Thr673_Met675del Unknown 2.6 x 10-5 
MA 
PA4156 Gly471FS NSM 1.4 x 10-6 
opr86 Arg668FS Unknown 4.0 x 10-6 
opr86 Thr673_Met675del Unknown 7.7 x 10-6 
xcpQ Glu417_Ser418delinsAla Unknown 7.0 x 10-5 
PA0144 Val191Ile Unknown 9.0 x 10-6 
AnO2 
PA2125 Lys67Thr SM 1.8 x 10-6 
pilQ Gln628FS Unknown 1.0 x 10-4 
* As predicted using PROVEAN software. 
NSM, nonsynonymous mutation; SM, synonymous mutation 
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Table 6.3 Synonymous and non-synonymous mutations identified within the genes determined to be significant following GWAS analysis and analysed using gene mapping and assembly. 
Origin CF STRAIN – AUST-02 CF STRAIN – AUST-06 ENVIRONMENTAL STRAINS 
Amino Acid 
Variation 
(compared to 
PAO1 *) 
Isolate Number A2-04 A2-06 A2-07 A2-08 A2-11 A2-13 A2-18 A2-19 A2-29 A2-41 A2-43 AUS727 AUS717 AUS883 AUS77 AUS884 AUS885 AUS396 AUS886 AUS222 AUS227 AUS276 AUS306 AUS343 AUS438 AUS449 AUS465 AUS502 AUS503 AUS504 
MLST ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 Novel ST ST-801 ST-801 ST-801 ST-801 ST-801 ST-209 ST-216 ST-9 ST-381 ST-266 ST-155 ST-930 ST-147 ST-179 ST-810 ST-389 
aprE 
                                                            82% NI 
                                                            USM 
                                                            W30* 
                                                            E75V 
                                                            A168S 
pscK 
                                                            RRL161_163R 
                                                            152delC 
PA1874                                                             10-93% NI 
flgK                                                             86-87% NI 
PA1908 
                                                            29-50% NI 
                                                            S70I 
                                                            G91A 
PA4881 
                                                            66-97% NI 
                                                            I52V 
clpB 
                                                            85% NI 
                                                            V846L 
fimV 
                                                            54-83% NI 
                                                            582_585delKLM 
                                                            GDLGSins683 
PA1997 
                                                            E11K 
                                                            G135D 
                                                            G215D 
                                                            L290F 
hpaA                                                             I477V 
PA0209 
                                                            41-56% NI 
                                                            A229V 
                                                            A275V 
xcpQ                                                             92-97% NI 
PA4781 
                                                            66% NI 
                                                            P65L 
                                                            L158F 
                                                            G339D 
PA4782                                                             A6V 
PA5484 
                                                            97% NI 
                                                            E54K 
PA5492                                                             V191I 
PA0683 
                                                            0-81% NI 
                                                            D83G 
                                                            E240G 
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Table 6.3, continued Synonymous and non-synonymous mutations identified within the genes determined to be significant following GWAS analysis and analysed using gene mapping and assembly. 
Origin CF STRAIN – AUST-02 CF STRAIN - AUST-06 ENVIRONMENTAL STRAINS 
Amino Acid 
Variation 
(compared to 
PAO1 *) 
Isolate Number A2-04 A2-06 A2-07 A2-08 A2-11 A2-13 A2-18 A2-19 A2-29 A2-41 A2-43 AUS727 AUS717 AUS883 AUS77 AUS884 AUS885 AUS396 AUS886 AUS222 AUS227 AUS276 AUS306 AUS343 AUS438 AUS449 AUS465 AUS502 AUS503 AUS504 
MLST ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 Novel ST ST-801 ST-801 ST-801 ST-801 ST-801 ST-209 ST-216 ST-9 ST-381 ST-266 ST-155 ST-930 ST-147 ST-179 ST-810 ST-389 
pilQ 
                                                            90-97% NI 
                                                            A106T 
PA2069 
                                                            G20D 
                                                            R310H 
                                                            A480E 
PA3292 
                                                            85-97% NI 
                                                            Y35S 
                                                            G56D 
                                                            Y126C 
                                                            V135E 
                                                            G153E 
                                                            S202P 
gcvP1 
                                                            S98P 
                                                            A157G 
                                                            H210Y 
                                                            I524N 
                                                            A581V 
                                                            R626C 
                                                            R793L 
opr86 
                                                            R668FS 
                                                            T673_M673del 
                                                            N669D 
                                                            P670G 
                                                            D671N 
                                                            T673N 
                                                            PMK674_676Q 
                                                            N677I 
                                                            Q678V 
                                                            V715F 
PA4156 
                                                            0% NI 
                                                            G471FS 
                                                            1 BP del (1413delG) 
                                                            K8T 
                                                            N272S 
                                                            R317H 
                                      ???                     D436N 
                                                            T459I 
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Table 6.3, continued Synonymous and non-synonymous mutations identified within the genes determined to be significant following GWAS analysis and analysed using gene mapping and assembly. 
Origin CF STRAIN - AUST-02 CF STRAIN - AUST-06 ENVIRONMENTAL STRAINS 
Amino Acid 
Variation 
(compared to 
PAO1 *) 
Isolate Number A2-04 A2-06 A2-07 A2-08 A2-11 A2-13 A2-18 A2-19 A2-29 A2-41 A2-43 AUS727 AUS717 AUS883 AUS77 AUS884 AUS885 AUS396 AUS886 AUS222 AUS227 AUS276 AUS306 AUS343 AUS438 AUS449 AUS465 AUS502 AUS503 AUS504 
MLST ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 ST-775 Novel ST ST-801 ST-801 ST-801 ST-801 ST-801 ST-209 ST-216 ST-9 ST-381 ST-266 ST-155 ST-930 ST-147 ST-179 ST-810 ST-389 
PA0144                                                             95-97% NI 
PA2125 
                                                            46-97% NI 
                                                            G28A 
                                                            K67T 
                                                            D316E 
                                                            L389P 
                                                            E395D 
                                                            H396R 
                                                            D419E 
                                                            V463G 
                                                            D316E 
                                                                 
Swim 
O2 + - - - - - - - - - - - - - + + - + + + + + + + + + + + + +  
MA + - - - - - - - - - + - - - + + + + + + + + + + + + + + + +  
AnO2 - - - - - - - - - - - - - + + + + + + + + + + + + + + + + +  
Swarm 
O2 + - + + - - - - + - - - - - - - - - - + - - + + + + + - - +  
MA - - - - - - - - - - - - - - - - - - - + - + + + - + + - + +  
AnO2 - - - - - - - + - - - - - - - - - - - - + + + + + + + - + +  
Twitch 
O2 - - - - - - + - - - - - - - - - - - - + + + - + + + + + + +  
MA - - - - - - - - - - - - - - - - + - - + + + + + + + + + + +  
AnO2 - - - - - - - - - - - - - - - - + - - - - + - - - - - - - +  
Adhesion 
O2 - - - - - - + - - + - + - - - - - - - + + + + + + + + + + +  
MA - - - - - - + - - - - + - - - - - - - + + + + + + + + + + +  
AnO2 - - - - - - - - - - - + - - - - - - - + + + + + + + + + + +  
Abbreviations: NI, Nucleotide Identity; O2, aerobic; MA, microaerophilic; AnO2, anaerobic; USM, upstream mutation; IFM, in-frame mutation; FS, frame-shift mutation; dup, duplicate; del, deletion; ins, insertion. 
Amino acid variations highlighted in Red were identified by GWAS analysis 
* PAO1 genome Accession number: NC_002516 
 No change in protein (nucleotide sequence identical to PAO1 or synonymous substitution detected) 
 Synonymous mutation not predicted to affect protein (based on Literature search or PROVEAN) 
 Non-synonymous mutation predicted to affect protein (based on Literature search or PROVEAN), gene missing or large genetic variation detected 
 Poor sequence quality, gene variant could not be confirmed 
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6.5 Discussion 
This study used two bioinformatics approaches to identify genetic variants which may infer a 
phenotypic trait. GWAS analysis was initially used as a comprehensive screening tool to identify 
genetic variants associated with a phenotype. Highly significant variants identified by GWAS were 
then assessed further using an in-depth genome mapping and assembly approach. This method 
focused on genetic determinants identified by GWAS as highly correlated with a particular phenotype 
along with those previously determined to be involved with bacterial motility and adhesion.  
 
Eleven isolates collected from a local river system and 19 isolates obtained from the sputum of 
patients with cystic fibrosis, chronically infected with P. aeruginosa, were analysed. The 
environmental isolates represented a range of different genotypes, whereas the clinical isolates 
belonged to one of two clinically relevant clades, AUST-02 or AUST-06 (Kidd et al. 2013; Kidd et 
al. 2012). Phenotypically the environmental and clinical isolates possessed very distinct 
characteristics. Overwhelmingly, the environmental isolates demonstrated a positive phenotypic 
profile, compared to the clinical strains which lacked the ability to adhere or be motile. However, 
within the clinical strains, further distinctions were recognised. AUST-06 displayed a more 
heterogeneous distribution for motility phenotypes compared to AUST-02 isolates, which were 
almost universally negative. In contrast, no adherence was observed amongst the AUST-06 isolates 
compared to a number of AUST-02 isolates which were able to adhere.  
 
GWAS analysis did not determine any variants to be completely correlated with swimming motility, 
regardless of the atmospheric conditions the tests were conducted under. However, two variants, aprE 
and pscK, previously characterised, were associated with swimming for this sample set. Interestingly, 
previous studies have demonstrated that during swarming activity, rather than swimming, these genes 
were upregulated (Overhage et al. 2008; Yeung et al. 2009). Results from this study and the previous 
analyses suggests that these genes may play a role in both flagella driven motilities and additional 
investigation is needed to determine the extent to which they are influencing motility.  
 
Using a GWAS approach a number of variants within genes (flgK, fimV, xcpQ and clpB) which have 
previously been linked to bacterial adaptation, were shown to be highly correlated with swarming. Of 
particular interest from this analysis was clpB. Both GWAS and genome mapping and assembly 
determined that this variant was strongly correlated with loss of function. Zhao and colleagues 
showed that clpB Bacillus spp. mutants show reduced swimming motility and fewer flagella 
compared to a wild type strain (Zhao et al. 2016). It is currently unknown if and how a mutation 
within clpB may affect flagella function and what impact this may have on the swarming ability of P. 
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aeruginosa strains; however, PROVEAN analysis indicated that this SNP in the clpB (Val846Leu) 
gene would not deleteriously affect protein function. The remaining genes identified by GWAS, have 
been previously associated with the flagellum mediated motility, swarming (flgK), the Type II 
secretion system (xcpQ) and twitching motility (fimV) (Ball et al. 2002; Bitter et al. 2007; Dasgupta 
et al. 2003; Homma et al. 1990; Leid et al. 2009; O'Toole and Kolter 1998; Overhage et al. 2007; 
Semmler et al. 2000; Van der Meeren et al. 2013; Wehbi et al. 2011; Zhang et al. 2007). While no 
direct association with swarming was confirmed following assessment of the flgK and xcpQ, gene 
sequences, the results from this study suggests that these variants contribute to the loss of swarming 
motility. Likewise, both approaches determined that an indel within the fimV gene was highly 
correlated with swarm motility, particularly under reduced oxygenated environments. Future 
mechanistic studies aimed at assessing the role of these genetic determinants in swarming motility 
are now indicated.  
 
Of note were the results from both analyses when assessing anaerobic twitching. Phenotypically, only 
three isolates, two environmental strains and one AUST-06, demonstrated a positive twitching 
phenotype under anaerobic conditions. GWAS was unsuccessful at identifying any specific genetic 
variants. These results suggest that bacterial respiration may influence impaired twitch motility within 
this isolate set. Not only has it been demonstrated that P. aeruginosa grows at a slower rate in 
anaerobic conditions, but the expression of many phenotypic traits and genetic pathways are also 
subdued (Alvarez-Ortega and Harwood 2007; Hogardt and Heesemann 2013; Lee et al. 2011; O'May 
et al. 2006; Schobert and Jahn 2010; Waite and Curtis 2009; Wu et al. 2005; Yoon et al. 2002). 
 
As described in Chapter 5, the flow cell apparatus is superior in determining in vitro biofilm 
development when compared to the microtitre plate based assay. Ideally, the GWAS comparison 
undertaken in this study would have been based on the flow cell-derived biofilm parameters (as 
described in Chapter 5) in conjunction with the motility capabilities, rather than the microtitre assay 
results which are presented here. Due to limitations with isolate selection and availability of 
sequencing, only a proportion of these isolates underwent both WGS and biofilm flow cell analysis, 
therefore the microtitre assay was used as a substitute to determine adhesion. Regardless, GWAS 
successfully identified a range of variants associated with bacterial adherence, as determined by the 
microtitre plate-based assay, including genes which have been previously associated with bacterial 
communication (PA0144), iron acquisition (PA4156) and fimbriae function. (PA2125), all of which 
are essential for the development of bacterial communities (Banin et al. 2005; Elias et al. 2011; 
Gilbert et al. 2009; Tashiro et al. 2008; Vallet-Gely et al. 2007). Of particular note was opr86, which 
has previously been associated with bacterial survival and is thought to play an important role in 
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biofilm formation. Tashiro and colleagues have demonstrated that antibodies against this gene impair 
biofilm formation (Tashiro et al. 2008). The current analysis confirms the importance of this genetic 
determinant in surface attachment, which is crucial for biofilm formation and development. A six bp 
opr86 deletion was observed in the AUST-02 strains, which collectively demonstrated poor 
adherence to the abiotic surface. This work not only described opr86 as important for bacterial 
adhesion, but closer inspection of the SMs identified showed that they correlated with a negative 
phenotype for swimming anaerobically. Data generated here now provide a platform for further 
analysis into the genetic mechanisms responsible for adhesion and biofilm formation.  
 
The bioinformatic analyses presented in this study showed synergy among several variants across the 
different phenotypic characteristics and varied atmospheric conditions. These data suggest that such 
traits are interlinked and controlled through a range of common genes. The greatest synergy was the 
swim motility phenotype, with five variants identified under aerobic conditions and microaerophilic 
conditions (PA3535, PA3536, PA3641, algE [Arg10Trp and Gly79Ala]) and four of the five indels 
also identified across both atmospheres (PA1536, PA1874, aprE, pscK). Despite being essential for 
type IV pili biosynthesis and twitching motility (Semmler et al. 2000; Wehbi et al. 2011), in this 
isolate set, a significant indel within fimV was predicted to affect swarming, twitching and adhesion 
capabilities.  
 
Another frequently identified variant from GWAS analysis was observed within the xcpQ gene; 
however as the majority of these isolates displayed large genetic variations this particular variant 
could not be identified. Nevertheless, this genetic variation was associated with twitch motility, 
swarm motility and adhesion under reduced oxygen conditions. Interestingly, while a direct 
association with motility or biofilm formation has yet to be confirmed, a study has demonstrated that 
xcpQ mutants retain the ability to develop biofilms (Ball et al. 2002; Bitter et al. 2007; Overhage et 
al. 2007; Van der Meeren et al. 2013). The clinical strains studied here all have low nucleotide identity 
with the reference strain and displayed impaired adhesion to an abiotic surface. Previous work 
presented in Chapters 4 and 5 demonstrated that static biofilm formation, focusing on initial 
adherence, is not predictive of bacterial biofilm formation in a flow cell experimental apparatus. 
Therefore, results generated from microtitre plate based assay which report that mutations within the 
xcpQ have no effect on phenotype warrant further investigation (Overhage et al. 2007). Furthermore, 
while the role of xcpQ in biofilm development remains uncertain, this gene has also been associated 
with a type II secretion system (Ball et al. 2002) that enables excretion of intracellular proteins into 
the extracellular space. Bacterial toxins associated with the breakdown of tissue and the establishment 
of infections can be released from the cells in this manner.  
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An indel in the pilQ gene was identified by GWAS during twitching and initial biofilm development 
under both aerobic and anaerobic conditions. A number of studies have demonstrated a strong 
association with mutations within this gene to the loss of surface fimbriae and twitching motility (Alm 
and Mattick 1997; Chang et al. 2007; Koo et al. 2013). The GWAS performed here identified a 
significant frameshift mutation in pilQ which correlated with anaerobic adhesion; however, the low 
level of amino acid identity together with several strains lacking this gene entirely may mean that this 
locus has been mutationally inactivated though multiple mechanisms. When this gene was analysed 
more closely, this study observed the AUST-02 and the environmental strains demonstrated a high 
level of sequence variance when compared to the reference strain, yet this did not match the 
phenotypic capabilities. Overall, the AUST-02 strains demonstrated poor twitching and attachment 
capabilities, in contrast with the environmental strains that showed enhance traits. All AUST-06 
isolates possessed a non-synonymous mutation not predicted to affect protein function; however, like 
AUST-02 these isolates were non-motile and non-adherent. These results suggest pilQ is not solely 
responsible for this phenotype and that other mechanisms must play a role in bacterial twitching and 
good adherence. GWAS analysis has shown high levels of synergy across the atmospheric conditions 
and between the phenotypic traits, highlighting the limitations of using a single approach to assess 
the impact of genetic variants on phenotypic traits. Rather, a multifaceted approach combining 
phenotypic, genomic, expression studies and knockout strains is needed to determine if any 
correlation can be identified.  
 
Results presented in this study need to be interpreted with caution as isolate selection may have 
influenced these analyses. Two-thirds of the isolates included in this data set were clinical strains, 
representing two predominant sequence types. In contrast, the environmental strains represented 11 
STs and each strain had a unique sequence type. As demonstrated the GWAS, many of the genetic 
variants identified as significant for a particular trait have been previously associated with antibiotic 
susceptibility rather than motility and adhesion and the results presented here may be influenced by 
the number of highly antibiotic resistant clinical strains. Therefore, if this approach is to be used to 
identify targets for further genomic analysis a larger isolate cohort should be used, including a broader 
range of isolates with varied genotypes, sourced from a range of different clinical and environmental 
settings (e.g. non-CF) and possessing a range of different phenotypic traits (e.g. antimicrobial 
resistance). Unlike the CF strains which have adapted within a unique environment having prolong 
exposure to high doses of antibiotics and a range of host defenses, isolates from acute infections are 
not likely to have undergone bacterial adaptation and are less likely to have developed acquired 
resistance. Additionally, the phenotypic heterogeneity and relatively small population within the 
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isolate categories (environmental, AUST-02 and AUST-06) reduce the power of the GWAS analysis. 
Despite technical replicates being performed on each isolate, repeat phenotypic testing is required to 
confirm any unexpected results. Finally, a large number of hypothetical proteins were also identified 
following GWAS analysis. As these genes have not been previously described further analysis using 
mapping and assembly techniques were not undertaken. Nevertheless, these variants may also play 
an important role in the expression of phenotypic characteristics. As such, these variants may provide 
a number of potential candidates for a more targeted approach to assess genes associated with motility 
and adhesion in future studies. While this study was unable to identify a single genetic variant that 
was associated with a discrete phenotypic trait, the methodology presented here could be adapted and 
used to identify the genetic underpinnings of particular bacterial phenotypes and clinical outcomes. 
As whole genome sequencing and bioinformatic analysis is increasing and the technology will be 
important in the development of diagnostic markers able to assist in rapid diagnosis. However, to 
better understand the mechanisms associated with P. aeruginosa motility and adhesion a larger 
sample size is required for bioinformatic analysis and to be able to determine clinical impact of these 
traits on the health outcomes for patients, corresponding clinical characteristics also need to be 
assessed.  
 
This study identified a number of genetic variants, which likely influence the phenotypic 
characteristics associated with development of chronic infections. It is anticipated that this 
preliminary analysis will form the basis of ongoing work; including additional GWAS and a targeted 
mutation approach to functionally assess the most significantly associated genetic variants. Finally, 
no single genetic mutation accounted for a discrete phenotype, which is likely to reflect the diversity 
and evolutionary history of the isolates studied. These analyses suggest parallel evolution of the 
AUST-02 and AUST-06 clades has occurred as these groups have evolved similar phenotypes 
through different genetic alterations. Through the inclusion of additional isolates and expansion of 
genetic analysis to include knockout strains, it is hoped that this work will further contribute to the 
existing knowledge of bacterial adaptation. 
 
 
 
 
Chapter 7: Overall Discussion and Thesis Conclusions 
7.1 Hypothesis and Aims 
To date the prevalent P. aeruginosa shared strains commonly isolated from CF patients residing in 
Queensland have not been isolated from other clinical or environmental settings. It is hypothesised 
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that these strains possess specific mechanisms which enable persistence and adaptation to the CF 
airways, different to other commonly isolated strains. Therefore, using the phenotypic and genomic 
analysis described in this PhD, comparison studies to elucidate these differences were undertaken. 
Motility, adhesion and biofilm development were chosen as these traits have been associated with 
antibiotic resistance, adaptation, virulence and infection persistence, all mechanisms relevant and 
important for infection development within the CF airways. The specific methodologies used 
throughout this thesis are commonly used and cited techniques to assess these traits. 
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7.2 Key Findings of thesis 
7.2.1 Chapter 2: Prevalence of Pseudomonas aeruginosa in an adult CF centre  
The data presented here is the first time the microbial pathogens present in the sputum of adult patients 
attending The Prince Charles Hospital have ever been collated and reported.  
The key findings from this chapter include demonstrating that: 
1. The prevalence of significant respiratory infections, including P. aeruginosa, has decreased 
over time. 
2. There has been an improvement in the lung function and nutritional status of young patients 
at the time of transition into the adult centre. 
3. The current protocol used to define chronic respiratory infections caused by P. aeruginosa 
(Lee et al. 2003) was unsuitable when applied to a contemporary adult patient population. 
The most significant contribution to the current knowledge of CF microbiology was: 
Modifications to the definition describing chronic P. aeruginosa to better represent patient sampling 
within a contemporary adult population. 
 
7.2.1.1 Limitations  
As outlined in Chapter 2 the major limitation of this study centred on the sampling and culture 
techniques utilised to generate these data. More specifically, the use of culture dependent techniques 
may have under estimated the airway microbial diversity within this patient population. 
 
This work would also have benefited from additional data pertaining to childhood eradication therapy 
following P. aeruginosa acquisition. Indeed, inclusion of details relating to P. aeruginosa acquisition, 
treatment regimens and outcomes would have further aided in the categorisation of patients. 
Comparisons between patients based on treatment regimens would have been used to determine if 
successful eradication delays the onset of chronic infection and if subsequently these patients were at 
a higher risk of respiratory infections caused by other common and emerging CF airway pathogens. 
 
7.2.1.2 Implications of Findings and Future Work  
As the number of patients reaching adulthood continues to grow, a significant challenge moving 
forward will be caring for patients, who are healthier than previous generations, within clinics with 
limited resources and finite funding. Therefore, approaches to help manage this increase including 
strategies to monitor and quantify changes to patient health are of utmost importance. Patient 
databases or data registries, collecting demographic and anthropometric measurements from patients 
can be used to monitor trends within a clinic and to assess patient health and outcomes against the 
187 
 
wider CF community. Therefore, clinical data registries play an important role in observing and 
reporting on the health of patients and can inform treatment and clinical practice.  
 
The development of an extensive microbiology database described in this Chapter can be linked with 
the local electronic medical records and national data registries (metadata). This has already been 
undertaken by our group to support the investigation of emerging CF pathogens such as NTM 
infection (Sherrard et al. 2017) and will be extended to collate data specifically used to screen, 
monitor and diagnose these ‘emerging’ health problems in the growing adult CF population. For 
example clinical data pertaining to increasing antibiotic exposure, such as allergies and toxicity, 
diseases related to lifestyle such as obesity and heart disease, the emergence of antibiotic-resistant 
airway pathogens, and others such as malignancy, bone disease and mental health illnesses will be 
included.  
 
Future studies planned to complement the findings presented in this chapter will include: 
i) The continuation of monitoring microbial prevalence and rates of chronic P. aeruginosa, 
within the patient population at TPCH.  
ii) Assessment of the effectiveness of childhood eradication therapies to determine how 
successful they are in predicting bacterial infection in adulthood. 
iii) Evaluation of the effectiveness of eradication programs in adults who are free of chronic  
P. aeruginosa infection. 
iv) Establishment of a database to record clinical information regarding the onset of ‘emerging 
clinical complications’ to improve the management of an ageing CF population. 
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7.2.2 Chapter 3: Longitudinal analysis of Pseudomonas aeruginosa genotypes 
Utilising two cross sectional collected isolate cohorts, this study assessed the prevalence, diversity 
and clinical impact of P. aeruginosa isolates collected from adults attending a single CF centre and 
determined that: 
1. Strain diversity and prevalence rates can fluctuate over time. 
2. Clinical outcome appears to be strain specific 
The most significant contribution to the current knowledge of CF microbiology was: 
In the absence of enhanced infection control practices, not all shared strain infections increase, 
indicating that mechanisms specific to the individual strains may be influencing transmissibility and 
infection. 
 
7.2.2.1 Limitations  
As described in Chapter 3, the key limitation of this work focused on the small number of isolates 
available for genotyping; therefore, it is feasible that P. aeruginosa genotypes in some patients have 
been underrepresented. Nevertheless, within-patient genotyping results generated in this study were 
similar to earlier work and indicate that the vast majority of patients are infected with a single  
P. aeruginosa strain (Kidd et al. 2013).  
 
The typing methodology utilised in this study can accurately discriminate the predominant Australian 
CF shared strains (i.e. AUST-01, AUST-02). However, compared to other molecular typing methods, 
the SNP typing strategy used here has a reduced capacity for discriminating between some less 
prevalent and unique P. aeruginosa strains (Syrmis et al. 2014). As such, the current analysis may 
have overlooked the emergence of some novel shared strain infections. Nevertheless, a thorough 
examination of this dataset looking for emergent strains revealed no cases.  
 
Unlike many previous studies describing the diversity and prevalence of P. aeruginosa strains within 
defined CF populations, this work did not include patient data pertaining to treatment regimens and 
co-pathogens. Therefore, this analysis was unable to comment on the impact of shared strain 
acquisition with respect to these variables within this cohort.  
 
Finally, while this study was designed to capture all incidence cases of shared strain infection and 
corresponding clinical data; it was not designed to capture these same data for the acquisition of a 
new non-shared strain infection. Therefore, accurate comparison of the clinical impact and risk factors 
associated with shared and non-shared strain infection could not be made.  
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7.2.2.2 Implications of Findings and Future Work  
This study reported several important findings following the genotyping of P. aeruginosa isolates 
within TPCH ACFC patient population, including: i) the majority of patients harbour shared strain 
infection rather than a minor shared or unique strain infections, ii) over recent years the prevalence 
of the AUST-06 shared strain substantially increased, iii) the prevalence of the AUST-02 shared 
strains appears to be decreasing and iv) the proportion of patients harbouring the AUST-01 shared 
strains has remained stable over time. Furthermore, this analysis demonstrated an association with an 
increased risk of death or transplantation for AUST-02 infection and a trend towards increased 
hospitalisations and lower lung function for AUST-06. 
 
The results presented here are independent of any intervention such as patient segregation based on 
P. aeruginosa genotype. However, following the commissioning of a new inpatient facility at the 
ACFC, TPCH in 2014, patients are now managed in single room accommodation which has the 
potential for reducing the risk of cross-infection. This change in practice coupled with longstanding 
strict infection control practices in the outpatient clinic, has led to a prospective study to determine 
the impact of the changes in care procedures leveraging from the results presented in Chapter 3. This 
study will determine the impact on rates of shared strain infection and their impact on clinical 
outcomes.  
 
Future studies planned to complement the findings presented in this chapter will include: 
i) To conduct a prospective epidemiological analysis examining strain diversity at TPCH 
following the implementation of complete patient segregation. This study is funded and 
commenced in 2016.  
ii) If subsequent P. aeruginosa infection ensues following lung transplantation, conduct 
genotyping of these isolates to determine if persistence in the upper respiratory tract has 
occurred. 
iii) Undertake additional analysis on AUST-02 and AUST-06 strain, focusing on virulence and 
antibiotic resistance, to better understand why infection with these strains result in such 
different clinical courses.  
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7.2.3 Chapter 4: Phenotypic characteristics of Pseudomonas aeruginosa 
Bacterial motility and adherence play an important role in the colonisation and the establishment of 
infection. Results from this study demonstrated that P. aeruginosa isolates obtained from different 
clinical and environmental niches display very distinct phenotypic characteristics.  
 
The key finding from the phenotypic analysis undertaken here showed that:  
1. Isolates which demonstrate enhance motility also display strong adhesion. 
2. Isolates obtained from the environment displayed enhanced motility and adhesion traits 
compared to all other isolates. 
3. The majority of isolates obtained from acute clinical infections (non-CF and animal sources) 
demonstrated the ability to adhere and be motile. 
The most significant contribution to the current knowledge of CF microbiology was: 
Isolates from chronically infected CF patients, in particular the shared strain, AUST-02, showed 
reduced motility and adhesion, suggesting high levels of adaptation to the airways. 
 
7.2.3.1 Limitations  
As described in Chapter 4 the key limitations of this work were the overrepresentation of the AUST-
02 strains, comprising one in three isolates studied here, and omission of AUST-02 sub-type 
information. Due to the limited diversity of sequence types included in this study, it is difficult to 
conclusively infer an association between genotype and phenotype. Therefore, with the inclusion of 
a greater variety of strains from people with CF, this study would have increased the power to confirm 
the phenotypic behaviours observed between isolates of different genetic backgrounds. The data 
selection and omission of more in-depth genotyping results may have led to the underestimation of 
the diversity of motility and adhesion within this isolate cohort. 
 
This study would also have benefited greatly from the inclusion of fitness studies. Currently it is 
unknown if the display of reduced phenotypic characteristics have been misinterpreted and rather 
these results are due to slow bacterial generation times. Therefore, determining the growth rates of 
bacterial isolates would have future enhanced the significance of the data presented in this chapter. 
 
7.2.3.2 Implications of Findings and Future Work  
The work presented in Chapter 4 was the first analysis undertaken on a cohort of locally collected 
isolates from a range of clinical and environmental niches to describe phenotypic characteristics. This 
work demonstrated reduced bacterial motility and abiotic adherence in the AUST-02 shared CF strain, 
whereas non-shared CF strains do not display the same degree of suppression. A study to more closely 
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assess the strains, functional cell surface organelles and the impact on patient health is planned. This 
will be a longitudinal study following a small number of patients from initial infection onwards. Two 
patient cohorts will be targeted, those who acquire AUST-02 and those who acquire a non-shared 
strain. It is hypothesised that despite being a new infection the AUST-02 strain will not possess 
functional cell surface organelles needed for motility and adherence, whereas, longitudinal 
monitoring of the non-shared strain, will report a gradual loss of function over time. These results 
will be matched with relevant clinical data to assess if a decline in bacterial phenotype corresponds 
with a decline in patient health. By monitoring of the loss of phenotypes, this study may help inform 
disease progression and along with other clinical and microbiological markers may identify strains 
which could potentially result in adverse clinical outcomes.  
 
As discussed in Chapter 3, there has been a rapid increase in the prevalence of the AUST-06 shared 
strain in recent years at TPCH. To better understand mechanisms, which may be influencing 
transmission and infection of this strain, phenotypic characteristics will be analysed on a larger cohort 
of isolates, including strains from early and chronic infection of AUST-06.  
 
Future studies planned to complement the findings presented in this chapter will include: 
i) To conduct a longitudinal study, utilising initial infecting stains, to more accurately determine 
if infection duration is: 
a. Associated with changes to bacterial phenotype and 
b. If change to bacterial phenotype corresponds to a decline in patient health. 
ii) Determine, using a subset of isolates with varied phenotypic characteristics, the presence or 
absence of the cell surface organelles using scanning electron microscopy and staining. 
iii) Assess the phenotypic characteristics of a larger cohort of AUST-06 strains to: 
a. Compare characteristics to AUST-02 strains  
b. Determine if phenotypic characteristics may be responsible for increased 
transmissibility.  
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7.2.4 Chapter 5: Biofilm development of Pseudomonas aeruginosa 
The continuous flow cell model was used here to determine if there was a correlation between biofilm 
development, bacterial adhesion as determined in the static biofilm model and motility.  
The key finding from this analysis demonstrated that: 
1. Clinical strains of P. aeruginosa formed larger biofilms consisting of greater biomass than 
those formed from isolates obtained from the environment. 
2. No change in the ability to form biofilms was noted from longitudinally collected isolates 
from chronically infected CF patients. 
The most significant contribution to the current knowledge of CF microbiology from Chapter 5 was: 
Adhesion capability as determined by the microtitre assay did not infer biofilm development within 
the flow cell model. 
 
7.2.4.1 Limitations  
The limitations of this study are described in detail in Chapter 5, however these include, a potential 
selection bias (all the isolates from patients were AUST-02 strains, whereas, the environmental 
isolates were more heterogeneous, including unrelated strains) and the omission of early or initial 
infecting strains for longitudinal analysis. Using this isolate selection, comprising mostly of  
AUST-02 strains from chronic infections it is difficult to determine if genotype or degree or bacterial 
adaptation is responsible for biofilm formation.  
 
A number of technical challenges were encountered whilst developing the protocols and setting up 
these experiments. Of significant note was the introduction of fluorescent stain by injection into the 
chamber. The use of this method to aid visualisation may have disturbed the delicate bacterial biofilm 
structure and as this was manually performed, leading to reduced reproducibility between biofilm 
experiments. The alternative approach, green fluorescent protein (GFP) was not utilised for this set 
of experiments.  
 
7.2.4.2 Implications of Findings and Future Work  
A key finding of this investigation was that the static microtitre plate biofilm assay designed to assess 
bacterial adhesion is not a reliable predictor of P. aeruginosa biofilm forming capacity in the 
continuous flow-cell model. Therefore, the use of static models to infer biofilm capacity is limited. 
Furthermore, continuous flow-cell models which support the study of dispersed cells may provide 
understanding of adaptation mechanisms and allow comparison with their parental strain. 
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Complementary studies to assess the biofilm capacity of a number of isolates and conducting 
comparisons with this original work have been planned. Isolates to be assessed in this follow up study 
include: previously identified significant shared strains within the TPCH cohort, including AUST-06 
(recent increase in prevalence as outline in Chapter 3) and the resistant AUST-02 sub-type, M3L7 
(Tai et al. 2015), as well as a range of non-CF and animal isolates as detailed in Chapter 4. These 
additional analyses will determine if AUST-02 shared strain infection is unique in its biofilm 
producing phenotype compared with other CF and non-CF strains. In addition, analysis of isogenic 
isolates (including AUST-02 and AUST-06) obtained periodically from early to chronic infection 
will be performed to determine if biofilm producing capacity evolves in conjunction with the 
evolution of infection. 
 
Finally, studies to assess how strains behave under exposure to environmental and clinical stressors 
will be conducted. Firstly, two murine models, a cutaneous abscess model and a chronic airway 
infection model, will be used to assess the growth and infection development of shared strains and 
non-CF isolates (Pletzer et al. 2017). It is hypothesised that AUST-02, which displays a high level of 
niche adaptation to the CF airways, will behave in a similar manner to all non-CF isolates under 
cutaneous infection conditions and will respond to eradication attempts, whereas, in the airway model 
this strain will display traits associated with enhanced adaptation (Facchini et al. 2014). Secondly, in 
collaboration with environmental scientists located in South Eastern Queensland,  
P. aeruginosa strains, including the AUST-02 will be inoculated into diffusion chambers and placed 
into a local waterway (Sidhu and Toze 2012). These experiments will assess bacterial decay, 
phenotypic, genomic and protein expression during and following a period of re-introduction into the 
natural environment. Antimicrobial susceptibility testing will be performed on all isolates to 
determine if a dispersal event results in the release of susceptible organisms back into the local 
environment. 
 
Future studies planned to complement the findings presented in this chapter will include: 
i) A range of clinically significant shared strains, non-CF and animal isolates will be assessed 
in the biofilm model and compared to results generated from AUST-02 and environmental 
strains. 
ii) Determine if isolates released during biofilm dispersal events differ from the original 
parental strains by: 
a. Undertaking phenotypic characterisation of daughter isolates and 
b. Performing antimicrobial susceptibility testing on both parental and daughter 
isolates. 
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iii) Using murine models assess the virulence of AUST-02 strains when compared to isolates 
obtained from acute non-CF infections and environmental settings. 
iv) To determine if environmental exposure will affect the phenotypic and genomic expression 
of isolates sourced from a range of clinical and environmental niches. 
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7.2.5 Chapter 6: Genomic analysis of Pseudomonas aeruginosa 
A genome-wide association study (GWAS) was performed on P. aeruginosa isolates displaying 
distinct phenotypic characteristics. Genome mapping and assembly was performed to locate, confirm 
and functionally characterise the polymorphisms identified by GWAS in each individual isolate. 
These results were compared and correlated with phenotypic data to determine if any gene variant 
could predict a specific phenotypic characteristic.  
The key finding from this analysis revealed: 
1. Regulation of bacterial motility and adhesion is complex and multifactorial. 
2. Several novel targets for which future mechanistic analyses can be undertaken. 
The most significant contribution to the current knowledge of CF microbiology was: 
Despite strong correlations observed in the GWAS analyses, no single genetic variant was able to 
fully explain the phenotypes observed. 
 
7.2.5.1 Limitations  
Given the cost and the complexity of these analyses only a small number of isolates were included in 
this study. Regardless, this study was able to demonstrate that many of the variants observed in the 
shared strains were present in a high proportion of the isolates analysed. It is likely that analysis of 
an expanded number of isolates would further strengthen these findings.  
 
For this initial study, select variants were chosen for additional analysis using the mapping and 
assembly approach. Firstly, all variants shown to be highly correlated with a phenotype as described 
by GWAS and phylogenetic analysis were selected. Secondly, based on results from a literature 
review only those variants currently associated with the aforementioned phenotypes were selected. 
This approach may have missed variants, in particular hypothetic proteins, with a strong correlation 
to a phenotype, but as all of the ‘strongly correlated variants’ as described by GWAS were followed 
up, this is unlikely.  
 
Five of the selected genes (flgK, xcpQ, pilQ, PA0144, PA1874) contained large genetic variations, 
for most if not all of the isolates, therefore mapping and assembly could not be undertaken. To assess 
if these genetic variations may be causing a loss of function, comparative genetic analyses utilising 
sophisticated bioinformatic software will need to be performed. This specialised analysis was outside 
the scope of this study, but is planned for future studies.  
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7.2.5.2 Implications of Findings and Future Work  
Using this dual approach these studies were able to identify a number of variant genetic loci which 
were strongly associated with bacterial motility and adhesion. To confirm their relationship with the 
relevant phenotype these genes will now undergo site directed mutagenesis with the mutants 
generated assessed in the relevant motility and/or adhesion assays. In addition, each knockout mutant 
showing a negative phenotype will undergo complementation with a wild-type copy of the relevant 
gene to confirm the genetic mechanism.  
 
Following on from the genomic analyses, a subset of isolates with different phenotypic and genomic 
profiles will undergo proteomic analysis. As well as assessing bacteria during planktonic growth, this 
approach allows for analysis to be conducted during different stages of biofilm development. This 
will prove to be helpful in determining the changes in expression associated with acute (planktonic) 
and chronic (biofilm) infections. Together with the genomic analysis, the proteomics will help to 
better understand the mechanisms involved during the establishment of an infection and may 
ultimately provide markers which may indicate if an isolate will respond to eradication therapy. 
 
Future studies planned to complement the findings presented in this chapter will include: 
i) Undertake a targeted analysis of the remaining variants and indels as identified by GWAS to 
assess correlation with specific phenotypes. 
ii) Undertake comparative genomic analysis to describe the mechanisms causing large genetic 
variations within this isolate cohort. 
iii) Using site directed mutagenesis, confirm that targeted mutations are associated with a loss of 
function. 
iv) To compare protein expression when strains of P. aeruginosa are grown in planktonic and 
biofilm growth modes to determine how growth mode affects phenotypic capabilities. 
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7.3 Concluding remarks  
Through the use of locally obtained P. aeruginosa isolates and the evaluation of a defined adult CF 
population, this thesis demonstrates high levels of strain diversity and phenotypic heterogeneity is 
common. Collectively the results presented in this thesis demonstrate a reduction in significant airway 
pathogens coupled with improved lung health outcomes of patients within a large adult CF cohort. 
Furthermore, high levels of strain diversity and heterogeneity was observed within the  
P. aeruginosa isolates from this patient cohort. Observations from these studies contradict prior 
analysis, confirming that cellular mechanisms driving bacterial motility and adhesion are not 
invariably required for the development of biofilm communities.  
 
Over the last decade much work has been conducted in describing the clinical aspects and 
microbiology of the patients in attendance at TPCH. Collectively, these studies have highlighted the 
presence of three dominant shared strains within this clinic. Closer analysis of AUST-02, including 
the additional evidence presented within this thesis, has demonstrated that this strain possesses 
numerous traits which lead it to being highly niche adapted to the CF airways. It is hypothesis that 
these strains have been circulating within the CF population for an extended period, and in turn have 
evolved to survive under the particular conditions in which they are exposed. They have adapted to 
avoid host defenses enabling proliferation but have also evolved to down regulate functions which 
are no longer advantageous to survival. Therefore, it is speculated that the high level of evolutionary 
changes which have taken place will no longer support survival in an environment outside the 
airways. Finally, a commonly utilised method to infer bacterial biofilm development was shown not 
to be consistent with results obtained from a continuous flow-cell model, indicating that caution when 
interpreting results needs to be taken. 
 
It is envisaged that work described in this thesis will assist in highlighting mechanisms used by  
P. aeruginosa to enhance niche adaptation within the CF airways and ultimately contribute to 
therapies aimed at eradication.  
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Appendix 1 Published Works Incorporated into the Thesis 
 
Ramsay, K.A., H. Sandhu, J.B. Geake, E. Ballard, P. O'Rourke, C.E. Wainwright, D.W. Reid, 
T.J. Kidd, and S.C. Bell (2017). The changing prevalence of pulmonary infection in adults with 
cystic fibrosis: A longitudinal analysis. J Cyst Fibros. 16(1): p. 70-77. 
 
http://www.sciencedirect.com.ezproxy.library.uq.edu.au/science/article/pii/S1569199316305677 
 
Justification to include the published manuscript into this thesis 
Throughout my research career I have been closely involved with a number of studies focusing on 
the epidemiology and transmissibility of Pseudomonas aeruginosa within the Australian cystic 
fibrosis (CF) population. These studies determined that within this cohort, two predominant shared 
strains, AUST-01 and AUST-02, were highly prevalent, isolated nationally from 22% and 18% of 
patients with CF, respectively. Furthermore, a number of strains appeared to have an affinity for a 
particular region or patient group. Of note, the AUST-02 strain was most commonly detected in 
Queensland and Western Australia, whereas the AUST-06 strain was almost universally identified 
from patients residing in South East Queensland (Kidd et al. 2013). Complementary to this study, an 
extensive epidemiological survey was unable to isolate shared strains in any setting (non-CF and 
animal infections, environmental isolates) other than the CF airway (Kidd et al. 2012). Through the 
use of innovative technology this group determined that patients harbouring P. aeruginosa within 
their airways are capable of coughing viable organisms into their immediate surroundings (Knibbs et 
al. 2014). Collectively these studies suggest that patients are not acquiring shared strains from 
common environmental sources and furthermore highlight the high level of niche adaptation to the 
CF airways which these strains display. 
 
Following on from these initial studies, my thesis aimed to understand the longitudinal epidemiology 
of P. aeruginosa infection in CF and to determine traits which may promote niche adaptation among 
shared CF strains. The overarching focus of my thesis was to thoroughly characterise a defined set of 
P. aeruginosa isolates obtained from a single patient population. By comparing the CF isolates to 
locally collected environmental and non-CF clinical isolates, I aimed to determine the key differences 
in phenotypic and genomic mechanisms and how they may influence adaptation. 
 
Results presented in this manuscript therefore comprise the initial study of my PhD. Focusing on CF 
patients managed within The Prince Charles Hospital (TPCH) in South East Queensland, Australia; 
this study presents four key findings. Firstly, this study describes the demographic and clinical 
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characteristics of patients over a 14 year period. Secondly, P. aeruginosa was identified as the most 
dominant pathogen within this patient cohort; however the prevalence of this bacterium and many 
other significant airway pathogens declined over the study period. Thirdly, due to the nature of patient 
attendance and data collection, the Leeds criteria (Lee et al. 2003) could not be utilised to determine 
chronic P. aeruginosa infection; therefore, following modifications to this definition it was 
demonstrated that chronic infection remained stable over time. Finally, this work demonstrated that 
the declining prevalence of P. aeruginosa in young patients showed a correlation with lung function 
improvement. 
 
Utilising isolates obtained from a subset of patients described in this manuscript, Chapter 3 defines 
the longitudinal diversity of P. aeruginosa strains within the TPCH cohort. Additionally, Chapter 3 
reports the clinical impact of stable and newly acquired shared strain infection. Following on from 
these two chapters, which clearly describe the TPCH cohort, Chapters 4, 5 and 6 use a number of 
phenotypic assays and genomic approaches to define the characteristics and mechanisms which 
distinguish P. aeruginosa strains collected from people with CF (as presented in Chapter 3), with 
those obtained from a range of clinical and environmental settings (Kidd et al. 2012). 
 
Overall, the work presented in this manuscript forms the foundation of this entire PhD thesis and 
presents data pertinent to patients attending this CF centre within South East Queensland. As such, I 
believe that the inclusion of this work is valid. 
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Appendix 2 Additional Published Works Relevant to the Thesis but not Forming Part of it.  
 
Ramsay, K. A., R. E. Stockwell, S. C. Bell and T. J. Kidd (2016). Infection in cystic fibrosis: 
impact of the environment and climate. Expert Rev Respir Med 10(5): 505-519. 
 
http://www.tandfonline.com.ezproxy.library.uq.edu.au/doi/abs/10.1586/17476348.2016.1162715 
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Appendix 3 Appendix to Chapter 4 
The following appendix constitutes data mentioned in Chapter 4: Phenotypic characteristics of 
Pseudomonas aeruginosa. 
 
Appendix 3.1 P. aeruginosa isolate selection for motility and adhesion assays obtained from 
environmental, animal, non-CF human and CF sources, n = 167. 
 
Appendix 3.2 Representative images of different P. aeruginosa colonial morphotypes, a) non-
mucoid, non-pigmented, b) mucoid, non-pigmented, c) pyocyanin production, and d) pyomelanin 
production. 
 
Appendix 3.3 Representative images of positive and negative P. aeruginosa motilities a) swim, b) 
swarm c) twitch (extended methodology). 
 
Appendix 3.4 A representative image of biofilm formation of P. aeruginosa using the microtitre 
plate-based assay. 
 
Appendix 3.5 Limits of agreements determining the reproducibility of a) swim, b) swarm and c) 
twitch motility assays for P. aeruginosa isolates tested under aerobic, microaerophilic and anaerobic 
conditions.  
 
Appendix 3.6 Comparison of motility and adhesion properties tested under aerobic and anaerobic 
atmospheric conditions for P. aeruginosa isolates obtained from patients with CF, non-CF human 
infections, animal infections, and environmental settings after 24 hours incubation. 
 
Appendix 3.7 Comparison of two methodologies used to determine twitch motility of  
P. aeruginosa isolates.  
 
Appendix 3.8 Pearson correlation coefficient results of log transformed data comparing swim, swarm 
and twitch results following 24hours incubation in microaerophilic and anaerobic conditions for P. 
aeruginosa isolates.  
 
Appendix 3.9 Limits of agreements determining the reproducibility of the microtitre plate-based 
assay for P. aeruginosa isolates tested under a) aerobic, b) microaerophilic and c) anaerobic 
conditions.  
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Appendix 3.10 Spearman correlation coefficient results of log transformed data comparing swim 
(mm2), swarm (mm
2
) and twitch (mm2) with adhesion (OD
595nm
) results after 24-hours incubation 
under each aerobic, microaerophilic and anaerobic atmospheric conditions for P. aeruginosa isolates.  
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Appendix 3.1 P. aeruginosa isolate selection for motility and adhesion assays obtained from 
environmental, animal, non-CF human and CF sources, n = 167. 
Isolate Selection 
The isolate selection for this study was based on results from epidemiological studies reporting the 
strain diversity of P. aeruginosa isolated from the clinical and environmental samples collected 
within the region of South Eastern Queensland, Australia (Kidd ERJ 2013, Kidd PloS One 2012). 
The strain types assessed here present the most commonly identified strain types, unique strains and 
strains identified in each of the different environmental niches. 
 
Number Source Sample Type 
Additional sample & genotype 
information 
Sequence 
Type 
1 Environment Swab; Air/Water Interface Brisbane River; Rural 3 
2 Environment Water Brisbane River; Urban 9 
3 Environment Swab; Household sink drain Home Study 27 
4 Environment Water Brisbane River; Urban 114 
5 Environment Swab; Air/Water Interface Brisbane River; Rural 144 
6 Environment Water Brisbane River; Industrial 147 
7 Environment Water Brisbane River; Urban 155 
8 Environment Swab; Air/Water Interface Logan River; Rural 179 
9 Environment Water Brisbane River; Urban 205 
10 Environment Swab; Air/Water Interface Brisbane River; Rural 209 
11 Environment Water Brisbane River; Urban 216 
12 Environment Swab; Air/Water Interface Brisbane River; PA14; Urban 253 
13 Environment Water Brisbane River; Urban 257 
14 Environment Water Brisbane River; Rural 266 
15 Environment Water Brisbane River; Urban 270 
16 Environment Water Brisbane River; Urban 381 
17 Environment Swab; Air/Water Interface Logan River; Urban 389 
18 Environment Water Brisbane River; Urban 471 
19 Environment Swab; Air/Water Interface Brisbane River; Industrial 532 
20 Environment Swab; Air/Water Interface Brisbane River; Urban 555 
21 Environment Water Brisbane River; Urban 685 
22 Environment Water Brisbane River; Industrial 802 
23 Environment Swab; Air/Water Interface Logan River; Urban 810 
24 Environment Swab; Air/Water Interface Brisbane River; Rural 838 
25 Environment Swab; Air/Water Interface Brisbane River; Rural 843 
26 Environment Swab; Air/Water Interface Brisbane River; Urban 850 
27 Environment Swab; Air/Water Interface Brisbane River; Urban 855 
28 Environment Swab; Air/Water Interface Brisbane River; Rural 867 
29 Environment Swab; Air/Water Interface Brisbane River; Rural 870 
30 Environment Swab; Air/Water Interface North Pine River; Rural 922 
31 Environment Swab; Air/Water Interface Logan River; Rural 923 
32 Environment Swab; Air/Water Interface Brisbane River; Urban 925 
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33 Environment Swab; Air/Water Interface Brisbane River; Urban 927 
34 Environment Water Brisbane River; Rural 930 
35 Animal Swab; Ear Canine 155 
36 Animal Milk Caprine 179 
37 Animal Swab; Clitoris Equine 242 
38 Animal Respiratory Sample Canine 244 
39 Animal Swab; Ear Canine; PA14 253 
40 Animal Swab; Ear Canine 266 
41 Animal Tracheal Washing Feline 274 
42 Animal Urine Feline 381 
43 Animal Swab; Ear Canine 471 
44 Animal Swab; Ear Canine 508 
45 Animal Swab; Ear Canine 789 
46 Animal Swab; Ear Canine 803 
47 Animal Swab; Uterus Equine 883 
48 Animal Swab; Ear Canine 893 
49 Non-CF Human Blood; Peripheral Clone C 17 
50 Non-CF Human Sputum Nosocomially Acquired 27 
51 Non-CF Human Swab; Ear  147 
52 Non-CF Human Swab; Ear  155 
53 Non-CF Human Urine; IDC  179 
54 Non-CF Human Sputum Community Acquired 242 
55 Non-CF Human Urine; Mid-Stream  244 
56 Non-CF Human Blood; Peripheral  245 
57 Non-CF Human Blood; Peripheral PA14 253 
58 Non-CF Human Urine  266 
59 Non-CF Human Swab; Wound Left Foot  270 
60 Non-CF Human Sputum Bronchiectasis 274 
61 Non-CF Human Blood; Peripheral  275 
62 Non-CF Human Swab; Cellulitis  381 
63 Non-CF Human Blood; Peripheral  803 
64 Non-CF Human Sputum Bronchiectasis 807 
65 Non-CF Human Sputum COAD 821 
66 Non-CF Human Sputum COAD 845 
67 Non-CF Human Urine; Mid-Stream  860 
68 Non-CF Human Sputum Bronchiectasis 914 
69 CF (Paediatric) Sputum Non-Shared CF Strain; Clone C 17 
70 CF (Paediatric) Sputum Non-Shared CF Strain 27 
71 CF (Adult) Sputum Shared CF Strain; LES 146 
72 CF (Adult) Sputum Shared CF Strain; LES 146 
73 CF (Adult) Sputum Shared CF Strain; LES 146 
74 CF (Adult) Sputum Shared CF Strain; LES 146 
75 CF (Adult) Sputum Non-Shared CF Strain 147 
76 CF (Paediatric) Sputum Non-Shared CF Strain 155 
77 CF (Paediatric) Sputum Non-Shared CF Strain 179 
78 CF (Adult) Sputum Non-Shared CF Strain 242 
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79 CF (Paediatric) Sputum Non-Shared CF Strain 244 
80 CF (Adult) Sputum Non-Shared CF Strain 245 
81 CF (Paediatric) Sputum Non-Shared CF Strain; PA14 253 
82 CF (Paediatric) Sputum Non-Shared CF Strain 257 
83 CF (Adult) Sputum Non-Shared CF Strain 266 
84 CF (Adult) Sputum Non-Shared CF Strain 270 
85 CF (Adult) Sputum Non-Shared CF Strain 274 
86 CF (Adult) Sputum Non-Shared CF Strain 275 
87 CF (Adult) Sputum Non-Shared CF Strain 381 
88 CF (Adult) Sputum Non-Shared CF Strain 389 
89 CF (Paediatric) Sputum Non-Shared CF Strain 471 
90 CF (Adult) Sputum Non-Shared CF Strain 508 
91 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
92 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
93 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
94 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
95 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
96 CF (Adult) Sputum Shared CF Strain; AUST-01 649 
97 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
98 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
99 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
100 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
101 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
102 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
103 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
104 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
105 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
106 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
107 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
108 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
109 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
110 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
111 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
112 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
113 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
114 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
115 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
116 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
117 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
118 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
119 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
120 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
121 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
122 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
123 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
124 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
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125 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
126 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
127 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
128 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
129 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
130 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
131 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
132 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
133 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
134 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
135 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
136 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
137 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
138 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
139 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
140 CF (Paediatric) Sputum Shared CF Strain; AUST-02 775 
141 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
142 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
143 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
144 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
145 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
146 CF (Adult) Sputum Shared CF Strain; AUST-02 775 
147 CF (Adult) Sputum Non-Shared CF Strain 789 
148 CF (Adult) Sputum Shared CF Strain; AUST-06 Novel ST* 
149 CF (Paediatric) Sputum Shared CF Strain; AUST-06 801 
150 CF (Adult) Sputum Shared CF Strain; AUST-06 801 
151 CF (Adult) Sputum Shared CF Strain; AUST-06 801 
152 CF (Adult) Sputum Shared CF Strain; AUST-06 801 
153 CF (Adult) Sputum Shared CF Strain; AUST-06 801 
154 CF (Paediatric) Sputum Non-Shared CF Strain 802 
155 CF (Adult) Sputum Non-Shared CF Strain 803 
156 CF (Adult) Sputum Non-Shared CF Strain 807 
157 CF (Adult) Sputum Non-Shared CF Strain 808 
158 CF (Adult) Sputum Non-Shared CF Strain 810 
159 CF (Paediatric) Sputum Non-Shared CF Strain 821 
160 CF (Paediatric) Sputum Non-Shared CF Strain 833 
161 CF (Adult) Sputum Non-Shared CF Strain 845 
162 CF (Adult) Sputum Non-Shared CF Strain 860 
163 CF (Paediatric) Sputum Non-Shared CF Strain 870 
164 CF (Adult) Sputum Non-Shared CF Strain 893 
165 CF (Adult) Sputum Non-Shared CF Strain 378, 638, 797 
166 CF (Adult) Sputum Non-Shared CF Strain 378, 638, 797 
167 CF (Adult) Sputum Non-Shared CF Strain 378, 638, 797 
*Double-locus variant to ST-801 
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Appendix 3.2 Representative images of different P. aeruginosa colonial morphotypes, a) non-
mucoid, non-pigmented, b) mucoid, non-pigmented, c) pyocyanin production, and d) pyomelanin 
production. 
 
A. 
D. C. 
B. 
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Appendix 3.3 Representative images of positive and negative P. aeruginosa motilities a) swim, b) swarm c) twitch (extended methodology). 
A. 
B. 
C. 
Positive Motility Negative Motility 
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Appendix 3.4 A representative image of biofilm formation of P. aeruginosa using the microtitre 
plate-based assay. 
 
Strong adhesion 
Moderate adhesion 
Weak adhesion 
Absent adhesion 
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Appendix 3.5 Limits of agreements determining the reproducibility of a) swim, b) swarm and c) twitch motility assays for P. aeruginosa isolates tested 
under aerobic, microaerophilic and anaerobic conditions.  
 
A. 
 Swim 
 Aerobic Microaerophilic Anaerobic 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.842 0.657 to 0.936 <0.001 0.487 0.033 to 0.749 0.020 0.537 0.185 to 0.753 0.004 
Animal (n = 14) 0.673 -0.054 to 0.928 0.030 0.922 0.799 to 0.976 < 0.001 0.774 0.437 to 0.925 0.001 
Non-CF (n = 20) 0.681 0.206 to 0.894 0.007 0.286 -0.719 to 0.750 0.220 0.815 0.579 to 0.930 < 0.001 
Cystic Fibrosis          
Non-Shared Strains (n = 33) 0.893 0.795 to 0.948 < 0.001 0.905 0.813 to 0.956 < 0.001 0.827 0.681 to 0.913 < 0.001 
AUST-02 (n = 50) 0.987 0.979 to 0.992 < 0.001 0.944 0.910 to 0.967 < 0.001 0.659 0.457 to 0.795 < 0.001 
AUST-06 (n = 6) 0.917 0.677 to 0.987 < 0.001 0.924 0.703 to 0.988 < 0.001 0.688 -0.212 to 0.952 0.045 
B. 
 Swarm 
 Aerobic Microaerophilic Anaerobic 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.953 0.916 to 0.975 < 0.001 0.968 0.944 to 0.983 < 0.001 0.941 0.897 to 0.969 < 0.001 
Animal (n = 14) 0.999 0.966 to 0.999 < 0.001 0.945 0.868 to 0.981 < 0.001 0.987 0.970 to 0.996 < 0.001 
Non-CF (n = 20) 0.697 0.355 to 0.873 0.001 0.920 0.834 to 0.966 < 0.001 0.978 0.954 to 0.991 < 0.001 
Cystic Fibrosis          
Non-Shared Strains (n = 33) 0.978 0.960 to 0.988 < 0.001 0.980 0.965 to 0.990 < 0.001 0.993 0.987 to 0.996 < 0.001 
AUST-02 (n = 50) 0.977 0.964 to 0.986 < 0.001 0.943 0.895 to 0.961 < 0.001 0.951 0.923 to 0.971 < 0.001 
AUST-06 (n = 6) 0.996 0.985 to 0.999 < 0.001 0.885 0.551 to 0.982 0.001 0.702 -0.158 to 0.954 0.040 
C. 
 Twitch 
 Aerobic Microaerophilic Anaerobic 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.979 0.964 to 0.989 < 0.001 0.792 0.643 to 0.889 < 0.001 0.696 0.465 to 0.838 < 0.001 
Animal (n = 14) 0.982 0.957 to 0.994 < 0.001 0.976 0.942 to 0.992 < 0.001 0.781 0.471 to 0.923 < 0.001 
Non-CF (n = 20) 0.989 0.977 to 0.995 < 0.001 0.982 0.963 to 0.992 < 0.001 0.735 0.446 to 0.886 < 0.001 
Cystic Fibrosis          
Non-Shared Strains (n = 33) 0.929 0.873 to 0.962 < 0.001 0.976 0.957 to 0.987 < 0.001 0.503 0.119 to 0.738 0.008 
AUST-02 (n = 50) 0.884 0.816 to 0.931 < 0.001 0.854 0.767 to 0.912 < 0.001 0.495 0.193 to 0.696 0.002 
AUST-06 (n = 6) -0.437 -4.59 to 0.780 0.637 0.991 0.967 to 0.999 < 0.001 0.683 -0.233 to 0.951 0.048 
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Appendix 3.6 Comparison of motility and adhesion properties tested under aerobic and anaerobic 
atmospheric conditions for P. aeruginosa isolates obtained from patients with CF, non-CF human 
infections, animal infections, and environmental settings after 24-hours incubation. 
 
 Swim-Positive Swarm-Positive Twitch-Positive Adhesion-Positive 
 n (%) n (%) n (%) n (%) 
  Environmental Isolates (n = 34) 
Aerobic Conditions 34 (100.0) 23 (67.6) 28 (82.4) 34 (100.0) 
Anaerobic Conditions 32 (94.1) 31 (91.2) 10 (29.4) 30 (88.2) 
Chi-Square Value †  - 4.407 17.239 - 
P value 0.493* 0.036 < 0.001 0.114 * 
     
  Animal Isolates (n = 14) 
Aerobic Conditions 12 (85.7) 9 (64.3) 10 (71.4) 10 (71.4) 
Anaerobic Conditions 9 (64.3) 5 (35.7) 4 (28.6) 10 (71.4) 
Chi-Square Value †  - 1.286 3.571 - 
P value 0.385* 0.257 0.059 1.000 * 
 
    
  Non-CF Isolates (n = 20) 
Aerobic Conditions 19 (95.0) 13 (65.0) 12 (60.0) 17 (85.0) 
Anaerobic Conditions 18 (90.0) 10 (50.0) 4 (20.0) 15 (75.0) 
Chi-Square Value †  - 0.409 5.104 - 
P value 1.000* 0.522 0.024 0.695 * 
 
    
  All CF Isolates (n = 99) 
Aerobic Conditions 49 (49.5) 22 (22.2) 18 (18.2) 41 (41.4) 
Anaerobic Conditions 37 (37.4) 16 (16.2) 3 (3.0) 18 (18.2) 
Chi-Square Value †  2.699 0.814 10.441 11.685 
P value 0.100 0.367 0.001 0.001 
* ≥ 1 cell had expected count less than 5, therefore Fisher’s Exact Test was used. 
† Chi-Square value with Yates Continuity Correction. 
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Appendix 3.7 Comparison of two methodologies used to determine twitch motility for P. aeruginosa isolates †.  
 
Conditions Method 
AUST-02 
vs. Non-CF 
AUST-02 
vs. Animal 
AUST-02 vs. 
Environment 
AUST-02 vs. 
Non-Shared  
AUST-02 vs. 
AUST-06 
AUST-06 
vs. Non-CF 
AUST-06 
vs. Animal 
AUST-06 vs. 
Environment 
AUST-06 vs. 
Non-Shared  
O2 
2- hours 
- - - 
< 0.001 
- - - - - 
Stain 0.121 
MA 
24-hours 
- - - - - - - - - 
Stain 
AnO2 
24-hours 
- - - - - - 
1.000 * 1.000 * 
- 
Stain 0.037 * 0.005 * 
 
Conditions Method 
CF vs. 
Non-CF 
CF vs. 
Animal 
CF vs. 
Environment 
Non-Shared 
vs. Non-CF 
Non-Shared 
vs. Animal 
Non-Shared vs. 
Environment 
Animal vs. 
Environment 
Animal vs. 
Non-CF 
Non-CF vs. 
Environment 
O2 
24-hours 
- - - - 
0.260 
- - - - 
Stain 0.022* 
MA 
24-hours 
- - - - - - 
0.036 * 
- 
0.006 * 
Stain 0.081 * 0.133 * 
AnO2 
24-hours 
- 
0.024 * 
- - 
0.023 * 0.010 
- - - 
Stain 0.240 0.302 * 0.056 
† Chi-Square value with Yates Continuity Correction. 
* ≥ 1 cell had expected count less than 5, therefore Fisher’s Exact Test was used. 
Cells containing a hyphen comprise those that showed similar results across the 24 hour and stained twitching motility assays. 
Results presented in bold represent P-values for the various pairwise comparisons which differed when tested in the 24 hour and stained twitching 
motility assays. 
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Appendix 3.8 Pearson correlation coefficient results of log transformed data comparing swim, swarm and twitch results following 24-hours incubation 
in microaerophilic and anaerobic conditions for P. aeruginosa isolates.  
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Appendix 3.9 Limits of agreements determining the reproducibility of the microtitre plate-based assay for P. aeruginosa isolates tested under 
a) aerobic, b) microaerophilic and c) anaerobic conditions.  
 
A. 
 Aerobic 
 Results from Run 1 Results from Run 2 Combined Results 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.965 0.939 to 0.981 <0.001 0.988 0.979 to 0.994 <0.001 0.979 0.968 to 0.986 <0.001 
Animal (n = 14) 0.925 0.819 to 0.947 <0.001 0.996 0.990 to 0.999 <0.001 0.965 0.934 to 0.982 <0.001 
Non-CF (n = 20) 0.953 0.902 to 0.980 <0.001 0.984 0.967 to 0.993 <0.001 0.969 0.948 to 0.983 <0.001 
Cystic Fibrosis                   
Non-Shared Strains (n = 33) 0.984 0.972 to 0.992 <0.001 0.944 0.898 to 0.971 <0.001 0.963 0.944 to 0.976 <0.001 
AUST-02 (n = 50) 0.971 0.954 to 0.983 <0.001 0.968 0.947 to 0.981 <0.001 0.969 0.956 to 0.978 <0.001 
AUST-06 (n = 6) 0.990 0.962 to 0.999 <0.001 0.935 0.748 to 0.990 <0.001 0.957 0.890 to 0.987 <0.001 
 
B. 
 Microaerophilic 
 Results from Run 1 Results from Run 2 Combined Results 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.961 0.932 to 0.979 <0.001 0.990 0.983 to 0.995 <0.001 0.976 0.964 to 0.984 <0.001 
Animal (n = 14) 0.979 0.949 to 0.993 <0.001 0.987 0.969 to 0.995 <0.001 0.982 0.967 to 0.991 <0.001 
Non-CF (n = 20) 0.989 0.978 to 0.995 <0.001 0.979 0.955 to 0.991 <0.001 0.984 0.973 to 0.991 <0.001 
Cystic Fibrosis                   
Non-Shared Strains (n = 33) 0.974 0.954 to 0.986 <0.001 0.994 0.988 to 0.997 <0.001 0.983 0.974 to 0.989 <0.001 
AUST-02 (n = 50) 0.984 0.975 to 0.990 <0.001 0.996 0.994 to 0.998 <0.001 0.991 0.988 to 0.994 <0.001 
AUST-06 (n = 6) 0.848 0.408 to 0.977 0.004 0.937 0.753 to 0.990 <0.001 0.898 0.735 to 0.968 <0.001 
 
C. 
 Anaerobic 
 Results from Run 1 Results from Run 2 Combined Results 
 ICC 95% CI P-value ICC 95% CI P-value ICC 95% CI P-value 
Environmental (n = 34) 0.981 0.967 to 0.990 <0.001 0.983 0.971 to 0.991 <0.001 0.982 0.973 to 0.988 <0.001 
Animal (n = 14) 0.973 0.936 to 0.991 <0.001 0.963 0.910 to 0.987 <0.001 0.967 0.939 to 0.984 <0.001 
Non-CF (n = 20) 0.988 0.976 to 0.995 <0.001 0.991 0.982 to 0.996 <0.001 0.989 0.982 to 0.994 <0.001 
Cystic Fibrosis                   
Non-Shared Strains (n = 33) 0.987 0.977 to 0.993 <0.001 0.99 0.982 to 0.995 <0.001 0.988 0.982 to 0.993 <0.001 
AUST-02 (n = 50) 0.988 0.980 to 0.993 <0.001 0.945 0.911 to 0.968 <0.001 0.967 0.954 to 0.977 <0.001 
AUST-06 (n = 6) 0.982 0.931 to 0.997 <0.001 0.976 0.907 to 0.996 <0.001 0.977 0.941 to 0.993 <0.001 
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Appendix 3.10 Spearman correlation coefficient results of log transformed data comparing swim (mm2), swarm (mm
2
) and twitch (mm2) with 
adhesion (OD
595nm
) results after 24-hours incubation under each aerobic, microaerophilic and anaerobic atmospheric conditions for  
P. aeruginosa isolates.  
R = 0.464; P < 0.001 R = 0.390; P < 0.001 R = 0.447; P < 0.001 
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Appendix 4 Appendix to Chapter 5  
The following appendix constitutes data mentioned in Chapter 5: Biofilm development of Pseudomonas 
aeruginosa 
 
Appendix 4.1 Representative images of biofilm formation and structure from clinical (AUST-02, (A)), 
environmental (B) and reference strain (C) of Pseudomonas aeruginosa.  
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Appendix 5 Appendix to Chapter 6 
The following appendix constitutes data mentioned in Chapter 6: Genomic analysis of Pseudomonas 
aeruginosa 
 
Appendix 5.1 The five most significant SNPs and indels identified from GWAS analysis for defined 
phenotypic characteristics of P. aeruginosa isolates. 
 
Appendix 5.2 List of References for Appendix 1 
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Appendix 5.1 The five most significant SNPs and indels identified from GWAS analysis for defined phenotypic characteristics of P. aeruginosa isolates. 
 
Morphology   SNP 
P-
value  
Function Reference   INDEL 
P-
value  
Function Reference 
Swim O2 
  PA3535 Ala687Thr 1.5 x 10-6 Putative serine protease [1]   aprE upstream modifier 4.4 x 10-7 
Alkaline protease secretion protein. This gene was upregulated when 
isolates were swarming compared to swimming 
[2]  
  PA3536  Ser122Gly 1.5 x 10-6 Hypothetical protein    PA1536 Ser19FS 4.4 x 10-7 Hypothetical protein  
  algE  Arg10Trp  1.5 x 10-6 Outer membrane protein associated with alginate synthesis and export [3-5]   pscK Cys152del 4.4 x 10-7 
Under swarm conditions this gene is up-regulated, whereas in a swarm 
mutant this gene is down-regulated 
 [2, 6] 
  algE  Gly79Ala 1.5 x 10-6 Outer membrane protein associated with alginate synthesis and export [3-5]   PA1874 Ser150_Gly151dup 4.4 x 10-7 
Novel efflux pump shown to enhance resistance of cells within a biofilm 
structure compared to planktonic cells 
 [7] 
  PA3641  Ala239Gly 1.5 x 10-6 Putative amino acid permease [8]   PA2049 Pro16_Leu17dup 4.4 x 10-7 Hypothetical protein   
Swim MA 
  PA3535 Ala687Thr 1.1 x 10-6 Putative serine protease [1]   pchC upstream modifier 2.8 x 10-7 
Pyochelin biosynthetic protein required for production and associated with 
iron uptake 
[9, 10]  
  PA3536  Ser122Gly 1.1 x 10-6 Hypothetical protein    aprE upstream modifier 5.2 x 10-7 
Alkaline protease secretion protein. This gene was upregulated when 
isolates were swarming compared to swimming 
 [2] 
  algE  Arg10Trp  1.1 x 10-6 Outer membrane protein associated with alginate synthesis and export [3-5]   PA1536 Ser19FS 5.2 x 10-7 Hypothetical protein  
  algE  Gly79Ala 1.1 x 10-6 Outer membrane protein associated with alginate synthesis and export [3-5]   pscK Cys152del 5.2 x 10-7 
Under swarming conditions this gene is up-regulated, whereas in a swarm 
mutant this gene is down-regulated 
[2, 6]  
  PA3641  Ala239Gly 1.1 x 10-6 Putative amino acid permease [8]   PA1874 Ser150_Gly151dup 5.2 x 10-7 
Novel efflux pump shown to enhance resistance of cells within a biofilm 
structure compared to planktonic cells 
 [7] 
Swim AnO2    Not included due to population bias   Not included due to population bias 
Swarm O2 
  PA5021 Pro317Gln 0.01 
Loss of this gene has been associated with a decrease in the production of 
pyocyanin in a plant model 
[11]  
No significant indels 
  PA1613 Gln679Glu 1.7 x 10-2 
Outer membrane protein associated with early P. aeruginosa airway 
infections 
[12]  
  PA0625 Val220Ala 1.8 x 10-2 
Evidence of upregulation in conditions of oxidative stress such as anaerobic 
conditions or exposure to hydrogen peroxide 
[13, 14]  
  flgK Asn372Ser 2.2 x 10-2 
Flagella hook associated protein. Mutations in flgK render the cells non-
motile (swim) and impair attachment to abiotic surfaces 
[15-19]  
Swarm MA 
  PA1908 Gly91Ala 2.5 x 10-10 Probable major facilitator superfamily transporter   PA3298 Lys67_Met94del 1.9 x 10-7 Hypothetical protein   
  PA4881 Ile52Val 1.5 x 10-8 Hypothetical protein   PA0636 Gly655del 1.5 x 10-6 Hypothetical protein  
  clpB Val846Leu 2.6 x 10-8 
Chaperone protein, mutants display reduced swimming and have less 
flagella present than wild types 
[20]  PA2927 Ala55_Thr80del 1.5 x 10-6 Hypothetical protein  
  PA0495 Ala97Val 3.7 x 10-8 Hypothetical protein   fimV Gly682_Asp683insGlyAspLeuGlySer 7.3 x 10-6 Mutations within the fimV gene results in the loss of twitching motility [21, 22]  
  PA1907 Gly162Asp 3.7 x 10-8 Hypothetical protein   opmQ Gln34FS 3.7 x 10-5 
Outer membrane protein comprising the efflux system PvdRT-OpmQ which 
has been associated with the secretion of pyoverdin 
 [23-25] 
Swarm 
AnO2 
  PA1997 Gly215Asp 2.0 x 10-8 
Probable AMP binding enzyme has been associated with increased drug 
susceptibility 
[26]  xcpQ Glu417_Ser418delinsAla 5.0 x 10-6 
Outer membrane secretin associated with Type II Secretion System and the 
transport of proteins across the outer membrane, no defect to swarming of 
biofilm development in xcpQ mutants  
 [27-30] 
  hpaA Ile477Val 2.0 x 10-8 
Transcriptional regulator which functions as a metabolic enzyme, has been 
associated with increased resistance to aminoglycosides 
[31]  PA4156 Gly471FS 6.6 x 10-6 
fvbA gene which enable P. aeruginosa utilise siderophores from Vibrio sp. 
as an iron source 
[32, 33]  
  PA0209 Ala229Val 5.0 x 10-8 
Up-regulated during chemotaxis displaying increased expression of 
twitching 
[34]  PA2268 Pro241FS 1.0 x 10-4 Hypothetical protein  
  purN Glu73Gln 1.2 x 10-6 Phosphoribosylaminoimidazole synthetase   fimV Gly682_Asp683insGlyAspLeuGlySer 2.0 x 10-4 Mutations within the fimV gene results in the loss of twitching motility [21, 22]  
  PA3025 Pro389Ala 1.2 x 10-6 Probable FAD-dependent glycerol-3-phosphate dehydrogenase   PA2793 Leu16_Cys17dup 3.0 x 10-4 Hypothetical protein   
Twitch O2 
  PA4781 Leu158Phe 1.6 x 10-8 
Cyclic-Di-GMP. Mutations in this gene have been associated with reduced 
swarming and twitching motility and biofilm development 
[35, 36]  PA2583 Gly13FS 2.4 x 10-6 
Probable sensor and or response regulator hybrid associated with increased 
resistance to Colistin 
[37]  
  PA4782 Ala6Val 1.6 x 10-8 Hypothetical protein   PA4156 Gly471FS 2.9 x 10-6 
fvbA gene which enable P. aeruginosa utilise siderophores from Vibrio sp. 
as an iron source 
[32, 33]  
  PA5484 Glu54Lys 1.6 x 10-8 
Mutation within kinB reduces biofilm production and prevents swimming 
motility 
[38, 39]  xcpQ Glu417_Ser418delinsAla 7.1 x 10-6 
Outer membrane secretin associated with Type II Secretion System and the 
transport of proteins across the outer membrane, no defect to swarming of 
biofilm development in xcpQ mutants 
[27-30]  
  PA5492 Pro189Leu 1.6 x 10-8 Hypothetical protein   pilQ Gln628FS 8.0 x 10-6 
Mutations within the pilQ gene results in the loss of twitching motility and 
surface fimbriae 
[40-43]  
  PA0683 Val191Ile 1.6 x 10-8 
HxcY, homologue of xcpY, part of the hxc gene cluster which may be 
involved in the type II secretion system 
[30]  PA3340 Glu601dup 1.5 x 10-5 Hypothetical protein   
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Appendix 5.1, continued The five most significant SNPs and indels identified from GWAS analysis for defined phenotypic characteristics of P. aeruginosa isolates. 
 
Morphology   SNP 
P-
value 
Function Reference   INDEL 
P-
value 
Function Reference 
Twitch MA 
  
No SNP's identified due to population bias 
  xcpQ Gl417_Ser418delinsAla 1.5 x 10-7 
Outer membrane secretin associated with Type II Secretion System and the 
transport of proteins across the outer membrane, no defect to swarming of 
biofilm development in xcpQ mutants 
 [27-30] 
    fimV Gly682_Asp683insGlyAspLeuGlySer 9.0 x 10-7 Mutations within the fimV gene results in the loss of twitching motility  [21, 22] 
    PA4156 Gly471FS 3.0 x 10-6 
fvbA gene which enable P. aeruginosa utilise siderophores from Vibrio sp. 
As an iron source 
[32]  
    treA Ser34_Trp35insSerSer 5.0 x 10-6 
Periplasmic trehalase precursor associated with the metabolism of trehalose, 
therefore cannot utilise trehalose as a carbon source 
[44]  
    mpl Met38FS 6.0 x 10-6 Ligase involved with the biosynthesis of bacterial cell wall peptidoglycan [45, 46]  
Twitch 
AnO2 
  No significant correlation   No significant correlation 
Adhesion 
O2 
  PA2069 Ala480Glu 7.0 x 10-7 
Probable carbamoyl transferase, not known to be involved in biofilm 
development 
[47]   PA3340 Glu601dup 1.5 x 10-5 Hypothetical protein 
  PA3292 Ser202Pro 7.0 x 10-7 Hypothetical protein    opr86 Arg668FS 2.6 x 10-5 opr86 is essential for survival. Antibodies against this gene have been shown 
to inhibit biofilm formation 
[48] 
  gcvP1 Ser98Pro 7.0 x 10-7 Glycine cleavage system protein    opr86 Thr673_Met675del 2.6 x 10-5 opr86 is essential for survival. Antibodies against this gene have been shown 
to inhibit biofilm formation 
[48] 
  PA0017 Lys195Gly 2.2 x 10-5 Hypothetical protein    PA1401 Val130del 6.3 x 10-5 Hypothetical protein 
  PA0669 Ser885Thr 2.2 x 10-5 Probable DNA polymerase alpha chain  [49, 50]   PA4156 Gly471FS 6.6 x 10-5 
fvbA gene which enable P. aeruginosa utilise siderophores from Vibrio sp. 
As an iron source 
[32, 33] 
Adhesion 
MA 
  PA0711 Leu49Phe 8.0 x 10-7 
Hypothetical protein, which has been shown to display high levels of 
recombination  
[51]   PA4156 Gly471FS 1.4 x 10-6 
fvbA gene which enable P. aeruginosa utilise siderophores from Vibrio sp. 
As an iron source 
[32, 33] 
  PA2291 Cys24Gly 8.0 x 10-7 
Probable glucose-sensitive porin, found in lower levels in AUST-01 
compared to reference strains 
[52]   opr86 Arg668FS 4.0 x 10-6 
opr86 is essential for survival. Antibodies against this gene have been shown 
to inhibit biofilm formation 
[48] 
  PA0690 Asn1364Asp 2.5 x 10-6 Phosphate depletion regulated TPS partner A, PdtA    opr86 Thr673_Met675del 7.7 x 10-6 opr86 is essential for survival. Antibodies against this gene have been shown 
to inhibit biofilm formation 
[48] 
  trpA Ile148Leu 9.0 x 10-6 Tryptophan synthase alpha chain    xcpQ Glu417_Ser418delinsAla 7.0 x 10-5 
Outer membrane secretin associated with Type II Secretion System and the 
transport of proteins across the outer membrane, no defect to swarming of 
biofilm development in xcpQ mutants 
[27-30] 
  PA0144 Val191Ile 9.0 x 10-6 
Hypothetical protein which has been shown to be activated during quorum 
sensing 
[53]   PA3340 Glu601dup 1.0 x 10-4 Hypothetical protein 
Adhesion 
AnO2 
  PA2125 Lys67Thr 1.8 x 10-6 
Associated with the cupA gene cluster which encodes the fimbrial structure 
enabling bacterial adhesion to abiotic surfaces under anaerobic conditions  
[54]   PA0636 Gly566del 1.5 x 10-6 Hypothetical protein 
  PA2283 Ala114Val 1.8 x10-6 Hypothetical protein    PA1797 Ser256_Ala257dup 9.0 x 10-5 Putative beta-lactamase [55] 
  PA3080 Ser18Leu 1.8 x 10-6 Hypothetical protein    PA2268 Pro241FS 9.8 x 10-5 Hypothetical protein 
  PA3360 Ala14Thr 1.8 x 10-6 Probable secretion protein    pilQ Gln628FS 1.0 x 10-4 Mutations within the pilQ gene results in the loss of twitching motility and 
surface fimbriae 
[40-42] 
  PA1997 Gly215Asp 1.9 x 10-6 
Probable AMP binding enzyme has been associated with increased drug 
susceptibility 
[26]   PA3298 Lys67_Met94del 2.0 x 10-4 Hypothetical protein 
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